EPICORE Embase Updates: 2025

Total documents retrieved: 135

Results Generated From:
Embase <1980 to 2025 Week 34>
Embase Weekly Updates (updates since 2025-08-15)

<1>
Accession Number
2038432593
Title
Comparison of Endoaortic Balloon Occlusion and Transthoracic Aortic Clamp
for Minimally Invasive Cardiac Surgery: Systematic Review and
Meta-analysis.
Source
International Journal of Angiology. 34(3) (pp 176-190), 2025. Date of
Publication: 21 Apr 2025.
Author
Naito N.; Takagi H.
Institution
(Naito, Takagi) Department of Cardiovascular Surgery, Shizuoka Medical
Center, Shizuoka, Japan
Publisher
Thieme Medical Publishers, Inc.
Abstract
This meta-analysis aimed to compare short-term outcomes in patients
undergoing minimally invasive cardiac surgery (MICS) using endoaortic
balloon (EAB) and transthoracic aortic clamp (TAC) techniques. A
comprehensive search of relevant databases was conducted through July
2024. Pooled results were calculated, and subgroup analyses of studies
published during early and late eras were performed. Additionally, a
meta-regression analysis based on the year of publication was conducted to
assess potential influences on outcomes. The systematic review identified
17 non-randomized studies encompassing a total of 8,253 patients. In terms
of intraoperative outcomes, no significant differences were observed in
operation duration, aortic cross-clamp time, cardiopulmonary bypass time,
or rates of sternotomy conversion and iatrogenic aortic dissection.
However, subgroup analysis of early-era studies demonstrated significantly
longer operation times in the EAB cohort (p 1/4 0.03). Meta-regression
analysis indicated that the standardized mean differences in
cardiopulmonary bypass time between the two groups decreased in favor of
EAB as publication years progressed (p 1/4 0.01). For postoperative
outcomes, no significant differences were found in postoperative stroke
rate, the rate of reoperation for bleeding, or length of hospital stay.
However, the EAB group had significantly lower rates of postoperative
atrial fibrillation (OR 1/4 0.82 [0.70-0.95], p < 0.01) and short-term
mortality (OR 1/4 0.60 [0.39-0.92], p 1/4 0.04). This meta-analysis
demonstrated that EAB is associated with perioperative outcomes comparable
to TAC in select patients. The cumulative experience and evolution of
techniques may have contributed to improved outcomes with EAB over
time. Copyright © 2025. International College of Angiology. All
rights reserved.

<2>
Accession Number
2039520511
Title
Comparative effectiveness and safety of self-expanding versus
balloon-expandable transcatheter aortic valve replacement: A systematic
review and meta-analysis.
Source
American Journal of the Medical Sciences. 370(3) (pp 224-230), 2025. Date
of Publication: 01 Sep 2025.
Author
Elkholy M.; Akkawi M.; Kidess G.G.; Abdulelah Z.; Rayyan A.; Al-Dqour
M.R.; Damlakhy A.; Bahar Y.; Alraies M.C.
Institution
(Elkholy, Akkawi, Damlakhy) Wayne State University School of Medicine,
Detroit Medical Center, Detroit, MI, United States
(Kidess) Wayne State University School of Medicine, Detroit, MI, United
States
(Abdulelah) Department of Cardiology, Royal Papworth Hospital, Cambridge,
United Kingdom
(Rayyan) School of Medicine, University of Jordan, Amman, Jordan
(Al-Dqour) Department of Internal Medicine, East Tennessee State
University, United States
(Bahar) Wayne State University, Detroit, MI, United States
(Alraies) Cardiovascular Institute, Detroit Medical Center, Detroit, MI,
United States
Publisher
Elsevier B.V.
Abstract
Background: Transcatheter aortic valve replacement (TAVR) is a safe
alternative to surgical aortic valve replacement for patients with
symptomatic severe aortic stenosis at increased surgical risk. However,
comparative data on self-expanding valves (SEV) versus balloon-expanding
valves (BEV) remain limited. Method(s): A comprehensive review of
PubMed and Embase was conducted through April 2024, identifying eight
studies (five randomized controlled trials and three propensity-matched
observational studies) comparing SEV and BEV in TAVR. Primary outcomes
included all-cause mortality, cardiovascular mortality, and device success
per Valve Academic Research Consortium criteria, while secondary outcomes
assessed bioprosthetic valve dysfunction and adverse events (annulus
rupture/dissection, coronary artery occlusion, valve
dislocation/embolization, valve thrombosis, moderate and severe
paravalvular aortic regurgitation, endocarditis, permanent pacemaker
implantation, major or life-threatening bleeding, acute kidney injury, and
stroke). Result(s): The analysis included 4032 patients (SEV = 2006;
BEV = 2017). SEV was associated with higher rates of moderate-to-severe
paravalvular aortic regurgitation [OR, 1.76; CI 1.13-2.74; P = 0.01] and
permanent pacemaker placement [OR, 1.57; CI, 1.23-2.00; P = 0.0002]
compared to BEV. No significant differences were observed in 30-day or
1-year all-cause mortality, cardiovascular mortality, device success,
bioprosthetic valve dysfunction, valve dislocation/embolization, valve
thrombosis, endocarditis, major or life-threatening bleeding, coronary
artery occlusion, stroke, rehospitalization, or acute kidney injury.
 Conclusion(s): SEV and BEV demonstrated comparable outcomes in
mortality and device success. However, the higher risk of
moderate-to-severe paravalvular aortic regurgitation and permanent
pacemaker placement with SEV should be considered when selecting the
optimal TAVR valve for individual patients. Copyright © 2025

<3>
[Use Link to view the full text]
Accession Number
645115512
Title
Safety and Patient Experience With Early Mobilization After Transcatheter
Aortic Valve Implantation: A Randomized Trial.
Source
The Journal of cardiovascular nursing. 40(5) (pp E231-E238), 2025. Date of
Publication: 01 Sep 2025.
Author
Kirk B.H.; Norgaard M.W.; Palm P.; Norekval T.M.; De Backer O.
Abstract
BACKGROUND: Immobilization after transcatheter aortic valve replacement
(TAVR) is the standard treatment for preventing access-related
complications. However, the length of bed rest varies, and possible
complications and patient experience remain unexplored. OBJECTIVE(S):
In this pilot study, our aim was to investigate safety and efficacy after
bed rest after TAVR. METHOD(S): This single-center randomized trial
included 298 patients. Patients were randomized to standard 6 hours (n =
149) or 3 hours (n = 149) of bed rest after TAVR. The primary safety
endpoint was a composite of access-related bleeding (Bleeding Academic
Research Consortium type >= 2), hematoma (>5 cm), pseudoaneurysm, and
vascular complications requiring intervention. The primary efficacy
endpoint was patient-reported back pain, rated >=6 on a numeric rating
scale 24 hours post procedure. The secondary endpoints were the individual
components of the primary safety endpoint, patient-reported pain,
urination problems, and comfort. RESULT(S): The primary safety
endpoint occurred in 14 (9.4%) and 12 (8.1%) patients in the 6-hour and
3-hour immobilization groups, respectively (risk ratio, 0.86 [95%
confidence interval, 0.41-1.79]; P = .68). There were no significant
differences in individual bleeding or vascular complication endpoints.
Patients with 3 hours of bed rest reported less back pain ( P < .001),
fewer urination problems ( P < .001), and better comfort ( P < .001) than
patients with 6 hours of bed rest. CONCLUSION(S): Mobilization as
early as 3 hours after TAVR was shown to be safe, not resulting in a
higher rate of bleeding or vascular complications as compared with 6 hours
of bed rest. However, there was a difference in patient-reported back
pain, urination problems, and comfort, favoring early
mobilization. Copyright © 2024 Wolters Kluwer Health, Inc. All
rights reserved.

<4>
Accession Number
2037192063
Title
Clinical Outcomes with High- versus Low-Dose Tranexamic Acid Infusion in
Patients Undergoing Cardiac Surgery: A Systematic Review and
Meta-Analysis.
Source
Thoracic and Cardiovascular Surgeon. 73(5) (pp 346-359), 2025. Date of
Publication: 22 Jan 2025.
Author
Rangwala H.S.; Rangwala B.S.; Alotaibi M.; Siddiq M.A.; Qamber A.; Zaidi
S.D.E.Z.; Naveed T.; Naveed H.; Azam S.T.; Hameed I.
Institution
(Rangwala, Rangwala, Siddiq, Qamber, Zaidi, Azam) Department of Medicine,
Jinnah Sindh Medical University, Sindh, Karachi, Pakistan
(Alotaibi) Department of Medicine, Imam Abdulrahman Bin Faisal University,
College of Medicine, Eastern, Dammam, Saudi Arabia
(Naveed, Naveed) Department of Medicine, Ziauddin Medical College, Sindh,
Karachi, Pakistan
(Hameed) Department of Medicine, MedStar Health, Baltimore, MD, United
States
Publisher
Georg Thieme Verlag
Abstract
Objectives Antifibrinolytics, such as tranexamic acid (TXA), are widely
used in cardiac surgery to reduce bleeding risks; however, the optimal
dosage for TXA infusion remains a subject of debate. Hence, this study
aims to evaluate the safety and efficacy of high-dose compared with
low-dose TXA infusion in cardiac surgery patients. Methods PubMed, SCOPUS,
and Cochrane Central Register of Controlled Trials (CENTRAL) were searched
until June 10, 2023, for studies assessing efficacy outcomes (e.g., blood
loss, transfusions) and safety outcomes (e.g., mortality, complications).
Results Results were analyzed via random-effects model, using
Mantel-Haenszel risk ratio (RR) and standard mean difference (SMD). P
-value < 0.05 was considered significant. We analyzed 17 studies involving
93,206 participants (mean age 59.3 years, study duration 3 months to 10
years). Our analysis found significant reductions in total blood loss
(SMD, -0.17 g; CI, -0.34 to -0.01; p = 0.04), 24-hour blood loss (SMD,
-0.23 g; p = 0.005), and the need for fresh frozen plasma (FFP)
transfusions (RR: 0.94; CI, 0.89 to 1.00; p = 0.05) with high-dose TXA.
Chest tube output was also lower (SMD, -0.12 g; p = 0.0006), but
postoperative seizures increased (RR: 2.23; CI, 1.70 to 2.93; p < 0.00001)
with high-dose TXA. For other outcomes like blood transfusions,
hospital/ICU stay, mortality, stroke, myocardial infarction, pulmonary
embolism, renal dysfunction, and reoperation, no significant differences
were found between high-dose and low-dose TXA regimens. Conclusion Our
study showed that high TXA dose effectively reduce postoperative bleeding,
chest tube drainage, and the need for FFP transfusion, but it increases
the risk of seizures. Increasing TXA dose did not affect thromboembolic
events or mortality. This emphasizes the importance of weighing the
benefits and risks when selecting the appropriate TXA regimen for each
patient. Copyright © 2025. Thieme. All rights reserved.

<5>
Accession Number
2035565343
Title
Intraoperative hypotension prediction in cardiac and noncardiac
procedures: is HPI truly worthwhile? A systematic review and
meta-analysis.
Source
BMC Anesthesiology. 25(1) (no pagination), 2025. Article Number: 388. Date
of Publication: 01 Dec 2025.
Author
Shirmohamadi E.; Dolama R.H.; Mohammadzadeh N.; Ebrahimi N.; Ghasemloo N.
Institution
(Shirmohamadi, Dolama, Mohammadzadeh, Ebrahimi, Ghasemloo) Surgery
Research Departement, Imam Hospital Complex, Keshavarz blvd, Tehran, Iran,
Islamic Republic of
Publisher
BioMed Central Ltd
Abstract
Background: Intraoperative hypotension (IOH), defined as a mean arterial
pressure (MAP) below 65 mmHg, is a common complication during surgery and
is associated with significant postoperative morbidity, including acute
kidney injury, myocardial injury, stroke, and increased mortality. Despite
the availability of traditional monitoring techniques, predicting and
preventing IOH remains a challenge. The Hypotension Prediction Index
(HPI), a machine-learning algorithm developed by Edwards Lifesciences,
aims to predict IOH by analyzing real-time arterial waveform data,
offering an opportunity for proactive management. Objective(s): This
systematic review and meta-analysis evaluate the efficacy of the HPI in
predicting and preventing IOH in cardiac and non-cardiac surgeries
compared to standard blood pressure monitoring techniques. Method(s):
A comprehensive search was conducted in PubMed, Scopus, Embase, and Web of
Science databases for studies published from January 2019 to May 2024.
Studies were included if they utilized machine learning algorithms,
including HPI, to predict or detect IOH in adult surgical patients.
Sensitivity, specificity, area under the curve (AUC), and time-weighted
average (TWA) of hypotension were the primary outcomes. Subgroup analyses
were performed to evaluate differences between cardiac and non-cardiac
surgeries. Meta-analytic methods were applied using random-effects models
to account for study variability. Result(s): A total of 22 studies
were included, encompassing both cardiac and non-cardiac procedures. The
HPI demonstrated an overall sensitivity of 83% and specificity of 83% in
predicting IOH. The pooled AUC for all surgeries was 0.90. However,
subgroup analysis revealed variability in HPI performance between cardiac
and non-cardiac surgeries, with lower diagnostic odds ratios (DOR) in
cardiac settings. HPI combined with invasive arterial blood pressure
monitoring reduced the TWA of hypotension more effectively than either
invasive or non-invasive methods alone. The comparison of HPI and MAP for
diagnostic accuracy showed minimal differences across all time frames,
with SMD values close to zero. Conclusion(s): Our study shows that
the HPI has high sensitivity and specificity in predicting intraoperative
hypotension, but its clinical advantage over standard MAP-based monitoring
is uncertain. While HPI reduces hypotension duration, this may not improve
cardiovascular or renal outcomes. Further independent trials are needed to
validate its effectiveness before widespread adoption, and it should be
considered alongside simpler interventions like staff education and MAP
targeting in the meantime. Copyright © The Author(s) 2025.

<6>
Accession Number
2036982717
Title
Ketamine for Acute Postoperative Pain Management and Prevention of Chronic
Postsurgical Pain: What Do Recent Meta-Analysis Teach?.
Source
Neuromethods. 225 (pp 3-17), 2025. Date of Publication: 2025.
Author
Labenbacher S.; Eichlseder M.; Bornemann-Cimenti H.
Institution
(Labenbacher, Eichlseder, Bornemann-Cimenti) Department of Anaesthesiology
and Intensive Care Medicine, Medical University of Graz, Graz, Austria
Publisher
Humana Press Inc.
Abstract
Perioperative pain management is a fundamental aspect of anesthesia care.
Immediate postoperative pain management is a challenging area with huge
variability in pain influenced by the surgical procedure, preoperative use
of opioids, preexisting disease, and many more factors. Especially
orthopedic, gynecological, and thoracic operations prove to be highly
painful. Postoperative pain results in complications including prolonged
hospitalization, risk of pain chronification, and a higher rate of
cardiovascular, pulmonary, and gastrointestinal complications. Despite the
mounting evidence in favor of multimodal analgesia, the majority of drugs
employed for postoperative pain management are opioids. Ketamine could
therefore be a valuable adjunct for perioperative analgesia. We performed
a narrative review of systematic reviews published between January 1,
1990, and February 29, 2024, on perioperative ketamine for postsurgical
pain published in Embase (via Ovid), Ovid MEDLINE, and Cochrane Database
of Systematic Reviews. The evidence on perioperative use of ketamine shows
a relevant pain reduction extending beyond the immediate postoperative
phase. Especially patients with high risk for severe, prolonged
postoperative pain may benefit from perioperative ketamine. With vast
dosing and application differences between studies, further research is
required to find optimized use schedules. Copyright © The
Author(s), under exclusive license to Springer Science+Business Media,
LLC, part of Springer Nature 2025.

<7>
Accession Number
2034691804
Title
Effectiveness and Safety of Myval Versus Other Transcatheter Valves in
Patients Undergoing TAVI: A Meta-Analysis.
Source
Catheterization and Cardiovascular Interventions. 106(2) (pp 820-829),
2025. Date of Publication: 01 Aug 2025.
Author
Apostolos A.; Ktenopoulos N.; Drakopoulou M.; Ielasi A.; Panoulas V.;
Baumbach A.; Tsioufis K.; Serruys P.; Toutouzas K.
Institution
(Apostolos, Ktenopoulos, Drakopoulou, Tsioufis, Toutouzas) Unit of
Structural Heart Diseases, First Department of Cardiology, Medical School,
National and Kapodistrian University of Athens, Hippocration General
Hospital of Athens, Athens, Greece
(Ielasi) U.O. Cardiologia Ospedaliera, IRCCS Ospedale Galeazzi
Sant'Ambrogio, Milan, Italy
(Panoulas) Royal Brompton and Harefield Hospitals, Guy's and St Thomas'
NHS Foundation Trust, London, United Kingdom
(Panoulas) National Heart and Lung Institute, Imperial College London,
London, United Kingdom
(Baumbach) Centre for Cardiovascular Medicine and Devices, William Harvey
Research Institute, Queen Mary University of London and Barts Heart
Centre, London, United Kingdom
(Baumbach) Cleveland Clinic, London, United Kingdom
(Serruys) Department of Cardiology, School of Medicine, University of
Galway, Galway, Ireland
Publisher
John Wiley and Sons Inc
Abstract
Transcatheter aortic valve implantation (TAVI) has changed the treatment
of aortic stenosis. The Myval transcatheter heart valve (THV), a novel
balloon-expandable THV, has shown promising outcomes. Our aim is to
compare the comparative safety and effectiveness of Myval THV against
established THVs, such as Sapien and Evolut. A systematic review and
meta-analysis was conducted, comparing the Myval THV with other
contemporary THVs. Primary endpoints were periprocedural, 30-day and
1-year all-cause mortality. Seven studies involving 3106 patients (1027
Myval; 2079 other THVs) were included. No significant differences were
observed in the primary endpoints. Myval demonstrated higher procedural
success (RR: 1.04, 95% CI: 1.01-1.07, I2 = 29%) and lower rates of
permanent pacemaker implantation (PPI) during the index hospitalization
(RR: 0.57, 95% CI: 0.36-0.92, I2 = 23%) and 30-days (RR: 0.60, 95% CI:
0.40-0.89, I2 = 43%), compared to other THV. At 30-day, Myval was
associated with lower rates of moderate or severe transvalvular aortic
regurgitation (RR: 0.33, 95% CI: 0.11-0.98, I2 = 57%) and minor vascular
complications (RR: 0.45, 95% CI: 0.23-0.90, I2 = 0%). When compared to
self-expandable THV, Myval was associated with higher procedural and
device success, higher early safety, lower risk for PPI, minor vascular
complications and at least moderate transvalvular AR. When compared to
Sapien, procedural success and risk for in-hospital PPI was borderline
higher and lower in favor of Myval, respectively. The Myval THV
demonstrates comparable safety and effectiveness to contemporary THVs,
with advantages in procedural success, PPI, and vascular
complications. Copyright © 2025 The Author(s). Catheterization
and Cardiovascular Interventions published by Wiley Periodicals LLC.

<8>
Accession Number
2034792526
Title
Combination of Suture-Plug Vascular Closure Devices Versus Suture-Only
Devices Following Transcatheter Aortic Valve Implantation: A Systematic
Review and Meta-Analysis.
Source
Catheterization and Cardiovascular Interventions. 106(2) (pp 1088-1097),
2025. Date of Publication: 01 Aug 2025.
Author
Haddad S.; Bashour G.; Mamas M.A.
Institution
(Haddad, Bashour) Faculty of Medicine, Tishreen University, Latakia,
Syrian Arab Republic
(Haddad, Bashour) Cancer Research Center, Tishreen University, Latakia,
Syrian Arab Republic
(Mamas) Keele Cardiovascular Research Group, Keele University, Keele,
United Kingdom
Publisher
John Wiley and Sons Inc
Abstract
Background: Transcatheter aortic valve implantation (TAVI) is an effective
and safe intervention for severe symptomatic aortic stenosis regardless of
surgical risk. Vascular complications following TAVI are considered among
the most common and serious complications, with a higher risk of
mortality. Aim(s): We aimed to perform a systematic review and
meta-analysis to evaluate the safety and efficacy of the combination of
suture-collagen plug vascular closure devices (VCDs) compared with
suture-only devices. Method(s): We have systematically searched the
literature from inception until January 4, 2025, for cohort studies and
clinical trials comparing the combination of suture-collagen plug vascular
closure devices (VCDs) versus suture-only VCDs. Result(s): A total of
2064 patients across six studies were included in the analysis. All
studies compared dual Perclose ProGlide versus 1 Perclose ProGlide + 1
Angio-Seal, except one study that used either one Prostar or dual ProGlide
in the suture group. The combination group of suture-plug VCDs was
associated with a statistically significant reduction of VCDs failure (RR
= 0.14, CI 95% [0.09-0.23], p < 0.0001, I2 = 58.6938%),
bleeding complications (RR = 0.35, CI95% [0.24-0.53], p < 0.0001, (Formula
presented.) 0.0%), major vascular complications (RR = 0.42, CI 95% [0.28,
0.63], p < 0.0001, I2 = 50.4%), and minor vascular
complications (RR = 0.54, CI 95% [0.43, 0.66], p < 0.0001, I2 =
0%). On the other hand, all-cause mortality did not have a statistically
significant difference between the two groups (RR = 0.54, CI 95% [0.28,
1.05], p = 0.0709, I2 = 0%). Conclusion(s): In patients
undergoing TAVI, the combination strategy of suture-plug VCDs is superior
to suture-only devices regarding major and minor vascular complications,
bleeding complications, and VCD failure. The significantly higher VCD
failure of the suture-only group observed in our study led to the use of
additional closure devices to secure hemostasis, raising concerns about a
higher risk of peripheral ischemia. Copyright © 2025 Wiley
Periodicals LLC.

<9>
[Use Link to view the full text]
Accession Number
2039349302
Title
Cardiac CT Versus Transesophageal Echocardiography Following Left Atrial
Appendage Closure: A Systematic Review and Meta-Analysis.
Source
Circulation: Cardiovascular Imaging. 18(8) (no pagination), 2025. Article
Number: e018151. Date of Publication: 01 Aug 2025.
Author
Tan B.E.-X.; Baqai F.; Padilla F.; Nimri N.; Cheung J.W.; Kottam A.;
Medina H.M.
Institution
(Tan, Nimri, Kottam) Section of Cardiology, Department of Medicine, United
States
(Baqai, Padilla) Section of General Internal Medicine, Department of
Medicine, United States
(Cheung) Baylor College of Medicine, Houston, TX, United States
(Cheung) Division of Cardiology, Department of Medicine, Weill Cornell
Medicine, New York, NY, United States
(Medina) Department of Cardiology, The Texas Heart Institute, Baylor
College of Medicine, Houston, United States
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: In the landmark WATCHMAN trials, transesophageal
echocardiography (TEE) was used to evaluate peri-device leak (PDL) and
device-related thrombus (DRT) after percutaneous left atrial appendage
closure (LAAC). We aimed to investigate the diagnostic utility of cardiac
computed tomography angiography (CCTA) compared with TEE for post-LAAC
device surveillance. METHOD(S): We conducted a literature search of 5
electronic databases to identify studies that included patients who
underwent both CCTA and TEE after LAAC. We performed a meta-analysis by
pooling outcomes for residual leak (left atrial appendage patency), any
PDL, large PDL (>5 mm), and DRT. RESULT(S): We included 17 cohort
studies with 1313 patients who underwent both CCTA and TEE after LAAC.
CCTA was associated with higher odds of detecting residual leak (58.8%
versus 34.6%, odds ratio, 2.26 [95% CI, 1.48-3.44], P=0.0002;
I2=73%; 15 studies, 975 patients; moderate certainty) and any
PDL (51.6% versus 35.5%, odds ratio, 1.59 [95% CI, 1.01-2.51], P=0.04;
I2=73%; 12 studies, 870 patients; moderate certainty) when
compared with TEE. There were no significant differences in the detection
rates of large PDL (>5 mm) between CCTA and TEE (2.8% versus 0.8%, odds
ratio, 3.12 [95% CI, 0.73-13.36], P=0.13; I2=0%; 5 studies, 338
patients; moderate certainty). The incidence of DRT was low (1.7%), and
the detection rate did not differ between the 2 modalities (1.7% versus
1.7%, odds ratio, 1.0 [95% CI, 0.41-2.42], P=1.0; I2=0%; 6
studies, 584 patients; high-certainty). CONCLUSION(S): Following
LAAC, CCTA had higher odds of detecting residual leak and any PDL compared
with TEE, whereas there were no significant differences in the detection
of large PDL (> 5mm) and DRT between the 2 modalities. The findings of
this meta-analysis should provide reassurance to patients and clinicians
who prefer CCTA over TEE after LAAC. While DRT and left atrial appendage
patency with visible PDL are known to be associated with thromboembolism,
the clinical significance of left atrial appendage patency without visible
PDL is uncertain and warrants further investigation. REGISTRATION: URL:
https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42024578802.
GRAPHICAL ABSTRACT: A graphical abstract is available for this
article. Copyright © 2025 American Heart Association, Inc.

<10>
Accession Number
2039984870
Title
Adult Transcatheter Pulmonary Valve Replacement.
Source
Cardiology in Review. (no pagination), 2025. Article Number:
10.1097/CRD.0000000000001021. Date of Publication: 2025.
Author
Weldehana A.; Yeneneh B.; Zewde S.; Zewde D.; Aronow W.; William F.; Fuisz
A.
Institution
(Weldehana, Aronow, William, Fuisz) Department of Cardiology, Westchester
Medical Center, Valhalla, NY, United States
(Yeneneh) Department of Cardiology, University of Arizona, Phoenix, AZ,
United States
(Zewde, Zewde) Department of Internal Medicine, College of Health Science,
Addis Ababa University, Addis Ababa, Ethiopia
Publisher
Lippincott Williams and Wilkins
Abstract
Transcatheter pulmonary valve replacement (TPVR) is one of the structural
interventions developed over the past 25 years. It is being used for
patients with moderate to severe pulmonary stenosis and regurgitation. It
is an alternative and preferred option to surgical pulmonary valve
replacement (SPVR). Common indications include isolated congenital native
valve pulmonary stenosis, right ventricular outflow tract obstruction with
or without right ventricular conduit stenosis, severe pulmonary
regurgitation with right ventricular dysfunctions, and lastly,
bioprosthetic pulmonary valve dysfunctions. TPVR is a complex procedure
that requires invasive hemodynamic assessments, a balloon test to exclude
coronary artery compressions, and preprocedural right ventricular outflow
tract preparation with balloon dilation and stenting. Once access to the
pulmonary valve is established and the catheter is positioned in the
preferred landing zone, bioprosthetic valves, compressed into various
delivery systems, are deployed using fluoroscopy guidance. Currently,
there are 7, either balloon-inflated or self-expanding, bioprosthetic
valves with different sizes and delivery systems. Conduit rupture and
coronary artery compressions are the 2 most feared but less common
complications of the procedure, while stent fracture, infective
endocarditis, and arrhythmias are among the short- and long-term
complications. Unlike the transcutaneous aortic valve replacement for
aortic stenosis, TPVR is not an extensively studied procedure. Limited
observational studies and meta-analyses have indicated a survival rate of
95%. Compared with SPVR, it has a similar risk of reinterventions with no
difference in mortality. However, it has an increased risk of infective
endocarditis and may incur slightly more cost than SPVR. Copyright
© 2025 Wolters Kluwer Health, Inc. All rights reserved.

<11>
Accession Number
2034804500
Title
Intravascular Lithotripsy Versus Rotational Atherectomy in the Management
of Calcific Coronary Lesions: A Systematic Review and Meta-Analysis.
Source
Catheterization and Cardiovascular Interventions. 106(2) (pp 1142-1152),
2025. Date of Publication: 01 Aug 2025.
Author
Moghadam A.S.; Kakavand N.; Shirmard F.O.; Poopak A.; Anaraki N.; Javadi
M.; Jenab Y.; Mehrani M.; Khanipour R.; Tehrani B.; Latib A.; Azizi K.A.;
Allana S.; Kolte D.; Hosseini K.
Institution
(Moghadam, Shirmard, Anaraki, Javadi, Jenab, Mehrani, Hosseini) Tehran
Heart Center, Cardiovascular Diseases Research Institute, Tehran
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Kakavand) School of Medicine, Isfahan University of Medical Sciences,
Isfahan, Iran, Islamic Republic of
(Poopak) Cardiovascular Intervention Research Center, Rajaie
Cardiovascular Medical Research Institute, Tehran, Iran, Islamic Republic
of
(Khanipour) Department of Internal Medicine and Cardiology, HCA Bayonet
Point Hospital, University of South Florida, Tampa, FL, United States
(Tehrani) Inova Heart and Vascular Institute, Falls Church, VA, United
States
(Latib) Division of Cardiology, Montefiore Medical Center, The Bronx, NY,
United States
(Azizi) Department of Cardiology Baylor Scott and White, The Heart
Hospital, Plano, TX, United States
(Allana) Division of Cardiology, University of Texas Southwestern Medical
Center, Dallas, TX, United States
(Kolte) Cardiology Division, Massachusetts General Hospital, Harvard
Medical School, Boston, MA, United States
Publisher
John Wiley and Sons Inc
Abstract
Background and Aims: Calcific coronary lesions pose significant challenges
to percutaneous coronary intervention (PCI), limiting stent delivery and
expansion. Intravascular lithotripsy (IVL) and rotational atherectomy (RA)
are widely used plaque modification techniques; however, comparative data
on their effectiveness remain limited. We aimed to compare clinical and
procedural outcomes between IVL and RA in the management of calcific
coronary lesions. Method(s): PubMed, Embase, Scopus, and Cochrane
Library were searched through January 2025 for randomized controlled
trials (RCTs) and observational studies comparing IVL with RA in calcific
coronary lesions undergoing PCI. The primary outcome was major adverse
cardiovascular events (MACE). Secondary outcomes included all-cause
mortality, myocardial infarction (MI), stroke, repeat revascularization,
procedural outcomes, and minimum stent area (MSA). Random-effect models
were used for outcome analysis, and meta-regression assessed the impact of
baseline characteristics. Result(s): A total of 14 studies (2 RCTs,
12 observational; 2056 IVL patients, 3099 RA patients) were included. IVL
and RA showed a comparable risk of MACE (OR 0.81; 95% CI 0.57-1.16; p:
0.26) and similar risks of all-cause mortality, MI, stroke, and repeat
revascularization. IVL was associated with a lower risk of coronary
perforation (OR 0.43; 95% CI 0.32-0.57; p < 0.001) and slow or no-reflow
(OR 0.34; 95% CI 0.14-0.79; p 0.02). Additionally, IVL resulted in shorter
procedure duration (SMD -0.30; 95% CI -0.61-0.00; p 0.05) and fluoroscopy
time (SMD -0.41; 95% CI -0.62, -0.20; p 0.004). Post-procedural MSA was
similar between IVL and RA. Conclusion(s): IVL and RA demonstrated
comparable efficacy in terms of MACE and clinical outcomes in patients
with calcific coronary lesions undergoing PCI. However, IVL was associated
with a lower risk of coronary perforation, slow or no-reflow phenomenon,
and reduced procedure duration and fluoroscopy time, suggesting a
potential procedural advantage over RA. Copyright © 2025 Wiley
Periodicals LLC.

<12>
Accession Number
2035742205
Title
Outcomes of mitral transcatheter edge-to-edge repair in patients with
mitral annular calcification: A meta-analysis.
Source
Cardiovascular Revascularization Medicine. 77 (pp 37-44), 2025. Date of
Publication: 01 Aug 2025.
Author
Samimi S.; Hatab T.; Kharsa C.; Bou Chaaya R.G.; Qamar F.; Khan S.U.; Aoun
J.; Zaid S.; Faza N.; Little S.H.; Atkins M.D.; Reardon M.J.; Kleiman
N.S.; Zoghbi W.A.; Goel S.S.
Institution
(Samimi, Hatab, Kharsa, Bou Chaaya, Qamar, Khan, Aoun, Faza, Little,
Kleiman, Zoghbi, Goel) Houston Methodist DeBakey Heart and Vascular
Center, Houston, TX, United States
(Zaid) Baylor College of Medicine, Michael E. Debakey Veterans Affairs
Medical Center, Houston, TX, United States
(Atkins, Reardon) Department of Cardiovascular Surgery, Houston Methodist
Hospital, Houston, TX, United States
Publisher
Elsevier Inc.
Abstract
Background: The impact of mitral annular calcification (MAC) on the
clinical outcomes of patients undergoing mitral transcatheter edge-to-edge
repair (MTEER) remains unclear. This meta-analysis aims to evaluate the
clinical outcomes of MTEER among patients with moderate to severe MAC
compared to those with mild or no MAC. Method(s): We systematically
searched PubMed, EMBASE, and Cochrane CENTRAL databases through March
31st, 2024, comparing clinical outcomes of MTEER among patients with
moderate/severe (MAC+) versus no/mild MAC (MAC-). We assessed pooled
estimates for procedural success, all-cause mortality, residual mitral
regurgitation (MR) <= moderate, and New York Heart Association (NYHA)
class III/IV status at one year. Result(s): Among five studies (2533
patients; mean age 76.4 +/- 10.9 years, 39.8 % women), MAC+ patients were
predominantly women (55.7 % vs 37.5 %, p < 0.001), older (87.9 +/- 11.1
vs. 75.9 +/- 9.1 years; mean difference (MD) = 3.99, p = 0.011) and had
higher STS scores (7.7 +/- 6.7 % vs. 4.9 +/- 4.6 %; MD = 1.34, p < 0.001).
MAC+ patients had comparable procedural success rates, residual MR <
moderate, and NYHA III/IV at 1 year. However, all-cause mortality at 1
year was higher for MAC+ patients (Relative Risk = 1.56, 95 % CI =
1.06-2.29). Conclusion(s): MTEER is a safe and feasible option for
carefully selected patients with MAC and significant MR, offering durable
MR reduction and functional status improvement. Significantly higher
one-year mortality associated with MAC despite significant MR reduction
suggests an increased risk unrelated to valvular dysfunction and
highlights the need for further investigation into identifying patients
who benefit the most from MTEER. Copyright © 2024

<13>
Accession Number
2039977964
Title
Long-Term Outcomes After Fractional Flow Reserve vs Intravascular
Ultrasound to Guide PCI: The FLAVOUR Trial Extended Follow-Up.
Source
Journal of the American College of Cardiology. 86(8) (pp 593-606), 2025.
Date of Publication: 26 Aug 2025.
Author
Koo B.-K.; Wang J.; Hu X.; Nam C.-W.; Koh J.-S.; Lee K.; Jung S.D.; Jiang
J.; Sun Y.; Li C.; Zhu L.; Gao F.; Dong L.; Zhang J.; Li S.; Park K.W.;
Kang J.; Hwang D.; Yang S.; Hahn J.-Y.; Lee J.M.; Choi K.H.; Cho Y.-K.;
Doh J.-H.; Lee B.-K.; Huang J.; Tong G.; Jiang F.; Xu W.; Kim W.; Woo
J.S.; Zhou H.; Chen C.; Chen P.; Ye S.; Tang L.; Du C.; Jiang W.; Chen H.;
Chen X.; Cui H.; He W.; Xie Y.; Ahn S.G.; Tahk S.-J.; Yoon M.-H.; Kim U.;
Shin E.-S.; Ki Y.-J.; Jang E.-C.; Lee S.H.; Jo J.-W.; Zheng G.
Institution
(Yang, Hwang, Kang, Koo) Seoul National University Hospital, Seoul, South
Korea
(Hu, Zhang, Jiang, Wang) The Second Affiliated Hospital of Zhejiang
University School of Medicine, State Key Laboratory of Transvascular
Implantation Devices, Heart Regeneration and Repair Key Laboratory of
Zhejiang Province, Transvascular Implantation Devices Research Institute,
Hangzhou, Hangzhou, China
(Hahn) Samsung Medical Center, Seoul, South Korea
(Doh) Inje University Ilsan Paik Hospital, Goyang, South Korea
(Lee) Kangwon National University Hospital, Gangwon-Do, Chuncheon, South
Korea
(Kim) Kyung Hee University Hospital, Seoul, South Korea
(Huang) Hangzhou First People's Hospital, Hangzhou, China
(Jiang) The Affiliated Hospital of Hangzhou Normal University, Hangzhou,
China
(Zhou) The First Affiliated Hospital of Wenzhou Medical University,
Wenzhou, China
(Chen) The Second Affiliated Hospital and Yuying Children's Hospital of
Wenzhou Medical University, Wenzhou, China
(Tang) Zhejiang Hospital, Hangzhou, China
(Jiang, Chen) The Third Clinical Institute Affiliated to Wenzhou Medical
University, Wenzhou, China
(Chen, He) The First Affiliated Hospital of Ningbo University, Ningbo,
China
(Ahn) Wonju Severance Christian Hospital, Gangwon-Do, Wonju, South Korea
(Tahk) Ajou University Hospital, Suwon, South Korea
(Kim) Yeungnam University Medical Center, Daegu, South Korea
(Ki) Uijeongbu Eulji Medical Center, Gyeonggi-Do, Uijeongbu, South Korea
(Shin) Ulsan University Hospital, University of Ulsan College of Medicine,
Ulsan, South Korea
(Nam) Keimyung University Dongsan Hospital, Daegu, South Korea
Publisher
Elsevier Inc.
Abstract
Background: The optimal treatment strategy for patients with intermediate
coronary stenosis remains uncertain. Objective(s): The aim of this
study was to investigate the long-term outcomes of a randomized,
open-label, multinational trial comparing fractional flow reserve
(FFR)-guided vs intravascular ultrasound (IVUS)-guided treatment
strategies. Method(s): Patients aged >=19 years with de novo
intermediate coronary stenosis (40%-70%) and target vessel diameters >=2.5
mm were randomized 1:1 to FFR- or IVUS-guided treatment across 18 sites in
Korea and China. The primary endpoint was a composite of all-cause death,
myocardial infarction, and any revascularization occurring after the index
procedure. Secondary endpoints included individual components of the
primary outcome and per vessel outcomes according to treatment type.
Extended follow-up continued through September 2024. Result(s):
Between July 2016 and August 2019, 1,682 patients were assigned to the
FFR-guided (n = 838) and IVUS-guided (n = 844) groups. Over a median
follow-up period of 6.3 years (Q1-Q3: 5.6-6.9 years), the primary outcome
occurred in 339 patients (22.0%), with no statistically significant
difference between groups (179 [23.1%] for FFR vs 160 [20.9%] for IVUS;
HR: 1.15; 95% CI: 0.93-1.42; P = 0.208). The revascularization rate after
the index procedure was higher in the FFR group (113 [14.9%] vs 87
[11.8%]; HR: 1.32; 95% CI: 1.00-1.75; P = 0.049), particularly for target
vessel revascularization (72 [9.6%] vs 44 [6.2%]; HR: 1.67; 95% CI:
1.15-2.43; P = 0.007). Landmark analysis at 2 years and per vessel
analyses indicated that the higher revascularization rate after the index
procedure was driven primarily by late (2-7 years) revascularizations in
vessels in which percutaneous coronary intervention (PCI) was initially
deferred. Nevertheless, the overall rate of target vessel PCI, including
procedures at index and during follow-up, was significantly lower in the
FFR group (38.8% vs 60.5%; P < 0.001), with no statistically significant
differences in the annual cumulative incidence of death or myocardial
infarction between groups. Conclusion(s): FFR-guided and IVUS-guided
treatment strategies resulted in comparable long-term outcomes, with no
significant difference in patient-oriented composite outcomes. Although
FFR-guided treatment was associated with a higher incidence of late target
vessel revascularization, the overall target vessel PCI rate, accounting
for both the index procedure and revascularization during follow-up,
remained significantly lower in the FFR-guided treatment group, with
comparable rates of hard outcomes between the 2 groups. Copyright
© 2025 American College of Cardiology Foundation

<14>
Accession Number
2038801721
Title
Clinical Response to Resynchronization Therapy: Conduction System Pacing
vs Biventricular Pacing: The CONSYST-CRT Trial.
Source
JACC: Clinical Electrophysiology. 11(8) (pp 1820-1831), 2025. Date of
Publication: 01 Aug 2025.
Author
Pujol-Lopez M.; Graterol F.R.; Borras R.; Garcia-Ribas C.; Guichard J.B.;
Regany-Closa M.; Jimenez-Arjona R.; Niebla M.; Poza M.; Carro E.; Castel
M.A.; Arbelo E.; Porta-Sanchez A.; Sitges M.; Roca-Luque I.; Doltra A.;
Guasch E.; Tolosana J.M.; Mont L.
Institution
(Pujol-Lopez, Graterol, Borras, Guichard, Regany-Closa, Jimenez-Arjona,
Niebla, Poza, Carro, Castel, Arbelo, Porta-Sanchez, Sitges, Roca-Luque,
Doltra, Guasch, Tolosana, Mont) Institut Clinic Cardiovascular (ICCV),
Hospital Clinic, Universitat de Barcelona, Catalonia, Spain
(Pujol-Lopez, Graterol, Borras, Garcia-Ribas, Guichard, Regany-Closa,
Niebla, Poza, Carro, Castel, Arbelo, Porta-Sanchez, Sitges, Roca-Luque,
Doltra, Guasch, Tolosana, Mont) Institut d'Investigacions Biomediques
August Pi i Sunyer (IDIBAPS), Catalonia, Barcelona, Spain
(Borras) Centro de Investigacion Biomedica en Red;, Salud Mental
(CIBERSAM), Instituto de Salut Carlos III, Madrid, Spain
(Guichard, Castel, Arbelo, Sitges, Roca-Luque, Guasch, Tolosana, Mont)
Centro de Investigacion Biomedica en Red, Enfermedades Cardiovasculares
(CIBERCV), Madrid, Spain
Publisher
Elsevier Inc.
Abstract
Background: Randomized studies comparing conduction system pacing (CSP)
with biventricular pacing (BiVP) are scarce and do not include clinical
outcomes. Objective(s): The CONSYST-CRT (Conduction System Pacing vs
Biventricular Resynchronization Therapy in Systolic Dysfunction and Wide
QRS) trial aimed to test the noninferiority of CSP as compared with BiVP
in patients with an indication for cardiac resynchronization therapy, with
respect to a combined clinical endpoint at 1-year follow-up.
 Method(s): A total of 134 patients with cardiac resynchronization
therapy indication were randomized to BiVP or CSP and followed up for 12
months. Crossover was allowed when the primary allocation procedure
failed. The atrioventricular interval was optimized to obtain fusion with
intrinsic conduction. The primary combined endpoint was all-cause
mortality, cardiac transplant, heart failure hospitalization, or left
ventricular ejection fraction (LVEF) improvement <5 points at 12 months.
Secondary endpoints were LVEF increase, LV end-systolic volume (LVESV)
decrease, echocardiographic response (>=15% LVESV decrease), QRS
shortening, septal flash correction, NYHA functional class improvement,
and a combined endpoint of all-cause mortality, cardiac transplantation,
and heart failure hospitalization. Result(s): Sixty-seven patients
were allocated to each group. Eighteen patients (26.9%) crossed from CSP
to BiVP; 5 (7.5%) crossed over from BiVP to CSP. Noninferiority (NI) was
observed for CSP compared with BiVP for the primary endpoint (23.9% vs
29.8%, respectively; mean difference -5.9; 95% CI: -21.1 to 9.2; P = 0.02)
and for the combined endpoint of all-cause mortality, cardiac
transplantation, and heart failure hospitalization (11.9% vs 17.9%; P <
0.01 NI); echocardiographic response (66.6% vs 59.7%; P = 0.03 NI); NYHA
functional class (P < 0.001 NI); and QRS shortening (P < 0.01). LVEF,
LVESV, and septal flash endpoint values were similar, but noninferiority
was not met (14.1% +/- 10% vs 14.4% +/- 10%, -27.9% +/- 27% vs -27.9% +/-
28%, -2.2 +/- 2.7 mm vs -2.7 +/- 2.4 mm, respectively).
 Conclusion(s): CSP was noninferior to BiVP in achieving clinical and
echocardiographic response, suggesting that CSP could be an alternative to
BiVP. (Conduction System Pacing vs Biventricular Resynchronization Therapy
in Systolic Dysfunction and Wide QRS [CONSYST-CRT];
NCT05187611) Copyright © 2025 The Authors

<15>
Accession Number
2035631278
Title
Double-lumen tubes verus single-lumen tube in patients undergoing
minimally invasive cardiac surgery: a randomised, controlled clinical
trial.
Source
Frontiers in Cardiovascular Medicine. 12 (no pagination), 2025. Article
Number: 1583360. Date of Publication: 2025.
Author
Wang Z.; Zhao J.; Ke Y.; Wang Q.; Li Y.; Ye Y.; Zhang J.; Guo X.; Zeng Q.;
Huang H.
Institution
(Wang, Zhao, Ke, Wang, Li, Huang) Department of Cardiac Surgery, Guangdong
Provincial People's Hospital (Guangdong Academy of Medical Sciences),
Guangzhou, China
(Ye, Zhang, Guo, Zeng) Department of Anaesthesia, Guangdong Provincial
People's Hospital (Guangdong Academy of Medical Sciences), Guangzhou,
China
Publisher
Frontiers Media SA
Abstract
Background: One-lung ventilation (OLV) with double-lumen tubes (DLT) are
prone to complications such as airway injury and hypoxemia. It is not
clear whether a two-lung ventilation (TLV) with single-lumen tube (SLT) is
beneficial for patients undergoing totally endoscopic cardiac valve
surgery (TECVS). Method(s): We conducted a pragmatic, single-centre,
single-blinded randomised controlled trial. Patients (aged >=18 years) who
underwent total endoscopic cardiac valve surgery were randomly assigned to
a DLT group or a SLT group. A two-week telephone follow-up was conducted.
The oxygenation index (PaO<inf>2</inf>/FiO<inf>2</inf>) was the primary
outcome. The secondary outcomes included PaCO<inf>2</inf>, postoperative
intubation complications, postoperative pulmonary complications and airway
injury. Result(s): A total of 220 patients were randomly assigned.
After randomisation, 20 patients were excluded, leaving 100 patients in
each of the two groups. The PaO<inf>2</inf>/FiO<inf>2</inf> were
significantly greater in the SLT group than in the DLT group (P < 0.001).
The incidence of postoperative intubation adverse events, postoperative
pulmonary atelectasis, and hoarseness was significantly lower in the SLT
group (P < 0.001, P = 0.029 and P = 0.028, respectively). The pre-exposure
time and intubation time were shorter in the SLT group (both P values <
0.001). We used t test, Mann-Whitney U test and Fisher's exact test to
account the difference of perioperative and follow-up outcomes.
 Conclusion(s): Two-lung ventilation with single-lumen tube is easy to
perform, significantly increases oxygenation, and decreases the incidence
of postoperative complications and airway injuries. Advantages remain
especially for patients with preoperative pulmonary dysfunction. Clinical
Trial Registration: https://www.chictr.org.cn/showproj.html?proj=165709,
identifier [ChiCTR2200066822]. Date: 19/12/2022. Copyright 2025 Wang,
Zhao, Ke, Wang, Li, Ye, Zhang, Guo, Zeng and Huang.

<16>
Accession Number
2036980684
Title
A Systematic Review and Meta-Analysis of the Valvular Insufficiency Status
after Surgical Closure of Ventricular Septal Defects.
Source
Heart Surgery Forum. 28(7) (pp E563-E576), 2025. Date of Publication: 23
Jul 2025.
Author
Li L.; Zhang M.; Liu A.; Su J.
Institution
(Li, Liu, Su) Department of Pediatric Cardiac Surgery, Beijing Anzhen
Hospital, Capital Medical University, Beijing Institute of Heart, Lung and
Blood Vessel Diseases, Beijing, China
(Zhang) Coronary Heart Disease Center, Beijing Anzhen Hospital, Capital
Medical University, Beijing Institute of Heart, Lung and Blood Vessel
Diseases, Beijing, China
Publisher
Forum Multimedia Publishing LLC
Abstract
Objective: This article aims to provide a reference for assessing surgical
safety by comparing postoperative outcomes of various degrees of valve
insufficiency associated with different surgical approaches after
ventricular septal defect (VSD) repair. Method(s): We conducted a
database search using the following methods: querying the PubMed database
through National Center for Biotechnology Information (NCBI), querying the
Embase database through Ovid, and querying the Web of Science database.
This article focused on comparing the improvement in aortic regurgitation
(AR), analyzing the incidence of tricuspid regurgitation (TR) following
exposure of the VSD through a right atrial approach using tricuspid valve
detachment (TVD) or conventional exposure (non-TVD), and pulmonary
regurgitation (PR) via a pulmonary artery approach. Result(s): AR was
included in nine studies, involving 329 children with VSDs. The combined
improvement rate of AR across these studies was approximately 0.487
(I2 = 50.3% p = 0.041). The proportion of patients who
underwent aortic valve repair or replacement (p = 0.029) and the
preoperative severity of AR >= moderate (p = 0.007) may have contributed
to heterogeneity. There were 245 cases in the isolated VSD repair group,
while the remaining 84 cases underwent combined aortic valve repair or
replacement. There was a significant difference in the improvement rate of
AR between the two groups during follow-up (I2 = 63.3%,
Relative Risk (RR) = 0.51, 95% CI = 0.34-0.76, p = 0.005). RR: The ratio
of the probability of the outcome event occurring in the exposed group to
the probability of the outcome event occurring in the unexposed group. A
total of 12 studies were related to TR and residual shunting. A total of
1338 children with VSD were included in 10 studies of TR, where the TVD
group had 599 cases and the non-TVD group had 739 cases. No significant
difference was noted in the rates of TR >= mild between these groups
during the follow-up (I2 = 14.4%, RR = 1, 95% CI = 0.82-1.21 p
= 0.311). Additionally, no significant difference existed in the residual
shunting rate through the ventricular septum during followup
(I2 = 0.0%, RR = 0.72, 95% CI = 0.37-1.40 p = 0.785). A total
of 285 children were included in three studies on PR, with a combined rate
of PR during follow-up of 23.0% (I2 = 46.567% p = 0.154).
 Conclusion(s): The improvement rate of AR during follow-up was lower
in the isolated VSD-repair group compared to the group undergoing
concomitant aortic valve repair or replacement. The proportion of
preoperative AR >= moderate showed a positive correlation with the
improvement rate of AR, whereas the percentage of isolated VSD repairs
exhibited a negative correlation with AR. Additionally, the TR status
during followup was similar between the TVD and non-TVD groups for VSD
repair. Furthermore, patients who underwent VSD repair via the pulmonary
artery approach had a higher incidence of PR in the long term. The
PROSPERO Registration: CRD42025630254 (https://www.crd.york.ac.uk/P
ROSPERO/view/CRD42025630254). Copyright © 2025 The Author(s).

<17>
Accession Number
2038690678
Title
Immediate transcatheter aortic valve replacement versus temporizing
balloon aortic valvuloplasty in severe aortic stenosis: A systematic
review and meta-analysis immediate TAVR vs. temporizing BAV.
Source
Cardiovascular Revascularization Medicine. 77 (pp 112-121), 2025. Date of
Publication: 01 Aug 2025.
Author
Doma M.; Huang W.; Hernandez S.; Fatima S.R.; Lingamsetty S.; Kritya M.;
Hemdanieh M.; Naji Z.; Gewehr D.M.; Martignoni F.V.; Goldsweig A.M.
Institution
(Doma) Alexandria Faculty of Medicine, Egypt
(Huang) University of Padjadjaran, Indonesia
(Hernandez) Universidad Xochicalco Campus Tijuana, Mexico
(Fatima) CMH Lahore Medical College and Institute of Dentistry, Pakistan
(Lingamsetty) Mamata Medical College, India
(Kritya) Armed Forces Medical College, India
(Hemdanieh) American University of Beirut, Lebanon
(Naji) Faculty of Medicine of Tunis, Al-Manar University, Tunisia
(Gewehr) Curitiba Heart Institute, Curitiba, Parana, Brazil
(Martignoni) Minneapolis Heart Institute and Foundation, MN, United States
(Goldsweig) Department of Cardiovascular Medicine, Baystate Medical Center
and Division of Cardiovascular Medicine, University of
Massachusetts-Baystate, Springfield, MA, United States
Publisher
Elsevier Inc.
Abstract
Background: Transcatheter aortic valve replacement (TAVR) is a first-line
therapy for severe aortic stenosis (AS). In patients with
contraindications to immediate TAVR, temporizing balloon aortic
valvuloplasty (BAV) may be performed to stabilize patients prior to TAVR.
The relative efficacy and safety of TAVR with or without temporizing BAV
remains inadequately described. Method(s): We searched PubMed,
Embase, and Cochrane databases for studies comparing TAVR with and without
temporizing BAV in patients with severe AS. Random-effects models were
used to calculate pooled odds, risk ratios (RRs) and mean differences with
95 % confidence intervals (CIs). Result(s): Nine studies (59,205
patients: 95.7 % immediate TAVR, 4.3 % BAV + TAVR) met inclusion criteria.
Mean age was 82.9 +/- 6.6 years old, and 45.9 % were males. Patients in
the TAVR group were a mean difference of 1 year younger with no difference
in gender distribution between groups. Direct TAVR was associated with a
lower risk of 30-day all-cause mortality than BAV + TAVR (RR = 0.62; 95 %
CI 0.41 to 0.93; p = 0.02). There were no significant differences in risks
of post-procedural pacemaker implantation, myocardial infarction, cardiac
tamponade, major vascular complications, ischemic stroke, major bleeding,
2+ or greater aortic regurgitation grade or acute kidney injury.
 Conclusion(s): While immediate TAVR was associated with slightly
lower short-term mortality compared to BAV + TAVR in patients with severe
AS, other binary endpoints were equivalent. This potential mortality
difference should be considered when offering BAV + TAVR in patients with
contraindications to immediate TAVR. Randomized studies are required to
confirm these results. Copyright © 2025 Elsevier Inc.

<18>
Accession Number
2036940653
Title
Comparative Hemodynamic Stability in Low-Dose versus Conventional-Dose
Bupivacaine for Spinal Anaesthesia in Elderly Patients.
Source
International Journal of Pharmacy Research and Technology. 15(2) (pp
633-638), 2025. Date of Publication: 16 Jun 2025.
Author
Patel A.; Yadav A.K.; Patel P.S.; Kumari R.; Deepesh
Institution
(Patel, Yadav) Department of Anaesthesia, UNS Autonomous State Medical
College, UP, Jaunpur, India
(Patel) RDMC, Banda, India
(Kumari) F.H. Medical college, Agra, Etmadpur, India
(Deepesh) CHC Cholapur, Varanasi, India
Publisher
Advanced Scientific Research
Abstract
Background: Spinal anaesthesia is favoured for lower-limb and
lower-abdominal surgery in the elderly, yet conventional doses of
hyperbaric bupivacaine frequently precipitate hypotension and bradycardia.
Reducing the intrathecal dose may mitigate these effects while preserving
surgical anaesthesia. Method(s): In this prospective, randomised,
double-blind trial we enrolled 120 patients aged >= 65 years (ASA II-III)
scheduled for elective hip or knee arthroplasty. Participants received
either low-dose (LD, 6 mg) or conventional-dose (CD, 12 mg) 0.5 %
hyperbaric bupivacaine with 25 microg fentanyl. Primary outcome was
incidence of clinically significant hypotension (>= 20 % fall in mean
arterial pressure or MAP < 65 mmHg) during the first 30 min after block.
Secondary outcomes included bradycardia (HR < 50 beats.min1), vasopressor
usage, sensory-motor block characteristics, surgeon satisfaction, and
major adverse events. Result(s): Baseline characteristics were
comparable. Clinically significant hypotension occurred in 17 % of LD
versus 48 % of CD patients (relative risk 0.35; p < 0.001). Mean MAP at 5,
10, 20 and 30 min was consistently higher in LD (84 +/- 9, 82 +/- 8, 80
+/- 7, 79 +/- 6 mmHg) than CD (72 +/- 11, 70 +/- 10, 68 +/- 9, 67 +/- 8
mmHg; p < 0.01 at all points). Bradycardia was less frequent in LD (10 %
vs 28 %; p = 0.02). Ephedrine requirements (median 0 mg [IQR 0-6] vs 12 mg
[6-18]; p < 0.001) and atropine administration (2 % vs 12 %; p = 0.04)
were reduced in LD. Surgical anaesthesia was adequate in both groups; time
to two-segment regression was shorter in LD (78 +/- 14 min vs 103 +/- 18
min; p < 0.001) but did not prolong recovery room discharge. No patient
required conversion to general anaesthesia. Conclusion(s): In elderly
patients, intrathecal low-dose 0.5 % bupivacaine (6 mg) supplemented with
fentanyl provides satisfactory surgical conditions while significantly
improving haemodynamic stability compared with the conventional 12 mg
dose. Routine dose reduction should be considered to diminish
peri-operative cardiovascular morbidity in this population. Copyright
© 2025, Advanced Scientific Research. All rights reserved.

<19>
Accession Number
2034784388
Title
Percutaneous Transcatheter Edge-to-Edge Repair for Functional Mitral
Regurgitation in Heart Failure: A Systematic Review and Meta-Analysis of
Randomized Controlled Trials With Reconstructed Time-to-Event Data.
Source
Catheterization and Cardiovascular Interventions. 106(2) (pp 1067-1077),
2025. Date of Publication: 01 Aug 2025.
Author
Ghaly R.; Amin A.M.; Kim S.; Taha H.I.; Elgendy M.S.; Rmilah A.A.;
Abuelazm M.; Khan M.S.
Institution
(Ghaly, Kim, Khan) University of Missouri-Kansas City, Kansas, MO, United
States
(Ghaly, Khan) Saint Luke's Mid America Heart Institute, Kansas, MO, United
States
(Amin) Faculty of Medicine, Mansoura University, Mansoura, Egypt
(Taha, Elgendy, Abuelazm) Faculty of Medicine, Tanta University, Tanta,
Egypt
(Rmilah) Internal Medicine Department, Magnolia Regional Health Center,
Corinth, MS, United States
(Rmilah) Cardiology Department, Mayo Clinic, Rochester, MN, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Mitral transcatheter edge-to-edge repair (TEER) is approved
for patients with severe functional mitral regurgitation (FMR) beyond
optimal medical therapy (OMT). Aim(s): We aimed to assess TEER's
efficacy beyond OMT in patients with severe FMR. Method(s): A
systematic review and meta-analysis were conducted, including randomized
controlled trials from PubMed, Cochrane, Scopus, and EMBASE up to
September 2024. Primary Outcome: heart failure hospitalization (HFH);
secondary outcomes: cardiovascular (CV) mortality, all-cause mortality,
and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores. Time-to-event
data from Kaplan-Meier curves were reconstructed for individual patient
data. Result(s): Three studies (1423 patients) were included. TEER
significantly reduced HFH (RR 0.73, 95% CI 0.58-0.92, p < 0.01) and CV
mortality (RR 0.79, 95% CI 0.66-0.95, p = 0.01), and improved KCCQ scores
(mean difference 14.32, 95% CI 10.85-17.80, p < 0.01) compared to OMT. No
significant difference was found for all-cause mortality (RR 0.80, 95% CI
0.63-1.02, p = 0.07). Prognostic meta-analysis showed a 34% reduced risk
of HFH (HR 0.66, 95% CI 0.45-0.96, p = 0.03), but no effect on all-cause
or CV mortality. Reconstructed Kaplan-Meier analysis confirmed a 34%
reduced risk of HFH (HR 0.65, p < 0.001), with effect attenuation after 15
months in landmark analysis (HR 0.64, p = 0.07). RMST analysis showed a
2.9-month longer HFH-free survival with TEER (p < 0.01).
 Conclusion(s): In patients with FMR, TEER significantly reduces HFH,
improves functional status, and lowers CV mortality at 24 months but does
not significantly affect all-cause mortality. The device group experienced
a modest, but significant, 2.9-month longer HFH-free survival compared to
the control group. However, the reduction in HFH showed attenuation beyond
15 months. Copyright © 2025 Wiley Periodicals LLC.

<20>
Accession Number
610196600
Title
Cardiovascular and other outcomes postintervention with insulin glargine
and omega-3 fatty acids (ORIGINALE).
Source
Diabetes Care. 39(5) (pp 709-716), 2016. Date of Publication: 01 May 2016.
Author
Gerstein H.C.; Bosch J.; Dagenais G.R.; Jung H.; Maggioni A.P.; Pogue J.;
Probstfield J.; Ramachandran A.; Riddle M.C.; Ryden L.E.; Yusuf S.;
Richardson L.; Diaz R.; Johnston P.; Vige R.; Birkeland K.; Budaj A.;
Cardona E.; Chazova I.; Commerford P.; Danilova L.; Davies M.; Fernando
R.; Fodor G.; Gilbert R.; Gomis R.; Hanefeld M.; Hildebrandt P.;
Kacerovsky-Bielesz G.; Keltai M.; Kim J.H.; Krum H.; Lanas F.; Lewis B.S.;
Lonn E.; Lopez-Jaramillo P.; Marin-Neto J.; Marre M.; McKelvie R.; McQueen
M.; Mendoza I.; Morillo C.; Pan C.; Pirags V.; Profozic V.; Ratner R.;
Rosenstock J.; Spinas G.A.; Sreenan S.; Stoel I.; Syvanne M.; Yale J.F.;
Avezum A.; Bahit M.C.; Bogaty P.; Bordeleau L.; Chacomicronn C.; Corson
M.; Harper W.L.; Halon D.; Magloire P.; Mann J.; Pavlova V.; Punthakee Z.;
Silva J.; Tsang B.; Yakubovich N.; Abdallah A.; Ahmad S.; Chandra J.;
Chandra R.; Cukierman-Yaffee T.; Dyal L.; Joldersma L.; MacRae L.; MacRae
S.; Malik S.; Mead A.; Pasha F.; Pazmino-Canizares J.; Pohl K.; Sakalas
A.; Tyrwhitt J.; Ahuad Guerrero R.; Alebuena A.; Alvarez N.; Alzogaray M.;
Amuchastegui M.; Andres M.; Angos M.; Baglivo H.; Barbieri M.; Bassi F.;
Bello F.; Bono J.; Bustamante Labarta M.; Bustos B.; Caccavo A.; Calveira
M.; Camino A.; Cantero M.; Capozzi M.; Cardone M.; Cartasegna L.;
Cassetari A.; Castellanos R.; Chavez Caballero R.; Cipullo M.; Contreras
A.; Coria J.; Corinaldesi F.; Costa G.; Crespo C.; Cruz M.; Cuello J.;
Cuneo C.; Del Corro I.; Diez R.; Dituro C.; Dominguez A.; Facta A.;
Faingold C.; Farah M.; Fares Taie A.; Fernandez A.; Ferrari A.; Ferrari
N.; Garcia Monteverde C.; Garrido M.; Giachello C.; Gonzalez M.; Gutierrez
N.; Guzman L.; Guzman P.; Hasbani E.; Henquin R.; Hershon A.; Hirschon
Alvarez Prado A.; Hominal M.; Hrabar A.; Imposti H.; La Grutta M.;
Lanchiotti P.; Lobo Marquez L.; Lopez Santi R.; Lowenstein J.; Lugo M.;
Luqueci M.; Mainini S.; Majul C.; Manzano R.; Manzur S.; Marcucci G.;
Marino M.; Massari F.; Mendez N.; Molina M.; Montana O.; Mulazzi M.;
Nardone L.; Odetto I.; Orlandini A.; Oviedo A.; Paez O.; Parnas A.; Patron
F.R.; Pedernera C.; Pelagagge M.; Plastino M.; Polari P.; Pomposiello J.;
Porta A.; Prado A.; Quiroz M.; Ramirez A.; Rodriguez M.; Ronderos R.; Sago
L.; Sanchez A.; Sanchez R.; Sandrin A.; Schygiel P.; Sernia V.; Sinay I.;
Smith Casabella T.; Sosa Liprandi A.; Sosa Liprandi M.; Soso L.; Sposetti
G.; Stisman D.; Streitenberger P.; Suarez G.; Tonin H.; Ulla M.; Valdez
J.; Vico M.; Villamil A.; Villarino A.; Viscaya Castro A.; Visco V.; Vogel
D.; Waisman F.; Zaidman C.; Amerena J.; Applebe A.; Aylward P.; Binnekamp
M.; Bruce I.; Burdeniuk C.; Burnet R.; Colman P.; Colquhoun D.; Davis S.;
De Looze F.; De Pasquale C.; D'Emden M.; Eaton H.; Farshid A.; Foulanos
S.; Galanos J.; Gordon G.; Guhu M.; Ho J.; Jeffery I.; Jerums G.; Kwan M.;
Lefkovits J.; Luu S.; MacIsaac R.; Marjason J.; Mohabbati V.; Nankervis
A.; O'Neal D.; Perera N.; Poynten A.; Rahman A.; Razak S.; Roberts T.;
Sebastian M.; Simpson R.; Soldatos G.; Sullivan D.; Teede H.; Tiong F.;
Topliss D.; Torpy D.; Waddell-Smith K.; Waites J.; Wenman J.; Whelan A.;
Williams L.; Yeap B.; Yeow W.; Yong G.; Aczel S.; Azimy N.; Bertha P.;
Blocher J.; Bohnel C.; Brath H.; Breuss J.; De Campo A.; Drexel H.;
Ettmuller Y.; Feder A.; Feinboeck C.; Gulz E.; Hofmann M.; Hoppichler F.;
Jahnel H.; Jankovic V.; Kann T.; Kathrein T.; Kotter T.; Kratz E.;
Kreuzwieser E.; Loreck C.; Ludvik B.; Marte T.; Mellitzer K.; Nistler S.;
Placher-Sorko G.; Prager R.; Rein P.; Riedl M.; Saly C.; Schernthaner G.;
Schichka E.; Seidlhofer C.; Sonnenfeld M.; Stefan H.; Steiner K.; Thomas
B.; Toplak H.; Urstoger K.; Vetter B.; Vonbank A.; Waldschutz W.; Wallner
F.; Winkler F.; Goncharik D.; Lazareva I.; Lichorad N.; Mrochek A.;
Murashko N.; Radyuk D.; Ramanovski A.; Sudzhaeva S.; Sujayeva V.;
Yarashevich N.; Campbell G.; Marshall S.; West A.; Abreu F.; Alves M.;
Ayoub-Aidar J.; Barros M.; Barros-Silveira J.; Blacher M.; Costa E.; Costa
F.; Daltro C.; Delana J.; Eliaschewitz F.; Facanha C.; Feitosa G.;
Figueiredo J.; Forti A.; Franco D.; Franken M.; Freire F.; Garcia V.;
Gouvea-Neto A.; Grofallo S.; Kanedlai N.; Kerr-Saraiva J.; Ladeira R.;
Leaes P.; Lemos M.; Lima F.; Lima Filho M.; Macedo L.; Manenti E.; Monte
O.; Mossman A.; Mothe F.; Mouco O.; Moyses Golbert M.; Nasser Hissa L.;
Nasser-Hissa M.; Nicolau J.; Nigro Maia L.; Ninno T.; Nunes C.; Oliveira
C.; Oliveira O.; Passos da silva R.; Pericles-Esteves J.; Rabelo L.;
Rabelo-Alves Junior A.; Rassi S.; Rech R.; Roldan F.; Salles J.; Sampaio
C.; Seabra A.; Sealissi N.; Seixas A.; Sena R.; Shehadeh I.; Teixeira M.;
Turin H.; Vicente Serrano C.; Vidigal M.; Vilela M.; Wajchenberg B.;
Abbott C.; Abu-Bakare A.; Ardilouze J.; Auersperg E.; Bailey A.; Bailey
G.; Baillargeon J.; Beaurivage C.; Belair J.; Belanger A.; Bellabarba D.;
Berlingieri J.; Bernier F.; Bhargava R.; Bhesania T.; Booth W.; Bose S.;
Boulianne M.; Bourgeois S.; Breton D.; Brossoit R.; Buithieu J.; Campeau
J.; Carlson B.; Carpentier A.; Cavalcanti R.; Cha J.; Chagnon P.; Chan Y.;
Chessex C.; Chiasson J.; Chouinard S.; Clayton D.; Conway J.; Crepeau J.;
Cudmore D.; D'Ignazio G.; Doig G.; Dominguez M.; Dube F.; Dumas R.; Dupuis
R.; Dyrda I.; Eddy D.; Eiley D.; Fox H.; Fratesi S.; Gallant S.; Garceau
C.; Garfield N.; Germain C.; Glazer S.; Gosselin G.; Gould D.; Grills G.;
Halle J.; Hardin P.; Harper W.; Heath J.; Heath V.; Hivert M.; Ho K.;
Houde G.; Hramiak I.; Hutchinson A.; Huynh T.; Ilie-Haynes R.; Imran S.;
Islam A.; Iwanochko M.; Jones C.; Joyce C.; Kirouac I.; Kumar R.; Lamothe
M.; Langlois M.; Lauzon C.; Lavoie M.; Leader R.; Lecours S.; Lepage S.;
Lochnan H.; Ma P.; McLean A.; Mecci S.; Mehta P.; Mercier M.; Miller D.;
Morisset A.; Nawaz S.; Nisker W.; Nyomba G.; O'Keefe D.; Palardy J.;
Parekh P.; Paul T.; Perron P.; Pesant M.; Phillips R.; Pruneau G.; Quintin
I.; Raby K.; Richard C.; Rosenfeld G.; Saulnier D.; Shaban J.; Shah A.;
Shu D.; Sigal R.; Silverman M.; Singh J.; Sivucha W.; Skamene A.;
Sliwowicz D.; Smith R.; St Hilaire R.; Steinson D.; Sussex B.; Tan K.;
Tannous R.; Telner A.; Theroux P.; Tsoukas C.; Tsoukas G.; van Buuren J.;
VanRossum N.; Vexler R.; Vizel S.; Warnica W.; Weingert M.; Wilson R.;
Wong W.; Woo V.; Acevedo M.; Alwyn C.; Baier E.; Baier S.; Galloso R.;
Lahsen R.; Lorenas G.; Montecinos A.; Montecinos M.; Pineda P.; Pollak F.;
Sapunar J.; Serrano V.; Stockins B.; Varleta P.; Yovanovich J.; Zambra F.;
Ba J.; Bao Y.; Bi Y.; Bu S.; Chen B.; Chen H.; Chen J.; Chen L.; Chen M.;
Chen Y.; Cui J.; Dong M.; Feng P.; Feng Z.; Gao C.; Gao F.; Gao X.; Gao
Z.; Gong Y.; Guang L.; Guo X.; Han F.; Han X.; Hou X.; Hu R.; Ji L.; Jia
J.; Jia W.; Jiao X.; Jin X.; Kuang J.; Li M.; Li Q.; Li X.; Li Y.; Ling
Y.; Liu F.; Liu Z.; Lu B.; Lu J.; Lu Z.; Lv X.; Ning G.; Peng Y.; Ren Y.;
Shao Y.; Shi Y.; Shu X.; Sun H.; Sun L.; Sun X.; Tang K.; Tian H.; Wang
C.; Wang F.; Wang L.; Wang Q.; Wang W.; Wang X.; Wang Y.; Wen J.; Wu C.;
Wu H.; Wu J.; Wu M.; Xing X.; Xue Y.; Yan L.; Yan S.; Yang H.; Yang N.;
Yang W.; Yang Z.; Yao J.; Yao L.; Yu D.; Yu H.; Yu M.; Yu X.; Yuan L.;
Yuan M.; Yuan S.; Yuan W.; Yuan Y.; Yuan Z.; Zeng T.; Zhang J.; Zhang R.;
Zhang X.; Zhao L.; Zheng B.; Zheng J.; Zhou W.; Zhu N.; Zhu Y.; Zou D.;
Zou J.; Accini J.L.; Bohorquez R.; Botero R.; Cure C.; Figueredo M.;
Hernandez E.; Kattah W.; Llamas A.; Orozco L.; Pava L.; Perez M.; Pineda
M.; Quintero A.; Quiros R.; Urina M.; Velez S.; Altabas V.; Baotic I.;
Berkovic M.; Goldoni V.; Kerum T.; Mirosevic G.; Tarle D.; Vidovic I.;
Zjacic-Rotkvic V.; Abbas R.; Andersen H.; Auscher S.; Baumbach L.;
Brockstedt H.; Christensen P.; Christiansen M.; Clemmensen K.; Egstrup K.;
Gislason G.; Haar D.; Hansen K.; Heden Andersen P.; Helleberg K.;
Hermansen K.; Holmer J.; Jeppesen J.; Klausen I.; Koustrup-Sonder T.;
Krarup T.; Lerche S.; Lervang H.; Linde B.; Lund P.; Lund S.; Madsbed S.;
Molvig J.; Orskov C.; Ostergaaard O.; Perrild H.; Pietraszek A.; Ralfkjaer
N.; Roenne H.; Rokkedal Nielsen J.; Seibaek M.; Soendergaard H.; Sorensen
L.; Sundahl Mortensen L.; Torp-Pedersen C.; Tuxen C.; Urhammer S.;
Vadstrup E.; Ambos A.; Janson A.; Rudenko P.; Viitas L.; Aranko S.; Badeau
M.; Eriksson J.; Haapamaki H.; Kajander O.; Kuusisto A.; Luukkonen S.;
Makela J.; Nieminen S.; Niskanen L.; Ripatti J.; Ruotsalainen S.; Saltevo
J.; Savela K.; Strand J.; Valle T.; Virkamaki A.; Aboud E.; Alavoine L.;
Bekherraz A.; Bohme P.; Bourezane H.; Catargi B.; Charpentier G.; Clergeot
A.; Courreges J.; Delmas T.; Duengler F.; Feknous C.; Gendre D.; Guerci
B.; Hadjadj S.; Kerlan V.; Laguerre N.; Le Potier J.; Lombardo F.;
Malville E.; Marechaud R.; Mattei C.; Moreira J.; Penfornis A.; Petit C.;
Pinel J.; Piquel X.; Raccah D.; Reznik Y.; Rod A.; Roudaut N.; Rousseau
E.; Schillo F.; Schmitt B.; Sonnet E.; Torremocha F.; Travert F.; Vanhoute
C.; Vimeux M.; Abdollahnia R.; Adamidou A.; Arslan S.; Bach-Kliegel B.;
Bartusch B.; Bauer N.; Bieler T.; Blankenfeld H.; Boeckmann U.; Busch K.;
Butzer R.; Chenchanna-Merzhaeuser M.; Denger R.; Deutsch C.; Diessel S.;
Donati-Hirsch I.; Dornisch M.; Enghofer K.; Fleig T.; Forst T.; Frommherz
M.; Goeller K.; Habbig J.; Hadziselimovic S.; Hamann A.; Hampel T.; Heger
S.; Helmes C.; Hoffman C.; Hohberg C.; Humpert P.; Kamke A.; Kamke W.;
Kindermann P.; Klein C.; Klein D.; Koehler A.; Kuehn A.; Langer K.; Limmer
S.; Loew A.; Maimer A.; Marck C.; Meier G.; Methner-Friederich M.; Metzler
W.; Meyer K.; Miftari N.; Milde J.; Minnich J.; Molkewehrum M.; Morcos M.;
Mueller-Hoff C.; Nguyen M.; Nishwitz M.; Oldenburg J.; Ott P.; Pauli K.;
Pauly B.; Pfeiffer A.; Pfuetzner A.; Pischa U.; Radke R.; Reismann P.;
Riemer M.; Rochlitz H.; Rudofsky G.; Ruhla S.; Sammler A.; Schaper F.;
Schiemenz K.; Scholz G.; Schumm-Draeger P.; Segiet T.; Segner A.; Seissler
J.; Spahn S.; Stier U.; Tonon G.; von Amelunxen S.; von Schacky C.;
Wilhelm B.; Wilhelm K.; Witt K.; Wuechner-Hofmann S.; Baranyai M.; Birkus
Z.; Foldesi I.; Gaal Z.; Harcsa E.; Hati K.; Hohmann Z.; Istenes I.;
Jozsef I.; Juhasz E.; Kempler P.; Keresztes B.; Keresztes K.; Kis-Gombos
P.; Kovacs I.; Kozma T.; Laszlo Z.; Noori E.; Nyirati G.; Papp Z.; Patkay
J.; Poor F.; Pusztai P.; Putz Z.; Rigo E.; Sereg M.; Simon K.; Somogyi A.;
Sumegi J.; Szabo A.; Szabo J.; Szigeti S.; Szilveszter D.; Tarko M.; Varga
C.; Varga Szabo L.; Voros P.; Arathi; Badgandi M.; Balaji M.; Balaji V.;
Chamukuttan S.; Aravind S.; Fatima S.; Ganapathy B.; George O.; George P.;
Jaffar M.; Jain P.; Kamath P.; Karthik V.; Koshy G.; Krishnan L.; Kumar
H.; Lal P.; Mithal A.; Modi S.; Mohan V.; Moses V.; Oomen R.; Pais P.;
Pati P.; Pendsey S.; Rai P.; Rajagopal R.; Ramu M.; Ranjit U.; Rao P.;
Senthil V.; Seshaiah V.; Sethi B.; Shah P.; Sharma R.; Shetty S.; Shobha
A.; Siddharth R.; Sridhar G.; Sudeep K.; Sunil C.; Sunitha S.; Suresh S.;
Thomas N.; Vageesh A.; Anwer Z.; Barton J.; Behan L.; Bell M.; Cullen M.;
Dineen S.; Draman Yusof M.; Dunne F.; Gibney J.; Hussain T.; Khan M.;
Kinsley B.; Kyithar P.; Lavin F.; McGowan A.; McGurk C.; Mirza A.;
Mohammadi B.; O'Brien T.; O'Connell J.; O'Halloran D.; O'Shea D.; Roberts
G.; Tomkin G.; Wan Mahmood W.; Abramod-Ness R.; Adawi F.; Aharon B.;
Backer M.; Beniashvili A.; Berliner A.; Bloch L.; Bugelman D.; Butnaru A.;
Cohen O.; Cohen Y.; Frenkel M.; Glant M.; Gustava B.; Guttman H.; Halabi
S.; Harman-Boehm I.; Ilany J.; Karkabi B.; Khader N.; Khaskia A.; Khudyak
Y.; Klainman E.; Kogan N.; Lender D.; Levin I.; Mardi T.; Marmor A.;
Mosseri M.; Nabriski D.; Omary M.; Orlovsky S.; Peres D.; Quasim M.; Raz
I.; Remesnik M.; Rogowski O.; Rozenfeld I.; Scharr D.; Shnifer I.; Shuster
T.; Solomon R.; Steiner H.; Tzivoni D.; Wolfson N.; Yossef Z.; Zahger D.;
Zeltser D.; Zimlichman R.; Aina F.; Ariatti C.; Bonetti R.; Cacciatore F.;
Calcinaro F.; Corona G.; De Maria P.; Del Prato S.; Derosa G.; Di Pasquale
G.; Falorni A.; Fanelli R.; Fedele D.; Filorizzo G.; Fogari R.; Furgi G.;
Ghio A.; Giorda C.; Gregori G.; Iannuzzi G.; Lapolla A.; Luciano B.;
Lucotti P.; Maggi A.; Marafetti L.; Marchese T.; Martino G.; Marzotti S.;
Miccoli R.; Monti L.D.; Moretti L.; Palvarini M.; Petacchi R.; Piarulli
F.; Piatti P.M.; Rudi S.; Santeusanio F.; Sesti G.; Setola E.; Sforza A.;
Shehaj E.; Veniani M.; Viviani G.; Zigoura E.; Chae S.; Cho D.; Cho E.;
Cho Y.; Choi Y.; Chung M.; Hong E.; Hong Y.; Jeong M.; Kim B.; Kim D.; Kim
H.; Kim I.; Kim J.; Kim P.; Kim S.; Koo B.; Kwok S.; Kwon H.; Lee J.; Lim
J.; Oh S.; Ohn J.; Park C.; Park H.; Park K.; Seung K.; Son H.; Woo J.;
Yoon K.; Ansmite B.; Balcere I.; Bumbure A.; Ducena K.; Lejnieks A.; Rasa
I.; Ritenberga R.; Romanova M.; Salmina I.; Steina S.; Badariene J.;
Gailiuniene S.; Grigonis S.; Juskiene R.; Petrulioniene Z.; Sakalyte G.;
Stasiunas T.; Sulskiene M.; Urbonaite B.; Zarankiene R.; Ziukaite R.;
Arechavaleta R.; Beltran-Jaramillo T.; Calvo-Vargas C.; Campillo-Cardenas
C.; Cardona D.; Carmona-Huerta J.; Cedano-Limon M.; Comellas-De M.;
Dominguez C.; Gomez-Cruz J.; Gonzalez-Perez R.; Illescas J.; Jimenez-Ramos
S.; Lopez-Alvarado A.; Marquez-Rodriguez E.; Martinez G.; Pascoe S.;
Plascencia Vazquez O.; Rodriguez H.; Ruiz-Cornejo M.; Velasco-Sanchez G.;
Vidrio-Velazquez M.; Villeda-Espinosa E.; Badings E.; Bartels G.;
Bruggink-Andre de la Porte P.; Bruijns E.; Cornel J.; De Milliano P.; De
Mulder M.; De Swart J.; Derks A.; Dirkali A.; Droste J.; Galjee M.;
Hautvast R.; Hermans W.; Holwerda N.; Ilmer B.; Kofflard M.;
Kooistra-Huizer J.; Kurvers M.; Langerveld J.; Leenders C.; Liem A.; Lok
D.; Neumann D.; Nierop P.; Plomp K.; Posma J.; Reichert C.; Roeters Van
Lennep H.; Ronner E.; Said S.; Takens L.; Umans V.; Van der Sluis A.A.;
Van der Zwaan C.; Van Dobbenburgh J.; Van Es A.; Van Hessen M.; Van
Mechelen R.; Van Miltenburg-Van Zijl A.; Van Zeijl L.; Veerhoek M.;
Viergever E.; Weijers E.E.; Willems F.; Blix I.; Cooper J.; Debowska A.;
Erichsen K.; Fossum J.; Gjertsen E.; Grill V.; Gudnason S.; Hoye K.; Istad
H.; Winther J.; Joakimsen R.; Jorde R.; Larsen I.; Mella B.; Otterstad J.;
Risberg K.; Skare K.; Skeie S.; Sommervoll L.; Tandberg A.; Whitfield R.;
Wium C.; Cunanan E.; Fernando-Catindig E.; Gomez M.; Jaring C.;
Lantion-Ang F.; Licaros M.; Lim-Abrahan M.; Madronio E.; Panelo A.; Raboca
J.; Ramos G.; Tugna S.; Aksamit-Bialoszewska E.; Bandurska-Stankiewicz E.;
Baranska M.; Bronisz A.; Bronisz M.; Chrustowski W.; Cieslak B.;
Czupryniak L.; Drazkowicz-Gozdzik B.; Galuszka-Bilinska A.; Gmytrasiewicz
M.; Janik K.; Jedynasty K.; Kania G.; Kawka-Urbanek T.; Kinalska I.;
Kincel K.; Kleszczewska U.; Kruszewski J.; Loba J.; Malicka J.;
Mielecka-Kincel M.; Milczarczyk A.; Milosz D.; Mrowczynska A.; Mytnik M.;
Nowakowski A.; Nowakowski P.; Oleskowska L.; Omelanczuk-Wiech E.;
Pawlowski M.; Poplawska A.; Rucinska M.; Rucinski M.; Rutkowska J.;
Saryusz-Wolska M.; Siewko K.; Sikora-Frac M.; Stecka-Wierzbicka J.;
Swiatkowski M.; Swierczynski R.; Szpajer M.; Szymkowiak K.; Tarach J.;
Tarasiewicz U.; Wiatr D.; Wojewoda P.; Woszczak-Marcinkowska H.; Zadrozny
J.; Hancu N.; Albota A.; Bala C.; Barbonta D.; Botnariu G.; Bradescu O.;
Busegeanu M.; Bzduch M.; Catrinoiu D.; Caziuc R.; Cerghizan A.; Cheta D.;
Cif A.; Ciomos D.; Cosma D.; Creteanu G.; Crisan I.; Danciulescu R.;
Dobjanschi C.; Dodan R.; Duma L.; Ferariu I.; Ghenes T.; Ghise G.; Graur
M.; Ilinca M.; Marton R.; Mindrescu N.; Morosanu A.; Morosanu M.; Mota M.;
Nafornita V.; Negrisan G.; Nicodim S.; Nicolau A.; Nita C.; Onaca A.;
Panus C.; Pletea N.; Pop C.; Pop L.; Popa B.; Roman G.; Rosu M.; Sandu N.;
Serban V.; Sima A.; Stamoran L.; Strugariu M.; Suciu G.; Szilagyi I.;
Vacaru G.; Veresiu I.; Vlad A.; Adasheva T.; Ageev F.; Akhmedganov N.;
Akinina A.; Alexandrov A.; Ambatiello L.; Ametov A.; Ausheva A.; Babaeva
L.; Babenko A.; Balyasnikova E.; Bart B.; Belova J.; Berstein L.;
Bondarenko I.; Bondarev E.; Bulkina O.; Chernikova N.; Chumak B.; Deeva
T.; Demicheva O.; Demidova T.; Doskina E.; Duganova A.; Dzhaiani N.;
Egorova I.; Ettinger O.; Feofanova S.; Fofanova T.; Galaktionov P.;
Gavrilova N.; Gilyarevsky S.; Gnidkina N.; Golubev A.; Gornyakova N.;
Grigorova S.; Grineva E.; Gurevich V.; Irtuganov N.; Ivanova L.; Jaiani
N.; Kalashnikova M.; Karpov Y.; Khalimov Y.; Khorocheva G.; Kirillova E.;
Kistner J.; Kobalava Z.; Kochergina I.; Kravchenko T.; Krylov K.; Kulkova
P.; Kuparev I.; Kurbanova E.; Lysenko T.; Markovich A.; Martyanova I.;
Martynyuk T.; Masiinvets M.; Mavlyavieva E.; Maychuk E.; Melnichenko G.;
Mikhailusova M.; Mkrtumyan A.; Mychka V.; Nebieridze D.; Nesterova E.;
Orlov V.; Orlova V.; Orlova Y.; Papov F.; Patroucherva I.; Petunina N.;
Pirozhinskaya S.; Podachina S.; Postnikova S.; Pshikova O.; Rogova L.;
Romashevskiy B.; Runikhina N.; Sadulayeva I.; Safaryan A.; Sakovich E.;
Saprikina T.; Sargsyan V.; Semikozova O.; Shkolnik E.; Shubina A.; Shustov
S.; Sinitsina I.; Solovyeva E.; Storogakov G.; Stovpyuk O.; Sussekov A.;
Telnova M.; Temirov A.; Terekhov V.; Tereschenko S.; Tiourina T.;
Tolkacheva V.; Tsoy U.; Urazgyldeeva S.; Vasyuk Y.; Vinnitskay N.;
Voevodina E.; Volkova A.; Zadionchenko V.; Zalevskaya A.; Zhelninova T.;
Zhukova N.; Zilov A.; Bernatova J.; Duris T.; Markova I.; Martinka E.;
Michalova L.; Minarik P.; Peter L.; Raslova K.; Silvia D.; Subadova M.;
Tisonova J.; Vohnout B.; Adam M.; Badat A.; Bester A.; Bester F.; Blacking
L.; Bouwer D.; Brice B.; Cassimjee S.; Cronje T.; Deftereos J.; Distiller
L.; Ellis G.; Forster O.; Fulat M.; Gani M.; Gibson G.; Hansa S.;
Hendricks N.; Herbst L.; Hitzeroth J.; Joffe B.; Kelbe C.; Kelbe D.; King
J.; Kramer B.; Landau S.; Levitt N.; Meyer-Nell S.; Moore R.; Muller D.;
Nell H.; Omar M.; Randeree H.; Seeber M.; Seedat; Siebert M.; Van den Berg
E.; Van der Walt P.; Van Dyk C.; Van Niekerk F.; Van Zyl L.; Wellman H.;
Bertomeu V.; Botella M.; Buno M.; Calle A.; Cano Perez J.; Coves M.;
Juanatey J.G.; Garcia-Mayor R.; Gaztambide S.; Gippini A.; Goikolea I.;
Gonzalez J.; Hillman N.; Lopez Garcia Aranda V.; Magueda I.; Mato J.;
Mazon P.; Morillas P.; Novials A.; Pallardo L.; Perez L.; Rodriguez J.;
Romero L.; Sagarra E.; Shamagian L.; Soto A.; Torrealday H.; Valero R.;
Agergaard S.; Agewall S.; Andersson K.; Bergstrom O.; Bjornstedt Bennermo
M.; Blomgren J.; Boman K.; Brohall G.; Cherfan C.; Dahlen C.; Dotevall A.;
Enander P.; Ericsson U.; Hallgren P.; Hansson A.; Henareh L.; Henriksson
P.; Herlitz J.; Holmqvist J.; Jarevi G.; Linderfalk C.; Jonasson L.;
Jovinge S.; Kalen J.; Kilstrup M.; Leosdotir M.; Leppert J.; Ljungberg J.;
Lofdahl B.; Lundman P.; Lysell-Bergstrom C.; Mathiesen U.; Mellbin L.;
Morner S.; Nathanson D.; Nilsson L.; Peterson M.; Quittenbaum S.;
Rosengren A.; Ryttberg B.; Scheel S.; Svensson K.; Tenerz A.; Vasko P.;
Waldenstrom A.; Wieloch M.; Spinas G.; Braendle M.; Felix B.; Gerber P.;
Moccetti T.; Pitteloud N.; Kultursay H.; Aydinalp A.; Balci M.; Cayli M.;
Hatipoglu E.; Ilkova H.; Kayikcioglu M.; Koc M.; Muderrisoglu H.; Sari R.;
Saygili F.; Tekin K.; Tutuncu N.; Yurekli B.; Adler A.; Ali A.;
Balasubramanian; Barakat O.; Barnett A.; Borthwick L.; Brookes; Cecil J.;
Chaterjee S.; Clark J.; Collinson D.; Collinson S.; Crasto W.; Donnelly
R.; du Plessis J.; Egan S.; Ellery A.; Evans R.; Ewing J.; Fox C.; Gibson
M.; Hall T.; Higgs E.; Hollway M.; Hughes E.; Jackson N.; Jalihawi H.;
Jones G.; Knights H.; Korsheed S.; Kumar Singh R.; Laithwaite D.; Lawrence
I.; Litchfield J.; Manning G.; McNally P.; Millar-Craig M.; Mohammed I.;
Narayanan R.; Nayani G.; Norris A.; Purohit J.; Quinn M.; Ramtoola; Rea
R.; Reckless J.; Richardson T.; Robertson D.; Robinson A.; Salem K.;
Sampson M.; Savage M.; Shaker J.; Srinivasan T.; Tracy I.; Tringham J.;
Viljoen A.; Ward A.; Waterhouse H.; Wijenaike N.; Wiles P.; Ahmann A.;
Ahmed I.; Alam A.; Arakaki R.; Asad S.; Banarer S.; Baum H.; Belew K.;
Bergenstal R.; Bethel M.; Boyer C.; Catton S.; Challans P.; Childs B.;
Christian R.; Clement S.; Cuddihy R.; Dailey G.; Damberg G.; De Bold C.;
De Lemos J.; Donovan D.; Dudl J.; Dunbar J.; Ebner S.; Failor R.; Feinglos
M.; Flaker G.; Freiburghaus M.; Furlong K.; Gardner D.; Gillespie E.;
Goland R.; Goldberg R.; Gotham A.; Guthrie R.; Hamaty M.; Hirsch I.;
Jabbour S.; Janci M.; Javorsky B.; Jones S.; Kamana V.; Kashyap M.;
Kaufman S.; Kearns P.; Khera A.; Klopfenstein B.; Kniffen W.; Kringas P.;
Licata A.; Lopez-Jimenez C.; Madden M.; Marx C.; McCall A.; McCallum J.;
McFarlane S.; McGuire D.; Melish J.; Meneghini L.; Miller S.;
Miranda-Palma B.; Mitchell R.; Nasr C.; Nelson J.; Niblack P.; Nylen E.;
Osei K.; Pandey A.; Papademetriou V.; Pilar Solano M.; Sameshima L.;
Savarese V.; Schnure J.; Schuster D.; Shin J.; Taylor A.; Thomson P.;
Ting-Ryan M.; Trence D.; Vo A.; Weiland K.; Wells K.; Wu P.; Zimering M.;
Zimmerman R.; Ascanio P.; Brajkovich I.; Carrillo E.; Coll J.; Gonzalez
K.; Gonzalez N.; Jimenez E.; Lopez R.; Marante D.; Morr I.; Paolillo M.;
Perche D.; Portillo M.; Valbuena H.; Velarde M.; Vergara G.; Augensen N.;
Azzalina J.; Fidaly S.; Bollero G.; Casiello A.I.; Ferraro F.; Guridi
M.J.; Ines M.; Martin M.E.; Pascual A.; Pereyra J.; Toscanelli M.; Appiah
M.; Grech S.; Pouras S.; Watts C.; Denke E.; Feik C.; Litvinenko M.;
Platonenko O.; Shadur S.; Johnson J.; Bonilla E.; Carraway B.; Faith J.;
Greer C.; Harding A.; Heston J.; Lin Y.; Mecca T.; Schuler M.; Rizk C.;
Sissoko A.; Strickland K.; Andrade A.; Lux L.; Machado D.; Mancin E.;
Aquino J.; Belanger B.; Bourque C.; Gagnier K.; Hagerimana A.; McNeil A.;
Osachoff J.; Richard B.; Rogan J.; Styner L.; Maturana X.; Naranjo M.E.;
Li E.; Liu Q.; Shuai M.; Tan Z.; Tang M.; Zhao J.; Ardila M.; Gomez A.M.;
Uscategui A.M.; Marinkovic N.; Miocevic V.V.; Pezo S.; Andersen I.;
Bastrup-Larsen B.; Jeppesen E.; Kofoed-Djursner M.; Joe H.; Hiironen V.;
Tarvainen M.; Von Hedenberg H.; Guillarme C.; Rastelli O.; Roy P.; Igel
L.; Lenz T.; Leptich A.; Peikert S.; Domokos S.; Szotyorine-Polcza G.;
Wenczl M.; Chaudhary S.; Jaiswal G.; Khatri P.; Shah K.; Gibson S.; Bechar
Y.; Erdheim D.; Eyal N.; Frankel M.; Shimoni S.; Tsuri J.; Bianco L.; Cali
R.; Sganga P.; Jang M.; Kim J.M.; Kim Y.; Lim S.; Park J.S.; Song Y.;
Kalve E.; Dienyte E.; Alvarado F.; Rodriguez R.; Bar J.; Lijfering-Lorie
K.; Palstra M.; Van der Kuijl K.; Van de Wetering A.; Eriksen S.;
Hejazifar S.; Jendeberg A.; Johannessen G.; Khammari I.; Meredith E.L.;
Dayag A.M.; Figueroa P.; Hoffmann Korpalska A.; Przemyk M.; Craciunescu
A.; Lupu D.; Osanu A.; Popscu L.; Toader C.; Kirsanova T.; Timoshina E.;
Gomez B.; Jankularova I.; Brett S.; Meyer A.; Pereira V.; Vawda N.;
Castano B.; Farre Avella J.M.; Jimenez I.; Turet N.; Froberg M.; Reppert
E.; Wessman S.; Boschung Y.; Carrozzino F.; Gerstl K.; Cetin Z.; Demirci
S.; Ovalioglu S.; Lenehan A.; McLean H.; Mutsaers K.; Redfern P.; Scoggins
A.; Isea Y.; Alvarez M.; Alvarez D'Amelio A.; Aqueveque S.; Argenta M.;
Aviles A.; Barreiro E.; Battistessa Y.; Bergamo S.; Bertran B.; Bocanera
M.; Bowen L.; Brescia H.; Caceres M.; Cappi A.; Cardelli A.; Carolini E.;
Carpintero S.; Carrique A.; Carrique P.; Casquero M.; Castro M.; Cendali
G.; Chatelain M.; Costanzi A.; Cristofaro C.; Crunger P.; Ehrich S.;
Espinosa M.; Esposito L.; Flenche M.; Fracaro V.; Funosas C.; Garrido I.;
Gomez Garrido A.; Guzman A.; Izzicupo M.; Luca S.; Luciani C.; Majul S.;
Moreno Cepeda I.; Moschin Y.; Niemann G.; Novas V.; Olmi M.; Palma F.;
Peralta A.; Puig A.; Rodera Vigil M.; Ronderos G.; Rosell M.; Samudio M.;
Santicchia C.; Szczygiel V.; Takla M.; Tinnirello C.; Tonin S.; Tristan
A.; Troncoso C.; Vignau S.; Yanez K.; Zarate M.; Appeldorf R.; Batrouney
B.; Bonner A.; Bonner M.; Cahill P.; Carr J.; Caruana M.; Chare J.; Doran
A.; Flavel; Griek S.; Hulley A.; Keays P.; Kent S.; Lai N.; Legg H.; Long
A.; Lynch L.; Maxwell V.; McNamara K.; Nairn J.; Nichols V.; Peeler C.;
Phillips J.; Gein J.; Ryan S.; Stockle P.; Tapp E.; Taverner P.; Tulloch
G.; Viola V.; Wilson L.; Beck A.; Damon S.; Drexel V.; Grabner E.;
Hofurthner A.; Kivioja P.; Kretschmer S.; Lener P.; Maiweg J.; Tscherner
D.; Weichelt H.; Winkler J.; Jones D.; Alves L.; Batista R.; Bernardes A.;
Demore de Souza A.; Ferraz R.; Ferreira A.; Freitas E.; Guanaes D.;
Kuschel K.; Muniz R.; Nasser-Hissa V.; Nhan P.; Osorio R.; Queirantes C.;
Reboucas R.; Souza C.; Tonani M.; Vicente C.; Zilli A.; Andersen K.; Aro
L.; Barber C.; Barnable B.; Berard L.; Bernier A.; Boudreault C.;
Bourbonnais A.; Bourgeois L.; Boutin D.; Boyer D.; Branco N.; Briol L.;
Brousseau M.; Burke M.; Chambers C.; Champoux A.; Chan S.; Colborne C.;
Coles K.; Couture M.; Cryderman C.; DeCurtis D.; Dewar C.; Drown J.; Dunn
P.; Eichmann D.; Eikel L.; Fox B.; Gauthier S.; Gibbons D.; Hicks R.; Ho
V.; Kitagawa H.; Kooistra L.; Landry F.; Lapointe F.; Larrivee L.; Leonard
P.; Louch D.; MacNair D.; Magennis L.; Mallette D.; Marchand C.; McLean
S.; Meilleur M.; Murdock H.; Naud M.; Olson K.; Otis J.; Ouimet F.;
Paquette H.; Peck C.; Pelletier A.; Perkins L.; Petrie F.; Pockett S.;
Poulin F.; Poulin M.; Primbas K.; Renton J.; Rouatt S.; Roy M.; Scarcelli
D.; Schellenberg S.; Schellevis K.; Schmidt N.; Scott L.; Skarpinsky B.;
Smith B.; Smith E.; Stafford C.; Stata C.; Sternberg B.; St-Jean N.;
Stoger S.; Thibodeau C.; Toupin A.; Ullyatt L.; Velonas J.; Vienneau R.;
Wall C.; Zaniol D.; Arau M.; Fuentes J.; Hidalgo J.; Landaeta O.; Padilla
I.; Sanzana S.; Tellos G.; Toro F.; Vergara R.; Che T.; Du Y.; He Y.;
Huang C.; Li H.; Liu S.; Luo X.; Ma Y.; Pan S.; Wan Q.; Wang H.; Wang S.;
Xie Y.; Xu X.; Xu Y.; Zhao F.; Zhou M.; Accini M.; Bello O.; Caceres A.;
Camargo S.; Figueroa J.; Florez M.; Gomez Morales K.; Granados L.;
Martinez M.; Medina Ramos M.; Mejia C.; Montoya L.; Ramos C.; Restrepo P.;
Rodriguez D.; Santamaria A.; Valencia T.; Spanic V.; Borre Hansen A.;
Bulow M.; Ehlers G.; Frederiksen A.; Gottschalck H.; Hejlskov B.; Holm
Fruesnsgaard Pedersen L.; Hornum H.; Jansen S.; Johansen A.; Jorgensen A.;
Kjaeulff Svaneborg T.; Kruse A.; Lund K.; Lundgaard M.; Madsen J.; Meier
A.; Muurholm A.; Nedergaard A.; Nielsen S.; Norgaard D.; Olsen A.; Raae
D.; Reiter P.; Sigsgaard U.; Vestergaar I.; Witt A.; Mitt T.; Timmusk P.;
Heikkila E.; Heiskanen R.; Huotari E.; Keskitalo A.; Kylmala L.; Laitinen
M.; Laukkanen M.; Leskinen S.; Liesivuori J.; Lukkari-Kuronen L.; Merisalo
P.; Muurinen E.; Nikkanen P.; Niskanen T.; Pasanen P.; Pekkonen L.; Retsu
A.; Soppela A.; Andreu N.; Ankotche A.; Bairras C.; Boch C.; Camachon L.;
Cherchouly A.; Coudret S.; Demer C.; Gilg R.; Lemonade L.; Madec O.;
Pinotti D.; Poirier I.; Tenne N.; Vogler C.; Amman M.; Andratschke-Gentsch
B.; Beckmann H.; Bischoff S.; Bleich B.; Bueschges G.; Busch E.;
Deigentasch S.; Dietze S.; Dollinger M.; El-Bahay C.; Flehmig G.; Frenzel
I.; Geissler K.; Guerro J.; Heike B.; Holler D.; Inhoffen C.; Klein K.;
Kraehe I.; Kress P.; Krueger H.; Lenz R.; Linnebach B.; Lueck A.; Markhof
P.; Matthies K.; Meier C.; Metzler E.; Moor E.; Noll I.; Paulsen S.;
Pfeffer B.; Promnitz N.; Saljew B.; Schad S.; Schoner C.; Sellmann R.;
Tanis M.; Vogelbusch J.; Wagner E.; Winkler S.; Zenker K.; Zvork S.;
Balogh E.; Buncsikne Molnar S.; Gulyasne Gaspar E.; Herold M.; Kovacs E.;
Kozmane Paszternak A.; Maarne Nagy S.; Nagyne Zoltan A.; Nemeth Z.; Roth
T.; Rozsa I.; Szalai M.; Anuradha M.; Bawa T.; Bhaskar B.; Chalkhore S.;
Choudhary D.; Dhanalaxmi T.; Dhingra V.; Gayatri R.; Gnanasundram R.;
Gopal U.; Govindaraj S.; Indira P.; James S.; Karkuzhli K.; Koppikar V.;
Malhotra N.; Manmohan B.; Mazher A.; Menon R.; Nalini S.; Panda M.; Patel
K.; Poongothai S.; Ramanathan S.; Ramu I.; Sangeetha K.; Sankar K.;
Savitha; Shrinivas K.; Sudha S.; Tripathi S.; Vaseem A.; Yamuna A.;
Banques R.; Chong J.; Courcy M.; Donnelly E.; Fauzi A.; Gately M.; Hanlon
G.; Kelly-Conroy M.; McAteer S.; McGovern G.; Meaney E.; Storey S.; Todd
M.; Aharonof-Segal M.; Aliazarov N.; Arbeli S.; Butbul E.; Chagai E.;
Confino K.; Domb L.; Dvir R.; Erez N.; Foiening O.; Frishberg A.; Genin
I.; Gertman R.; Golan L.; Grosberd A.; Hadad D.; Israeli S.; Kaplunski Y.;
Karpf D.; Katzir A.; Kivity Z.; Li L.; Livshitz L.; Nachmias A.; Orr I.;
Peer E.; Platner N.; Pritulo L.; Rojansky A.; Rosenblat T.; Saranga H.;
Schterchman G.; Shenhar S.; Shkliar T.; Stam T.; Stinmann S.; Suliman A.;
Tsirulnikov E.; Uziel K.; Weinshtock S.; Yedid-Am S.; Yuval R.; Zuker S.;
Brunella L.; Durante A.; Nada E.; Pugolotti M.; Robusto A.; Testa M.;
Toniato R.; Ha I.; Jung S.; Kim C.; Mi Ran K.; Song B.; Wi Y.; Yang K.;
You J.; Gaisute R.; Ozolina L.; Dzagajeva N.; Kasperaviciene V.;
Krikstaponiene Z.; Montviliene R.; Morkunaite K.; Piepoliene L.; Stoniene
E.; Stonkus S.; Ulpaityte I.; Arenas-Vanhorn M.; Espitia-Serrato L.;
Garcia-Munoz E.; Nunez V.; Sainz T.; Bakker H.; Danse I.; De Greef S.; De
Jong C.; De Wit M.; Didden E.; Dommerholt R.; Goddrie M.; Haazer C.;
Havenaar J.; Hendriks-Van Woerden M.; Jongenotter M.; Kort I.; Koster L.;
Kramer H.; Maarssen E.; Posthuma-Visscher M.; Reijnierse-Buitenwerf H.;
Rood P.; Swets E.; Tousain W.A.; Van Buchem-Damming G.; Van
Buijsen-Nutters A.; Van de Loo R.; Van den Hondel M.; Van den Berg A.; Van
der Knaap-van Keulen M.; Van der Zeijst M.; Van Setten-Van der Meer L.;
Von Bannisseht E.E.; Wouda Z.; Aarsland T.; Amlie L.; Andresen B.;
Bakketun A.; Bognaes A.; Botten C.; Coucheron S.; Halsne A.; Hansen H.;
Holthe T.; Husby E.; Iversen E.; Kvalvik A.; Landbakk T.; Lovseth E.; Moen
S.; Orvik E.; Ovrehus G.; Salater S.; Sorgard B.; Sorstrom A.; Tandberg
L.; Veiding B.; Vinje G.; Winge A.; Abquina G.; Patena B.; Reyes R.;
Tamondong A.; Vega A.; Vitug L.; Makuch M.; Torun A.; Adam A.; Basaraba
M.; Chira C.; Darida C.; Haica C.; Nedelcu A.; Patru D.; Patrut L.; Rau
I.; Rotaru N.; Szabo L.; Vrinceanu G.; Sovenko T.; Zatsevskaya O.;
Horynova Z.; Vankova L.; Barkhuizen M.; Barnard L.; Bekker D.; Botha D.;
Commerford A.; de Klerk A.; De Waal A.; Devchand S.; Drummond F.; Du Toit
A.; Du Toit S.; Ellis T.; Engelbrecht M.; Eramus T.; Fonda K.; Goosen A.;
Gopel E.; Govender P.; Hodge E.; Ismael F.; Jonker E.; Jonker L.; Joubert
A.; Kilian M.; Koegenlenberg N.; Lehner L.; Lingham R.; Llyod T.; Mangoeng
P.; Mapele S.; Meiring J.; Methusi P.; Mmethi M.; Mohamed K.; Moore A.;
Ndiweni H.; Parker F.; Schoneman J.; Smit M.; Steyn A.; Van Dongren J.;
Van Schalkwyk S.; Van Staden L.; van Wyngaard G.; Wolf A.; Ashbaugh R.;
Bande C.; Barquero R.; Gaspar R.; Martin E.; Megia B.; Rodriguez C.;
Seoane A.; Viaplana J.; Akesson Jacobsson I.; Andersson C.; Asperen M.;
Backlund M.; Berglund M.; Bjorck L.; Borjesson M.; Brolin G.; Danielsson
Frojd M.; Duckert A.; Eriksson K.; Fehling K.; Glaas A.; Hage C.; Hoglund
K.; Jernhed H.; Johansson K.; Johansson S.; Lidin M.; Lundell L.; Lundgren
C.; Magnusson K.; Matsson E.; Norman J.; Nystrom K.; Ojutkangas M.;
Olofsson M.; Olsson C.; Pettersson U.; Pramberg E.; Raschperger A.; Sjolin
M.; Soderlund M.; Stensgaard Nake E.; Torebo E.; Uggeldahl I.; Walldin C.;
Welin-Berger B.; Dwyer A.; Meyer-Lazzarini V.; Morello R.; Schefer M.;
Oney S.; Seker T.; Tavlayan S.; Appleby M.; Astin J.; Baker M.; Brann H.;
Brennan C.; Bryan L.; Campbell D.; Carey J.; Cox K.; Davis C.; Dyson B.;
Everdell R.; Gammon B.; Godden J.; Gray T.; Griffiths E.; Grimes Y.; Hall
D.; Hall K.; Holme A.; Howe J.; Lambley-Burke R.; Nation M.; Norcott K.;
Mitchell K.; Poxon S.; Quick C.; Shute C.; Thomas J.; Vinnell T.; Bawa S.;
Bogan C.; Fallye O.; Ginsberg J.; Gregory B.; House B.; Isonaga M.;
Keanne-Richmond P.; Kelly C.; Kimpel J.; Leiby A.; Lyons L.; McCoy B.;
Monk A.; Pelayo E.; Perron M.; Posey D.; Rehan M.; Suarez R.; Tilton L.;
Waite K.; White G.; Chacon R.; Meza Y.; Misticchio F.; Torres M.; Urbaneja
H.
Publisher
American Diabetes Association Inc.
Abstract
OBJECTIVE: The Outcome Reduction With Initial Glargine Intervention
(ORIGIN) trial reported neutral effects of insulin glargine on
cardiovascular outcomes and cancers and reduced incident diabetes in
high-cardiovascular risk adults with dysglycemia after 6.2 years of active
treatment. Omega-3 fatty acids had neutral effects on cardiovascular
outcomes. The ORIGIN and Legacy Effects (ORIGINALE) study measured
posttrial effects of these interventions during an additional 2.7 years.
RESEARCH DESIGN AND METHODS: Surviving ORIGIN participants attended up to
two additional visits. The hazard of clinical outcomes during the entire
follow-up period from randomization was calculated. RESULT(S): Of
12,537 participants randomized, posttrial data were analyzed for 4,718
originally allocated to insulin glargine (2,351) versus standard care
(2,367), and 4,771 originally allocatedto omega-3 fatty acid supplements
(2,368) versus placebo (2,403). Posttrial, small differences in median
HbA1c persisted (glargine 6.6% [49 mmol/mol], standard care 6.7% [50
mmol/mol], P = 0.025). From randomization to the end of posttrial
follow-up, no differences were found between the glargine and standard
care groups in myocardial infarction, stroke, or cardiovascular death
(1,185 vs. 1,165 events; hazard ratio 1.01 [95%CI 0.94-1.10]; P = 0.72);
myocardial infarction, stroke, cardiovascular death, revascularization, or
hospitalization for heart failure (1,958 vs. 1,910 events; 1.03
[0.97-1.10]; P = 0.38); or any cancer (524 vs. 529 events; 0.99
[0.88-1.12]; P = 0.91) or between omega-3 and placebo groups in
cardiovascular death (688 vs. 700; 0.98 [0.88-1.09]; P = 0.68) or other
outcomes. CONCLUSION(S): During >6 years of treatment followed by
>2.5 years of observation, insulin glargine had neutral effects on health
outcomes and salutary effects on metabolic control, whereas omega-3 fatty
acid supplementation had no effect. Copyright © 2016 by the
American Diabetes Association.

<21>
Accession Number
2035564827
Title
Methylprednisolone and Endothelial Dysfunction in Cardiac Surgery: A Pilot
Randomized Trial.
Source
Acta Anaesthesiologica Scandinavica. 69(8) (no pagination), 2025. Article
Number: e70109. Date of Publication: 01 Sep 2025.
Author
Halenarova K.W.; De Backer D.; Njimi H.; Taccone F.S.; Van Obbergh L.
Institution
(Halenarova, Njimi, Taccone) Department of Intensive Care, Erasme
Hospital, Hopitaux Universitaires de Bruxelles, Brussels, Belgium
(De Backer) Intensive Care Unit, CHIREC Hospital Group, Universite Libre
de Bruxelles, Brussels, Belgium
(Van Obbergh) Department of Anesthesia, Erasme Hospital, Hopitaux
Universitaires de Bruxelles, Brussels, Belgium
Publisher
John Wiley and Sons Inc
Abstract
Background: Cardiac surgery involving cardiopulmonary bypass (CPB) serves
as a clinical model of ischemia-reperfusion injury and endothelial
dysfunction. Endothelial injury is often manifested clinically by
vasoplegia and microcirculatory disturbances. The administration of a
single dose of corticosteroids at the time of anesthesia induction has
been hypothesized to exert a protective effect. Method(s): In this
parallel-group, randomized, controlled single-center trial, patients
scheduled for elective cardiac surgery with CPB were assigned to receive
intravenous methylprednisolone or placebo at anesthesia induction. The
primary outcome was the occurrence of endothelial dysfunction, assessed
using flow-mediated dilation (FMD) during a vascular occlusion test.
Secondary outcomes included peripheral tissue reperfusion slope measured
by near-infrared spectroscopy (NIRS StO<inf>2</inf>) and syndecan-1
levels, variations of FMD, NIRS StO<inf>2</inf>, and syndecan-1 over time,
and the correlation between the three measurements. Result(s):
Thirty-nine patients were assigned to receive either methylprednisolone (n
= 20) or placebo (n = 20). Maximal post-CPB median FMD was 5.7% (IQR:
3.4%-7.0%) in the methylprednisolone group and 4.7% (2.2%-6.6%) in the
placebo group (difference: 0.60, 95% CI: -1.5 to 2.7; p = 0.57). On the
first postoperative day, median FMD was 6.9% (3.6%-9.8%) in the
methylprednisolone group and 8.1% (4.3%-11.6%) in the placebo group
(difference: -1.0, 95% CI: -3.6 to 1.6; p = 0.46). No other significant
differences between groups were observed for other measurements. A
significant correlation was found between the severity of FMD alteration
and syndecan-1 levels (r = 0.21, p = 0.03). Conclusion(s):
Methylprednisolone did not significantly affect CPB-associated endothelial
dysfunction markers in elective cardiac surgery patients. Nevertheless, a
correlation between syndecan-1 levels and the peak arterial dilation
suggests a link between the severity of glycocalyx damage and vascular
reactivity. Editorial Comment: Glycocalyx damage has been associated with
impaired vascular reactivity. This pilot trial assessed methylprednisolone
effect on flow-mediated arterial dilation and also tissue oxygen
saturation during a vascular occlusion test as well as syndecan-1 levels,
these in an elective cardiac surgical cohort, to see if a single steroid
dose could limit cardiopulmonary bypas-related endothelial dysfunction.
Single steroid dose here did not effect the main outcome, flow mediated
areterial dilation, in this cohort. Copyright © 2025 Acta
Anaesthesiologica Scandinavica Foundation.

<22>
[Use Link to view the full text]
Accession Number
365300092
Title
Basal insulin and cardiovascular and other outcomes in dysglycemia.
Source
New England Journal of Medicine. 367(4) (pp 319-328), 2012. Date of
Publication: 26 Jul 2012.
Author
Gerstein H.C.; Bosch J.; Dagenais G.R.; Jung H.; Maggioni A.P.; Pogue J.;
Probstfield J.; Ramachandran A.; Riddle M.C.; Ryden L.E.; Yusuf S.;
Richardson L.; Diaz R.; Johnston P.; Vige R.; Birkeland K.; Budaj A.;
Cardona E.; Chazova I.; Commerford P.; Danilova L.; Davies M.; Fernando
R.; Fodor G.; Gilbert R.; Gomis R.; Hanefeld M.; Hildebrandt P.;
Kacerovsky-Bielesz G.; Keltai M.; Kim J.H.; Krum H.; Lanas F.; Lewis B.S.;
Lonn E.; Lopez-Jaramillo P.; Marin-Neto J.; Marre M.; McKelvie R.; McQueen
M.; Mendoza I.; Morillo C.; Pan C.; Pirags V.; Profozic V.; Ratner R.;
Rosenstock J.; Spinas G.A.; Sreenan S.; Stoel I.; Syvanne M.; Yale J.F.;
Avezum A.; Bahit M.C.; Bogaty P.; Bordeleau L.; Chacomicronn C.; Corson
M.; Harper W.L.; Halon D.; Magloire P.; Mann J.; Pavlova V.; Punthakee Z.;
Silva J.; Tsang B.; Yakubovich N.; Abdallah A.; Ahmad S.; Chandra J.;
Chandra R.; Cukierman-Yaffee T.; Dyal L.; Joldersma L.; MacRae L.; MacRae
S.; Malik S.; Mead A.; Pasha F.; Pazmino-Canizares J.; Pohl K.; Sakalas
A.; Tyrwhitt J.; Ahuad Guerrero R.; Alebuena A.; Alvarez N.; Alzogaray M.;
Amuchastegui M.; Andres M.; Angos M.; Baglivo H.; Barbieri M.; Bassi F.;
Bello F.; Bono J.; Bustamante Labarta M.; Bustos B.; Caccavo A.; Calveira
M.; Camino A.; Cantero M.; Capozzi M.; Cardone M.; Cartasegna L.;
Cassetari A.; Castellanos R.; Chavez Caballero R.; Cipullo M.; Contreras
A.; Coria J.; Corinaldesi F.; Costa G.; Crespo C.; Cruz M.; Cuello J.;
Cuneo C.; Del Corro I.; Diez R.; Dituro C.; Dominguez A.; Facta A.;
Faingold C.; Farah M.; Fares Taie A.; Fernandez A.; Ferrari A.; Ferrari
N.; Garcia Monteverde C.; Garrido M.; Giachello C.; Gonzalez M.; Gutierrez
N.; Guzman L.; Guzman P.; Hasbani E.; Henquin R.; Hershon A.; Hirschon
Alvarez Prado A.; Hominal M.; Hrabar A.; Imposti H.; La Grutta M.;
Lanchiotti P.; Lobo Marquez L.; Lopez Santi R.; Lowenstein J.; Lugo M.;
Luqueci M.; Mainini S.; Majul C.; Manzano R.; Manzur S.; Marcucci G.;
Marino M.; Massari F.; Mendez N.; Molina M.; Montana O.; Mulazzi M.;
Nardone L.; Odetto I.; Orlandini A.; Oviedo A.; Paez O.; Parnas A.; Patron
F.R.; Pedernera C.; Pelagagge M.; Plastino M.; Polari P.; Pomposiello J.;
Porta A.; Prado A.; Quiroz M.; Ramirez A.; Rodriguez M.; Ronderos R.; Sago
L.; Sanchez A.; Sanchez R.; Sandrin A.; Schygiel P.; Sernia V.; Sinay I.;
Smith Casabella T.; Sosa Liprandi A.; Sosa Liprandi M.; Soso L.; Sposetti
G.; Stisman D.; Streitenberger P.; Suarez G.; Tonin H.; Ulla M.; Valdez
J.; Vico M.; Villamil A.; Villarino A.; Viscaya Castro A.; Visco V.; Vogel
D.; Waisman F.; Zaidman C.; Amerena J.; Applebe A.; Aylward P.; Binnekamp
M.; Bruce I.; Burdeniuk C.; Burnet R.; Colman P.; Colquhoun D.; Davis S.;
De Looze F.; De Pasquale C.; D'Emden M.; Eaton H.; Farshid A.; Foulanos
S.; Galanos J.; Gordon G.; Guhu M.; Ho J.; Jeffery I.; Jerums G.; Kwan M.;
Lefkovits J.; Luu S.; MacIsaac R.; Marjason J.; Mohabbati V.; Nankervis
A.; O'Neal D.; Perera N.; Poynten A.; Rahman A.; Razak S.; Roberts T.;
Sebastian M.; Simpson R.; Soldatos G.; Sullivan D.; Teede H.; Tiong F.;
Topliss D.; Torpy D.; Waddell-Smith K.; Waites J.; Wenman J.; Whelan A.;
Williams L.; Yeap B.; Yeow W.; Yong G.; Aczel S.; Azimy N.; Bertha P.;
Blocher J.; Bohnel C.; Brath H.; Breuss J.; De Campo A.; Drexel H.;
Ettmuller Y.; Feder A.; Feinboeck C.; Gulz E.; Hofmann M.; Hoppichler F.;
Jahnel H.; Jankovic V.; Kann T.; Kathrein T.; Kotter T.; Kratz E.;
Kreuzwieser E.; Loreck C.; Ludvik B.; Marte T.; Mellitzer K.; Nistler S.;
Placher-Sorko G.; Prager R.; Rein P.; Riedl M.; Saly C.; Schernthaner G.;
Schichka E.; Seidlhofer C.; Sonnenfeld M.; Stefan H.; Steiner K.; Thomas
B.; Toplak H.; Urstoger K.; Vetter B.; Vonbank A.; Waldschutz W.; Wallner
F.; Winkler F.; Goncharik D.; Lazareva I.; Lichorad N.; Mrochek A.;
Murashko N.; Radyuk D.; Ramanovski A.; Sudzhaeva S.; Sujayeva V.;
Yarashevich N.; Campbell G.; Marshall S.; West A.; Abreu F.; Alves M.;
Ayoub-Aidar J.; Barros M.; Barros-Silveira J.; Blacher M.; Costa E.; Costa
F.; Daltro C.; Delana J.; Eliaschewitz F.; Facanha C.; Feitosa G.;
Figueiredo J.; Forti A.; Franco D.; Franken M.; Freire F.; Garcia V.;
Gouvea-Neto A.; Grofallo S.; Kanedlai N.; Kerr-Saraiva J.; Ladeira R.;
Leaes P.; Lemos M.; Lima F.; Lima Filho M.; Macedo L.; Manenti E.; Monte
O.; Mossman A.; Mothe F.; Mouco O.; Moyses Golbert M.; Nasser Hissa L.;
Nasser-Hissa M.; Nicolau J.; Nigro Maia L.; Ninno T.; Nunes C.; Oliveira
C.; Oliveira O.; Passos da silva R.; Pericles-Esteves J.; Rabelo L.;
Rabelo-Alves Junior A.; Rassi S.; Rech R.; Roldan F.; Salles J.; Sampaio
C.; Seabra A.; Sealissi N.; Seixas A.; Sena R.; Shehadeh I.; Teixeira M.;
Turin H.; Vicente Serrano C.; Vidigal M.; Vilela M.; Wajchenberg B.;
Abbott C.; Abu-Bakare A.; Ardilouze J.; Auersperg E.; Bailey A.; Bailey
G.; Baillargeon J.; Beaurivage C.; Belair J.; Belanger A.; Bellabarba D.;
Berlingieri J.; Bernier F.; Bhargava R.; Bhesania T.; Booth W.; Bose S.;
Boulianne M.; Bourgeois S.; Breton D.; Brossoit R.; Buithieu J.; Campeau
J.; Carlson B.; Carpentier A.; Cavalcanti R.; Cha J.; Chagnon P.; Chan Y.;
Chessex C.; Chiasson J.; Chouinard S.; Clayton D.; Conway J.; Crepeau J.;
Cudmore D.; D'Ignazio G.; Doig G.; Dominguez M.; Dube F.; Dumas R.; Dupuis
R.; Dyrda I.; Eddy D.; Eiley D.; Fox H.; Fratesi S.; Gallant S.; Garceau
C.; Garfield N.; Germain C.; Glazer S.; Gosselin G.; Gould D.; Grills G.;
Halle J.; Hardin P.; Harper W.; Heath J.; Heath V.; Hivert M.; Ho K.;
Houde G.; Hramiak I.; Hutchinson A.; Huynh T.; Ilie-Haynes R.; Imran S.;
Islam A.; Iwanochko M.; Jones C.; Joyce C.; Kirouac I.; Kumar R.; Lamothe
M.; Langlois M.; Lauzon C.; Lavoie M.; Leader R.; Lecours S.; Lepage S.;
Lochnan H.; Ma P.; McLean A.; Mecci S.; Mehta P.; Mercier M.; Miller D.;
Morisset A.; Nawaz S.; Nisker W.; Nyomba G.; O'Keefe D.; Palardy J.;
Parekh P.; Paul T.; Perron P.; Pesant M.; Phillips R.; Pruneau G.; Quintin
I.; Raby K.; Richard C.; Rosenfeld G.; Saulnier D.; Shaban J.; Shah A.;
Shu D.; Sigal R.; Silverman M.; Singh J.; Sivucha W.; Skamene A.;
Sliwowicz D.; Smith R.; St Hilaire R.; Steinson D.; Sussex B.; Tan K.;
Tannous R.; Telner A.; Theroux P.; Tsoukas C.; Tsoukas G.; van Buuren J.;
VanRossum N.; Vexler R.; Vizel S.; Warnica W.; Weingert M.; Wilson R.;
Wong W.; Woo V.; Acevedo M.; Alwyn C.; Baier E.; Baier S.; Galloso R.;
Lahsen R.; Lorenas G.; Montecinos A.; Montecinos M.; Pineda P.; Pollak F.;
Sapunar J.; Serrano V.; Stockins B.; Varleta P.; Yovanovich J.; Zambra F.;
Ba J.; Bao Y.; Bi Y.; Bu S.; Chen B.; Chen H.; Chen J.; Chen L.; Chen M.;
Chen Y.; Cui J.; Dong M.; Feng P.; Feng Z.; Gao C.; Gao F.; Gao X.; Gao
Z.; Gong Y.; Guang L.; Guo X.; Han F.; Han X.; Hou X.; Hu R.; Ji L.; Jia
J.; Jia W.; Jiao X.; Jin X.; Kuang J.; Li M.; Li Q.; Li X.; Li Y.; Ling
Y.; Liu F.; Liu Z.; Lu B.; Lu J.; Lu Z.; Lv X.; Ning G.; Peng Y.; Ren Y.;
Shao Y.; Shi Y.; Shu X.; Sun H.; Sun L.; Sun X.; Tang K.; Tian H.; Wang
C.; Wang F.; Wang L.; Wang Q.; Wang W.; Wang X.; Wang Y.; Wen J.; Wu C.;
Wu H.; Wu J.; Wu M.; Xing X.; Xue Y.; Yan L.; Yan S.; Yang H.; Yang N.;
Yang W.; Yang Z.; Yao J.; Yao L.; Yu D.; Yu H.; Yu M.; Yu X.; Yuan L.;
Yuan M.; Yuan S.; Yuan W.; Yuan Y.; Yuan Z.; Zeng T.; Zhang J.; Zhang R.;
Zhang X.; Zhao L.; Zheng B.; Zheng J.; Zhou W.; Zhu N.; Zhu Y.; Zou D.;
Zou J.; Accini J.L.; Bohorquez R.; Botero R.; Cure C.; Figueredo M.;
Hernandez E.; Kattah W.; Llamas A.; Orozco L.; Pava L.; Perez M.; Pineda
M.; Quintero A.; Quiros R.; Urina M.; Velez S.; Altabas V.; Baotic I.;
Berkovic M.; Goldoni V.; Kerum T.; Mirosevic G.; Tarle D.; Vidovic I.;
Zjacic-Rotkvic V.; Abbas R.; Andersen H.; Auscher S.; Baumbach L.;
Brockstedt H.; Christensen P.; Christiansen M.; Clemmensen K.; Egstrup K.;
Gislason G.; Haar D.; Hansen K.; Heden Andersen P.; Helleberg K.;
Hermansen K.; Holmer J.; Jeppesen J.; Klausen I.; Koustrup-Sonder T.;
Krarup T.; Lerche S.; Lervang H.; Linde B.; Lund P.; Lund S.; Madsbed S.;
Molvig J.; Orskov C.; Ostergaaard O.; Perrild H.; Pietraszek A.; Ralfkjaer
N.; Roenne H.; Rokkedal Nielsen J.; Seibaek M.; Soendergaard H.; Sorensen
L.; Sundahl Mortensen L.; Torp-Pedersen C.; Tuxen C.; Urhammer S.;
Vadstrup E.; Ambos A.; Janson A.; Rudenko P.; Viitas L.; Aranko S.; Badeau
M.; Eriksson J.; Haapamaki H.; Kajander O.; Kuusisto A.; Luukkonen S.;
Makela J.; Nieminen S.; Niskanen L.; Ripatti J.; Ruotsalainen S.; Saltevo
J.; Savela K.; Strand J.; Valle T.; Virkamaki A.; Aboud E.; Alavoine L.;
Bekherraz A.; Bohme P.; Bourezane H.; Catargi B.; Charpentier G.; Clergeot
A.; Courreges J.; Delmas T.; Duengler F.; Feknous C.; Gendre D.; Guerci
B.; Hadjadj S.; Kerlan V.; Laguerre N.; Le Potier J.; Lombardo F.;
Malville E.; Marechaud R.; Mattei C.; Moreira J.; Penfornis A.; Petit C.;
Pinel J.; Piquel X.; Raccah D.; Reznik Y.; Rod A.; Roudaut N.; Rousseau
E.; Schillo F.; Schmitt B.; Sonnet E.; Torremocha F.; Travert F.; Vanhoute
C.; Vimeux M.; Abdollahnia R.; Adamidou A.; Arslan S.; Bach-Kliegel B.;
Bartusch B.; Bauer N.; Bieler T.; Blankenfeld H.; Boeckmann U.; Busch K.;
Butzer R.; Chenchanna-Merzhaeuser M.; Denger R.; Deutsch C.; Diessel S.;
Donati-Hirsch I.; Dornisch M.; Enghofer K.; Fleig T.; Forst T.; Frommherz
M.; Goeller K.; Habbig J.; Hadziselimovic S.; Hamann A.; Hampel T.; Heger
S.; Helmes C.; Hoffman C.; Hohberg C.; Humpert P.; Kamke A.; Kamke W.;
Kindermann P.; Klein C.; Klein D.; Koehler A.; Kuehn A.; Langer K.; Limmer
S.; Loew A.; Maimer A.; Marck C.; Meier G.; Methner-Friederich M.; Metzler
W.; Meyer K.; Miftari N.; Milde J.; Minnich J.; Molkewehrum M.; Morcos M.;
Mueller-Hoff C.; Nguyen M.; Nishwitz M.; Oldenburg J.; Ott P.; Pauli K.;
Pauly B.; Pfeiffer A.; Pfuetzner A.; Pischa U.; Radke R.; Reismann P.;
Riemer M.; Rochlitz H.; Rudofsky G.; Ruhla S.; Sammler A.; Schaper F.;
Schiemenz K.; Scholz G.; Schumm-Draeger P.; Segiet T.; Segner A.; Seissler
J.; Spahn S.; Stier U.; Tonon G.; von Amelunxen S.; von Schacky C.;
Wilhelm B.; Wilhelm K.; Witt K.; Wuechner-Hofmann S.; Baranyai M.; Birkus
Z.; Foldesi I.; Gaal Z.; Harcsa E.; Hati K.; Hohmann Z.; Istenes I.;
Jozsef I.; Juhasz E.; Kempler P.; Keresztes B.; Keresztes K.; Kis-Gombos
P.; Kovacs I.; Kozma T.; Laszlo Z.; Noori E.; Nyirati G.; Papp Z.; Patkay
J.; Poor F.; Pusztai P.; Putz Z.; Rigo E.; Sereg M.; Simon K.; Somogyi A.;
Sumegi J.; Szabo A.; Szabo J.; Szigeti S.; Szilveszter D.; Tarko M.; Varga
C.; Varga Szabo L.; Voros P.; Arathi; Badgandi M.; Balaji M.; Balaji V.;
Chamukuttan S.; Devi Manduva P.; Fatima S.; Ganapathy B.; George O.;
George P.; Jaffar M.; Jain P.; Kamath P.; Karthik V.; Koshy G.; Krishnan
L.; Kumar H.; Lal P.; Mithal A.; Modi S.; Mohan V.; Moses V.; Oomen R.;
Pais P.; Pati P.; Pendsey S.; Rai P.; Rajagopal R.; Ramu M.; Ranjit U.;
Rao P.; Senthil V.; Seshaiah V.; Sethi B.; Shah P.; Sharma R.; Shetty S.;
Shobha A.; Siddharth R.; Sridhar G.; Sudeep K.; Sunil C.; Sunitha S.;
Suresh S.; Thomas N.; Vageesh A.; Anwer Z.; Barton J.; Behan L.; Bell M.;
Cullen M.; Dineen S.; Draman Yusof M.; Dunne F.; Gibney J.; Hussain T.;
Khan M.; Kinsley B.; Kyithar P.; Lavin F.; McGowan A.; McGurk C.; Mirza
A.; Mohammadi B.; O'Brien T.; O'Connell J.; O'Halloran D.; O'Shea D.;
Roberts G.; Tomkin G.; Wan Mahmood W.; Abramod-Ness R.; Adawi F.; Aharon
B.; Backer M.; Beniashvili A.; Berliner A.; Bloch L.; Bugelman D.; Butnaru
A.; Cohen O.; Cohen Y.; Frenkel M.; Glant M.; Gustava B.; Guttman H.;
Halabi S.; Harman-Boehm I.; Ilany J.; Karkabi B.; Khader N.; Khaskia A.;
Khudyak Y.; Klainman E.; Kogan N.; Lender D.; Levin I.; Mardi T.; Marmor
A.; Mosseri M.; Nabriski D.; Omary M.; Orlovsky S.; Peres D.; Quasim M.;
Raz I.; Remesnik M.; Rogowski O.; Rozenfeld I.; Scharr D.; Shnifer I.;
Shuster T.; Solomon R.; Steiner H.; Tzivoni D.; Wolfson N.; Yossef Z.;
Zahger D.; Zeltser D.; Zimlichman R.; Aina F.; Ariatti C.; Bonetti R.;
Cacciatore F.; Calcinaro F.; Corona G.; De Maria P.; Del Prato S.; Derosa
G.; Di Pasquale G.; Falorni A.; Fanelli R.; Fedele D.; Filorizzo G.;
Fogari R.; Furgi G.; Ghio A.; Giorda C.; Gregori G.; Iannuzzi G.; Lapolla
A.; Luciano B.; Lucotti P.; Maggi A.; Marafetti L.; Marchese T.; Martino
G.; Marzotti S.; Miccoli R.; Monti L.D.; Moretti L.; Palvarini M.;
Petacchi R.; Piarulli F.; Piatti P.M.; Rudi S.; Santeusanio F.; Sesti G.;
Setola E.; Sforza A.; Shehaj E.; Veniani M.; Viviani G.; Zigoura E.; Chae
S.; Cho D.; Cho E.; Cho Y.; Choi Y.; Chung M.; Hong E.; Hong Y.; Jeong M.;
Kim B.; Kim D.; Kim H.; Kim I.; Kim J.; Kim P.; Kim S.; Koo B.; Kwok S.;
Kwon H.; Lee J.; Lim J.; Oh S.; Ohn J.; Park C.; Park H.; Park K.; Seung
K.; Son H.; Woo J.; Yoon K.; Ansmite B.; Balcere I.; Bumbure A.; Ducena
K.; Lejnieks A.; Rasa I.; Ritenberga R.; Romanova M.; Salmina I.; Steina
S.; Badariene J.; Gailiuniene S.; Grigonis S.; Juskiene R.; Petrulioniene
Z.; Sakalyte G.; Stasiunas T.; Sulskiene M.; Urbonaite B.; Zarankiene R.;
Ziukaite R.; Arechavaleta R.; Beltran-Jaramillo T.; Calvo-Vargas C.;
Campillo-Cardenas C.; Cardona D.; Carmona-Huerta J.; Cedano-Limon M.;
Comellas-De M.; Dominguez C.; Gomez-Cruz J.; Gonzalez-Perez R.; Illescas
J.; Jimenez-Ramos S.; Lopez-Alvarado A.; Marquez-Rodriguez E.; Martinez
G.; Pascoe S.; Plascencia Vazquez O.; Rodriguez H.; Ruiz-Cornejo M.;
Velasco-Sanchez G.; Vidrio-Velazquez M.; Villeda-Espinosa E.; Badings E.;
Bartels G.; Bruggink-Andre de la Porte P.; Bruijns E.; Cornel J.; De
Milliano P.; De Mulder M.; De Swart J.; Derks A.; Dirkali A.; Droste J.;
Galjee M.; Hautvast R.; Hermans W.; Holwerda N.; Ilmer B.; Kofflard M.;
Kooistra-Huizer J.; Kurvers M.; Langerveld J.; Leenders C.; Liem A.; Lok
D.; Neumann D.; Nierop P.; Plomp K.; Posma J.; Reichert C.; Roeters Van
Lennep H.; Ronner E.; Said S.; Takens L.; Umans V.; Van der Sluis A.A.;
Van der Zwaan C.; Van Dobbenburgh J.; Van Es A.; Van Hessen M.; Van
Mechelen R.; Van Miltenburg-Van Zijl A.; Van Zeijl L.; Veerhoek M.;
Viergever E.; Weijers E.E.; Willems F.; Blix I.; Cooper J.; Debowska A.;
Erichsen K.; Fossum J.; Gjertsen E.; Grill V.; Gudnason S.; Hoye K.; Istad
H.; Winther J.; Joakimsen R.; Jorde R.; Larsen I.; Mella B.; Otterstad J.;
Risberg K.; Skare K.; Skeie S.; Sommervoll L.; Tandberg A.; Whitfield R.;
Wium C.; Cunanan E.; Fernando-Catindig E.; Gomez M.; Jaring C.;
Lantion-Ang F.; Licaros M.; Lim-Abrahan M.; Madronio E.; Panelo A.; Raboca
J.; Ramos G.; Tugna S.; Aksamit-Bialoszewska E.; Bandurska-Stankiewicz E.;
Baranska M.; Bronisz A.; Bronisz M.; Chrustowski W.; Cieslak B.;
Czupryniak L.; Drazkowicz-Gozdzik B.; Galuszka-Bilinska A.; Gmytrasiewicz
M.; Janik K.; Jedynasty K.; Kania G.; Kawka-Urbanek T.; Kinalska I.;
Kincel K.; Kleszczewska U.; Kruszewski J.; Loba J.; Malicka J.;
Mielecka-Kincel M.; Milczarczyk A.; Milosz D.; Mrowczynska A.; Mytnik M.;
Nowakowski A.; Nowakowski P.; Oleskowska L.; Omelanczuk-Wiech E.;
Pawlowski M.; Poplawska A.; Rucinska M.; Rucinski M.; Rutkowska J.;
Saryusz-Wolska M.; Siewko K.; Sikora-Frac M.; Stecka-Wierzbicka J.;
Swiatkowski M.; Swierczynski R.; Szpajer M.; Szymkowiak K.; Tarach J.;
Tarasiewicz U.; Wiatr D.; Wojewoda P.; Woszczak-Marcinkowska H.; Zadrozny
J.; Hancu N.; Albota A.; Bala C.; Barbonta D.; Botnariu G.; Bradescu O.;
Busegeanu M.; Bzduch M.; Catrinoiu D.; Caziuc R.; Cerghizan A.; Cheta D.;
Cif A.; Ciomos D.; Cosma D.; Creteanu G.; Crisan I.; Danciulescu R.;
Dobjanschi C.; Dodan R.; Duma L.; Ferariu I.; Ghenes T.; Ghise G.; Graur
M.; Ilinca M.; Marton R.; Mindrescu N.; Morosanu A.; Morosanu M.; Mota M.;
Nafornita V.; Negrisan G.; Nicodim S.; Nicolau A.; Nita C.; Onaca A.;
Panus C.; Pletea N.; Pop C.; Pop L.; Popa B.; Roman G.; Rosu M.; Sandu N.;
Serban V.; Sima A.; Stamoran L.; Strugariu M.; Suciu G.; Szilagyi I.;
Vacaru G.; Veresiu I.; Vlad A.; Adasheva T.; Ageev F.; Akhmedganov N.;
Akinina A.; Alexandrov A.; Ambatiello L.; Ametov A.; Ausheva A.; Babaeva
L.; Babenko A.; Balyasnikova E.; Bart B.; Belova J.; Berstein L.;
Bondarenko I.; Bondarev E.; Bulkina O.; Chernikova N.; Chumak B.; Deeva
T.; Demicheva O.; Demidova T.; Doskina E.; Duganova A.; Dzhaiani N.;
Egorova I.; Ettinger O.; Feofanova S.; Fofanova T.; Galaktionov P.;
Gavrilova N.; Gilyarevsky S.; Gnidkina N.; Golubev A.; Gornyakova N.;
Grigorova S.; Grineva E.; Gurevich V.; Irtuganov N.; Ivanova L.; Jaiani
N.; Kalashnikova M.; Karpov Y.; Khalimov Y.; Khorocheva G.; Kirillova E.;
Kistner J.; Kobalava Z.; Kochergina I.; Kravchenko T.; Krylov K.; Kulkova
P.; Kuparev I.; Kurbanova E.; Lysenko T.; Markovich A.; Martyanova I.;
Martynyuk T.; Masiinvets M.; Mavlyavieva E.; Maychuk E.; Melnichenko G.;
Mikhailusova M.; Mkrtumyan A.; Mychka V.; Nebieridze D.; Nesterova E.;
Orlov V.; Orlova V.; Orlova Y.; Papov F.; Patroucherva I.; Petunina N.;
Pirozhinskaya S.; Podachina S.; Postnikova S.; Pshikova O.; Rogova L.;
Romashevskiy B.; Runikhina N.; Sadulayeva I.; Safaryan A.; Sakovich E.;
Saprikina T.; Sargsyan V.; Semikozova O.; Shkolnik E.; Shubina A.; Shustov
S.; Sinitsina I.; Solovyeva E.; Storogakov G.; Stovpyuk O.; Sussekov A.;
Telnova M.; Temirov A.; Terekhov V.; Tereschenko S.; Tiourina T.;
Tolkacheva V.; Tsoy U.; Urazgyldeeva S.; Vasyuk Y.; Vinnitskay N.;
Voevodina E.; Volkova A.; Zadionchenko V.; Zalevskaya A.; Zhelninova T.;
Zhukova N.; Zilov A.; Bernatova J.; Duris T.; Markova I.; Martinka E.;
Michalova L.; Minarik P.; Peter L.; Raslova K.; Silvia D.; Subadova M.;
Tisonova J.; Vohnout B.; Adam M.; Badat A.; Bester A.; Bester F.; Blacking
L.; Bouwer D.; Brice B.; Cassimjee S.; Cronje T.; Deftereos J.; Distiller
L.; Ellis G.; Forster O.; Fulat M.; Gani M.; Gibson G.; Hansa S.;
Hendricks N.; Herbst L.; Hitzeroth J.; Joffe B.; Kelbe C.; Kelbe D.; King
J.; Kramer B.; Landau S.; Levitt N.; Meyer-Nell S.; Moore R.; Muller D.;
Nell H.; Omar M.; Randeree H.; Seeber M.; Seedat; Siebert M.; Van den Berg
E.; Van der Walt P.; Van Dyk C.; Segynu D.; Van Zyl L.; Wellman H.;
Bertomeu V.; Botella M.; Buno M.; Calle A.; Cano Perez J.; Coves M.;
Juanatey J.G.; Garcia-Mayor R.; Gaztambide S.; Gippini A.; Goikolea I.;
Gonzalez J.; Hillman N.; Lopez Garcia Aranda V.; Magueda I.; Mato J.;
Mazon P.; Morillas P.; Novials A.; Pallardo L.; Perez L.; Rodriguez J.;
Romero L.; Sagarra E.; Shamagian L.; Soto A.; Torrealday H.; Valero R.;
Agergaard S.; Agewall S.; Andersson K.; Bergstrom O.; Bjornstedt Bennermo
M.; Blomgren J.; Boman K.; Brohall G.; Cherfan C.; Dahlen C.; Dotevall A.;
Enander P.; Ericsson U.; Hallgren P.; Hansson A.; Henareh L.; Henriksson
P.; Herlitz J.; Holmqvist J.; Jarevi G.; Linderfalk C.; Jonasson L.;
Jovinge S.; Kalen J.; Kilstrup M.; Leosdotir M.; Leppert J.; Ljungberg J.;
Lofdahl B.; Lundman P.; Lysell-Bergstrom C.; Mathiesen U.; Mellbin L.;
Morner S.; Nathanson D.; Nilsson L.; Peterson M.; Quittenbaum S.;
Rosengren A.; Ryttberg B.; Scheel S.; Svensson K.; Tenerz A.; Vasko P.;
Waldenstrom A.; Wieloch M.; Spinas G.; Braendle M.; Felix B.; Gerber P.;
Moccetti T.; Pitteloud N.; Kultursay H.; Aydinalp A.; Balci M.; Cayli M.;
Hatipoglu E.; Ilkova H.; Kayikcioglu M.; Koc M.; Muderrisoglu H.; Sari R.;
Saygili F.; Tekin K.; Tutuncu N.; Yurekli B.; Adler A.; Ali A.;
Balasubramanian; Barakat O.; Barnett A.; Borthwick L.; Brookes; Cecil J.;
Chaterjee S.; Clark J.; Collinson D.; Collinson S.; Crasto W.; Donnelly
R.; du Plessis J.; Egan S.; Ellery A.; Evans R.; Ewing J.; Fox C.; Gibson
M.; Hall T.; Higgs E.; Hollway M.; Hughes E.; Jackson N.; Jalihawi H.;
Jones G.; Knights H.; Korsheed S.; Kumar Singh R.; Laithwaite D.; Lawrence
I.; Litchfield J.; Manning G.; McNally P.; Millar-Craig M.; Mohammed I.;
Narayanan R.; Nayani G.; Norris A.; Purohit J.; Quinn M.; Ramtoola; Rea
R.; Reckless J.; Richardson T.; Robertson D.; Robinson A.; Salem K.;
Sampson M.; Savage M.; Shaker J.; Srinivasan T.; Tracy I.; Tringham J.;
Viljoen A.; Ward A.; Waterhouse H.; Wijenaike N.; Wiles P.; Ahmann A.;
Ahmed I.; Alam A.; Arakaki R.; Asad S.; Banarer S.; Baum H.; Belew K.;
Bergenstal R.; Bethel M.; Boyer C.; Catton S.; Challans P.; Childs B.;
Christian R.; Clement S.; Cuddihy R.; Dailey G.; Damberg G.; De Bold C.;
De Lemos J.; Donovan D.; Dudl J.; Dunbar J.; Ebner S.; Failor R.; Feinglos
M.; Flaker G.; Freiburghaus M.; Furlong K.; Gardner D.; Gillespie E.;
Goland R.; Goldberg R.; Gotham A.; Guthrie R.; Hamaty M.; Hirsch I.;
Jabbour S.; Janci M.; Javorsky B.; Jones S.; Kamana V.; Kashyap M.;
Kaufman S.; Kearns P.; Khera A.; Klopfenstein B.; Kniffen W.; Kringas P.;
Licata A.; Lopez-Jimenez C.; Madden M.; Marx C.; McCall A.; McCallum J.;
McFarlane S.; McGuire D.; Melish J.; Meneghini L.; Miller S.;
Miranda-Palma B.; Mitchell R.; Nasr C.; Nelson J.; Niblack P.; Nylen E.;
Osei K.; Pandey A.; Papademetriou V.; Pilar Solano M.; Sameshima L.;
Savarese V.; Schnure J.; Schuster D.; Shin J.; Taylor A.; Thomson P.;
Ting-Ryan M.; Trence D.; Vo A.; Weiland K.; Wells K.; Wu P.; Zimering M.;
Zimmerman R.; Ascanio P.; Brajkovich I.; Carrillo E.; Coll J.; Gonzalez
K.; Gonzalez N.; Jimenez E.; Lopez R.; Marante D.; Morr I.; Paolillo M.;
Perche D.; Portillo M.; Valbuena H.; Velarde M.; Vergara G.; Augensen N.;
Azzalina J.; Fidaly S.; Bollero G.; Casiello A.I.; Ferraro F.; Guridi
M.J.; Ines M.; Martin M.E.; Pascual A.; Pereyra J.; Toscanelli M.; Appiah
M.; Grech S.; Pouras S.; Watts C.; Denke E.; Feik C.; Litvinenko M.;
Platonenko O.; Shadur S.; Johnson J.; Bonilla E.; Carraway B.; Faith J.;
Greer C.; Harding A.; Heston J.; Lin Y.; Mecca T.; Schuler M.; Rizk C.;
Sissoko A.; Strickland K.; Andrade A.; Lux L.; Machado D.; Mancin E.;
Aquino J.; Belanger B.; Bourque C.; Gagnier K.; Hagerimana A.; McNeil A.;
Osachoff J.; Richard B.; Rogan J.; Styner L.; Maturana X.; Naranjo M.E.;
Li E.; Liu Q.; Shuai M.; Tan Z.; Tang M.; Zhao J.; Ardila M.; Gomez A.M.;
Uscategui A.M.; Marinkovic N.; Miocevic V.V.; Pezo S.; Andersen I.;
Bastrup-Larsen B.; Jeppesen E.; Kofoed-Djursner M.; Joe H.; Hiironen V.;
Tarvainen M.; Von Hedenberg H.; Guillarme C.; Rastelli O.; Roy P.; Igel
L.; Lenz T.; Leptich A.; Peikert S.; Domokos S.; Szotyorine-Polcza G.;
Wenczl M.; Chaudhary S.; Jaiswal G.; Khatri P.; Shah K.; Gibson S.; Bechar
Y.; Erdheim D.; Eyal N.; Frankel M.; Shimoni S.; Tsuri J.; Bianco L.; Cali
R.; Sganga P.; Jang M.; Kim J.M.; Kim Y.; Lim S.; Park J.S.; Song Y.;
Kalve E.; Dienyte E.; Alvarado F.; Rodriguez R.; Bar J.; Lijfering-Lorie
K.; Palstra M.; Van der Kuijl K.; Van de Wetering A.; Eriksen S.;
Hejazifar S.; Jendeberg A.; Johannessen G.; Khammari I.; Meredith E.L.;
Dayag A.M.; Figueroa P.; Hoffmann Korpalska A.; Przemyk M.; Craciunescu
A.; Lupu D.; Osanu A.; Popscu L.; Toader C.; Kirsanova T.; Timoshina E.;
Gomez B.; Jankularova I.; Brett S.; Meyer A.; Pereira V.; Vawda N.;
Castano B.; Farre Avella J.M.; Jimenez I.; Turet N.; Froberg M.; Reppert
E.; Wessman S.; Boschung Y.; Carrozzino F.; Gerstl K.; Cetin Z.; Demirci
S.; Ovalioglu S.; Lenehan A.; McLean H.; Mutsaers K.; Redfern P.; Scoggins
A.; Isea Y.; Alvarez M.; Alvarez D'Amelio A.; Aqueveque S.; Argenta M.;
Aviles A.; Barreiro E.; Battistessa Y.; Bergamo S.; Bertran B.; Bocanera
M.; Bowen L.; Brescia H.; Caceres M.; Cappi A.; Cardelli A.; Carolini E.;
Carpintero S.; Carrique A.; Carrique P.; Casquero M.; Castro M.; Cendali
G.; Chatelain M.; Costanzi A.; Cristofaro C.; Crunger P.; Ehrich S.;
Espinosa M.; Esposito L.; Flenche M.; Fracaro V.; Funosas C.; Garrido I.;
Gomez Garrido A.; Guzman A.; Izzicupo M.; Luca S.; Luciani C.; Majul S.;
Moreno Cepeda I.; Moschin Y.; Niemann G.; Novas V.; Olmi M.; Palma F.;
Peralta A.; Puig A.; Rodera Vigil M.; Ronderos G.; Rosell M.; Samudio M.;
Santicchia C.; Szczygiel V.; Takla M.; Tinnirello C.; Tonin S.; Tristan
A.; Troncoso C.; Vignau S.; Yanez K.; Zarate M.; Appeldorf R.; Batrouney
B.; Bonner A.; Bonner M.; Cahill P.; Carr J.; Caruana M.; Chare J.; Doran
A.; Flavel; Griek S.; Hulley A.; Keays P.; Kent S.; Lai N.; Legg H.; Long
A.; Lynch L.; Maxwell V.; McNamara K.; Nairn J.; Nichols V.; Peeler C.;
Phillips J.; Price-Smith S.; Ryan S.; Stockle P.; Tapp E.; Taverner P.;
Tulloch G.; Viola V.; Wilson L.; Beck A.; Damon S.; Drexel V.; Grabner E.;
Hofurthner A.; Kivioja P.; Kretschmer S.; Lener P.; Maiweg J.; Tscherner
D.; Weichelt H.; Winkler J.; Jones D.; Alves L.; Batista R.; Bernardes A.;
Demore de Souza A.; Ferraz R.; Ferreira A.; Freitas E.; Guanaes D.;
Kuschel K.; Muniz R.; Nasser-Hissa V.; Nhan P.; Osorio R.; Queirantes C.;
Reboucas R.; Souza C.; Tonani M.; Vicente C.; Zilli A.; Andersen K.; Aro
L.; Barber C.; Barnable B.; Berard L.; Bernier A.; Boudreault C.;
Bourbonnais A.; Bourgeois L.; Boutin D.; Boyer D.; Branco N.; Briol L.;
Brousseau M.; Burke M.; Chambers C.; Champoux A.; Chan S.; Colborne C.;
Coles K.; Couture M.; Cryderman C.; DeCurtis D.; Dewar C.; Drown J.; Dunn
P.; Eichmann D.; Eikel L.; Fox B.; Gauthier S.; Gibbons D.; Hicks R.; Ho
V.; Kitagawa H.; Kooistra L.; Landry F.; Lapointe F.; Larrivee L.; Leonard
P.; Louch D.; MacNair D.; Magennis L.; Mallette D.; Marchand C.; McLean
S.; Meilleur M.; Murdock H.; Naud M.; Olson K.; Otis J.; Ouimet F.;
Paquette H.; Peck C.; Pelletier A.; Perkins L.; Petrie F.; Pockett S.;
Poulin F.; Poulin M.; Primbas K.; Renton J.; Rouatt S.; Roy M.; Scarcelli
D.; Schellenberg S.; Schellevis K.; Schmidt N.; Scott L.; Skarpinsky B.;
Smith B.; Smith E.; Stafford C.; Stata C.; Sternberg B.; St-Jean N.;
Stoger S.; Thibodeau C.; Toupin A.; Ullyatt L.; Velonas J.; Vienneau R.;
Wall C.; Zaniol D.; Arau M.; Fuentes J.; Hidalgo J.; Landaeta O.; Padilla
I.; Sanzana S.; Tellos G.; Toro F.; Vergara R.; Che T.; Du Y.; He Y.;
Huang C.; Li H.; Liu S.; Luo X.; Ma Y.; Pan S.; Wan Q.; Wang H.; Wang S.;
Xie Y.; Xu X.; Xu Y.; Zhao F.; Zhou M.; Accini M.; Bello O.; Caceres A.;
Camargo S.; Figueroa J.; Florez M.; Gomez Morales K.; Granados L.;
Martinez M.; Medina Ramos M.; Mejia C.; Montoya L.; Ramos C.; Restrepo P.;
Rodriguez D.; Santamaria A.; Valencia T.; Spanic V.; Borre Hansen A.;
Bulow M.; Ehlers G.; Frederiksen A.; Gottschalck H.; Hejlskov B.; Holm
Fruesnsgaard Pedersen L.; Hornum H.; Jansen S.; Johansen A.; Jorgensen A.;
Kjaeulff Svaneborg T.; Kruse A.; Lund K.; Lundgaard M.; Madsen J.; Meier
A.; Muurholm A.; Nedergaard A.; Nielsen S.; Norgaard D.; Olsen A.; Raae
D.; Reiter P.; Sigsgaard U.; Vestergaar I.; Witt A.; Mitt T.; Timmusk P.;
Heikkila E.; Heiskanen R.; Huotari E.; Keskitalo A.; Kylmala L.; Laitinen
M.; Laukkanen M.; Leskinen S.; Liesivuori J.; Lukkari-Kuronen L.; Merisalo
P.; Muurinen E.; Nikkanen P.; Niskanen T.; Pasanen P.; Pekkonen L.; Retsu
A.; Soppela A.; Andreu N.; Ankotche A.; Bairras C.; Boch C.; Camachon L.;
Cherchouly A.; Coudret S.; Demer C.; Gilg R.; Lemonade L.; Madec O.;
Pinotti D.; Poirier I.; Tenne N.; Vogler C.; Amman M.; Andratschke-Gentsch
B.; Beckmann H.; Bischoff S.; Bleich B.; Bueschges G.; Busch E.;
Deigentasch S.; Dietze S.; Dollinger M.; El-Bahay C.; Flehmig G.; Frenzel
I.; Geissler K.; Guerro J.; Heike B.; Holler D.; Inhoffen C.; Klein K.;
Kraehe I.; Kress P.; Krueger H.; Lenz R.; Linnebach B.; Lueck A.; Markhof
P.; Matthies K.; Meier C.; Metzler E.; Moor E.; Noll I.; Paulsen S.;
Pfeffer B.; Promnitz N.; Saljew B.; Schad S.; Schoner C.; Sellmann R.;
Tanis M.; Vogelbusch J.; Wagner E.; Winkler S.; Zenker K.; Zvork S.;
Balogh E.; Buncsikne Molnar S.; Gulyasne Gaspar E.; Herold M.; Kovacs E.;
Kozmane Paszternak A.; Maarne Nagy S.; Nagyne Zoltan A.; Nemeth Z.; Roth
T.; Rozsa I.; Szalai M.; Anuradha M.; Bawa T.; Bhaskar B.; Chalkhore S.;
Choudhary D.; Dhanalaxmi T.; Dhingra V.; Gayatri R.; Gnanasundram R.;
Gopal U.; Govindaraj S.; Indira P.; James S.; Karkuzhli K.; Koppikar V.;
Malhotra N.; Manmohan B.; Mazher A.; Menon R.; Nalini S.; Panda M.; Patel
K.; Poongothai S.; Ramanathan S.; Ramu I.; Sangeetha K.; Sankar K.;
Savitha; Shrinivas K.; Sudha S.; Tripathi S.; Vaseem A.; Yamuna A.;
Banques R.; Chong J.; Courcy M.; Donnelly E.; Fauzi A.; Gately M.; Hanlon
G.; Kelly-Conroy M.; McAteer S.; Seeli Abraham C.; Meaney E.; Storey S.;
Todd M.; Aharonof-Segal M.; Aliazarov N.; Arbeli S.; Butbul E.; Chagai E.;
Confino K.; Domb L.; Dvir R.; Erez N.; Foiening O.; Frishberg A.; Genin
I.; Gertman R.; Golan L.; Grosberd A.; Hadad D.; Israeli S.; Kaplunski Y.;
Karpf D.; Katzir A.; Kivity Z.; Li L.; Livshitz L.; Nachmias A.; Orr I.;
Peer E.; Platner N.; Pritulo L.; Rojansky A.; Rosenblat T.; Saranga H.;
Schterchman G.; Shenhar S.; Shkliar T.; Stam T.; Stinmann S.; Suliman A.;
Tsirulnikov E.; Uziel K.; Weinshtock S.; Yedid-Am S.; Yuval R.; Zuker S.;
Brunella L.; Durante A.; Nada E.; Pugolotti M.; Robusto A.; Testa M.;
Toniato R.; Ha I.; Jung S.; Kim C.; Mi Ran K.; Song B.; Wi Y.; Yang K.;
You J.; Gaisute R.; Ozolina L.; Dzagajeva N.; Kasperaviciene V.;
Krikstaponiene Z.; Montviliene R.; Morkunaite K.; Piepoliene L.; Stoniene
E.; Stonkus S.; Ulpaityte I.; Arenas-Vanhorn M.; Espitia-Serrato L.;
Garcia-Munoz E.; Nunez V.; Sainz T.; Bakker H.; Danse I.; De Greef S.; De
Jong C.; De Wit M.; Didden E.; Dommerholt R.; Goddrie M.; Haazer C.;
Havenaar J.; Hendriks-Van Woerden M.; Jongenotter M.; Kort I.; Koster L.;
Kramer H.; Maarssen E.; Posthuma-Visscher M.; Reijnierse-Buitenwerf H.;
Rood P.; Swets E.; Tousain W.A.; Van Buchem-Damming G.; Van
Buijsen-Nutters A.; Van de Loo R.; Van den Hondel M.; Van den Berg A.; Van
der Knaap-van Keulen M.; Van der Zeijst M.; Van Setten-Van der Meer L.;
Von Bannisseht E.E.; Wouda Z.; Aarsland T.; Amlie L.; Andresen B.;
Bakketun A.; Bognaes A.; Botten C.; Coucheron S.; Halsne A.; Hansen H.;
Holthe T.; Husby E.; Iversen E.; Kvalvik A.; Landbakk T.; Lovseth E.; Moen
S.; Orvik E.; Ovrehus G.; Salater S.; Sorgard B.; Sorstrom A.; Tandberg
L.; Veiding B.; Vinje G.; Winge A.; Abquina G.; Patena B.; Reyes R.;
Tamondong A.; Vega A.; Vitug L.; Makuch M.; Torun A.; Adam A.; Basaraba
M.; Chira C.; Darida C.; Haica C.; Nedelcu A.; Patru D.; Patrut L.; Rau
I.; Rotaru N.; Szabo L.; Vrinceanu G.; Sovenko T.; Zatsevskaya O.;
Horynova Z.; Vankova L.; Barkhuizen M.; Barnard L.; Bekker D.; Botha D.;
Commerford A.; de Klerk A.; De Waal A.; Devchand S.; Drummond F.; Du Toit
A.; Du Toit S.; Ellis T.; Engelbrecht M.; Eramus T.; Fonda K.; Goosen A.;
Gopel E.; Govender P.; Hodge E.; Ismael F.; Jonker E.; Jonker L.; Joubert
A.; Kilian M.; Koegenlenberg N.; Lehner L.; Lingham R.; Llyod T.; Mangoeng
P.; Mapele S.; Meiring J.; Methusi P.; Mmethi M.; Mohamed K.; Moore A.;
Ndiweni H.; Parker F.; Schoneman J.; Smit M.; Steyn A.; Van Dongren J.;
Van Schalkwyk S.; Van Staden L.; van Wyngaard G.; Wolf A.; Ashbaugh R.;
Bande C.; Barquero R.; Gaspar R.; Martin E.; Megia B.; Rodriguez C.;
Seoane A.; Viaplana J.; Akesson Jacobsson I.; Andersson C.; Asperen M.;
Backlund M.; Berglund M.; Bjorck L.; Borjesson M.; Brolin G.; Danielsson
Frojd M.; Duckert A.; Eriksson K.; Fehling K.; Glaas A.; Hage C.; Hoglund
K.; Jernhed H.; Johansson K.; Johansson S.; Lidin M.; Lundell L.; Lundgren
C.; Magnusson K.; Matsson E.; Norman J.; Nystrom K.; Ojutkangas M.;
Olofsson M.; Olsson C.; Pettersson U.; Pramberg E.; Raschperger A.; Sjolin
M.; Soderlund M.; Stensgaard Nake E.; Torebo E.; Uggeldahl I.; Walldin C.;
Welin-Berger B.; Dwyer A.; Meyer-Lazzarini V.; Morello R.; Schefer M.;
Oney S.; Seker T.; Tavlayan S.; Appleby M.; Astin J.; Baker M.; Brann H.;
Brennan C.; Bryan L.; Campbell D.; Carey J.; Cox K.; Davis C.; Dyson B.;
Everdell R.; Gammon B.; Godden J.; Gray T.; Griffiths E.; Grimes Y.; Hall
D.; Hall K.; Holme A.; Howe J.; Lambley-Burke R.; Nation M.; Norcott K.;
Mitchell K.; Poxon S.; Quick C.; Shute C.; Thomas J.; Vinnell T.; Bawa S.;
Bogan C.; Fallye O.; Ginsberg J.; Gregory B.; House B.; Isonaga M.;
Keanne-Richmond P.; Kelly C.; Kimpel J.; Leiby A.; Lyons L.; McCoy B.;
Monk A.; Pelayo E.; Perron M.; Posey D.; Rehan M.; Suarez R.; Tilton L.;
Waite K.; White G.; Chacon R.; Meza Y.; Misticchio F.; Torres M.; Urbaneja
H.
Institution
(Gerstein, Yusuf) Department of Medicine, Population Health Research
Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON,
Canada
(Bosch) Population Health Research Institute and School of Rehabilitation
Science, McMaster University and Hamilton Health Sciences, Hamilton, ON,
Canada
(Dagenais) Institut Universitaire de Cardiologie et de Pneumologie de
Quebec, Quebec, QC, Canada
(Diaz) Estudios Clinicos Latino America, Rosario, Argentina
(Jung) McMaster University and Hamilton Health Sciences, Hamilton, ON,
Canada
(Maggioni) Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO)
Research Center, Florence, Italy
(Pogue) Population Health Research Institute, McMaster University and
Hamilton Health Sciences, Hamilton, ON, Canada
(Probstfield) University of Washington, Seattle, United States
(Ramachandran) India Diabetes Research Foundation, Chennai, India
(Riddle) Oregon Health and Science University, Portland, United States
(Ryden) Department of Medicine, Karolinska Institute, Stockholm, Sweden
Publisher
Massachussetts Medical Society
Abstract
Background: The provision of sufficient basal insulin to normalize fasting
plasma glucose levels may reduce cardiovascular events, but such a
possibility has not been formally tested. Method(s): We randomly
assigned 12,537 people (mean age, 63.5 years) with cardiovascular risk
factors plus impaired fasting glucose, impaired glucose tolerance, or type
2 diabetes to receive insulin glargine (with a target fasting blood
glucose level of <=95 mg per deciliter [5.3 mmol per liter]) or standard
care and to receive n-3 fatty acids or placebo with the use of a 2-by-2
factorial design. The results of the comparison between insulin glargine
and standard care are reported here. The coprimary outcomes were nonfatal
myocardial infarction, nonfatal stroke, or death from cardiovascular
causes and these events plus revascularization or hospitalization for
heart failure. Microvascular outcomes, incident diabetes, hypoglycemia,
weight, and cancers were also compared between groups. Result(s): The
median follow-up was 6.2 years (interquartile range, 5.8 to 6.7). Rates of
incident cardiovascular outcomes were similar in the insulin-glargine and
standard-care groups: 2.94 and 2.85 per 100 person-years, respectively,
for the first coprimary outcome (hazard ratio, 1.02; 95% confidence
interval [CI], 0.94 to 1.11; P = 0.63) and 5.52 and 5.28 per 100
person-years, respectively, for the second coprimary outcome (hazard
ratio, 1.04; 95% CI, 0.97 to 1.11; P = 0.27). New diabetes was diagnosed
approximately 3 months after therapy was stopped among 30% versus 35% of
1456 participants without baseline diabetes (odds ratio, 0.80; 95% CI,
0.64 to 1.00; P = 0.05). Rates of severe hypoglycemia were 1.00 versus
0.31 per 100 person-years. Median weight increased by 1.6 kg in the
insulin-glargine group and fell by 0.5 kg in the standard-care group.
There was no significant difference in cancers (hazard ratio, 1.00; 95%
CI, 0.88 to 1.13; P = 0.97). Conclusion(s): When used to target
normal fasting plasma glucose levels for more than 6 years, insulin
glargine had a neutral effect on cardiovascular outcomes and cancers.
Although it reduced new-onset diabetes, insulin glargine also increased
hypoglycemia and modestly increased weight. Copyright © 2012
Massachusetts Medical Society.

<23>
Accession Number
2035650274
Title
Comparison of continuous Serratus Anterior Plane Block (cSAPB) with
bupivacaine versus single liposomal bupivacaine block in postoperative
analgesia after Video-Assisted Thoracoscopic Surgery (VATS): a randomized
controlled trial.
Source
BMC Anesthesiology. 25(1) (no pagination), 2025. Article Number: 399. Date
of Publication: 01 Dec 2025.
Author
Zhang M.; Zheng Z.; Xie X.; Dai Y.; Zhao M.; Gao K.; Liu S.
Institution
(Zhang, Zheng, Xie, Liu) Department of Anesthesiology, Chengdu Second
People's Hospital, Sichuan Province, Chengdu, China
(Dai) Department of Pain Clinic, School of Medicine, Sichuan Provincial
People's Hospital, University of Electronic Science and Technology of
China, Chengdu, China
(Zhao, Gao) Department of Thoracic Surgery, Chengdu Second People's
Hospital, Sichuan Province, Chengdu, China
Publisher
BioMed Central Ltd
Abstract
Background: Video-Assisted Thoracoscopic Surgery (VATS) is a commonly used
minimally invasive technique in thoracic surgery. The continuous serratus
anterior plane block (cSAPB) involves the placement of a catheter deep in
the serratus anterior fascia for the slow and continuous infusion of local
anesthetics. Liposomal bupivacaine is a formulation of bupivacaine
encapsulated in liposomes, which prolongs the release of the drug. This
study compares the impact of cSAPB with bupivacaine and single-shot SAPB
with liposomal bupivacaine on postoperative recovery quality and pain
control after VATS. Method(s): This study is a Randomized Controlled
Trial. Patients were randomly assigned to two groups: one receiving cSAPB
with conventional bupivacaine (cSAPB + CB) (n = 35) and the other
receiving SAPB with liposomal bupivacaine (SAPB + LB) (n = 35). The
primary outcome measure was the Quality of Recovery (QoR-15) scores at 24
and 48 h post-surgery. Secondary outcomes included: pain intensity
assessed using the Visual Analog Scale (VAS) pain scale at rest and during
deep breathing at 24 and 48 h postoperatively, postoperative pulmonary
function, total opioid consumption during and after surgery, and adverse
events. Result(s): QoR-15 scores were significantly elevated in the
SAPB + LB group at both 24 and 48 h post-surgery(24 h: p = 0.001; 48 h: p
= 0.02). Comparative analysis revealed no statistically significant
differences between the SAPB + CB group and the SAPB + LB group in terms
of VAS scores for pain at rest at 24 and 48 h (24 h: p = 0.06; 48 h: p =
0.46), or during deep breathing (24 h: p = 0.45; 48 h: p = 0.73).
Additionally, there were no significant differences in lung function tests
(FEV1/FVC ratio, p = 0.95), total intraoperative opioid consumption (p =
0.76), or total postoperative opioid consumption (p = 0.69). However, the
incidence of local complications such as swelling and pain was
significantly reduced in the SAPB + LB group (p = 0.03).
 Conclusion(s): The use of single liposomal bupivacaine serratus
anterior plane block provides superior early postoperative recovery
quality and reduces the incidence of local complications. Trial
registration: Chinese Clinical Trial Registry, identifier
ChiCTR2100054089, June 28,2024. Copyright © The Author(s) 2025.

<24>
[Use Link to view the full text]
Accession Number
2037109444
Title
Long-term outcomes of second-generation drug-eluting stents versus
coronary artery bypass graft: a systematic review and meta-analysis of
randomized trials and multivariable adjusted data.
Source
Coronary Artery Disease. 36(6) (pp 518-524), 2025. Date of Publication: 01
Sep 2025.
Author
Carvalho Ferreira A.L.; Benitez M.E.; Lima A.E.; Alamino Lacalle A.; Saad
G.; Guida C.M.
Institution
(Carvalho Ferreira) Department of Medicine, Pontifical Catholic University
of Parana, Curitiba, Brazil
(Benitez) Department of Medicine, Advocate Illinois Masonic Medical
Center, Chicago, IL, United States
(Lima) Department of Medicine, Bahiana School of Medicine and Public
Health, Salvador, Brazil
(Alamino Lacalle) Division of Cardiology, University of Sao Paulo,
Ribeirao Preto, Brazil
(Saad, Guida) Division of Cardiology, Dante Pazzanese Institute of
Cardiology, Sao Paulo, Brazil
Publisher
Lippincott Williams and Wilkins
Abstract
Long-term data are limited comparing percutaneous coronary intervention
(PCI) with second-generation drug-eluting stents (S-DES) vs coronary
artery bypass grafting (CABG) in patients with complex coronary artery
disease (CAD). We aimed to conduct a systematic review and meta-analysis
comparing these interventions in patients with left main or multivessel
CAD. We systematically reviewed PubMed, Embase, and Cochrane for studies
that compared PCI with S-DES and CABG in patients with left main or
multivessel CAD with a minimum mean follow-up period of 3 years. Outcomes
of interest were all-cause mortality, myocardial infarction (MI), stroke,
and major adverse cardiovascular events (MACE). We extracted data from
observational studies as multivariable-adjusted or propensity
score-matched hazard ratio to minimize confounding and pooled hazard
ratios with 95% confidence intervals (CIs) using a random effects model in
Review Manager 5.4.1. We included 10 studies, 3 of which were randomized
controlled trials, comprising a total of 26964 patients, of whom 14928
underwent PCI. As compared with CABG, S-DES had a significantly higher
risk of all-cause mortality (hazard ratio 1.35; 95% CI 1.22-1.49; P <
0.001; I2 = 0%), MACE (hazard ratio 1.27; 95% CI 1.08-1.50; P =
0.005; I2 = 67%), and MI (hazard ratio 2.43; 95% CI 1.80-3.28;
P < 0.01; I2 = 0%). There was no significant difference between
groups in incidence of stroke. In this meta-analysis of patients with
complex CAD, PCI with S-DES was associated with an increased risk of
mortality, MI, and MACE compared with CABG. Copyright © 2025
Wolters Kluwer Health, Inc. All rights reserved.

<25>
Accession Number
2039925068
Title
Effects of Oxygen on Perioperative Vascular Function: A Randomized
Clinical Trial.
Source
Journal of the American Heart Association. 14(15) (no pagination), 2025.
Article Number: e041778. Date of Publication: 2025.
Author
Lopez M.G.; Pandey A.K.; Hennessy C.; Hughes C.G.; Absi T.S.; Shah A.S.;
Shotwell M.S.; Harrison D.G.; Billings F.T.
Institution
(Lopez, Hughes, Billings) Division of Anesthesiology Critical Care
Medicine, Department of Anesthesiology, Vanderbilt University Medical
Center, Nashville, TN, United States
(Pandey) Division of Cardiovascular Medicine, Department of Medicine,
Brigham and Women's Hospital, Boston, MA, United States
(Absi, Shah) Department of Cardiac Surgery, Vanderbilt University Medical
Center, Nashville, TN, United States
(Hennessy, Shotwell) Department of Biostatistics, Vanderbilt University
Medical Center, Nashville, TN, United States
(Harrison, Billings) Division of Clinical Pharmacology, Department of
Medicine, Vanderbilt University Medical Center, Nashville, TN, United
States
Publisher
American Heart Association Inc.
Abstract
BACKGROUND: Vascular dysfunction contributes to postoperative organ
injury. Exposure to high concentrations of oxygen during surgery is common
and may impair vascular function. We tested the hypothesis that hyperoxia
during cardiac surgery impairs vascular function compared with normoxia.
 METHOD(S): We recruited and randomly assigned patients having
elective cardiac surgery to hyperoxia or normoxia during surgery, measured
endothelium-mediated vasodilation via brachial artery flow-mediated
dilation and fingertip pulse amplitude tonometry (reactive hyperemia
index), assessed endothelium-dependent, endothelium-independent, and
heme-independent soluble guanylyl cyclase activator-induced vasodilation
ex vivo in mediastinal fat arterioles using wire myography, and quantified
plasma markers of vascular function and oxidative stress. RESULT(S):
Two hundred participants completed the study. Oxygen treatment did not
affect flow-mediated dilation (primary outcome, P=0.377) or reactive
hyperemia index (P=0.898). In isolated mediastinal fat arterioles,
however, hyperoxia impaired endothelium-independent relaxation (P<0.001)
but not endothelium-dependent relaxation (P=0.759) or heme-independent
soluble guanylyl cyclase activation (P=0.650). Hyperoxia also increased
plasma plasminogen activator inhibitor-1 postoperatively but not
e-selectin or syndecan-1. Hyperoxia increased intraoperative
concentrations of F2-isoprostanes and isofurans, which were associated
with plasminogen activator inhibitor-1 but not other measurements of
vascular function. CONCLUSION(S): Among adults receiving cardiac
surgery, intraoperative hyperoxia did not affect endothelium-dependent
vasodilation but impaired endothelium-independent vasodilation, likely via
soluble guanylyl cyclase heme oxidation. Soluble guanylyl cyclase is a
potential therapeutic target to enhance vascular function. REGISTRATION:
URL: https://www.clini caltr ials. gov; Unique identifier:
NCT02361944. Copyright © 2025 The Author(s).

<26>
Accession Number
2039925257
Title
Cost-Effectiveness of Drug-Coated Balloons in the Treatment of Coronary
Small Vessel Disease: A Report From the BASKET-SMALL 2 Randomized
Controlled Trial.
Source
Journal of the American Heart Association. 14(15) (no pagination), 2025.
Article Number: e037214. Date of Publication: 2025.
Author
Cattaneo M.E.G.V.; Coslovsky M.; Malkin S.J.P.; Fahrni G.; Kaiser C.;
Gilgen N.; Scheller B.; Jeger R.V.
Institution
(Cattaneo, Coslovsky, Fahrni, Gilgen, Jeger) University Hospital Basel,
Department of Clinical Research, University of Basel, Basel, Switzerland
(Malkin) Ossian Health Economics and Communications GmbH, Basel,
Switzerland
(Fahrni, Jeger) Triemli Hospital, Zurich, Switzerland
(Kaiser) University Hospital Basel, Department of Cardiology, University
of Basel, Basel, Switzerland
(Scheller) Clinical and Experimental Interventional Cardiology, Saarland
University, Homburg, Germany
Publisher
American Heart Association Inc.
Abstract
BACKGROUND: Drug-coated balloons (DCB) are noninferior to
second-generation drug-eluting stents (DES) in the treatment of small
vessel coronary artery disease regarding major adverse cardiac events
(MACE). However, the economic implication of this finding is unclear.
 METHOD(S): In the BASKET-SMALL 2 study (Basel Stent
Kosten-Effektivitats Trial: Drug-Coated Balloons Versus Drug-Eluting
Stents in Small Vessel Interventions 2), 738 patients were treated with
either DCB or DES and followed up regarding MACE, that is, target vessel
revascularization, myocardial infarction, or cardiac death, over 3years. A
cost-effectiveness analysis was performed using German diagnosis-related
group data to evaluate total expected costs and quality-adjusted life
expectancy, expressed in quality-adjusted life-years, for the entire
cohort and each treatment option. RESULT(S): DCB led to fewer MACE
than DES (14.5% versus 15.3%) but also reduced quality-adjusted life
expectancy during the 3-year follow-up (2.35 versus 2.36 quality-adjusted
life-years). Regarding direct costs, DCB was less expensive than DES: 5243
versus 5341 EUR during the first 3years. The incremental
cost-effectiveness ratio for DES versus DCB was 6863 EUR per
quality-adjusted life-year gained, whereas DCB was more effective and less
costly than DES in terms of MACE avoided. Sensitivity analyses emphasized
the uncertainty in the results. CONCLUSION(S): Despite reducing the
probability of MACE, in terms of quality-adjusted life expectancy DCB was
less cost effective than DES at 3years in the treatment of small vessel
coronary artery disease, although results varied substantially when
accounting for uncertainty in model parameters. Copyright © 2025
The Author(s) and Ossian Health Economics and Communications GmbH.

<27>
Accession Number
2035611895
Title
The Utilization of Superficial Femoral Artery Access for Transcatheter
Aortic Valve Replacement and Peripheral Vascular Interventions: A
Systematic Review and Meta-Analysis.
Source
Catheterization and Cardiovascular Interventions. (no pagination), 2025.
Date of Publication: 2025.
Author
Dave P.; Alfaifi A.; Traynor B.; Attumalil T.; Bisleri G.; Latter D.; Deva
D.; Wheatcroft M.; Ong G.; Alhazzani W.; Fam N.P.; Alnasser S.M.
Institution
(Dave, Alfaifi, Traynor, Attumalil, Bisleri, Latter, Deva, Ong, Fam,
Alnasser) Structural Heart Program, St. Michael's Hospital, University of
Toronto, Toronto, ON, Canada
(Wheatcroft) Division of Vascular Surgery, St. Michael's Hospital,
University of Toronto, Toronto, ON, Canada
(Alhazzani) Department of Medicine, St. Joseph's Healthcare, McMaster
University, Hamilton, ON, Canada
Publisher
John Wiley and Sons Inc
Abstract
The superficial femoral artery (SFA) is a vascular access alternative for
various cardiovascular interventions, especially when the common femoral
artery CFA is deep, calcified or in high bifurcation. SFA use, however,
was associated with pseudoaneurysms in older literature, and its
utilization for large-bore access is not well established. We conducted a
systematic review, including randomized and observational studies that
reported on SFA vascular access for peripheral arterial disease (PAD), and
transcatheter aortic valve replacement (TAVR) from inception until October
2024. The pooled weighted averages of SFA-related vascular complications
were calculated. In addition, the random-effects model was used to
estimate the pooled odds ratio (OR) comparison between SFA and CFA across
the included studies. The primary endpoint was vascular complications. The
search yielded 1269 articles; 27 (22 in PAD, 5 in TAVR) met our
pre-specified inclusion criteria. Among the PAD studies, 19 were
observational, and three were randomized clinical trials. The weighted
averages for vascular complications and pseudoaneurysms were 9.8% (95% CI
6.1%-15.6%) and 2.7% (95% CI 1.5%-4.9%), respectively. The meta-analysis
included six studies (five observational and one randomized) that compared
outcomes of SFA (838 patients) and CFA (604 patients) and showed no
significant difference in the rates of vascular complications (5.4% in the
SFA group and 6.4% in the CFA group, OR 0.71, 95% CI [0.40-1.27]; p =
0.25%). Among the TAVR studies, SFA was used as the primary access in 18
patients, with no significant bleeding, vascular complications, or
unplanned interventions. In this analysis, SFA access was associated with
good safety in selected patients undergoing peripheral arterial procedures
(low to intermediate risk of bias). It was also feasible as the primary
access route for TAVR in a very small, highly selected group with
unfavorable CFA anatomy (high risk of bias) and therefore is
hypothesis-generating, requiring validation in larger
studies. Copyright © 2025 The Author(s). Catheterization and
Cardiovascular Interventions published by Wiley Periodicals LLC.

<28>
[Use Link to view the full text]
Accession Number
2039881209
Title
The Impact of Coronary Artery Disease in Patients With Peripheral Artery
Disease Undergoing Lower-Extremity Revascularization for Chronic
Limb-Threatening Ischemia.
Source
Circulation. 152(5) (pp 346-348), 2025. Date of Publication: 05 Aug 2025.
Author
Beckman J.A.; Drooz A.T.; Farber A.; Hamdan A.; Huber T.; Hussein M.; Jaff
M.R.; Kashyap V.S.; McGinigle K.L.; Menard M.T.; Rosenfield K.; Semel
M.E.; Strong M.B.; Doros G.; Creager M.A.
Institution
(Beckman) Division of Vascular Medicine, University of Texas Southwestern
Medical Center, Dallas, United States
(Drooz) Division of Vascular and Interventional Radiology, Fairfax
Radiological Consultants & INOVA Fairfax Hospital, VA, United States
(Farber) Division of Vascular and Endovascular Surgery, Boston Medical
Center, Boston University Chobanian & Avedisian School of Medicine, MA,
United States
(Hamdan) Division of Vascular and Endovascular Surgery, Beth Israel
Deaconess Medical Center, Harvard Medical School, Boston, MA, United
States
(Huber) Vascular Surgery Department, University of Florida College of
Medicine, Gainesville, United States
(Hussein, Menard, Semel, Strong) Division of Vascular and Endovascular
Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA,
United States
(Jaff) Retired from Harvard Medical School, Boston, MA, United States
(Kashyap) Frederik Meijer Heart and Vascular Institute, Corewell Health,
Grand Rapids, MI, United States
(McGinigle) Division of Vascular Surgery, School of Medicine, University
of North Carolina, Chapel Hill, United States
(Rosenfield) Section of Vascular Medicine and Intervention, Massachusetts
General Hospital, Harvard Medical School, Boston, United States
(Doros) Boston University, School of Public Health, MA, United States
(Creager) Heart and Vascular Center, Dartmouth Hitchcock Medical Center,
Geisel School of Medicine at Dartmouth, Lebanon, NH, United States
Publisher
Lippincott Williams and Wilkins

<29>
[Use Link to view the full text]
Accession Number
2037228944
Title
Short-term effects of upstream high bolus dose of tirofiban in patients
with ST segment elevation myocardial infarction undergoing primary
percutaneous coronary intervention.
Source
Coronary Artery Disease. 36(6) (pp 488-495), 2025. Date of Publication: 01
Sep 2025.
Author
Abouelnour A.E.I.; Mohammed E.Q.; Fouad D.A.; Tohamy A.
Institution
(Abouelnour, Mohammed, Fouad, Tohamy) Department of Cardiovascular
Medicine, Assiut University Heart Hospital, Assiut, Egypt
Publisher
Lippincott Williams and Wilkins
Abstract
Background No-reflow following primary percutaneous coronary intervention
(PPCI) is challenging to treat. Objectives The objective of this study is
to evaluate the efficacy and safety of upstream high-bolus-dose tirofiban
administration in ST-segment elevation myocardial infarction (STEMI) cases
undergoing PPCI on top of dual antiplatelet therapy, including ticagrelor,
in comparison to selective bailout administration. Methods This
hospital-based, randomized, single-blinded prospective interventional
study was conducted on 150 patients at Assiut University Heart Hospital.
Patients with STEMI within 12 h after symptom onset who underwent PPCI
were randomized to an upstream group (n = 75) and a selective bailout
group (n = 75) based on the timing of the tirofiban bolus administration
(25 microg/kg intravenously over 5 min). Results The bailout group's
thrombolysis in myocardial infarction (TIMI) frame count was higher than
the upstream group's, despite comparable TIMI flow and myocardial blush
grade between the two groups, but only approached statistical significance
[14.4 (4-36) vs 12.2 (5-55), P = 0.08]. The enzymatic infarct size tended
to be lower in the upstream group. All echocardiographic findings were
comparable between the two studied groups, with no significant difference
(P > 0.05). There was no significant difference between the two groups
regarding clinical outcomes. Conclusion Compared to selective bailout
administration, upstream high bolus dose of tirofiban in STEMI patients
undergoing primary coronary intervention did not significantly affect
angiographic outcomes, left ventricular remodeling, or function, despite
smaller infarction size. Copyright © 2025 Wolters Kluwer Health,
Inc. All rights reserved.

<30>
Accession Number
2035503823
Title
Safety and Efficacy of Zero Fluoroscopy Patent Ductus Arteriosus Closure
in Comparison to the Standardized Fluoroscopy-Guided Procedure: A
Systematic Review and Meta-Analysis.
Source
Current Cardiology Reviews. 21(5) (no pagination), 2025. Article Number:
E1573403X338573. Date of Publication: 2025.
Author
Mendel B.; Kohar K.; Djiu R.J.; Yumnanisha D.A.; Vidya A.P.; Winarta J.;
Arifin K.H.; Erlangga Mumtaz M.D.; Nugroho A.K.Z.; Jagannatha G.N.P.;
Siagian S.N.; Prakoso R.
Institution
(Mendel, Siagian, Prakoso) Division of Pediatric Cardiology and Congenital
Heart Disease, Department of Cardiology and Vascular Medicine, National
Cardiovascular Center Harapan Kita, Universitas Indonesia, Jakarta,
Indonesia
(Mendel) Department of Cardiology and Vascular Medicine, Sultan Sulaiman
Government Hospital, Serdang Bedagai, North Sumatera, Indonesia
(Kohar, Djiu, Yumnanisha, Vidya, Winarta, Arifin, Erlangga Mumtaz,
Nugroho) Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
(Jagannatha) Faculty of Medicine, Udayana University, Prof. Dr. I.G.N.G.
Ngoerah General Hospital, Bali, Denpasar, Indonesia
Publisher
Bentham Science Publishers
Abstract
Background: Patent Ductus Arteriosus (PDA) is a common condition in
premature infants requiring intervention to avoid problems. Despite
improvements in lowering radiation exposure and employing better contrast
agents, fluoroscopy is still the most widely employed technique, which
exposes interventional echocardiographers to radiation risks. Techniques,
such as Transthoracic Echocardiography (TTE)-guided procedures or
Transesophageal Echocardiography (TEE)-guided procedures, provide
radiation-free options. This systematic review and meta-analysis aimed to
evaluate the safety and effectiveness of fluoroscopy-guided versus
non-fluoroscopy-guided PDA closure techniques with respect to the
reduction in procedural risks and improved clinical decision-making when
treating hemodynamically severe PDAs in premature newborns. As there is no
specific age or cutoff for this procedure, it is crucial to perform it as
early as possible to prevent complications, especially if symptoms are
already present. Method(s): This systematic review has been
registered in PROSPERO with registration number CRD42024516321. Three
electronic databases (PubMed, Scopus, and Google Scholar) have been
reviewed up to February 2024 to search the literature. The main outcome
has been the procedural success rate. The additional outcomes have
included procedural-related complications rate. We have performed a
proportional meta-analysis using the random-effects model and the
DerSimonian-Laird method. The risk of bias in all included studies has
been evaluated using the STROBE guideline. Result(s): A total of 85
(78 fluoroscopy and 7 zero-fluoroscopy) studies have been included in this
study. Percutaneous PDA closure success rate has been significantly higher
in zero-fluoroscopy group compared to fluoroscopy guidance [99.4% (95%CI:
98.1-100%) and 94.6% (95%CI: 92.3-97%, test for subgroup differences p <
0.01), respectively]. The complication rate has been similar in both
groups [4% (95%CI: 0-10%) in zero-fluoroscopy and 8.9% (95%CI: 6.5-11.3%)
in fluoroscopy group, test for subgroup differences; p = 0.14]. Device
embolization has been the most common complication reported in the
fluoroscopy group [1.7% patients (95%CI: 1.1-2.3%)]. Meanwhile, the
residual leak has been the only complication reported in the
zero-fluoroscopy group [15.6% patients (95%CI: 0-37.5%)].
 Conclusion(s): Patent Ductus Arteriosus (PDA) is common in preemies
and requires intervention. While fluoroscopy is widely used with lower
radiation and better contrast agents, it still carries radiation risks.
Thus, this review has evaluated the safety and effectiveness of
fluoroscopy versus zero-fluoroscopy-guided PDA closures, aiming to reduce
procedural risks and enhance clinical decisions for treating PDA. Zero
fluoroscopy techniques for percutaneous PDA closure have been found to
yield comparable success rates and procedural outcomes to
fluoroscopy-guided procedures. Considering its reduced side effects,
zero-fluoroscopy is safe and can be the preferred method to guide
closures. However, future randomized controlled trials are necessary to
better understand the exact role of interventional echocardiography in PDA
closures. Copyright © 2025 Bentham Science Publishers.

<31>
Accession Number
52169225
Title
Hypotheses, rationale, design, and methods for prognostic evaluation of
cardiac biomarker elevation after percutaneous and surgical
revascularization in the absence of manifest myocardial infarction. A
comparative analysis of biomarkers and cardiac magnetic resonance. The
MASS-V Trial.
Source
BMC Cardiovascular Disorders. 12 (no pagination), 2012. Article Number:
65. Date of Publication: 16 Aug 2012.
Author
Hueb W.; Gersh B.J.; Rezende P.C.; Garzillo C.L.; Lima E.G.; Vieira R.D.;
Garcia R.M.R.; Favarato D.; Segre C.A.W.; Pereira A.C.; Soares P.R.;
Ribeiro E.; Lemos P.; Perin M.A.; Strunz C.C.; Dallan L.A.O.; Jatene F.B.;
Stolf N.A.G.; Hueb A.C.; Dias R.; Gaiotto F.A.; da Costa L.M.A.; Oikawa
F.T.C.; de Melo R.M.V.; Serrano Junior C.V.; de Avila L.F.R.; Villa A.V.;
Filho J.R.P.; Nomura C.; Ramires J.A.F.; Filho R.K.
Institution
(Hueb, Rezende, Garzillo, Lima, Vieira, Garcia, Favarato, Segre, Pereira,
Soares, Ribeiro, Lemos, Perin, Strunz, Dallan, Jatene, Stolf, Hueb, Dias,
Gaiotto, da Costa, Oikawa, de Melo, Serrano Junior, de Avila, Villa,
Filho, Nomura, Ramires, Filho) Heart Institute of the University of Sao
Paulo, Sao Paulo, Brazil
(Gersh) Mayo Clinic, Rochester, MN, United States
(Hueb) Av. Dr. Eneas de Carvalho Aguiar 44 AB-114 Cerqueira Cesar, Sao
Paulo-SP, 05403-000, Brazil
Publisher
BioMed Central Ltd
Abstract
Background: Although the release of cardiac biomarkers after percutaneous
(PCI) or surgical revascularization (CABG) is common, its prognostic
significance is not known. Questions remain about the mechanisms and
degree of correlation between the release, the volume of myocardial tissue
loss, and the long-term significance. Delayed-enhancement of cardiac
magnetic resonance (CMR) consistently quantifies areas of irreversible
myocardial injury. To investigate the quantitative relationship between
irreversible injury and cardiac biomarkers, we will evaluate the extent of
irreversible injury in patients undergoing PCI and CABG and relate it to
postprocedural modifications in cardiac biomarkers and long-term
prognosis.Methods/Design: The study will include 150 patients with
multivessel coronary artery disease (CAD) with left ventricle ejection
fraction (LVEF) and a formal indication for CABG; 50 patients will undergo
CABG with cardiopulmonary bypass (CPB); 50 patients with the same arterial
and ventricular condition indicated for myocardial revascularization will
undergo CABG without CPB; and another 50 patients with CAD and preserved
ventricular function will undergo PCI using stents. All patients will
undergo CMR before and after surgery or PCI. We will also evaluate the
release of cardiac markers of necrosis immediately before and after each
procedure. Primary outcome considered is overall death in a 5-year
follow-up. Secondary outcomes are levels of CK-MB isoenzyme and I-Troponin
in association with presence of myocardial fibrosis and systolic left
ventricle dysfunction assessed by CMR. Discussion(s): The MASS-V
Trial aims to establish reliable values for parameters of enzyme markers
of myocardial necrosis in the absence of manifest myocardial infarction
after mechanical interventions. The establishments of these indices have
diagnostic value and clinical prognosis and therefore require relevant and
different therapeutic measures. In daily practice, the inappropriate use
of these necrosis markers has led to misdiagnosis and therefore wrong
treatment. The appearance of a more sensitive tool such as CMR provides an
unprecedented diagnostic accuracy of myocardial damage when correlated
with necrosis enzyme markers. We aim to correlate laboratory data with
imaging, thereby establishing more refined data on the presence or absence
of irreversible myocardial injury after the procedure, either percutaneous
or surgical, and this, with or without the use of cardiopulmonary bypass.
© 2012 Hueb et al.; licensee BioMed Central Ltd.

<32>
Accession Number
2035654221
Title
Effectiveness of a Single-Use Polyurethane Foam Positioning Pad Compared
With Five-Layer Foam Sacral Dressing for Pressure Ulcer Prevention in the
Operating Room: A Randomized Controlled Clinical Trial.
Source
Health Science Reports. 8(8) (no pagination), 2025. Article Number:
e70963. Date of Publication: 01 Aug 2025.
Author
Elhihi E.A.; Almuwallad S.A.; Alqrashi B.M.; Nada E.M.; Alduaiji N.A.;
Alfakeeh A.A.
Institution
(Elhihi) Nursing Research and Evidence-Based Practice Department, King
Abdullah Medical City, Makkah, Saudi Arabia
(Almuwallad) Wound Care Department, King Abdullah Medical City, Makkah,
Saudi Arabia
(Alqrashi, Nada, Alduaiji, Alfakeeh) Operating Room, King Abdullah Medical
City, Makkah, Saudi Arabia
Publisher
John Wiley and Sons Inc
Abstract
Background and Aims: Among cardiac surgery patients, risk factors for
pressure ulcers include prolonged pressure exposure during lengthy
surgeries, vascular disease, and postoperative vasopressor use.
Conventional pressure ulcer prevention methods may be inadequate for these
high-risk patients. This study evaluated the effectiveness of polyurethane
foam (pink pad) versus a five-layer sacral foam dressing in preventing
pressure ulcers in the operating room. Method(s): A randomized
controlled trial was conducted at a tertiary care hospital in Western
Saudi Arabia, including 100 cardiac surgery patients undergoing procedures
lasting over 4 h. Patients were randomly allocated (1:1) to receive either
a polyurethane foam pink pad (n = 50) or a five-layer foam sacral dressing
(n = 50), with all receiving standard pressure ulcer prevention per
hospital policy. The head of the wound management team conducted wound
assessments using the Bates-Jensen wound assessment tool immediately
postoperatively and on days 3 and 7. This study was conducted in
accordance with the CONSORT guidelines. The data were analyzed using SPSS
version 26 employing a Chi-square test and Fisher's exact test
(significance level: p < 0.05). Result(s): In total, 111 patients
were screened for eligibility, and 100 patients were included and
allocated to both groups. Results showed that 6% of patients in the
polyurethane foam group developed Stage I pressure ulcers, while no cases
were observed in the five-layer foam sacral dressing group, with no
statistically significant difference (p > 0.24). No statistically
significant relationship was found between pressure ulcer development and
demographic or health data (all p > 0.05). Regarding the surgery length,
no statistically significant difference was found between both groups
(t-test 0.69, p = 0.48). Conclusion(s): Both dressings were effective
in minimizing pressure ulcer incidence, although the five-layer foam
sacral dressing showed slightly better performance, achieving complete
pressure ulcer prevention. Trial Registration: ClinicalTrials.gov
(NCT06790277). Copyright © 2025 The Author(s). Health Science
Reports published by Wiley Periodicals LLC.

<33>
Accession Number
2035571243
Title
A computer-driven ventilator liberation protocol in pediatric patients: a
single-center pilot randomized controlled trial.
Source
Frontiers in Pediatrics. 13 (no pagination), 2025. Article Number:
1594160. Date of Publication: 2025.
Author
Chen S.; Xiao C.; Lu X.; Liao M.; Liu C.; Xu F.; Li J.
Institution
(Chen, Xiao, Lu, Liao, Liu, Xu, Li) Department of Critical Care Medicine,
Children's Hospital of Chongqing Medical University, National Clinical
Research Center for Child Health and Disorders, Ministry of Education Key
Laboratory of Child Development and Disorders, Chongqing Key Laboratory of
Pediatric Metabolism and Inflammatory Diseases, Chongqing, China
Publisher
Frontiers Media SA
Abstract
Objective: Timely liberation from invasive mechanical ventilation (IMV) is
important. We aimed to determine the feasibility of our study protocol for
the conduction of a larger prospective trial to examine the utility of a
computer-driven liberation protocol in pediatric patients. Design(s):
Single-center pilot randomized controlled trial. Setting(s): Single,
tertiary care, 52-bed, academic pediatric intensive care unit (PICU).
 Patient(s): Patients aged from 28 days to 18 years undergoing IMV for
more than 24 h. Intervention(s): Patients were randomly assigned to
test and control groups in a ratio of 1:1. The test group underwent
ventilator liberation driven by a computerized algorithm combining
protocolized screening, air leak testing, and spontaneous breathing
testing. The control group underwent ventilator liberation driven by the
attending physician according to standard care. Measurements and Main
Results: A total of 40 patients (20 in each group) were randomized.
Baseline characteristics of the two groups were similar. Durations of IMV
were 95.3 h (95%CI, 9.07-181.53) in the test group and 113.3 h (95%CI,
85.90-140.70) in the control group and were similar (p = 0.62). PICU
length of stay [6.9 days [95%CI, 5.00-8.86] vs. 7.0 days [95%CI,
5.58-8.40]; p = 0.74] and hospital length of stay [22.9 days [95%CI,
11.48-34.24] vs. 26.9 days [95%CI, 17.86-35.94]; p = 0.31] were similar
between the test and control groups, respectively. Conclusion(s): Our
pilot study suggests that the conduction of a larger prospective trial of
a computer-driven ventilator liberation protocol is feasible in our PICU.
And a larger trial is needed to further explore the utility of a
computer-driven ventilator liberation protocol. Clinical Trial
Registration: https://www.chictr.org.cn/showproj.html?proj=168024, Chinese
Clinical Trial Registry ChiCTR2200060033. Copyright 2025 Chen, Xiao,
Lu, Liao, Liu, Xu and Li.

<34>
Accession Number
2034944573
Title
Long-Term Mortality and Morbidity Impact on Patients with Pulmonary
Arterial Hypertension (PAH) If Access to Sotatercept Is Delayed: A
Simulation Model.
Source
Advances in Therapy. 42(8) (pp 3902-3921), 2025. Date of Publication: 01
Aug 2025.
Author
Alsumali A.; McLaughlin V.; Chevure J.; Klok R.; Zhang W.; Martinez E.C.;
Pausch C.; De Oliveira Pena J.; van de Wetering G.; Jootun M.; Lautsch D.;
Hoeper M.M.
Institution
(Alsumali, Klok, Martinez, De Oliveira Pena, Lautsch) BARDS-Health
Economics and Decision Science, Merck & Co., Inc., 126 E. Lincoln Ave.,
Rahway, NJ, United States
(McLaughlin) Division of Cardiovascular Medicine, Department of Internal
Medicine, University of Michigan Health System, Ann Arbor, MI, United
States
(Chevure, Jootun) Merck Sharp & Dohme (UK) Ltd., London, United Kingdom
(Zhang) OPEN Health, Bethesda, MD, United States
(Pausch) Innovation Center Real-World Evidence, GWT-TUD GmbH, Dresden,
Germany
(van de Wetering) OPEN Health, Rotterdam, Netherlands
(Hoeper) Department for Respiratory Medicine and Infectious Diseases,
German Centre of Lung Research (DZL), Hannover Medical School, Hannover,
Germany
Publisher
Adis
Abstract
Introduction: Pulmonary arterial hypertension (PAH) is a rare, progressive
disease associated with significant morbidity and mortality. The phase 3
STELLAR trial tested sotatercept plus background therapy (BGT) versus
placebo plus BGT, where BGT included mono-, double-, or triple-PAH
targeted therapy. Building on the trial's findings, a population health
model was recently published assessing the long-term clinical impact of
sotatercept. This analysis expands on this model and compares the clinical
outcomes of immediate treatment initiation with sotatercept plus BGT
against delayed treatment initiation with sotatercept plus BGT using a
six-state Markov-type model and over a lifetime horizon. Method(s):
State-transition probabilities were obtained from STELLAR, while mortality
rates adjusted for risk strata and probabilities of lung/heart-lung
transplants were derived from COMPERA PAH registry data and literature.
 Result(s): In the base case, a 2-year delay in treatment with
sotatercept plus BGT resulted in an average of 12.4 years life expectancy,
whereas immediate initiation of sotatercept led to an average of 16.5
years, a difference of 4.1 years. Immediate treatment with sotatercept
plus BGT was also associated with a gain in infused prostacyclin-free
life-years and resulted in 210 PAH hospitalizations avoided and 5
lung/heart-lung transplant avoided per 1000 patients. Conclusion(s):
This research suggests that early addition of sotatercept to BGT has the
potential to increase life expectancy among patients with PAH and to
reduce PAH hospitalizations, prostacyclin-use, and lung/heart-lung
transplants needs. Real-world data are needed to confirm these findings,
guiding clinicians and healthcare decision-makers in optimizing PAH
treatment strategies. Trial Registration: ClinicalTrials.gov identifier,
NCT04576988 (STELLAR). Copyright © Merck & Co., Inc., Rahway, NJ,
USA and its affiliates, and Vallerie McLaughlin, Christine Pausch, Marius
M. Hoeper 2025.

<35>
Accession Number
2034803978
Title
Acetylsalicylic acid alone or in combination with either enoxaparin or
unfractionated heparin for postoperative thromboprophylaxis in coronary
artery bypass surgery patients. A randomised clinical trial assessing
surrogate outcomes.
Source
Cardiovascular Revascularization Medicine. 77 (pp 66-74), 2025. Date of
Publication: 01 Aug 2025.
Author
Lorenzen U.S.; Arendrup H.; Johansson P.I.; Jakobsen J.C.
Institution
(Lorenzen) Department of Vascular Surgery, Rigshospitalet, Copenhagen,
Denmark
(Arendrup) Department of Thoracic Surgery, Rigshospitalet, Copenhagen,
Denmark
(Johansson) CAG Center for Endotheliomics, Rigshospitalet, Copenhagen,
Denmark
(Jakobsen) Copenhagen Trial Unit, Capitol Region, Copenhagen, Denmark
(Jakobsen) Department of Regional Health Research, The Faculty of Heath
Sciences, University of Southern Denmark, Denmark
(Johansson) Department of Clinical Medicine, University of Copenhagen,
Copenhagen, Denmark
Publisher
Elsevier Inc.
Abstract
Introduction: Coronary artery bypass graft surgery has considerable
effects on patient haemostasis. Heparins as thromboprophylaxis may be
beneficial but may also increase the risk of bleeding complications.
 Objective(s): To assess the effects of heparins on haemostasis in
post-coronary artery bypass graft patients. Method(s): Across one
year, we randomised 60 participants scheduled for an elective coronary
artery bypass graft-procedure with or without aortic valve replacement.
The trial was a prospective, open-label (though blinded for the
laboratory), randomised, single-centre trial with three intervention
groups (n = 20 in each): group 1 received acetylsalicylic acid, group 2
received subcutaneous low molecular weight heparin and acetylsalicylic
acid, and group 3 received intravenous unfractionated heparin and
acetylsalicylic acid. Primary outcomes were platelet activation
(Multiplate ASPI-test) and time to clot initiation (TEG R-time). We
secondly assessed several additional Multiplate and TEG parameters.
 Result(s): Group 3 (intravenous unfractionated heparin) compared with
group 1 (acetylsalicylic acid alone) showed evidence of 1) increased clot
initiation time (R-time + 0.9 min; 95 % CI: +0.4 to +1.4 min; P = 0.009),
and 2) decreased 30-min lysis (-1.3 %; 95 % CI: -2.1 to -0.5 %; P = 0.02).
The remaining analyses of primary and secondary outcomes showed no
evidence of a difference between the three groups. Discussion(s):
Intravenous unfractionated heparins may increase the clot initiation time
post-operatively after coronary artery bypass graft surgery and reduce
lysis. Otherwise, there seems to be no effect of low molecular weight or
unfractionated heparin on haemostatic parameters after coronary artery
bypass surgery patients. Copyright © 2024 The Authors

<36>
Accession Number
2032639935
Title
Phone-based telemonitoring of arterial hypertension versus usual care: the
HOROSCOPE study.
Source
Hypertension Research. 48(3) (pp 1135-1143), 2025. Date of Publication: 01
Mar 2025.
Author
Saafi M.; Bel Haj Ali K.; Dhaoui R.; Toumia M.; Sassi S.; Bendaya Y.;
Bouchoucha M.; Hafaeidh S.B.; Trabelsi I.; Sekma A.; Bakir A.; Jaballah
R.; Yaakoubi H.; Youssef R.; Zorgati A.; Beltaief K.; Mezgar Z.; Khrouf
M.; Sghaier A.; Jerbi N.; Razgallah R.; Bouida W.; Grissa M.H.; Saad J.;
Boubaker H.; Dridi Z.; Boukef R.; Msolli M.A.; Nouira S.; Ben Hafeidh S.;
Saadallah F.; Harzallah O.; Hassine F.; Said S.B.; Chebil M.; Gtari A.;
Khedher S.; Ghedira L.; Sahtout M.; Zayene S.; Hafsa M.; Belkacem N.
Institution
(Saafi, Bel Haj Ali, Dhaoui, Sassi, Trabelsi, Sekma, Beltaief, Bouida,
Grissa, Boubaker, Boukef, Msolli, Nouira) Research Laboratory LR12SP18,
Monastir University, Monastir, Tunisia
(Bel Haj Ali, Dhaoui, Sassi, Sekma, Beltaief, Bouida, Grissa, Boubaker,
Msolli, Nouira) Emergency Department, Fattouma Bourguiba University
Hospital, Monastir, Tunisia
(Toumia) Emergency Department, Haj Ali Soua Regional Hospital, Ksar
Hellal, Monastir, Tunisia
(Bendaya, Bouchoucha, Hafaeidh, Ben Hafeidh) Medis Laboratories, Tunis,
Tunisia
(Bakir, Jaballah, Yaakoubi, Youssef, Zorgati, Boukef) Emergency
Department, Sahloul University Hospital, Sousse, Tunisia
(Mezgar, Khrouf) Emergency Department, Farhat Hached University Hospital,
Sousse, Tunisia
(Sghaier, Jerbi) Emergency Department, Taher Sfar University Hospital,
Mahdia, Tunisia
(Razgallah) DACIMA Consulting, Tunis, Tunisia
(Saad) Department of imaging and interventional radiology, Fattouma
Bourguiba University Hospital, Monastir, Tunisia
(Dridi) Cardiology Department of Fattouma Bourguiba University Hospital,
Monastir, Tunisia
(Belkacem) Teboulba Regional Hospital, Monastir, Tunisia
(Hafsa) Liberal Physician, Ksar Hlel, Monastir, Tunisia
(Chebil, Zayene) Liberal Physician, Teboulba, Monastir, Tunisia
(Sahtout) C2 Primary Health Center, Monastir Health Group, Lamta,
Monastir, Tunisia
(Saadallah, Hassine, Said, Gtari, Ghedira) Liberal Physician, Monastir,
Tunisia
(Khedher) Primary Health Center, Jemmel, Monastir, Tunisia
(Harzallah) Liberal Physician, Lamta, Monastir, Tunisia
Publisher
Springer Nature
Abstract
The Horoscope trial aimed to assess the efficacy of home blood pressure
(BP) telemonitoring (TLM) in controlling BP reduction in hypertensive
patients compared with usual care. This is a multi-center, prospective
randomized, parallel-group trial comparing TLM with usual care during a
period of 6 months in patients with hypertension. We included 525 patients
randomly assigned in a 1-1 ratio to telemonitoring (TLM group; n = 260) or
usual care (control group; n = 265). After 6 months of follow up, mean
values of 24-h systolic and diastolic blood pressure decreased in both TLM
and control groups. The mean decrease was significantly greater in the TLM
group vs control group (-3.29 mmHg Vs -1.19; p = 0.009) and (-2.9 mmHg Vs,
-0.07; p = 0.002) for systolic and diastolic blood pressure, respectively.
This study shows that TLM results in significant BP reduction compared to
usual care in a Tunisian population of patients with hypertension. Our
findings highlight the importance of integrating telemedicine in the
management of hypertensive patients; it has the potential to improve the
quality of the delivered care and to prevent cardiovascular consequences
of uncontrolled BP. (Figure presented.) Copyright © The
Author(s), under exclusive licence to The Japanese Society of Hypertension
2024.

<37>
Accession Number
2035617102
Title
Impact of a specialized care program in the prevention and managing of
skin integrity disorder in pediatric patients after open heart surgery.
Source
BMC Pediatrics. 25(1) (no pagination), 2025. Article Number: 603. Date of
Publication: 01 Dec 2025.
Author
Kalhor F.; Mlekpour M.; Yazdannik A.; Bigdelian H.
Institution
(Mlekpour) Faculty of Nursing and Midwifery, Isfahan University of Medical
Sciences, Isfahan, Iran, Islamic Republic of
(Yazdannik) Department of Critical Care, Nursing and Midwifery Care
Research Center, Faculty of Nursing and Midwifery, Isfahan University of
Medical Sciences, Isfahan, Iran, Islamic Republic of
(Kalhor) Department of Neonatal and Pediatric Care, Nursing and Midwifery
Care Research Center, Faculty of Nursing and Midwifery, Isfahan University
of Medical Sciences, Isfahan, Iran, Islamic Republic of
(Kalhor) Trauma Nursing Research Center, Faculty of Nursing and Midwifery,
Kashan University of Medical Science, Kashan, Iran, Islamic Republic of
(Bigdelian) Department of Cardiovascular Surgery, School of Medicine,
Isfahan University of Medical Sciences, Isfahan, Iran, Islamic Republic of
Publisher
BioMed Central Ltd
Abstract
Background: Patients undergoing cardiac surgery, particularly children,
are at an increased risk of experiencing skin integrity disorders and
pressure ulcers, attributed to the underlying disease and prolonged
surgical durations. This study aims to examine the impact of a specialized
care program on the incidence and advancement of skin integrity disorders
in children aged 1 month to 6 years after open heart surgery.
 Material(s) and Method(s): This quasi-experimental study, registered
with the Iranian Registry of Clinical Trials (IRCT) under the identifier
IRCT202008250458515N12 on November 11, 2020, involved 80 children admitted
to the critical care unit of a teaching hospital. The participants were
divided into two groups: an intervention group and a control group, each
consisting of 40 children. The intervention group received targeted care
program measures, while the control group followed standard care
procedures. The risk of pressure ulcer development, incidence of skin
damage, and pressure ulcer status were assessed and recorded using the
Braden Q Scale and the Pressure Ulcer Scale for Healing (PUSH) both before
the intervention and seven days after hospitalization. Finding(s):
The incidence of skin damage in the intervention group (45%) was
significantly lower than that in the control group (62.5%) (P < 0.001).
Additionally, the average scores for PUSH and Braden Q in the intervention
group were 2.95 +/- 0.67 and 27.48 +/- 1.50, respectively, whereas in the
control group, they were 5.70 +/- 1.07 and 25.05 +/- 2.22, respectively.
These differences were statistically significant (P < 0.001).
 Conclusion(s): According to the results, the designed focused care
program can lead to the reduction of the risk of skin damage and the
improvement in pressure ulcers; thus, it is recommended to be considered
in the special care units. Copyright © The Author(s) 2024.

<38>
Accession Number
2035196555
Title
Predictors of Post-TAVR Left Bundle Branch Block: A Systematic Review and
Meta-Analysis.
Source
Journal of Cardiovascular Electrophysiology. 36(8) (pp 2041-2060), 2025.
Date of Publication: 01 Aug 2025.
Author
Alzu'bi H.; Rmilah A.A.; Bahmad H.F.; Urina-Jassir D.; Elajami M.K.;
Rogers E.; Elgozair M.; Ghssein G.; Salami A.; Welty F.K.; Escolar E.;
Mihos C.G.; Beohar N.; Elajami T.K.
Institution
(Alzu'bi, Escolar, Elajami) Columbia University Division of Cardiology,
Mount Sinai Heart Institute, Miami Beach, FL, United States
(Rmilah, Elgozair) Department of Cardiology, Mayo Clinic, Rochester, MN,
United States
(Rmilah) Department of Internal Medicine, Magnolia Regional Health Center,
Corinth, MS, United States
(Bahmad) Department of Pathology and Laboratory Medicine, University of
Miami Miller School of Medicine, Miami, FL, United States
(Urina-Jassir) Department of Cardiology, John W. Deming Department of
Medicine, Tulane University School of Medicine, New Orleans, LA, United
States
(Elajami, Rogers) Department of Internal Medicine, Mount Sinai Medical
Center, Miami Beach, FL, United States
(Ghssein) Department of Biology, Faculty of Sciences, Lebanese University,
Nabatieh, Lebanon
(Salami) Department of Mathematics, Faculty of Sciences, Lebanese
University, Nabatieh, Lebanon
(Welty) Division of Cardiology, Beth Israel Deaconess Medical Center,
Boston, MA, United States
(Mihos, Elajami) Echocardiography Laboratory, Columbia University Division
of Cardiology, Mount Sinai Heart Institute, Miami Beach, FL, United States
(Beohar) Cardiac Catheterization Laboratory, Columbia University Division
of Cardiology, Mount Sinai Heart Institute, Miami Beach, FL, United States
Publisher
John Wiley and Sons Inc
Abstract
Left bundle branch block (LBBB) is the most common conduction abnormality
following transcatheter aortic valve replacement (TAVR) and has been
associated with adverse clinical outcomes. While multiple predictors of
post-TAVR LBBB have been proposed, data remain limited. This systematic
review and meta-analysis aims to identify and summarize predictors of
new-onset LBBB post-TAVR. A systematic literature search was performed to
identify studies that reported predictors of new-onset post-TAVR LBBB.
Extracted data included patient factors, electrocardiographic (ECG) and
anatomic parameters, and device-related factors. A random-effects model
was used to calculate crude risk ratios (RRs), mean differences, and 95%
confidence intervals (CI) of the predictors. Of 450 articles screened, 17
studies comprising a total of 6357 patients were included. Among these,
26.4% developed post-TAVR LBBB. Increased risk was associated with
diabetes mellitus (RR: 1.22, p < 0.001), use of 29-mm valve (RR: 1.59, p <
0.001), and use of Medtronic CoreValve (MCV) (RR: 2.25, p = 0.008).
Significant differences were found between patients with and without LBBB
in interventricular septal thickness (IVS; by -0.66 mm), membranous septal
length (MSL; by -0.9 mm), left ventricular outflow tract (LVOT) diameter
(by -0.48 mm), PR interval (by +13.95 ms), and prosthesis implantation
depth (by +2.6 mm). Diabetes Mellitus, use of 29-mm valve or MCV,
decreased IVS thickness, shorter MSL, smaller LVOT diameter, increased
prosthesis implantation depth, and prolonged PR duration were all
associated with an elevated risk of post-TAVR LBBB. Early identification
of these predictors may help reduce the risk of conduction abnormalities
after TAVR. Copyright © 2025 Wiley Periodicals LLC.

<39>
Accession Number
2039903907
Title
Ultrasound-Guided Stellate Ganglion Block Regulates Inflammatory Cytokines
and Improves Short-Term Outcome after Cardiac Surgery with Cardiopulmonary
Bypass: A Randomized Clinical Trial.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2025.
Date of Publication: 2025.
Author
Lv H.; Lv X.; Ai Z.; Huang Z.; Yu H.; Yu X.
Institution
(Lv, Ai, Huang) College of Medicine, Zhejiang University, Hangzhou, China
(Lv, Yu) Department of Anesthesiology, Sir Run Run Shaw Hospital of
Zhejiang University, Hangzhou, China
(Yu) Department of General Surgery, Sir Run Run Shaw Hospital of Zhejiang
University, Hangzhou, China
Publisher
W.B. Saunders
Abstract
Objectives: To evaluate the effectiveness of left stellate ganglion block
(SGB) for inflammatory cytokines and short-term outcomes in cardiac
surgery with cardiopulmonary bypass (CPB). Design(s): Prospective,
randomized, double-blinded clinical trial. Setting(s): Single
academic center hospital. Participant(s): We included patients aged
18 to 70 scheduled for cardiac surgery with CPB. Intervention(s):
Before anesthesia induction, the patients who were allocated to either the
SGB group or the control group received SGB using either 0.5% ropivacaine
or 0.9% saline. Measurements and Main Results: The primary outcome
was the inflammatory cytokine concentration before (T0) and 6 hours (T1),
24 hours (T2), and 5 days (T3) after the block. Secondary outcomes
included the incidence of SIRS 24 hours after surgery, immune function at
each time point, intraoperative and postoperative complications, 30-day
mortality, intensive care unit and hospital stay, and hospitalization
costs. The analysis included 25 SGB and 25 control patients. Compared with
the control group, the SGB group significantly inhibited elevated
TNF-alpha concentration at 6 hours and 24 hours after the block (p <
0.05). SGB significantly reduced the SIRS 24 hours after surgery,
decreased the neutrophil percentage at 6 hours after the block, and
increased the lymphocyte percentage at 5 days after the block.
Additionally, SGB decreased the incidence of ventricular fibrillation
after reperfusion, postoperative delirium, and the occurrence of
Clavien-Dindo grade III-IV. Conclusion(s): SGB effectively improves
short-term outcomes in patients with cardiac surgery and CPB, possibly
through modulating the neuro-endocrine-immune network to normalize
sympathetic nervous system activity and stabilize perioperative tumor
necrosis factor-alpha concentration. Copyright © 2025

<40>
Accession Number
2035194212
Title
Routine invasive vs. conservative strategy in elderly patients with
non-ST-elevation acute coronary syndrome.
Source
Expert Review of Cardiovascular Therapy. 23(7) (pp 345-356), 2025. Date of
Publication: 03 Jul 2025.
Author
Diaz-Arocutipa C.; Salguero R.; Martin-Asenjo R.; Puerto E.; Costabel
J.P.; Hernandez A.V.; Vicent L.
Institution
(Diaz-Arocutipa, Hernandez) Unidad de Revisiones Sistematicas y
Meta-analisis (URSIGET), Vicerrectorado de Investigacion, Universidad San
Ignacio de Loyola, Lima, Peru
(Salguero, Martin-Asenjo, Puerto, Vicent) Department of Cardiology,
Hospital Universitario 12 de Octubre, Instituto de Investigacion Sanitaria
Hospital 12 de Octubre (imas12), Madrid, Spain
(Salguero, Martin-Asenjo, Puerto, Vicent) Centro de Investigacion
Biomedica en Red Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
(Costabel) Division of Cardiology, Instituto Cardiovascular de Buenos
Aires (ICBA), Buenos Aires, Argentina
(Hernandez) Health Outcomes, Policy, and Evidence Synthesis (HOPES) Group,
University of Connecticut School of Pharmacy, Storrs, CT, United States
Publisher
Taylor and Francis Ltd.
Abstract
Introduction: The optimal management of elderly patients with
non-ST-segment elevation acute coronary syndrome (NSTE-ACS) remains
uncertain. This systematic review assessed routine invasive versus
conservative strategies in this population. Method(s): PubMed,
Embase, and Scopus were searched through September 2024 for randomized
controlled trials comparing both strategies. The primary outcome was major
adverse cardiovascular events (MACE); secondary outcomes included
all-cause mortality, cardiovascular mortality, non-cardiovascular
mortality, myocardial infarction, revascularization, stroke, and bleeding.
Evidence certainty was evaluated using GRADE, and meta-analyses applied
random-effects models. Result(s): Seven RCTs (n = 2,997; mean age
81-86 years; 49% female) were included. Invasive strategy reduced MACE
risk (HR 0.77, 95% CI 0.65-0.92), with consistent point estimate direction
across trials. Myocardial infarction (HR 0.70, 95% CI 0.59-0.84) and
revascularization (HR 0.45, 95% CI 0.23-0.90) were also significantly
reduced. No significant differences were observed for all-cause mortality
(HR1.04, 95% CI 0.90-1.19), cardiovascular mortality (HR 1.10, 95% CI
0.86-1.41), stroke (HR 0.78, 95% CI 0.53-1.16), or bleeding (RR1.23, 95%
CI 0.90-1.69). Evidence certainty was moderate for most outcomes.
 Conclusion(s): In elderly NSTE-ACS patients, routine invasive
strategy reduces cardiovascular events without significantly increasing
bleeding, supporting individualized treatment decisions. Registration: The
protocol for this study was registered in the PROSPERO repository
(CRD42024600769). Copyright © 2025 Informa UK Limited, trading as
Taylor & Francis Group.

<41>
[Use Link to view the full text]
Accession Number
2039799912
Title
Effects of continuous pecto-intercostal fascial block for management of
post-sternotomy pain in patients undergoing cardiac surgery: a randomized
controlled trial.
Source
International Journal of Surgery. 111(2) (pp 2037-2045), 2025. Date of
Publication: 01 Feb 2025.
Author
Zhao Y.; He D.; Zhou W.; Chen C.; Liu Z.; Xia P.; Ye Z.; Li C.
Institution
(Zhao, He, Zhou, Chen, Liu, Xia, Ye, Li) Department of Anesthesiology,
Xiangya Hospital of Central South University, Hunan Province, Changsha,
China
(Liu, Xia, Ye, Li) National Clinical Research Center for Geriatric
Disorders, Central South University, Hunan Province, Changsha, China
Publisher
Wolters Kluwer Health Inc
Abstract
Background: Managing postoperative pain following median sternotomy has
long been a notable challenge for anesthesiologists. The administration of
postoperative analgesia traditionally relies on intravenous pumps for the
delivery of opioids. With the development of regional block techniques and
postoperative multimodal analgesia, pecto-intercostal fascial block (PIFB)
has gained widespread utilization due to its distinctive advantages.
However, its application is limited to a single block. This study aimed to
indicate whether continuous PIFB analgesia in cardiac surgery via
sternotomy could possess clinical advantages compared with intravenous
analgesia in terms of postoperative pain management. If continuous PIFB
analgesia was the priority, the secondary objective would involve
determining the most effective administration method, making it a critical
area of exploration. Method(s): Totally, 114 patients were randomly
allocated to three groups: the patient-controlled intravenous analgesia
(PCIA) group, receiving intravenous opioid infusion exclusively via pump,
and the constant infusion pecto-intercostal fascial block (C-PIFB) and
intermittent infusion pecto-intercostal fascial block (I-PIFB) groups,
where ultrasound-guided PIFB with a nerve-blocking pump was administered.
The C-PIFB group received a constant basal infusion, while programmed
intermittent boluses were administered in the I-PIFB group. The primary
end point was postoperative visual analog scale (VAS) scores, and
secondary outcomes included intraoperative sufentanil consumption, time to
extubation, mobilization, length of stay in the intensive care unit (ICU)
and hospital, and the incidence of postoperative complications.
 Result(s): The VAS scores at rest and during coughing were noticeably
diminished in the two block groups relative to the intravenous pump group
at 12, 24, 48, and 72 h postoperatively. Notably, intraoperative
sufentanil consumption was significantly reduced in the C-PIFB group [3.12
(0.93) microg kg-1] and the I-PIFB group [3.42 (0.77) microg
kg-1] compared with the PCIA group [4.66 (1.02) microg
kg-1, P < 0.001]. Time to extubation, mobilization, length of
stay in ICU and hospital, and use of rescue analgesics did not exhibit
statistically significant differences among the three groups. However, the
postoperative complication rates were markedly lower in the C-PIFB group
(42.11%) and I-PIFB group (36.84%) relative to the PCIA group (81.58%, P <
0.001). There were no significant differences between C-PIFB and I-PIFB
groups regarding VAS score, secondary outcomes, and postoperative
complications. Conclusion(s): Continuous PIFB can provide
satisfactory postoperative analgesia while reducing perioperative opioid
consumption, diminishing the risk of postoperative complications, and
accelerating postoperative recovery for patients undergoing median
sternotomy in cardiac surgery. The constant basal infusion method may be
the optimal approach for administering continuous PIFB. Copyright
© 2025 The Author(s)

<42>
[Use Link to view the full text]
Accession Number
2039228100
Title
Bridging antiplatelet therapies in patients undergoing surgery: a
meta-analysis.
Source
Journal of Cardiovascular Medicine. 26(8) (pp 405-408), 2025. Date of
Publication: 01 Aug 2025.
Author
Scalamera R.; Benenati S.; Vergallo R.; Porto I.
Institution
(Scalamera, Benenati, Vergallo, Porto) Department of Internal Medicine and
Medical Specialities (DIMI), University of Genoa Genoa, Italy
(Vergallo, Porto) Cardiothoracic and Vascular Department (DICATOV), IRCCS
Policlinic Hospital San Martino, Genoa, Italy
Publisher
Lippincott Williams and Wilkins

<43>
Accession Number
2039820073
Title
Sternal advancement surgery for pectus excavatum: a systematic review and
meta-analysis of cardiac and respiratory function outcomes.
Source
Journal of Thoracic Disease. 17(7) (pp 4897-4908), 2025. Date of
Publication: 31 Jul 2025.
Author
Belgacem A.; Abane C.; Tricard J.; Felix P.; Lavrand F.; Laloze J.; Lopez
P.; Bothorel P.; Auditeau E.; Fourcade L.; Ballouhey Q.
Institution
(Belgacem, Lopez, Fourcade, Ballouhey) Department of Pediatric Surgery,
Children Hospital, Limoges, France
(Abane) Department of Orthopedy and Traumatology, Hopital Dupuytren,
Limoges, France
(Tricard, Felix) Department of Thoracic Surgery, Hopital Dupuytren,
Limoges, France
(Lavrand) Department of Pediatric Surgery, Hospital Pellegrin Bordeaux,
Bordeaux, France
(Laloze) Department of Plastic Surgery, Hopital Dupuytren, Limoges, France
(Bothorel) Department of Pediatric Cardiology, Children Hospital, Limoges,
France
(Auditeau) Department of Epidemiology, Hopital Dupuytren, Limoges, France
Publisher
AME Publishing Company
Abstract
Background: Pectus excavatum (PE) is the most common malformation of the
anterior chest wall, affecting around 1 in 400 births, with a male/female
sex ratio of 5:1. Even if the functional repercussions and management of
PE are still the subject of many debates, the cardiorespiratory function
improvement after surgical correction of PE with sternal advancement seem
to be confirmed in the recent literature. This study aims to assess the
impact of sternal advancement surgery-specifically minimally invasive
repair of PE (MIRPE) and sternochondroplasty-on cardiorespiratory function
at rest and during exercise in patients with PE. Method(s): A
meta-analysis was conducted on 21 studies reporting pre- and
post-operative cardiac and/or respiratory function at rest and during
exercise. Result(s): A total of 1,087 patients (mean age, 18.93
years) were included. Significant improvements were found in resting
cardiac function, including cardiac output (P=0.04), cardiac index
(P=0.03), left ventricular systolic ejection volume (LVSEV, P=0.001), and
ejection fraction (P=0.03). Exercise capacity also improved significantly,
with increases in VO<inf>2</inf>max and O<inf>2</inf> pulse (both
P<0.001). No significant changes were observed in respiratory parameters.
 Conclusion(s): Cardiac output assessment should be central to
surgical decision-making in PE. Techniques involving sternal mobilization
can yield meaningful improvements in cardiopulmonary function, unlike
procedures that do not remodel the osteocartilaginous
deformity. Copyright © AME Publishing Company.

<44>
Accession Number
2036958963
Title
Assessment of Pain Control using Ultrasound-guided Bilateral
Pecto-intercostal Fascial Plane Block in Pediatric Cardiac Surgeries on
Cardiopulmonary Bypass.
Source
Journal of Cardiac Critical Care. 9(3) (pp 164-170), 2025. Date of
Publication: 01 Jul 2025.
Author
Badge M.; Kapoor P.M.; Nagaswetha L.S.; Rajgopalan K.; Choudhury M.
Institution
(Badge, Kapoor, Nagaswetha, Rajgopalan, Choudhury) Department of Cardiac
Anaesthesia and Critical Care, All India Institute of Medical Sciences,
New Delhi, India
Publisher
Scientific Scholar LLC
Abstract
Objectives: Acute post-operative pain can be a cause of significant
morbidity in pediatric cardiac surgical patients. The purpose of this
study was to evaluate the efficacy and safety of ultrasound-guided
bilateral pecto-intercostal fascial plane block (PIFB) in pediatric
cardiac surgical patients. Material(s) and Method(s): It was a
randomized, prospective, single-blinded, comparative study in a tertiary
care cardiac center. The study comprised 90 patients with acyanotic and
cyanotic congenital heart disease undergoing cardiac surgery through
midline sternotomy on cardiopulmonary bypass (CPB), randomized into two
groups - Group P (PIFB) and Group C (control). Following surgical skin
closure, Group P was administered bilateral PIFB using 3 mg/kg of 0.2%
ropivacaine. Fentanyl was provided before extubation, while tramadol was
employed post-extubation as rescue analgesia. Paracetamol was administered
to both groups as part of a multimodal analgesia protocol. Result(s):
Resting modified objective pain score (MOPS) at 1, 2, 4, 6, 8, 10, 12, 24,
and 36 h was measured post-extubation. After exclusions, 83 patients were
evaluated. MOPS at all-time intervals for 36 h was comparatively less in
the PIFB group (P < 0.01). Time to extubate (P < 0.001), post-operative
fentanyl pre-extubation (P < 0.001), time to first rescue analgesia (P <
0.001), tramadol post-extubation (P < 0.001), paracetamol requirement (P <
0.001), intensive care unit length of stay (P = 0.008), and the hospital
length of stay (P = 0.007) were significantly less in Group P. No adverse
events attributable to PIFB were observed. Conclusion(s):
Ultrasound-guided bilateral PIFB represents a safe and effective modality
for the management of acute post-operative pain in pediatric patients
undergoing cardiac surgery with CPB. Copyright ©2025 Published by
Scientific Scholar on behalf of Journal of Cardiac Critical Care TSS.

<45>
Accession Number
2039206194
Title
Temporal Trends and Severity of Postoperative Delirium in Cardiac Surgery:
Insights from a Systematic Review and Meta-analysis.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 39(9) (pp 2424-2435),
2025. Date of Publication: 01 Sep 2025.
Author
Shamsi T.; Janga S.R.; Baskaran N.U.; Rangasamy V.; Ramachandran R.V.;
Chen M.; Ganesh S.; Novack V.; Subramaniam B.
Institution
(Shamsi, Janga, Baskaran, Rangasamy, Chen) Beth Israel Deaconess Medical
Center, Boston, MA, United States
(Ramachandran) University of Washington Medicine, Seatle, WA, United
States
(Ganesh) New York Institute of Technology College of Osteopathic Medicine,
New York, NY, United States
(Novack) Soroka University Medical Center, Beer-Sheva, Israel
(Subramaniam) Harvard Medical School, Sadhguru Center for a Conscious
Planet, Beth Israel Deaconess Medical Center, Boston, MA, United States
Publisher
W.B. Saunders
Abstract
Postoperative delirium (POD) is one of the most common neurocognitive
complications following cardiac surgery, typically occurring within 72
hours and leading to serious consequences, including falls, prolonged
hospitalization, and increased healthcare costs. Annually, over two
million cardiac surgeries, including coronary artery bypass grafting, are
performed worldwide. This study systematically reviews and meta-analyzes
the incidence, duration, time to onset, and severity of delirium following
cardiac surgery. No previous comprehensive analysis has addressed all
these outcomes, particularly regarding temporal patterns and severity of
POD. A systematic review was performed following PRISMA guidelines. The
studies included adult patients who underwent cardiac surgery and were
assessed for delirium using validated tools. Statistical analyses included
random-effects meta-analysis for incidence rates and subgroup analyses.
Twenty-seven studies involving 5,126 participants from 2009 to March 2024
were included. The overall incidence of POD was 25.1% (95% confidence
interval [CI]: 21.8%-28.3%), with a mean duration of 2.378 days (95% CI:
2.086-2.671), and onset occurring at 1.706 days (95% CI: 1.198-2.214).
Only three studies assessed the severity of delirium, reporting a maximum
Confusion Assessment Method score of 9.308 (95% CI: 7.309-11.307) on a
scale of 0 to 19. Subgroup analyses were conducted to examine
heterogeneity but revealed no significant differences in outcomes.
Therefore, a meta-regression analysis focusing on age, surgery duration,
assessment length, study design, and assessment tools was performed. The
incidence and burden of POD highlight the need for regular screening and
effective management strategies. Copyright © 2025 Elsevier Inc.

<46>
Accession Number
2039799504
Title
Comparison of thoracoscopic-guided intercostal nerve block and
ultrasound-guided intercostal nerve block in postoperative analgesia of
uniportal video-assisted lobectomy: a pilot randomized controlled trial.
Source
International Journal of Surgery. 111(2) (pp 1995-2001), 2025. Date of
Publication: 01 Feb 2025.
Author
Li Y.; Wei L.; Du J.-H.; He J.-X.; Xu X.; Hu L.-H.
Institution
(Li, Wei, Du, Xu, Hu) Department of Anesthesiology, China
(He) Department of Thoracic Surgery, The affiliated Lihuili Hospital of
Ningbo University, Ningbo, China
Publisher
Wolters Kluwer Health Inc
Abstract
Background: Ultrasound-guided intercostal nerve block (UINB) and
thoracoscopic-guided intercostal nerve block (TINB) are often used for
analgesia after thoracic surgery. Herein, we compared the application of
TINB and UINB for analgesia after uniportal video-assisted lobectomy.
 Method(s): Sixty patients were randomly allocated into two groups:
UINB and TINB. The surgical time of intercostal nerve block (INB), the
success rate of the first needle, visual analog scale (VAS) scores, the
time of the first patient-controlled intravenous analgesia (PCIA) press,
the time for removing the thoracic drainage tube, consumption of
sufentanil and the number of PCIA presses within 24 hours postoperatively,
and adverse reactions (ARs) were compared between the two groups.
 Result(s): The surgical time of INB was significantly shorter in the
TINB group than in the UINB group (P < 0.001). The time of the first press
of PCIA was significantly earlier in the TINB group than in the UINB group
(P < 0.001). The success rate of the first needle was significantly higher
in the TINB group than in the UINB group (P < 0.001). No significant
differences were observed between the two groups regarding VAS scores,
time for removing the thoracic drainage tube, the consumption of
sufentanil, the number of PCIA presses within 24 hours postoperatively,
and ARs. Conclusion(s): TINB and UINB have similar analgesic effects
after uniportal video-assisted lobectomy. However, TINB demonstrates
shorter surgical time and a higher success rate than UINB. Copyright
© 2025 The Author(s).

<47>
[Use Link to view the full text]
Accession Number
2039944632
Title
Aortic Valve Replacement and Repair With or Without Concomitant Ascending
Aorta Replacement: Impact on Outcomes A Systematic Review.
Source
Cardiology in Review. 33(5) (pp 407-418), 2025. Date of Publication: 01
Sep 2025.
Author
Zhang C.; Butt S.; Kashif H.; Rowe C.; Harky A.; Zeinah M.
Institution
(Zhang) Faculty of Medicine and Health, University of New South Wales,
Sydney, Australia
(Butt) Department of Plastic Surgery, Nottingham City Hospital,
Nottingham, United Kingdom
(Kashif) Department of Acute Medicine, King's College Hospital, London,
United Kingdom
(Rowe) Faculty of Medicine, Department of Medicine, Imperial College
London, London, United Kingdom
(Harky, Zeinah) Department of Cardiothoracic Surgery, Liverpool Heart and
Chest Hospital, Liverpool, United Kingdom
(Harky) Liverpool Centre for Cardiovascular Science, University of
Liverpool, Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
(Zeinah) Faculty of Medicine, Ain Shams University, Cairo, Egypt
Publisher
Lippincott Williams and Wilkins
Abstract
Aortic valve surgery is a common procedure used to treat significant
aortic valve stenosis or insufficiency. Some of these patients have
coexisting pathology affecting the ascending aorta requiring ascending
aorta replacement (AAR). Although the outcomes of these procedures are
independently positive, it is proposed that concomitant AAR improves
outcomes and minimizes the chances of future ascending aorta replacement.
A comprehensive literature search for relevant studies published since
2010 comparing outcomes of aortic valve repair and replacement with or
without concomitant ascending aorta replacement was undertaken using
electronic databases PubMed, Cochrane Library, Embase Ovid, and SCOPUS.
Major exclusion criteria were (1) conference posters, literature reviews,
editorials; (2) aortic root surgery, aortic arch surgery, or other
surgeries (3) case series with less than 5 participants. A total of 1189
patients from 6 retrospective cohort studies were included in the final
review, from which clinical outcomes such as mortality and complications
were compared. Mortality rates were similar in both intervention groups.
No significant differences were found between the 2 groups in
reexploration rates due to bleeding, stroke, postoperative dialysis, and
atrial fibrillation. Survival rates varied but had no significant
difference between interventions. Both isolated aortic valve surgery and
concomitant AAR procedures offer comparable favourable outcomes in terms
of mortality, survival rates, and complication risks. However, the
evidence is limited by the lack of randomized controlled trials. We
recommend that future studies should standardize reporting on
postoperative recovery, complications, long-term freedom from
reoperations, and long-term changes to aorta dimensions. Copyright
© 2023 Wolters Kluwer Health, Inc. All rights reserved.

<48>
[Use Link to view the full text]
Accession Number
2039809498
Title
Efficacy of mitral valve repair in combination with coronary
revascularization for moderate ischaemic mitral regurgitation: a
systematic review and meta-analysis of randomized controlled trials.
Source
International Journal of Surgery. 110(6) (pp 3879-3887), 2024. Date of
Publication: 01 Jun 2024.
Author
Li X.; Hou B.; Hou S.; Jiang W.; Liu Y.; Zhang H.
Institution
(Li, Hou, Jiang, Zhang) Department of Cardiac Surgery Center, Beijing
Anzhen Hospital, Beijing Institute of Heart, Lung, and Blood Vascular
Diseases, Capital Medical University, Chaoyang district, Beijing, China
(Hou, Liu) Department of Cardiovascular Surgery, The First Affiliated
Hospital of Anhui Medical University, Shushan district, Hefei, China
Publisher
Wolters Kluwer Health Inc
Abstract
Background: The efficacy of mitral valve repair (MVR) in combination with
coronary artery bypass grafting (CABG) for moderate ischaemic mitral
regurgitation (IMR) remains unclear. To evaluate whether MVR + CABG is
superior to CABG alone, the authors conducted a systematic review and
meta-analysis of existing randomized controlled trials (RCTs).
 Method(s): The authors searched PubMed, Web of Science, and the
Cochrane Central Register of Controlled Trials for eligible RCTs from the
date of their inception to October 2023. The primary outcomes were
operative (in-hospital or within 30 days) and long-term (>= 1 year)
mortality. The secondary outcomes were postoperative stroke, worsening
renal function (WRF), and reoperation for bleeding or tamponade. The
authors performed random-effects meta-analyses and reported the results as
risk ratios (RRs) with 95% CIs. Result(s): Six RCTs were eligible for
inclusion. Compared with CABG alone, MVR + CABG did not increase the risk
of operative mortality (RR, 1.244; 95% CI, 0.514-3.014); however, it was
also not associated with a lower risk of long-term mortality (RR, 0.676;
95% CI, 0.417-1.097). Meanwhile, there was no difference between the two
groups in terms of postoperative stroke (RR, 2.425; 95% CI, 0.743-7.915),
WRF (RR, 1.257; 95% CI, 0.533-2.964), and reoperation for bleeding or
tamponade (RR, 1.667; 95% CI, 0.527-5.270). Conclusion(s): The
findings of this meta-analysis suggest that MVR + CABG fails to improve
the clinical outcomes of patients with moderate IMR compared to CABG
alone. Copyright © 2024 The Author(s). Published by Wolters
Kluwer Health, Inc.

<49>
Accession Number
2038874034
Title
Concomitant Percutaneous Coronary Intervention During Transcatheter Aortic
Valve Implantation: New Literature Supports Clinical Benefit.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 39(9) (pp 2232-2235),
2025. Date of Publication: 01 Sep 2025.
Author
Harvey R.E.; Disque A.; Poorsattar S.; Hernandez-Morgan M.; Ho J.K.;
Neelankavil J.
Institution
(Harvey, Disque, Poorsattar, Hernandez-Morgan, Ho, Neelankavil) Department
of Anesthesiology and Perioperative Medicine, David Geffen School of
Medicine, University of California Los Angeles, Los Angeles, CA, United
States
Publisher
W.B. Saunders

<50>
Accession Number
2015242145
Title
Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After
Coronary Stenting: Insights From the AFIRE Trial.
Source
JACC: Cardiovascular Interventions. 14(21) (pp 2330-2340), 2021. Date of
Publication: 08 Nov 2021.
Author
Matoba T.; Yasuda S.; Kaikita K.; Akao M.; Ako J.; Nakamura M.; Miyauchi
K.; Hagiwara N.; Kimura K.; Hirayama A.; Matsui K.; Ogawa H.
Institution
(Matoba) Department of Cardiovascular Medicine, Faculty of Medical
Sciences, Kyushu University, Fukuoka, Japan
(Yasuda) Department of Cardiovascular Medicine, Tohoku University Graduate
School of Medicine, Sendai, Japan
(Yasuda, Ogawa) National Cerebral and Cardiovascular Center, Suita, Japan
(Kaikita) Department of Cardiovascular Medicine, Graduate School of
Medical Sciences, Kumamoto University, Kumamoto, Japan
(Kaikita) Division of Cardiovascular Medicine and Nephrology, Department
of Internal Medicine, Faculty of Medicine, University of Miyazaki,
Kiyotake, Japan
(Akao) Department of Cardiology, National Hospital Organization Kyoto
Medical Center, Kyoto, Japan
(Ako) Department of Cardiovascular Medicine, Kitasato University School of
Medicine, Sagamihara, Japan
(Nakamura) Division of Cardiovascular Medicine, Toho University Ohashi
Medical Center, Tokyo, Japan
(Miyauchi) Department of Cardiovascular Medicine Juntendo Tokyo Koto
Geriatric Medical Center, Tokyo, Japan
(Hagiwara) Department of Cardiology, Tokyo Women's Medical University,
Tokyo, Japan
(Kimura) Cardiovascular Center, Yokohama City University Medical Center,
Yokohama, Japan
(Hirayama) Department of Cardiology Osaka Police Hospital, Osaka, Japan
(Matsui) Department of General Medicine and Primary Care, Kumamoto
University Hospital, Kumamoto, Japan
(Ogawa) Kumamoto University, Kumamoto, Japan
Publisher
Elsevier Inc.
Abstract
Objectives: The aim of this AFIRE (Atrial Fibrillation and Ischemic Events
With Rivaroxaban in Patients With Stable Coronary Artery Disease) trial
subgroup analysis was to examine rivaroxaban monotherapy benefits and
their relation to the time between stenting and enrollment among patients
after coronary stenting. Background(s): Of 2,215 patients with atrial
fibrillation and stable coronary artery disease in the AFIRE trial,
rivaroxaban monotherapy was noninferior to rivaroxaban plus antiplatelet
therapy (combination therapy) in terms of efficacy and superior for safety
endpoints. However, thrombotic risk after antiplatelet therapy cessation
remained a concern among 1,444 patients who had undergone coronary
stenting >1 year before enrollment. Method(s): The benefits of
rivaroxaban monotherapy in coronary stenting subgroups were assessed for
efficacy (a composite of stroke, systemic embolism, myocardial infarction,
unstable angina requiring revascularization, or death of any cause),
safety (major bleeding defined according to International Society on
Thrombosis and Haemostasis criteria), ischemic endpoints, net adverse
clinical event, and time between stenting and enrollment. Result(s):
Efficacy and safety endpoints for monotherapy were superior to combination
therapy, with HRs of 0.70 for efficacy (95% CI: 0.50-0.98; P = 0.036) and
0.55 for safety (95% CI: 0.33-0.92; P = 0.019). For ischemic endpoints,
the HR was 0.82 (95% CI: 0.58-1.15; P = 0.240). The HR became smaller with
longer time between stenting and enrollment (efficacy, P for interaction =
0.158; safety, P = 0.097). Conclusion(s): In patients with atrial
fibrillation after coronary stenting, the benefits of rivaroxaban
monotherapy for efficacy and safety endpoints were consistent with those
in the whole AFIRE trial population. The benefits became apparent with
longer time between stenting and enrollment. (Atrial Fibrillation and
Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery
Disease Study [AFIRE]; UMIN000016612, NCT02642419) Copyright ©
2021 American College of Cardiology Foundation

<51>
Accession Number
2039633242
Title
The IASLC uncertain resection, general overview, current evidence, and
future prospects: a systematic review and meta-analysis.
Source
Therapeutic Advances in Medical Oncology. 17 (no pagination), 2025.
Article Number: 17588359251344789. Date of Publication: 01 Jan 2025.
Author
Hu M.; Li X.; Zheng M.; Yu J.; Lu B.; Wang Y.; Cao X.; Su C.; Dong Y.;
Zhang X.; Zhang T.
Institution
(Hu) Department of Oncology, Beijing Chest Hospital, Capital Medical
University, Beijing, China
(Hu) Laboratory for Clinical Medicine, Capital Medical University,
Beijing, China
(Li, Zheng) Department of Oncology, Beijing Institute of Tuberculosis and
Thoracic Cancer, Beijing, China
(Yu) Department of Thoracic and Cardiac Surgery, Affiliated Hospital of
Shaanxi University of Chinese Medicine, Shaanxi, Xianyang, China
(Lu, Wang) Department of Oncology, Beijing Chest Hospital, Capital Medical
University, Beijing, China
(Cao, Su) Department of Thoracic Surgery, Beijing Chest Hospital, Capital
Medical University, Beijing, China
(Dong) Department of Pathology, Beijing Chest Hospital, Capital Medical
University, Beijing, China
(Zhang) Department of Radiotherapy, Beijing Chest Hospital, Capital
Medical University, Beijing, China
(Zhang) Department of Oncology, Beijing Chest Hospital, Capital Medical
University, No. 9 Beiguan Street, District, Beijing, Tongzhou, China
(Zhang) Laboratory for Clinical Medicine, Capital Medical University,
Beijing, China
Publisher
SAGE Publications Inc.
Abstract
Background:Introduced by the International Association for the Study of
Lung Cancer (IASLC) in 2005, uncertain resection (Run) categorizes a new
subclass of residual tumor. Despite several studies, the prognostic
significance of Run in operable non-small cell lung cancer (NSCLC) remains
unclear. Objective(s):This study aimed to investigate the prognostic
influence of Run in operable NSCLC, focusing on the impact of the four
elements that comprise R descriptors on patient survival. Design(s):A
systematic review and meta-analysis were conducted to synthesize data from
relevant clinical studies. Method(s):We developed search strategies
to identify relevant clinical studies across databases including PubMed,
Embase, Cochrane Library, Web of Science, CNKI, and Wanfang up to June
2024. Quantitative analysis was performed with Stata 15 to investigate the
prognostic influence of Run, the extent of mediastinal lymph node removal,
and the highest mediastinal lymph node involvement (HMLI). We also
summarized the main findings from studies on pleural lavage cytology (PLC)
and carcinoma in situ in operable NSCLC. Result(s):Compared to
complete resection, Run-associated patients exhibited inferior 5-year
overall survival (OS) and disease-free survival (DFS; risk ratio (RR) =
1.31, 95% confidence interval (CI) 1.19-1.44; RR = 1.43, 95% CI
1.28-1.60). Limited lymphadenectomy (L-LA) in cI stage showed similar
survival benefit (OS, RR = 0.97, 95% CI 0.90-1.06; DFS, RR = 1.06, 95% CI
0.97-1.15), in contrast with systematic lymph node dissection (SLND). For
pN2-III patients, HMLI indicated poorer OS (hazard ratio (HR) = 1.22, 95%
CI 1.14-1.31) and DFS (HR = 1.25, 95% CI 1.14-1.36).
 Conclusion(s):IASLC's residual tumor classification correlated with
significant survival differences. Compared with R0, Run was associated
with inferior 5-year OS and DFS. L-LA seemed to provide equivalent
survival benefits, in contrast to SLND. For patients with low invasiveness
in stage cI, L-LA could be considered as a preferred option. HMLI predicts
poorer survival in pN2-III patients, and positive PLC significantly
worsened long-term survival in operable NSCLC, particularly at early
stage. Copyright © The Author(s), 2025. This article is
distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License
(https://creativecommons.org/licenses/by-nc/4.0/) which permits
non-commercial use, reproduction and distribution of the work without
further permission provided the original work is attributed as specified
on the SAGE and Open Access page
(https://us.sagepub.com/en-us/nam/open-access-at-sage).

<52>
Accession Number
2039808610
Title
Prospective Randomized Study Comparing Indigenous Tas Scope and
Conventional Macintosh Laryngoscope for Cormack Lehane Grading and
Intubation in Patients Undergoing Elective Coronary Bypass Surgery.
Source
European Journal of Cardiovascular Medicine. 15(7) (pp 728-732), 2025.
Date of Publication: 01 Jul 2025.
Author
Patel M.D.; Manjunatha K.R.; Nanjappa S.N.; Bharathi K.S.
Institution
(Patel, Manjunatha, Bharathi) Department of Anaesthesiology, Sri Jayadeva
Institute of Cardiovascular Sciences and Research, Karnataka, Mysore,
India
(Nanjappa) Department of Anaesthesiology, Sri Jayadeva Institute of
Cardiovascular Sciences and Research, Karnataka, Mysore, India
Publisher
Healthcare Bulletin
Abstract
Background: General anaesthesia (GA) with endotracheal intubation is the
mainstay of anaesthesia for elective coronary bypass surgeries. The study
was aimed to compare a new indigenous TAS (The anaesthesia society) scope
with conventional Macintosh laryngoscope in Cormack Lehane grading (CLG)
of larynx and ease of intubation along with hemodynamic response.
Materials and Methods 120 patients undergoing coronary artery bypass
surgery with GA were randomized into two groups and named after A device
which was used for both laryngoscope and intubation. In Group TAS,
patients were intubated with TAS Scope after initial laryngoscopy with
Macintosh. In Group MAC, Intubated with Macintosh after initial
laryngoscope /CLG with TAS scope. CLG, Time to intubate, number of
attempts, hemodynamic parameters were noted. Result(s): Patients
having Cormack Lehane grading of gr 3 and 4 (11.6%) in MAC group changed
gr 1 and 2 when laryngoscopy was performed with TAS scope and none had gr
3 and 4 when TAS scope was performed. Mean time to intubate were 23.73
+/-3.48 and 12.50 +/-2.50 (p=0.006) seconds in TAS and MAC groups
respectively. Conclusion(s): Indigenous TAS can be used to get better
visualization of larynx with improved Cormack Lehane gradings with
acceptable hemodynamic changes. Copyright © 2025 Healthcare
Bulletin. All rights reserved.

<53>
Accession Number
2039816210
Title
Superficial vs. deep serratus anterior plane block for analgesia in
patients undergoing single-port video-assisted thoracoscopic surgery: A
randomized prospective trial.
Source
Journal of Clinical Anesthesia. 106 (no pagination), 2025. Article Number:
111950. Date of Publication: 01 Sep 2025.
Author
Meng G.; Chen W.; Shi D.; Mei B.; Liu X.
Institution
(Meng, Chen, Shi, Mei, Liu) Department of Anesthesiology, The First
Affiliated Hospital of Anhui Medical University, Hefei, China
Publisher
Elsevier Inc.
Abstract
Study objective: Postoperative pain following thoracic surgery is often
severe, and serratus anterior plane block (SAPB) is widely used for
perioperative analgesia in such patients. Local anesthetics injected on
the surface of the serratus anterior muscle are called superficial SAPB
(SSAPB), while those injected on the deep surface are called deep SAPB
(DSAPB). We observed the differences in analgesic effects of two variants
of SAPB (superficial and deep) on patients receiving single-port
video-assisted thoracoscopic surgery (VATS). Design(s): A randomized
prospective trial. Setting(s): Single university teaching hospital.
 Patient(s): Eighty patients who underwent single-port VATS under
general anesthesia. Intervention(s): Eighty patients who received
single-port VATS were randomly assigned to Group S (patients who received
SSAPB) and Group D (patients who received DSAPB). Measurements: The
primary outcome was opioid consumption within 24 h after surgery.
Secondary outcomes were pain scores at rest and on coughing before
surgery, immediately after surgery, 6, 12, and 24 h after surgery.
 Main Result(s): Within 24 h after surgery, the total opioid
consumption of patients in Group S was lower than that of patients in
Group D (P = 0.001). The pain scores of patients in Group S were lower
than those in Group D at rest or coughing 6 h after surgery (P = 0.000, P
= 0.000). The pain score on coughing in Group S was lower than that in
Group D at 12 h after surgery (P = 0.000), and there was no difference in
postoperative pain scores between the two groups at other time points.
 Conclusion(s): For patients undergoing single-port VATS lobectomy,
SSAPB was associated with reduced opioid consumption and lower pain scores
compared to DSAPB. Copyright © 2025

<54>
[Use Link to view the full text]
Accession Number
2039857026
Title
Left Atrial Appendage Closure Versus Oral Anticoagulation for Stroke
Prevention in Atrial Fibrillation: An Updated Systematic Review and
Meta-Analysis.
Source
American Journal of Therapeutics. (no pagination), 2025. Article Number:
10.1097/MJT.0000000000001992. Date of Publication: 2025.
Author
Naeem F.; Qamar U.; Waqas M.; Tabassum S.; Munir M.B.; Asad Z.U.A.
Institution
(Naeem) Department of Cardiology, Massachusetts General Hospital, Harvard
Medical School, Boston, MA, United States
(Qamar) Department of Internal Medicine, Mayo Clinic, Rochester, NY,
United States
(Waqas) Department of Internal Medicine, Wah Medical College, Wahcantt,
Pakistan
(Tabassum) Department of Internal Medicine, King Edward Medical
University, Lahore, Pakistan
(Munir) Division of Cardiovascular Medicine, University of California
Davis, Sacramento, CA, United States
(Asad) Department of Medicine, Cardiovascular Section, University of
Oklahoma Health Sciences Center, Oklahoma City, OK, United States
Publisher
Lippincott Williams and Wilkins

<55>
Accession Number
2039907865
Title
A New Perspective in Cardiac Surgery: Single- and Two-level Deep
Parasternal Intercostal Plane Blocks for Median Sternotomy Pain.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2025.
Date of Publication: 2025.
Author
Dolgun I.; Cevirme D.; Bayram E.; Zilifli C.; Erdogan M.B.
Institution
(Dolgun) Haseki Training and Research Hospital, Clinic of Anesthesiology
and Reanimation, Istanbul, Turkey
(Cevirme, Erdogan) Istinye University Faculty of Medicine, Department of
Cardiovascular Surgery, Istanbul, Turkey
(Bayram) Department of Anesthesiology and Reanimation, Faculty of
Medicine, Istinye University Medicalpark Gaziosmanpasa Hospital, Istanbul,
Turkey
(Zilifli) Istinye University Faculty of Medicine, Cardiovascular Surgery
Intensive Care Unit, Istanbul, Turkey
Publisher
W.B. Saunders
Abstract
Objectives: To compare the efficacy of single-level and two-level deep
parasternal intercostal plane (DPIP) blocks in managing postoperative pain
in cardiac surgery patients undergoing median sternotomy. Design(s):
A prospective, randomized controlled study. Setting(s): A cardiac
surgery unit in a tertiary hospital, conducted under institutional ethical
approval. Participant(s): Adult patients (>=18 years) undergoing
elective coronary artery bypass grafting (CABG), valve surgery, or
combined CABG + valve procedures. Exclusion criteria included allergies to
local anesthetics, emergency surgeries, reoperations, chronic pain, and
major comorbidities. Intervention(s): Single-level DPIP block: 10 mL
of 0.25% bupivacaine bilaterally at the T4/5 intercostal space. Two-level
DPIP block: 5 mL bilaterally at T2/3 and T5/6 intercostal spaces. All
blocks were administered preoperatively under ultrasound guidance.
 Measurements and Main Results: Both techniques provided effective
analgesia. However, single-level blocks yielded significantly lower pain
scores at 4, 6, and 8 hours, particularly during movement and in patients
undergoing CABG. Differences decreased at 12 hours and disappeared by 24
hours. Pain scores were inversely correlated with age. No block-related
complications were observed. Conclusion(s): Single-level DPIP blocks
demonstrated more consistent early analgesia and were technically simpler
to perform. Given their efficacy, safety, and efficiency, single-level
blocks may serve as a practical alternative for routine use in cardiac
surgery. Further research is warranted to optimize block level, volume,
and concentration based on patient and surgical
characteristics. Copyright © 2025 Elsevier Inc.

<56>
Accession Number
646384046
Title
The Effect of Music Combined With Preoperative Education on Perioperative
Anxiety in Patients Undergoing Open Cardiac Surgery: A Randomized
Controlled Trial.
Source
Journal of perianesthesia nursing : official journal of the American
Society of PeriAnesthesia Nurses. 40(4) (pp 925-929), 2025. Date of
Publication: 01 Aug 2025.
Author
Zhou B.; Hu Z.
Institution
(Zhou) Department of Anesthesiology, First Affiliated Hospital, Jiangxi
Medical College, Nanchang University, Nanchang, Jiangxi, China
(Hu) Department of Anesthesiology, First Affiliated Hospital, Jiangxi
Medical College, Nanchang University, Nanchang, Jiangxi, China
Abstract
PURPOSE: The aim of this study is to observe the effect of music combined
with preoperative education on perioperative anxiety in patients
undergoing open cardiac surgery. DESIGN: This was a randomized controlled
study. METHOD(S): A group of 322 patients undergoing elective open
cardiac surgery were randomly allocated to receive either music combined
with preoperative education (the experimental group) or routine
preoperative preparation (the control group). The primary endpoint was
perioperative anxiety scores. The secondary outcome measures included
length of stay in the intensive care unit, length of hospital stay,
perioperative mean blood pressure, heart rate, respiratory rate, and
quality of life score measured with the SF-36 subscale scores. This study
collected data at the following 6 time points: T0 (preoperative baseline
value), T1 (10 minutes after preoperative combined intervention), T2
(after patient extubation), T3 (10 minutes after intensive care unit
intervention), T4 (the first day after patient admission), and T5 (1 month
after patient discharge). FINDINGS: The experimental group reported
significantly lower anxiety scores than the control group at both T1 and
T4 time points. The experimental group had a significantly shorter length
of stay in the intensive care unit and length of hospital stay than the
control group. Heart rate, mean blood pressure, and respiratory rate were
significantly lower in the experimental group at T1, T3, and T4 time
points. The mean blood pressure and heart rate were significantly lower in
the experimental group at the T2 time point. The SF-36 subscale scores
were significantly higher in the experimental group at the T5 time point.
 CONCLUSION(S): The combination of music and preoperative education
provides effective antianxiety and accelerates recovery in patients
undergoing open cardiac surgery. Copyright © 2025 The American
Society of PeriAnesthesia Nurses. Published by Elsevier Inc. All rights
reserved.

<57>
Accession Number
2039904465
Title
2025 SCAI/HRS clinical practice guidelines on transcatheter left atrial
appendage occlusion.
Source
Heart Rhythm. (no pagination), 2025. Date of Publication: 2025.
Author
Goldsweig A.M.; Glikson M.; Joza J.; Kavinsky C.J.; Khalique O.;
Lakkireddy D.; Mackensen G.B.; Naccarelli G.V.; Nair D.G.; Saw J.; Sharma
R.P.; Sherwood M.; Szerlip M.; Falck-Ytter Y.; Morgan R.L.; Armah C.;
Firestone S.; Fix A.; Senerth E.; Ellis C.R.
Institution
(Goldsweig) Department of Cardiovascular Medicine, Baystate Medical Center
and Division of Cardiovascular Medicine, University of
Massachusetts-Baystate, Springfield, Massachusetts, United States
(Glikson) Jesselson Integrated Heart Center, Shaare Zedek Medical Center
and Hebrew University Faculty of Medicine, Jerusalem, Israel
(Joza) Division of Cardiology, McGill University, Montreal, Quebec, Canada
(Kavinsky) Beth Israel Deaconess Medical Center, Harvard Medical School,
Boston, Massachusetts, United States
(Khalique) Division of Cardiovascular Imaging, St. Francis Hospital and
Heart Center, Roslyn, New York, United States
(Lakkireddy) Kansas City Heart Rhythm Institute and Research Foundation,
Overland Park, KS, United States
(Mackensen) Division of Cardiothoracic Anesthesiology, Department of
Anesthesiology and Pain Medicine, University of Washington, Seattle, WA,
United States
(Naccarelli) Heart and Vascular Institute, Penn State University College
of Medicine, Hershey, Pennsylvania, United States
(Nair) St. Bernard's Heart and Vascular Center, Jonesboro, AR, United
States
(Saw) Division of Cardiology, Vancouver General Hospital, University of
British Columbia, Vancouver, Canada
(Sharma) Stanford University Medical Center, Palo Alto, California, United
States
(Sherwood) Division of Cardiology, Inova Heart and Vascular Institute,
Fairfax, Virginia, United States
(Szerlip) Baylor Scott & White the Heart Hospital - Plano, Plano, Texas,
United States
(Falck-Ytter, Morgan) Case Western Reserve University, Cleveland, Ohio,
United States
(Armah, Firestone) Society for Cardiovascular Angiography & Interventions,
Washington, District of Columbia, United States
(Fix) Heart Rhythm Society, Washington, District of Columbia, United
States
(Morgan, Senerth) Evidence Foundation, Cleveland, Ohio, United States
(Ellis) Division of Cardiovascular Medicine at Vanderbilt University
Medical Center, Nashville, TN, United States
(Morgan) Department of Health Research Methods, Evidence, and Impact,
McMaster University, Hamilton, ON, Canada
(Falck-Ytter) VA Northeast Ohio Healthcare System, Cleveland, Ohio, United
States
Publisher
Elsevier B.V.
Abstract
Background: Left atrial appendage occlusion (LAAO) devices reduce the risk
of atrial fibrillation-associated stroke relative to no oral
anticoagulation. However, uncertainty and practice variation persist in
the areas of patient selection, periprocedural imaging, adjunctive
antithrombotic therapy, and management of peridevice leak (PDL) and
device-related thrombus. The Society for Cardiovascular Angiography &
Interventions and Heart Rhythm Society developed these evidence-based
guidelines to support clinicians, patients, and other stakeholders in
management decisions regarding LAAO. Method(s): The Society for
Cardiovascular Angiography & Interventions and Heart Rhythm Society
convened a balanced, multidisciplinary guideline panel with <50% of
members reporting significant conflicts of interest with the industry.
Evidence Foundation, a registered 501(c)(3) nonprofit organization,
provided methodological support for guideline development. The guideline
panel formulated and prioritized clinical questions following the Grading
of Recommendations Assessment, Development, and Evaluation approach in a
population, intervention, comparison, outcome format. A technical review
team of clinical and methodological experts conducted systematic reviews
of the published evidence, synthesized data, and graded the certainty of
evidence across outcomes. The guideline panel then developed
recommendations and supporting statements informed by the technical review
and using the Grading of Recommendations Assessment, Development, and
Evaluation evidence-to-decision framework. Result(s): The guideline
panel developed 8 evidence-based recommendations to address variations in
care related to LAAO. The panel also identified 2 knowledge gaps.
 Conclusion(s): Key recommendations address patient selection for
LAAO, periprocedural imaging, adjunctive antithrombotic therapy, and
management of PDL and device-related thrombus. The panel also recommended
necessary future research regarding the use of single antiplatelet therapy
following LAAO and regarding the management of PDL. Copyright ©
2025 Society for Cardiovascular Angiography & Interventions Foundation and
Heart Rhythm Society

<58>
Accession Number
2039825866
Title
Safety, Efficacy, and Effectiveness of Coronary Sinus Reducer Implantation
in Refractory Angina: A Meta-Analysis.
Source
JACC: Cardiovascular Interventions. 18(15) (pp 1864-1877), 2025. Date of
Publication: 11 Aug 2025.
Author
Ojha U.; Mohsin M.; Macierzanka K.; Ahmed-Jushuf F.; Rajkumar C.A.; Chotai
S.; Simader F.A.; Shun-Shin M.J.; Foley M.J.; Al-Lamee R.K.
Institution
(Ojha) East Kent Hospitals University NHS Foundation Trust, Queen
Elizabeth The Queen Mother Hospital, Margate, United Kingdom
(Mohsin, Macierzanka, Ahmed-Jushuf, Rajkumar, Chotai, Simader, Shun-Shin,
Foley, Al-Lamee) National Heart and Lung Institute, Imperial College
London, London, United Kingdom
(Ahmed-Jushuf, Rajkumar, Chotai, Simader, Shun-Shin, Foley, Al-Lamee)
Imperial College Healthcare NHS Trust, Hammersmith Hospital, London,
United Kingdom
Publisher
Elsevier Inc.
Abstract
Background: Previous coronary sinus reducer (CSR) meta-analyses in
refractory angina (RA) focused on single-arm studies, capturing observed
effectiveness-comprising the physical effect of CSR, contextual effects
(eg, placebo), and non-treatment-related phenomena (eg, confounding).
Efficacy evaluation requires comparative estimates from randomized
controlled trials (RCTs), ideally double blind and placebo controlled, to
isolate the physical effect. Objective(s): The aims of this study
were to evaluate the safety and efficacy of CSR in RA and to compare its
efficacy with observed effectiveness. Method(s): The study was
preregistered with the International Prospective Register of Systematic
Reviews (CRD42023399099). Electronic databases were searched until April
2024. Random-effects models separately pooled single-arm, isolated RCT
intervention-arm, and RCT placebo-controlled estimates. Therapeutic
outcomes included improvements in Canadian Cardiovascular Society
classification, Seattle Angina Questionnaire scores, and treadmill
exercise time. Safety outcomes, summarized descriptively, comprised
procedural success and adverse events. Result(s): Three double-blind,
placebo-controlled RCTs (n = 180) and 13 single-arm studies (n = 668) were
analyzed. The overall unweighted procedural success rate was 98.3% (95%
CI: 97.0%-99.1%). Single-arm studies and RCT intervention arms
demonstrated statistically significant improvements across therapeutic
outcomes. For Canadian Cardiovascular Society classification,
placebo-controlled rates were 26% (95% CI: 11%-38%; P < 0.001) for
>=1-class improvement and 17% (95% CI: 2%-37%; P = 0.02) for >=2-class
improvement, representing approximately one-third of single-arm
improvement rates. Seattle Angina Questionnaire domain analyses
demonstrated insufficient placebo-controlled evidence of benefit.
Placebo-controlled exercise time change was 49.62 seconds (95% CI:
1.84-97.40 seconds; P = 0.04). Conclusion(s): CSR implantation is
safe and feasible and demonstrates promising antianginal efficacy in
patients with RA. However, uncertainty in current efficacy findings and
susceptibility of effectiveness data to nonphysical influences preclude
definitive conclusions about clinical utility, warranting larger
placebo-controlled trials. Copyright © 2025 The Authors

<59>
Accession Number
2039904438
Title
SCAI/HRS technical review on transcatheter left atrial appendage
occlusion.
Source
Heart Rhythm. (no pagination), 2025. Date of Publication: 2025.
Author
Cronin E.M.; Filby S.; Field M.E.; Huded C.; Indik J.H.; Sharma A.; Armah
C.; Firestone S.; Fix A.M.; Senerth E.; Morgan R.L.; Falck-Ytter Y.
Institution
(Cronin) Lewis Katz School of Medicine at Temple University, Philadelphia,
Pennsylvania, United States
(Filby) University Hospitals Cleveland Medical Center, Cleveland, Ohio,
United States
(Field) Roper St. Francis Healthcare, Charleston, South Carolina, United
States
(Huded) Saint Luke's Mid America Heart Institute, Kansas City, Missouri,
United States
(Indik) Sarver Heart Center, University of Arizona, Tucson, AZ, United
States
(Sharma) Rutgers New Jersey Medical School, Newark, New Jersey, United
States
(Armah, Firestone) Society for Cardiovascular Angiography & Interventions,
Washington, DC, United States
(Fix) Heart Rhythm Society, Washington, DC, United States
(Senerth, Morgan, Falck-Ytter) Evidence Foundation, Cleveland Heights, OH,
United States
(Morgan) School of Medicine, Case Western Reserve University, Cleveland,
Ohio, United States
(Morgan) Department of Health Research Methods, Evidence, and Impact,
McMaster University, Hamilton, ON, Canada
(Falck-Ytter) Case Western Reserve University, Cleveland, Ohio, United
States
(Falck-Ytter) Division of Gastroenterology and Hepatology, Veterans
Affairs Northeast Ohio Healthcare System, Cleveland, Ohio, United States
Publisher
Elsevier B.V.
Abstract
Background: Nonvalvular atrial fibrillation (NVAF) is associated with an
increased risk of stroke due to thrombus formation in the left atrial
appendage, where over 90% of thrombi originate. While oral anticoagulation
(OAC) is the standard therapy for stroke prevention, many patients cannot
tolerate long-term OAC due to bleeding risks. Percutaneous left atrial
appendage occlusion (LAAO) has emerged as an alternative strategy. Despite
its rapid adoption, substantial variability exists in clinical practice
regarding patient selection, imaging techniques, procedural guidance, and
postprocedural management. This systematic review aims to collect and
synthesize evidence to inform the development of new Society for
Cardiovascular Angiography & Interventions (SCAI) and the Heart Rhythm
Society (HRS) guidelines on LAAO. Method(s): We searched PubMed,
Embase, and Cochrane Library from inception through January 5, 2024, for
studies of the percutaneous LAAO procedure. Eligible studies were
conducted in adults with NVAF undergoing LAAO, or with peridevice leak or
device-related thrombus after an occlusion procedure. Studies of surgical
LAAO, double device or combined procedures, and devices that are not
currently marketed in the United States were excluded. Data were extracted
from studies in duplicate and summarized using meta-analysis and narrative
synthesis. Risk of bias (RoB) was assessed using the RoB in nonrandomized
studies of interventions tool, and version 2 of the Cochrane RoB tool for
randomized trials (RoB 2.0). Overall certainty of evidence was assessed
using the Grading of Recommendations Assessment, Development, and
Evaluation (GRADE) approach. Result(s): Our search identified 3769
titles and abstracts, of which 27 studies met eligibility criteria and
contributed data to the analysis. Data were abstracted to address outcomes
of LAAO for stroke prevention in patients with NVAF, in comparison to OAC,
no therapy, and across various approaches including preprocedure imaging,
intraprocedure guidance, and postprocedure antithrombotic regimens.
 Conclusion(s): Left atrial appendage occlusion is an effective
alternative to OAC for stroke prevention in NVAF patients with bleeding
risks, but uncertainties remain regarding imaging strategies and
postprocedural management. Copyright © 2025 Society for
Cardiovascular Angiography & Interventions Foundation and Heart Rhythm
Society.

<60>
Accession Number
2033481171
Title
An increase in micro-vessels beneath the pleural surface on computed
tomography as a preoperative predictor of pleural adhesions: a prospective
study.
Source
Surgery Today. 55(8) (pp 1198-1204), 2025. Date of Publication: 01 Aug
2025.
Author
Kawamura T.; Kobayashi N.; Yanagihara T.; Goto Y.; Ichimura H.; Sato Y.
Institution
(Kawamura, Kobayashi, Yanagihara, Goto, Ichimura, Sato) Department of
Thoracic Surgery, University of Tsukuba Hospital, 2-1-1 Amakubo, Ibaraki,
Tsukuba, Japan
Publisher
Springer
Abstract
Purpose: Pleural adhesions, which may be present in varying degrees and
involve blood vessels, often complicate thoracic surgery. The blood flow
within pleural adhesions can be identified on computed tomography (CT) as
micro-vessels beneath the pleural surface (MVBP). We conducted a
prospective study to assess if MVBP can be detected on preoperative CT to
predict intraoperative pleural adhesions. Method(s): This prospective
study investigated the preoperative CT images of patients scheduled to
undergo surgery for lung tumors. MVBP was defined as positive when lung
vessels were identified below the pleura on CT. MVBP was evaluated for
each lung segment, and intraoperative findings of pleural adhesions on the
segments were then recorded. Result(s): This study included 173
patients, with 1532 segments evaluated. Pleural adhesions were found in 51
patients and confirmed in 92 segments. The number of segments evaluated
preoperatively as MVBP-positive was 134 (9%), of which 36 (26.9%) had
pleural adhesions. Multivariable analysis identified that MVBP was an
independent significant predictor (odds ratio = 2.29, 95% confidence
interval 1.09-4.80, P = 0.028) of pleural adhesions on a per-patient
basis. Conclusion(s): MVBP is a valuable predictor of pleural
adhesions. The method is useful in clinical practice because it does not
require additional examinations and is easy to assess. Copyright
© The Author(s) 2025.

<61>
Accession Number
2034574383
Title
Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male
but Not Female Coronary Artery Disease Patients.
Source
Aging Cell. 24(8) (no pagination), 2025. Article Number: e70108. Date of
Publication: 01 Aug 2025.
Author
Mury P.; Dagher O.; Fortier A.; Diaz A.; Lamarche Y.; Noly P.-E.; Ibrahim
M.; Page P.; Demers P.; Bouchard D.; Bernier P.-L.; Poirier N.; Moss E.;
Durrleman N.; Jeanmart H.; Pellerin M.; Lettre G.; Thorin-Trescases N.;
Carrier M.; Thorin E.
Institution
(Mury, Dagher, Lamarche, Noly, Ibrahim, Page, Demers, Bouchard, Bernier,
Poirier, Moss, Durrleman, Jeanmart, Pellerin, Lettre, Thorin-Trescases,
Carrier, Thorin) Montreal Heart Institute, Research Center, Universite de
Montreal, Montreal, QC, Canada
(Mury, Dagher) Department of Pharmacology & Physiology, Faculty of
Medicine, Universite de Montreal, Montreal, QC, Canada
(Dagher) Department of Cardiac Sciences, Libin Cardiovascular Institute,
Calgary, AB, Canada
(Fortier) Department of Biostatistics, Montreal Health Innovations
Coordinating Centre (MHICC), Montreal, QC, Canada
(Diaz) CIUSSS-MCQ, Universite de Montreal, Campus Mauricie,
Trois-Rivieres, QC, Canada
(Lamarche, Noly, Ibrahim, Page, Demers, Bouchard, Bernier, Poirier, Moss,
Durrleman, Jeanmart, Pellerin, Carrier, Thorin) Faculty of Medicine,
Department of Surgery, Universite de Montreal, Montreal, QC, Canada
(Lettre) Department of Medicine, Faculty of Medicine, Universite de
Montreal, Montreal, QC, Canada
Publisher
John Wiley and Sons Inc
Abstract
Recent studies suggest that vascular senescence and its associated
inflammation fuel the inflammaging to favor atherogenesis; whether these
pathways can be therapeutically targeted in coronary artery disease (CAD)
patients remains unknown. In a randomized, double-blind trial, 97 patients
(78 men) undergoing coronary artery bypass graft surgery were treated with
either quercetin (500 mg twice daily, 47 patients) or placebo (50
patients) for two days pre-surgery through hospital discharge. Primary
outcomes were reduced inflammation and improved endothelial function ex
vivo. Exploratory analyses included plasma proteomics and single-nuclei
RNA sequencing of internal thoracic artery (ITA) samples. Quercetin
treatment showed a trend toward reduced C-reactive protein at discharge (p
= 0.073) and differentially modulated circulating inflammatory protein
expression between men and women, with a pro-inflammatory effect of
quercetin in females. Endothelial acetylcholine-induced relaxation
improved significantly with quercetin (p = 0.049), with effects in men (p
= 0.043) but not in women (p = 0.852). ITA transcriptomics revealed the
overexpression of senescence and inflammaging pathways in male vascular
cells, which quercetin reversed. In female cells, quercetin had minimal
endothelial benefit and increased inflammaging in fibroblasts. In male
cells, a candidate target of quercetin involves interactions between the
receptor PLAUR and its ligands PLAU and SERPINE1. Post-operative atrial
fibrillation incidence was significantly lower with quercetin,
representing 4% of the patients compared to 18% in the placebo group (p =
0.033). In conclusion, short-term quercetin treatment effectively targeted
vascular senescence in male CAD patients, improving inflammatory and
functional outcomes. However, these benefits were not observed in female
patients. Trial Registration: https://clinicaltrials.gov,
NCT04907253. Copyright © 2025 The Author(s). Aging Cell published
by Anatomical Society and John Wiley & Sons Ltd.

<62>
Accession Number
2039825869
Title
Sentinel Cerebral Embolic Protection During Transcatheter Aortic Valve
Replacement: An Updated Meta-Analysis.
Source
JACC: Cardiovascular Interventions. 18(15) (pp 1948-1950), 2025. Date of
Publication: 11 Aug 2025.
Author
Goel S.; Khera S.; Krishnamoorthy P.; Hooda A.; Lerakis S.; Safi L.M.;
Kini A.S.; Sharma S.K.; Dangas G.D.; Tang G.H.L.
Publisher
Elsevier Inc.

<63>
Accession Number
2034076538
Title
Hemoadsorption use in adult cardiac surgery for infective endocarditis: A
comprehensive meta-analysis.
Source
Asian Cardiovascular and Thoracic Annals. 33(2-3) (pp 105-115), 2025. Date
of Publication: 01 Mar 2025.
Author
Dutta P.; Ganduboina R.; Muderrisoglu C.; Obulareddy A.C.R.; Palagati K.;
Areddy V.R.; Reddy G.A.; Sainathan S.
Institution
(Dutta, Muderrisoglu) Department of Surgery, University of Illinois,
Chicago, IL, United States
(Ganduboina) Department of Surgery, NRI Institute of Medical Sciences,
Visakhapatnam, India
(Obulareddy) Division of Surgery, SVS Medical College, Mahbubnagar, India
(Palagati) Division of Surgery, Government Medical College, Anantapur,
India
(Areddy) Division of Surgery, Sri Venkateswara Medical College, Tirupati,
India
(Reddy) Division of Internal Medicine, New York Medical College at St
Mary's General Hospital and St Claire's Health, New York, NY, United
States
(Sainathan) Division of Cardiothoracic Surgery, University of Miami,
Miami, FL, United States
Publisher
SAGE Publications Inc.
Abstract
Introduction: Infective endocarditis (IE) is a severe infection of the
endocardium, primarily affecting the heart valves, exhibiting high
morbidity and mortality rates. Cardiac surgery for IE with cardiopulmonary
bypass (CPB) can further exacerbate the inflammatory response and cytokine
production from IE. The current meta-analysis evaluates the use of
CytoSorb hemoadsorption in IE patients undergoing cardiac
surgery to determine its efficacy in reducing inflammatory mediators and
improving clinical outcomes. Method(s): PubMed, Cochrane, Google
Scholar, Clinical Trials, and Google Scholar were searched for articles
until July 2024. After performing a risk of bias and quality assessment,
data on operative times, mortality, and morbidity were extracted for
meta-analysis. Statistical Software R (version 4.4.0) was used to
calculate odds ratio (OR) and standardized mean differences using a
random-effect model with a 95% confidence interval (CI) and p-value less
than 0.05. Result(s): Eight studies, encompassing 1076 patients, were
included in the analysis. These comprised three randomized controlled
trials and five nonrandomized studies. The majority of these studies
exhibited some concerns regarding bias. Hemoadsorption group showed lower
discharge mortality (OR: 0.58, 95% CI: 0.33-1.00, p = 0.05) compared to
controls, but no significant disparity is observed in other outcomes.
In-hospital outcomes also showed higher heterogeneity, with an I2 value
greater than 50%. Conclusion(s): CytoSorb use in patients undergoing
cardiac surgery with CPB used for IE has no impact on operative mortality
and morbidity but has a beneficial effect on discharge
mortality. Copyright © The Author(s) 2025

<64>
Accession Number
2038253991
Title
Effectiveness of Point-of-Care High-Sensitivity Troponin Testing in the
Emergency Department: A Randomized Controlled Trial.
Source
Annals of Emergency Medicine. 86(2) (pp 124-135), 2025. Date of
Publication: 01 Aug 2025.
Author
Thulin V.I.L.; Jordalen S.M.F.; Myrmel G.M.S.; Lekven O.C.; Krishnapillai
J.; Steiro O.T.; Body R.; Collinson P.; Apple F.S.; Cullen L.; Norekval
T.M.; Wisloff T.; Vikenes K.; Bjorneklett R.O.; Omland T.; Aakre K.M.
Institution
(Thulin, Jordalen, Lekven, Krishnapillai, Bjorneklett) Emergency Care
Clinic, Haukeland University Hospital, Bergen, Norway
(Myrmel, Lekven, Krishnapillai, Steiro, Norekval, Vikenes, Aakre)
Department of Heart Disease, Haukeland University Hospital, Bergen, Norway
(Body) Division of Cardiovascular Sciences, Faculty of Biology, the
University of Manchester, Manchester, United Kingdom
(Body) Emergency Department, Manchester University NHS Foundation Trust,
Manchester, United Kingdom
(Collinson) St George's University of London, London, United Kingdom
(Apple) Department of Laboratory Medicine and Pathology, Hennepin
Healthcare/HCMC, Minneapolis, MN, United States
(Apple) Department of Laboratory Medicine and Pathology, University of
Minnesota, Minneapolis, MN, United States
(Cullen) Department of Emergency Medicine, Royal Brisbane and Women's
Hospital, Brisbane, Australia
(Cullen) School of Medicine, University of Queensland, Brisbane, Australia
(Cullen) Faculty of Health, Queensland University of Technology, Brisbane,
Australia
(Norekval, Vikenes, Aakre) Department of Clinical Science, University of
Bergen, Bergen, Norway
(Wisloff) Health Services Research Unit, Akershus University Hospital,
Lorenskog, Norway
(Wisloff, Omland) Institute of Clinical Medicine, University of Oslo,
Oslo, Norway
(Bjorneklett) Department of Clinical Medicine, University of Bergen,
Bergen, Norway
(Omland) Department of Cardiology, Akershus University Hospital,
Lorenskog, Norway
(Aakre) Department of Medical biochemistry and Pharmacology, Haukeland
University Hospital, Bergen, Norway
Publisher
Elsevier Inc.
Abstract
Study objective: To compare the effectiveness of high-sensitivity cardiac
troponin (hs-cTn) point-of-care testing to central laboratory hs-cTn
measurements when investigating patients presenting to the emergency
department (ED) with symptoms of acute coronary syndrome. Method(s):
The WESTCOR point-of-care study was a single-center prospective randomized
controlled trial where we randomized patients presenting with possible
acute coronary syndrome in a 1:1 fashion to receive either 0/1-hour
centralized hs-cTnT measurements (control) or 0/1-hour point-of-care
hs-cTnI testing (intervention). We defined length of stay (LOS) in the ED
as the primary endpoint and the minimum clinically meaningful difference
as 15 minutes. Result(s): We included 1,494 patients in the final
analysis, 728 in the point-of-care group, and 766 in the control group.
The median (interquartile range) age was 61 (22) years, and 635 (42.5%)
were women. Median LOS in the ED was 174 (95% confidence interval [CI] 167
to 181) and 180 (95% CI 175 to 189) minutes in the point-of-care and
control group, respectively, resulting in a reduction in median LOS of 6
minutes (95% CI -4 to 17). Acute myocardial infarction, death, or acute
revascularization occurred in 83/728 (11.4%) of point-of-care and 72/766
(9.4%) of control patients. Conclusion(s): We found that implementing
point-of-care hs-cTnI testing in the ED with a 0/1-hour diagnostic
algorithm did not lead to a clinically meaningful reduction in ED LOS. We
observed no difference in the incidence of myocardial infarction, acute
coronary revascularization, or death during 30 days
follow-up. Copyright © 2025 American College of Emergency
Physicians

<65>
Accession Number
2035188051
Title
Effect of multimodal home-based prehabilitation on objectively measured
physical activity in patients undergoing elective cardiac or non-cardiac
major surgery: secondary outcomes from a randomised controlled trial.
Source
Perioperative Medicine. 14(1) (no pagination), 2025. Article Number: 69.
Date of Publication: 01 Dec 2025.
Author
Vetsch T.; Dueblin S.W.-S.; Eser P.; Beilstein C.M.; Wuethrich P.Y.;
Wilhelm M.; Engel D.
Institution
(Vetsch, Dueblin, Beilstein, Wuethrich, Engel) Department of
Anaesthesiology and Pain Medicine, Inselspital, Bern University Hospital,
University of Bern, Bern, Switzerland
(Vetsch, Eser, Wilhelm) Centre for Rehabilitation & Sports Medicine,
Inselspital, Bern University Hospital, University of Bern, Bern,
Switzerland
(Vetsch) Graduate School for Health Sciences, University of Bern, Bern,
Switzerland
Publisher
BioMed Central Ltd
Abstract
Objective: To assess physical activity (PA) measured in steps per day in
the preoperative period in high-risk cardiac and non-cardiac surgical
patients receiving home-based tele-supervised prehabilitation compared to
standard of care and to compare steps per day with raw acceleration
metrics. Study design: It is an analysis of secondary outcome data of a
prospective, two-arm parallel group, randomised controlled trial.
 Setting(s): It is a single university hospital in Switzerland.
 Participant(s): These are patients >= 65 years awaiting elective
cardiac or non-cardiac major surgery with a proven fitness deficit
measured by a cardiopulmonary exercise test (CPET). Analysis of PA data
after successfully enrolling 200 patients (167 with complete data) in the
trial. Average age was 73.8 years (SD 5.3) in cardiac and 76.0 years (SD
6) in non-cardiac patients. Intervention(s): The intervention arm
consists of a multimodal, home-based tele-supervised prehabilitation
programme over 2-4 weeks addressing deficits in physical fitness,
nutrition, and preoperative anaemia. Primary Outcome: Steps per day
are assessed by an open-source algorithm from wrist-worn accelerometer
data. Secondary outcome: Raw acceleration as overall Euclidean Norm Minus
One (ENMO) is expressed in milligravitational units (mg). Result(s):
Non-cardiac (n = 107) patients had more steps per day in the intervention
group versus standard of care (4662 [2817; 6807] vs 3378 [1919; 4831], p =
0.042). Overall, ENMO was higher in the intervention group but not
statistically significant. No significant differences in PA measures were
observed between randomisation groups in cardiac (n = 60) patients.
Cardiac patients had overall higher PA levels and were younger than
non-cardiac. The difference remained after adjusting for age. Steps per
day correlated strongly with overall ENMO. Conclusion(s): Simple
preoperative PA recommendations effectively improve steps per day in
high-risk non-cardiac surgery patients. To detect changes in PA in the
high-risk surgical patient, steps per day can be used as an intuitive
measure. To compare with other populations, overall ENMO is preferable.
Trial registration number: ClinicalTrials.gov Identifier:
NCT04461301. Copyright © The Author(s) 2025.

<66>
Accession Number
2035026105
Title
Metabolic dysfunction-associated steatotic liver disease and sex-specific
risk of fatal and non-fatal cardiovascular events: A meta-analysis.
Source
Diabetes, Obesity and Metabolism. 27(9) (pp 5171-5181), 2025. Date of
Publication: 01 Sep 2025.
Author
Jamalinia M.; Zare F.; Mantovani A.; Targher G.; Lonardo A.
Institution
(Jamalinia, Zare) Gastroenterohepatology Research Center, Shiraz
University of Medical Sciences, Shiraz, Iran, Islamic Republic of
(Mantovani) Section of Endocrinology, Diabetes and Metabolism, Department
of Medicine, University and Azienda Ospedaliera Universitaria Integrata of
Verona, Verona, Italy
(Targher) Metabolic Diseases Research Unit, IRCCS Sacro Cuore - Don
Calabria Hospital, Verona, Italy
(Targher) Department of Medicine, University of Verona, Verona, Italy
(Lonardo) Department of Internal Medicine, Azienda
Ospedaliero-Universitaria di Modena, Modena, Italy
Publisher
John Wiley and Sons Inc
Abstract
Aims: Since sex is a significant modifier of cardiovascular disease (CVD)
and metabolic dysfunction-associated steatotic liver disease (MASLD), we
performed a meta-analysis to estimate the sex-specific risk of fatal and
non-fatal CVD events in adults with MASLD. Material(s) and Method(s):
We searched four major electronic databases from inception to November
2024 to identify observational cohort studies examining sex-specific
associations between MASLD and the risk of fatal and/or non-fatal CVD
events. The diagnosis of MASLD and its severity were assessed using serum
biomarkers/scores, International Classification of Diseases codes, imaging
or histology. Result(s): Thirty-six cohort studies with aggregate
data on ~18.5 million individuals were included (~25% with MASLD; 48%
women; mean age of 50.2 years). During a median follow-up of 6.9 years
(IQR 5.0-12.3), approximately 515 000 fatal and/or non-fatal CVD events
occurred (42% in women). MASLD was associated with a higher risk of fatal
or non-fatal CVD events in women (pooled hazard ratio [HR] 1.59, 95%
confidence interval [CI] 1.44-1.75; I2 = 96.10%) than in men
(pooled HR 1.37, 95% CI 1.27-1.48; I2 = 96.26%) (p-value for
sex difference = 0.018). The severity of MASLD (variably assessed) further
increased the magnitude of this risk, especially in women (pooled HR 2.40,
95% CI 1.73-3.32; I2 = 57.29%). Sensitivity analyses did not
modify these findings. The funnel plot and Egger's test showed no
significant publication bias. Conclusion(s): Women with MASLD are at
higher risk of incident fatal and non-fatal CVD events compared with men,
especially as the severity of MASLD increases. These findings emphasize
the necessity for sex-specific CVD risk assessment and management
strategies. Copyright © 2025 John Wiley & Sons Ltd.

<67>
Accession Number
2039509814
Title
Inhaled Levosimendan Vs Inhaled Milrinone in children with congenital
heart disease with left to right shunt and pulmonary hypertension
undergoing surgical correction under cardiopulmonary bypass.
Source
European Journal of Cardiovascular Medicine. 15(7) (pp 98-108), 2025. Date
of Publication: 01 Jul 2025.
Author
Majumdar S.; Pal S.; De P.; Das S.; Dasgupta C.S.; Das P.K.
Institution
(Das, Majumdar) Dept of Cardiac Anaesthesiology, IPGMER, SSKM Hospital,
West Bengal, Kolkata, India
(Pal) Dept of Cardiac Anaesthesiology, R N Tagore International Institute
of Cardiac Sciences, Mukundapur, West Bengal, Kolkata, India
(De) Dept of Anaesthesiology, North Bengal Medical College and Hospital,
Sushrutanagar, West Bengal, Darjeeling, India
(Das) Dept Cardiac Anaesthesiology, Medical College & Hospital, West
Bengal, Kolkata, India
(Dasgupta) Dept of Cardiac Anaesthesiology, IPGMER, SSKM Hospital, 244
A.J.C. Bose Road, West Bengal, Kolkata, India
(Das) Dept of Psychiatry, Nil Ratan Sircar MedicalCollege & Hospital.,
West Bengal, Kolkata, India
Publisher
Healthcare Bulletin
Abstract
Background: Surgical closure of intracardiac left to right shunt in
children with pre-existing Pulmonary Atrial Hypertension (PAH) can
aggravate the elevated Pulmonary Atrial Pressure (PAP) and exacerbate
episodes of hypertensive crisis and acute right ventricular dysfunction.
Pulmonary vasodialators like Milrinone and Levosimendan when used in
systemic route also cause systemic hypotension and their feasibility as
selective pulmonary vasodialator when administered in inhaled route is
subject of investigation. Objective(s): To compare the efficacy of
inhaled milrinone and inhaled levosimendan in reducing elevated PAP in
such children. Method(s): In this one-way, parallel group,single
blinded, Randomised Trial, child of 1 to18 years of age with left to right
shunt with mean PAP more than 30mm Hg have been studied. They were
randomly allocated two equal groups, Group 1 received inhaled milrinone
(50 mug/kg) and group 2 received inhaled Levosimendan (24 mug/kg) after
arrival in the post-operative cardiac ICU room post-surgical correction
and evaluated for Transthoracic Echo variables like changes in Pulmonary
Artery Systolic Pressure (PASP) at different time points up to 6 hr after
completion of inhalation of study drug. Numerical variables have been
compared by Student's t-test. Result(s): Although both Inhaled
Milrinone and Inhaled Levosimendan are effective in reducing elevated
pulmonary artery systolic pressure without causing systemic hypotension in
children with congenital heart disease with left to right intra cardiac
shunt with pulmonary hypertension undergoing surgical correction under
CPB, inhaled levosimendan has longer duration of action.
 Conclusion(s): Inhaled levosimendan lowered pulmonary artery pressure
like inhaled milrinone in post-surgical closure in such children but for
longer duration making Inhaled Levosimendan a better option. Copyright
© 2025 Healthcare Bulletin. All rights reserved.

<68>
Accession Number
2039700090
Title
Prognostic scores of extracorporeal membrane oxygenation: a scoping
review.
Source
World Journal of Emergency Medicine. 16(4) (pp 303-312), 2025. Date of
Publication: 01 Jul 2025.
Author
Zhu J.; Lu S.; Wu Y.; Zhao Q.; Pei W.; Hu Y.; Li M.; Li Y.; Wu X.
Institution
(Zhu, Lu, Wu, Zhao, Pei, Hu, Li, Li, Wu) The Second Hospital & Clinical
Medical School, Lanzhou University, Lanzhou, China
(Zhao, Pei, Hu, Li, Wu) Department of Cardiac Surgery, the Second Hospital
& Clinical Medical School, Lanzhou University, Lanzhou, China
Publisher
Second Affiliated Hospital, Zhejiang University School of Medicine
Abstract
BACKGROUND: Extracorporeal membrane oxygenation (ECMO) is an effective
measure for saving the lives of critically ill patients. Prompt
identification of the risk factors for mortality among patients receiving
ECMO and comprehensive analysis of the long-term prognosis of survivors
are vital. This scoping review summarized the representative prognostic
scoring systems, aiming to help clinicians in selecting an appropriate
scoring system to avoid unnecessary medical resource consumption and
reduce ECMO-associated mortality. METHOD(S): A comprehensive search
of multiple databases, including PubMed, Embase, and the Cochrane Library,
was conducted. After removing duplicate studies, a full-text review was
performed, and all studies that reported score systems before and/or after
ECMO support were included. This protocol adheres to the Preferred
Reporting Items for Systematic reviews and Meta-Analyses extension for
Scoping Reviews (PRISMA-ScR) and has been registered with the Open Science
Framework (osf.io/zp4ge). RESULT(S): Among the 114 studies included,
we identified three scores for patients receiving veno-venous ECMO
(VV-ECMO), five scores for patients receiving veno-arterial ECMO
(VA-ECMO), and three critical illness scores, which apply to both VV-and
VA-ECMO conditions. All characteristics of these scoring systems, their
advantages, and their limitations were summarized. CONCLUSION(S): The
implementation of an ECMO scoring system helps to assess the condition of
critically ill patients, predict outcome, and provide objective indicators
to determine the optimal timing for ECMO intervention. Due to the
limitations of the currently available scores, further efforts in
improving and validating the ECMO scoring system are needed to achieve the
goals of minimizing unnecessary consumption of medical resources and
reducing mortality rates. Copyright © 2025 World Journal of
Emergency Medicine.

<69>
Accession Number
2035520101
Title
Features and Prognosis of Patients With Retroperitoneal Fibrosis
Developing Fibrosing Mediastinitis: Case-Control Study and Systematic
Review.
Source
ACR Open Rheumatology. 7(8) (no pagination), 2025. Article Number: e70065.
Date of Publication: 01 Aug 2025.
Author
Ding Y.; Li Z.; Liu S.; Li M.; Ren Y.; Xu K.-F.; Luo C.; Pan C.; Gao H.
Institution
(Ding) Department of Research and Education, Peking University
International Hospital, Beijing, China
(Ding, Gao) Peking University Eighth Clinical Medical School, Beijing,
China
(Li, Pan) Center for Intelligent Medicine Research, Greater Bay Area
Institute of Precision Medicine (Guangzhou), School of Life Sciences,
Fudan University, Guangzhou, China
(Liu) Department of Retroperitoneal Tumor Surgery, Peking University
International Hospital, Beijing, China
(Li) Department of Pulmonary and Critical Care Medicine, Peking University
International Hospital, Beijing, China
(Ren) Department of Pathology, Peking University International Hospital,
Beijing, China
(Xu) Department of Pulmonary and Critical Care Medicine, Peking Union
Medical College Hospital, Chinese Academy of Medical Sciences, Beijing,
China
(Luo) Department of General Surgery, Peking University People's Hospital,
Beijing, China
(Pan) Bioscience and Biomedical Engineering Thrust, Systems Hub, The Hong
Kong University of Science and Technology, Guangzhou, China
(Gao) Department of Rheumatology and Immunology, Peking University
International Hospital, Beijing, China
Publisher
John Wiley and Sons Inc
Abstract
Objective: Retroperitoneal fibrosis (RPF) complicated by mediastinal
fibrosis (MF) is rare but fatal. We aimed to explore the features and
indicators of poor prognosis for the population of those affected.
 Method(s): Patients with idiopathic RPF were recruited in Peking
University International Hospital. Literature related to RPF with MF was
searched from PubMed, Web of Science, and Embase until September 2024.
Systematic review and case-control studies were conducted. Result(s):
One patient with RPF and MF from our center and nine cases identified
through literature search formed the study group. The remaining 51
patients with RPF who did not have MF were enrolled as the control group.
Patients with RPF and MF were more likely to present specific symptoms,
including emaciation (30% vs 2%), fever (20% vs 0), pericardial effusion
(30% vs 0), pleurisy (20% vs 0) and dyspnea (40% vs 0) (all P < 0.05).
Hyperglobulinemia (elevated IgG levels) was also more predominant in the
study group, whereas low back pain (20% vs 56.9%, P = 0.043) was less
prevalent. Four of 10 patients in the study group died, but none died in
the control group. A second case-control study was performed among
patients with RPF and MF, with the three patients who died of fibrosis
disease as the study group and the surviving six patients as the control
group. It was found that pleural effusions (100% versus 16.7%, P = 0.048)
and the absence of glucocorticoid treatment were risk factors for death in
patients with RPF and MF. Conclusion(s): RPF with MF has specific
clinical features and poor prognosis. Early detection and
glucocorticoids-based treatment could improve the outcome. Copyright
© 2025 The Author(s). ACR Open Rheumatology published by Wiley
Periodicals LLC on behalf of American College of Rheumatology.

<70>
Accession Number
2035395451
Title
Clinical and economic consequences of medication nonadherence: a review of
systematic reviews.
Source
Frontiers in Pharmacology. 16 (no pagination), 2025. Article Number:
1570359. Date of Publication: 2025.
Author
Achterbosch M.; Aksoy N.; Obeng G.D.; Ameyaw D.; Agh T.; van Boven J.F.M.
Institution
(Achterbosch, van Boven) Department of Clinical Pharmacy & Pharmacology,
University Medical Center Groningen, University of Groningen, Groningen,
Netherlands
(Aksoy) Department of Clinical Pharmacy, School of Pharmacy, Altinbas
University, Istanbul, Turkey
(Obeng, Ameyaw, Agh) Syreon Research Institute, Budapest, Hungary
(Obeng, Ameyaw) Syreon Research Africa, Accra, Ghana
(Agh) Medication Adherence Research Group, Center for Health Technology
Assessment and Pharmacoeconomic Research, University of Pecs, Pecs,
Hungary
(van Boven) Department of Clinical Pharmacy & Pharmacology, Medication
Adherence Expertise Center of the Northern Netherlands (MAECON),
University Medical Center Groningen, University of Groningen, Groningen,
Netherlands
Publisher
Frontiers Media SA
Abstract
Background: Medication efficacy observed in clinical trials may differ
from its effectiveness during real-world usage. Medication nonadherence is
one of the key factors being responsible for this efficacy-effectiveness
gap. The World Health Organization estimated that only 50% of chronic
medication users is adherent and nonadherence results in both negative
health outcomes for the patient and higher societal costs. An overview of
the consequences across disease groups may allow some comparison and could
contribute to identification of priority clinical areas.
 Objective(s): We aimed to provide an overview the impact of
nonadherence on clinical and economic outcomes. Method(s): We
narratively reviewed systematic reviews published between 2014 and 2024 on
the effect of medication nonadherence on clinical and economic outcomes.
 Result(s): Overall, 43 systematic reviews were identified, including
over 410 original studies on clinical outcomes and 174 on economic
outcomes, covering different clinical areas (e.g., organ transplantation,
cardiovascular diseases, diabetes, depression and chronic lung diseases
[asthma/COPD]). Beyond diminished treatment effects, medication
nonadherence has been associated with elevated mortality, increased
healthcare utilization (including hospital admissions), and higher direct
(e.g., more healthcare provider visits) and indirect financial cost burden
(e.g., work productivity losses due to absenteeism and presenteeism) for
patients and society. Conclusion(s): Medication nonadherence is
associated with poor clinical and economic outcomes across disease areas.
Given the significant impact of nonadherence, raising awareness among
healthcare professionals and policymakers, early stakeholder engagement in
intervention design, and eventually implementation of cost-effective
interventions on both health policy, system and individual patient level
are urgently required. Copyright © 2025 Achterbosch, Aksoy,
Obeng, Ameyaw, Agh and van Boven.

<71>
Accession Number
2037940938
Title
Optimal timing for percutaneous coronary intervention in patients
undergoing transcatheter aortic valve replacement: A network
meta-analysis.
Source
Cardiovascular Revascularization Medicine. 76 (pp 56-63), 2025. Date of
Publication: 01 Jul 2025.
Author
Carvalho P.E.P.; Nascimento B.R.; Gewehr D.M.; Rivera A.; Clemente M.;
Braga M.A.P.; Pansani L.N.; Almeidinha L.; Felix N.; Veiga T.M.A.;
Barbanti M.; Lemos P.A.; Marino M.A.; Taramasso M.; Garot P.
Institution
(Carvalho) Center for Coronary Artery Disease, Minneapolis Heart
Institute, Minneapolis, United States
(Gewehr) Department of Internal Medicine, Federal University of Minas
Gerais, Belo Horizonte, Brazil
(Rivera) Interventional Cardiology Department, Hospital Madre Teresa, Belo
Horizonte, Brazil
(Clemente) Curitiba Heart Institute, Curitiba, Brazil
(Braga) Department of Medicine, Nove de Julho University, Sao Bernardo do
Campo, Brazil
(Pansani) Department of Medicine, Petropolis School of Medicine,
Petropolis, Brazil
(Almeidinha) Department of Medicine, Federal University of Rio de Janeiro,
Rio de Janeiro, Brazil
(Nascimento) Department of Cardiovascular Surgery, Faculty of Medicine of
Sao Jose do Rio Preto, Sao Jose do Rio Preto, Brazil
(Nascimento, Marino) Department of Internal Medicine, Rochester General
Hospital, Rochester, United States
(Felix) Department of Medicine, Federal University of Campina Grande,
Campina Grande, Brazil
(Veiga) Department of Medicine, Federal University of Minas Gerais, Belo
Horizonte, Brazil
(Barbanti) Universita degli Studi di Enna "Kore", Enna, Italy
(Barbanti) Ospedale Umberto I, ASP 4 di Enna, Enna, Italy
(Lemos) Hospital Israelita Albert Einstein, Sao Paulo, Brazil
(Lemos) Heart Institute - InCor, University of Sao Paulo Medical School,
Sao Paulo, Brazil
(Taramasso) Cardiovascular Surgical Department, University Hospital of
Zurich, Zurich, Switzerland
(Garot) Institut Cardiovasculaire Paris Sud (ICPS), Hopital Jacques
Cartier, Ramsay-Sante, Massy, France
Publisher
Elsevier Inc.
Abstract
Background: The optimal timing for percutaneous coronary intervention
(PCI) in patients undergoing transcatheter aortic valve replacement (TAVR)
is uncertain. Objective(s): To compare different PCI timings in
patients with CAD undergoing TAVR. Method(s): MEDLINE, Embase, and
Cochrane were systematically searched for studies comparing different
timings of PCI in patients with aortic stenosis and coronary artery
disease (CAD) undergoing TAVR. PCI in a staged procedure to TAVR and PCI
concomitantly to TAVR were compared with TAVR alone without PCI. A
frequentist random-effects network meta-analysis calculates the odds ratio
(OR) with a 95 % confidence interval (CI). Treatments were ranked using
P-score analysis. Result(s): Two randomized controlled trials and 24
observational studies comprising 10,901 patients with aortic stenosis and
CAD were included. Compared with PCI and concomitant TAVR, staged PCI was
associated with lower rates of stroke (OR 0.54; 95 % CI 0.37-0.78),
myocardial infarction (OR 0.54; 95 % CI 0.31-0.91), and all-cause
mortality at 30 days (OR 0.62; 95 % CI 0.41-0.95). In addition, a subgroup
analysis showed that staged PCI performed after TAVR is associated with
the lowest rates of all-cause mortality of all strategies. In P-score
analysis, staged PCI presented the highest likelihood of preventing stroke
and myocardial infarction. Conclusion(s): In patients with aortic
stenosis and CAD undergoing TAVR, staged PCI is associated with lower
rates of stroke, myocardial infarction, and short-term mortality compared
with other timings. Copyright © 2025 Elsevier Inc.

<72>
Accession Number
2039853070
Title
High vasoactive-inotropic score is associated with poor outcomes in
patients undergoing coronary artery bypass grafting: A systematic review
and meta-analysis.
Source
Perfusion (United Kingdom). (no pagination), 2025. Article Number:
02676591251364482. Date of Publication: 2025.
Author
Damarlapally N.; Vempati R.; Vasudevan S.S.; Mathur G.; Banda P.; Mourad
D.; Khan A.; Polamarasetty H.; Desai R.; Nunna K.R.
Institution
(Damarlapally) Health Sciences, Houston Community College - Coleman
Campus, Houston, TX, United States
(Vempati) Internal Medicine, Trinity Health Oakland Hospital, Pontiac, MI,
United States
(Vasudevan) Louisiana State University Health Sciences Center, Shreveport,
LA, United States
(Mathur) Mahatma Gandhi Memorial Medical College, Indore, India
(Banda) Internal Medicine, Gandhi Medical College and Hospital, Telangana,
Secunderabad, India
(Mourad, Khan) Internal Medicine, Central Michigan University, Saginaw,
MI, United States
(Polamarasetty) Biomedical Engineering, University of Houston, Houston,
TX, United States
(Desai) Outcomes Research, Independent Researcher, Atlanta, GA, United
States
(Nunna) Critical Care Medicine, Bon Secours - Southside Medical Center,
Petersburg, VA, United States
Publisher
SAGE Publications Ltd
Abstract
Background: Vasoactive-inotropic score (VIS) has been previously utilized
as one of the predictors in open heart procedures postoperatively, but its
association with poor outcomes in patients who underwent coronary artery
bypass graft (CABG) is still unclear. We aim to find the association in
this population. Method(s): PubMed, Google Scholar, and Scopus were
systematically searched for studies showing an association of poor
cardiovascular (CV) outcomes, including mortality with VIS from inception
to May 2024 following CABG surgery. Pooled effect sizes (aOR, OR, and ROC
AUC) were estimated using CMA version 4 with a fixed-effect model and 95%
confidence intervals (CI). I2-Statistic was used to measure heterogeneity.
Leave-one-out sensitivity analysis and meta-regression analysis were
utilized to measure the robustness of our findings and detect influencing
confounding variables, respectively. Quality assessment of the studies was
done through the Joanna Briggs Institute (JBI) tool. p-value <0.05 was
considered significant. Result(s): Six studies with a total sample
size of 6504 patients following CABG surgery, with a mean age of 63.6 +/-
3.15 years, containing predominantly males (71.8%) reported poor outcomes
such as CV morbidity, cardiopulmonary resuscitation, mechanical
ventilation, stroke, and mortality. Most studies had hypertension,
diabetes, and chronic kidney disease as comorbidities. VIS greater than 5
is validated by pooled ROC AUC of 80.1% [95% CI: 73.5-85.4]. Our
meta-analysis found a significant association between VIS >5 and poor
outcomes, including mortality in six studies with pooled unadjusted
OR-1.08 [95% CI: 1.06-1.10, p < 0.0001] and in four studies with adjusted
OR-1.07 [95% CI: 1.04-1.09, p < .0001] among those who underwent CABG.
Sensitivity analysis showed no variations among studies and confirmed the
robustness of our findings. Additionally, meta-regression analysis
indicated that mean age was associated with a minimal progression rate of
mortality in patients succeeding CABG with a VIS > 5 (p = .04). High
scores in the JBI tool revealed high quality among the studies selected.
 Conclusion(s): Our study suggests a significant association of VIS >
5 with poor cardiovascular outcomes in patients following CABG surgery.
This association can help in predicting deleterious cardiovascular
outcomes. Copyright © The Author(s) 2025

<73>
Accession Number
2035249136
Title
Importance of extracorporeal membrane oxygenation (ECMO) in congenital
heart diseases: a systematic review.
Source
Egyptian Heart Journal. 77(1) (no pagination), 2025. Article Number: 70.
Date of Publication: 01 Dec 2025.
Author
Faheem M.S.B.; Khan A.A.; Cheema S.; Akhtar M.; Ashraf D.A.
Institution
(Faheem) Karachi Institute of Medical Sciences, KIMS, Karachi, Pakistan
(Khan, Ashraf) Foundation University Medical College, Islamabad, Pakistan
(Cheema) King Edward Medical University, Lahore, Pakistan
(Akhtar) Gujranwala Medical College, Gujranwala, Pakistan
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: Congenital heart diseases (CHDs) represent a significant
healthcare challenge with incidence rates of 17.9 per 1000 live births.
Extracorporeal membrane oxygenation (ECMO) has become an invaluable
therapeutic option providing essential aid to support both cardiac as well
as pulmonary failure. Method(s): A systematic search was performed
using PubMed, Embase, and Scopus from 2000 till date. Observational
studies involving pediatric patients with CHD undergoing cardiac surgery
using ECMO were included. The main outcomes were to determine short-term
mortality, weaning off ECMO, complications, hospital and ICU length of
stay, and indications for ECMO. Assessment of the risk of bias of included
studies was done by Newcastle-Ottawa scale. Result(s): 24
retrospective observational studies, encompassing 1,658 patients, were
ultimately included in our review. The overall incidence of mortality
across these studies was 45.2%. Successful weaning from ECMO was achieved
in 73.9% of patients. The most frequently reported complications included
bleeding, which affected 42.9% of patients, renal failure in 42.5%, and
sepsis in 27.5%. The mean duration of hospital stay was 47.8 +/- 41.1
days, while the mean length of stay in the ICU was 33.4 +/- 32.6 days.
 Conclusion(s): ECMO benefits pediatric heart patients but comes with
risks like bleeding and high mortality. Percutaneous techniques can reduce
complications; more research on minimally invasive approaches is
needed. Copyright © The Author(s) 2025.

<74>
[Use Link to view the full text]
Accession Number
2039879770
Title
Continued Versus Interrupted Oral Anticoagulation During Transcatheter
Aortic Valve Implantation: A Systematic Review and Meta-Analysis.
Source
Cardiology in Review. (no pagination), 2025. Article Number: 01005. Date
of Publication: 2025.
Author
Naeem F.; Tabassum S.; Rakab M.S.; Gadelmawla A.F.; Naeem A.; Paul T.K.
Institution
(Naeem) Department of Cardiology, Massachusetts General Hospital, Boston,
MA, United States
(Tabassum) Department of Internal Medicine, King Edward Medical
University, Lahore, Pakistan
(Rakab) Department of Internal Medicine, Mansoura University, Mansoura,
Egypt
(Gadelmawla) Faculty of Medicine, Menoufia University Menoufia Egypt,
Egypt
(Gadelmawla) Medical Research Group of Egypt (MRGE), Negida Academy,
Arlington, MA, United States
(Naeem) Department of Internal Medicine, The Wright Center for Graduate
Medical Education, Scranton, PA, United States
(Paul) University of Tennessee Health Science Center at Nashville,
Ascension St. Thomas Hospital, Nashville, TN, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Given the lack of evidence and guideline-based recommendations on the best
preoperative oral anticoagulation (OAC) management strategies for
transcatheter aortic valve implantation (TAVI), this study aims to compare
continued oral anticoagulation (cOAC) versus interrupted oral
anticoagulation (iOAC) strategies. We conducted a comprehensive search
across PubMed, Embase, Cochrane Central, and ClinicalTrials.gov from
inception till February 2025 for studies comparing periprocedural cOAC or
iOAC in patients undergoing TAVI. Outcomes were analyzed using a
random-effects model to pool odds ratios (ORs) with 95% confidence
intervals (CIs). Four studies, comprising a total of 3117 patients, were
included in the final analysis. The early (30-day) safety outcome and
composite ischemic events were comparable between the approaches. There
was no significant difference between cOAC and iOAC in terms of any
bleeding, major bleeding, or life-threatening bleeding. However, cOAC was
associated with a slightly higher incidence of minor bleeding events (OR:
1.40, 95% CI: 1.02-1.93, P = 0.04). Additionally, major vascular
complications, all-cause mortality, cardiac-specific mortality, stroke,
transient ischemic attack, myocardial infarction, and length of hospital
stay were comparable between the 2 strategies. Both cOAC and iOAC
approaches demonstrated comparable outcomes, with cOAC being associated
with a slightly higher incidence of minor bleeding events. Copyright
© 2025 Wolters Kluwer Health, Inc. All rights reserved.

<75>
Accession Number
2035296451
Title
Arrhythmogenic mitral valve prolapse-a systematic review of ventricular
arrhythmia and sudden cardiac death outcomes before and after mitral valve
surgery.
Source
Journal of Arrhythmia. 41(4) (no pagination), 2025. Article Number:
e70108. Date of Publication: 01 Aug 2025.
Author
Cameron J.N.; Sutherland N.; Chow C.L.; Han H.-C.; Yudi M.; Mahajan R.;
Ganesan A.; Sabbag A.; Haugaa K.H.; Raman J.; Sanders P.; Farouque O.; Lim
H.S.
Institution
(Cameron, Yudi, Farouque, Lim) Department of Cardiology, Austin Health,
Melbourne, VIC, Australia
(Cameron, Chow, Yudi, Farouque, Lim) Faculty of Medicine, Dentistry and
Health Sciences, University of Melbourne, Melbourne, VIC, Australia
(Sutherland, Chow) Department of Cardiology, Northern Health, Melbourne,
VIC, Australia
(Han) Victorian Heart Institute, Monash University, Clayton, VIC,
Australia
(Mahajan) Adelaide Medical School, University of Adelaide, Adelaide, SA,
Australia
(Mahajan) Lyell McEwin Hospital, Northern Adelaide Health Local Health
Network, Elizabeth Vale, SA, Australia
(Ganesan) Department of Cardiovascular Medicine, Flinders Medical Centre,
Adelaide, SA, Australia
(Sabbag) The Davidai Center for Rhythm Disturbances and Pacing, Chaim
Sheba Medical Center, Tel Hashomer, Israel
(Haugaa) ProCardio Center for Cardiological Innovation, Department of
Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
(Haugaa) University of Oslo, Oslo, Norway
(Raman) Department of Cardiac Surgery, Austin Health, Melbourne, VIC,
Australia
(Sanders) Centre for Heart Rhythm Disorders, South Australian Health and
Medical Research Institute, University of Adelaide and Royal Adelaide
Hospital, Adelaide, SA, Australia
Publisher
John Wiley and Sons Inc
Abstract
Background: Several autopsy and observational studies have investigated
the link between mitral valve prolapse (MVP) and sudden cardiac death
(SCD) given the well accepted yet rare occurrence of ventricular
arrhythmias (VA). Whether surgical intervention for arrhythmogenic MVP
(aMVP) reduces VA and SCD risk remains unknown. Method(s): A
systematic literature review was conducted using the PubMed database in
December 2024. Studies documented in English were included if patients had
undergone mitral valve (MV) surgery (MVS; repair or replacement) for MVP
with documented rates of VA or SCD pre- and postintervention.
 Result(s): Sixteen identified studies (8 cohort and 8 case studies)
comprised 1233 patients (receiving medical or surgical treatment) with a
pooled mean age of 61.5 years and 41.9% being female. A total of 657 MVP
patients underwent MVS. Seven cohort studies reported rates of VA pre- and
postintervention, with six of these and all case studies reporting a
significant reduction. The remaining cohort study reported a reduction in
SCD. Conclusion(s): This systematic review indicates a reduction in
VA following current guideline-directed MVS for MVP. However, a residual
risk of VA and SCD may remain postintervention. Copyright © 2025
The Author(s). Journal of Arrhythmia published by John Wiley & Sons
Australia, Ltd on behalf of Japanese Heart Rhythm Society.

<76>
Accession Number
2037797955
Title
Efficacy and Safety of Distal Radial Artery Access versus Proximal Radial
Artery Access for Cardiac Procedures: A Systematic Review and
Meta-Analysis.
Source
Medical Principles and Practice. 34(4) (pp 328-337), 2025. Date of
Publication: 04 Feb 2025.
Author
Ur Rehman M.E.; Raja H.A.A.; Osama M.; Kakakhail A.; Waseem M.H.; Mukhlis
M.; Ali M.A.; Abideen Z.U.; Shoaib M.; Din Z.U.; Tahir A.; Hassan M.Z.U.;
Mazhar U.; Haider S.T.; Saeed S.; Nashwan A.J.
Institution
(Ur Rehman, Raja, Mazhar, Haider, Saeed) Department of Medicine,
Rawalpindi Medical University, Rawalpindi, Pakistan
(Osama, Ali, Shoaib, Din, Hassan) Khyber Medical College, Peshawar,
Pakistan
(Kakakhail) Khyber Girls Medical College, Peshawar, Pakistan
(Waseem) Allama Iqbal Medical College, Lahore, Pakistan
(Mukhlis) Ayub Medical College, Abbottabad, Pakistan
(Abideen) Department of Medicine, King Edward Medical University, Lahore,
Pakistan
(Tahir) Department of Medicine, Liaquat University of Medical and Health
Sciences, Jamshoro, Pakistan
(Nashwan) Hamad Medical Corporation, Doha, Qatar
Publisher
S. Karger AG
Abstract
Objective: Cardiac catheterization using the distal radial artery (DRA)
access, at the level of the anatomical snuff box post-radial artery
bifurcation, may be linked to a lower rate of arterial occlusion and
better hemostasis. In this meta-analysis, we compare DRA versus proximal
radial artery (PRA) access in cardiac catheterization or angiography.
 Method(s): A detailed literature search was performed on PubMed,
Cochrane, Em-base, and Clinicaltrials.gov from inception till June 2024.
Risk ratios (RRs) and mean differences (MDs) were pooled for categorical
and continuous outcomes, respectively. Random effects meta-analysis was
undertaken on RevMan. Result(s): Our meta-analyses include 21
randomized controlled trials with 9,539 patients (DRA 4,761, PRA 4,778).
DRA significantly reduced 24-h radial artery occlusion rates (RR 0.30, 95%
CI: 0.23 to 0.40, p <= 0.00001) and time to hemostasis (minutes) (MD
-44.46, 95% CI: -50.64 to -38.92, p < 0.00001), whereas PRA was
significantly superior in terms of the puncture success rate (RR 0.96, 95%
CI: 0.93 to 0.99, p < 0.01), the crossover rate (RR 2.89, 95% CI: 2.02 to
4.15, p < 0.00001), and puncture attempts (MD 0.69, 95% CI: 0.37 to 1.00,
p = 0.00001). Conclusion(s): DRA was associated with a lower risk of
occlusion and lower time to hemostasis, but required a greater number of
puncture attempts and had lower success rate. Further research is required
to elucidate the most optimal approach. Copyright © 2025 The
Author(s)

<77>
Accession Number
2035312877
Title
Evaluating long-term outcomes and the impact of small aortic annulus on
valve replacement-a novel systematic review and meta-analysis comparing
surgery vs. transcatheter interventions.
Source
Frontiers in Cardiovascular Medicine. 12 (no pagination), 2025. Article
Number: 1555853. Date of Publication: 2025.
Author
Amin A.; Mohammed C.; Kajitani S.; AlMashari K.; Kumar R.; Sabir A.;
Briz-Echeverria P.; Mokhtassi S.; Kallikere Lakshmana S.K.; Bokhari A.;
Ehsan M.; Ahmad H.; Ahmed R.; Bahrami T.
Institution
(Amin, Mokhtassi) Department of Cardiothoracic Surgery, Harefield
Hospital, Guy's and St Thomas NHS Foundation Trust, London, United Kingdom
(Mohammed) Department of Orthopaedic Surgery, Sangre Grande Hospital,
Sangre Grande, Trinidad and Tobago
(Kajitani) School of Medicine, University College Cork, Cork, Ireland
(AlMashari) College of Medicine, Imam Abdulrahman Bin Faisal University,
Dammam, Saudi Arabia
(Kumar) Department of CTVS, Jay Prabha Medanta Super Speciality Hospital,
Patna, India
(Sabir) Department of Cardiac Surgery, Rawalpindi Institute of Cardiology,
Rawalpindi, Pakistan
(Briz-Echeverria) Department of Cardiac Surgery, Hospital Universitario de
Toledo, Toledo, Spain
(Kallikere Lakshmana) Cardiothoracic Surgery, Royal Brompton Hospital,
London, United Kingdom
(Bokhari) Department of Cardiothoracic Surgery, Jazan University, Jazan,
Saudi Arabia
(Ehsan) Department of Medicine, King Edward Medical University, Lahore,
Pakistan
(Ahmad, Ahmed) National Heart and Lung Institute, Imperial College London,
London, United Kingdom
(Bahrami) Department of Cardiac Surgery, Royal Brompton and Harefield
Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United
Kingdom
Publisher
Frontiers Media SA
Abstract
Background: Transcatheter aortic valve implantation (TAVI) is often
compared to surgical aortic valve replacement (SAVR) for aortic stenosis
treatment. This meta-analysis evaluates the long-term efficacy and safety
of TAVI vs. SAVR in aortic stenosis patients, as well as their respective
impact on patients with small aortic annulus (SAA). Method(s):
MEDLINE, Embase, Cochrane Library, and ClinicalTrials.gov were searched
for randomized controlled trials (RCTs) and comparative observational
studies on TAVI vs. SAVR with long-term follow-up (3-5 years) or SAA. Risk
of bias was assessed using the Cochrane Risk of Bias tool (RoB 2.0) and
the Newcastle Ottawa Scale. Meta-analyses were conducted with RevMan 5.4
using a random-effects model, with risk ratio (RR) and mean difference
(MD) as effect measures. Result(s): A total of 17 studies were
included in our review. In the long-term analysis, all-cause mortality was
significantly higher in the TAVI group [RR 1.10; 95% CI: 1.01-1.19], but
the incidence of major bleeding [RR 0.79; 95% CI: 0.68-0.90] and atrial
fibrillation was significantly lower [RR 0.37; 95% CI: 0.29-0.48] in the
TAVI group. No significant difference was found between the two groups
regarding other long-term outcomes. For SAA outcomes, there was no
significant difference in terms of all-cause mortality [RR 0.92; 95% CI:
0.63-1.35], although cardiovascular mortality was significantly increased
in the TAVI group [RR 2.08; 95% CI: 1.09-3.98]. TAVI significantly
increased the rate of major vascular complications [RR 3.58; 95% CI:
1.10-11.61], aortic regurgitation/PVL [RR 6.91; 95% CI: 2.66-17.97], and
pacemaker implantation (RR 2.87; 95% CI: 1.74-4.75]. TAVI significantly
improved the incidence of prosthesis patient mismatch [RR 0.70; 95% CI:
0.54-0.89], effective orifice valve area (EOA) [MD 0.10; 95% CI:
0.01-0.19], and length of stay in hospital [MD -4.88; 95% CI: -5.52 to
-4.23]. There were no significant differences in other clinical or
echocardiographic outcomes. Conclusion(s): TAVI was associated with
higher long-term all-cause mortality compared to SAVR in the overall
population. Among patients with small aortic annulus, no survival benefit
was observed with TAVI, and cardiovascular mortality was significantly
increased. Future RCTs should explore SAA-related outcomes with
standardized diagnostic criteria. Systematic Review Registration:
https://www.crd.york.ac.uk, PROSPERO CRD42024541862. Copyright 2025
Amin, Mohammed, Kajitani, AlMashari, Kumar, Sabir, Briz-Echeverria,
Mokhtassi, Kallikere Lakshmana, Bokhari, Ehsan, Ahmad, Ahmed and Bahrami.

<78>
Accession Number
2037428756
Title
Aspirin and Hemocompatibility after LVAD Implantation in Patients with
Atherosclerotic Vascular Disease: A Secondary Analysis from the ARIES-HM3
Randomized Clinical Trial.
Source
JAMA Cardiology. 10(3) (pp 235-242), 2025. Date of Publication: 12 Mar
2025.
Author
Gustafsson F.; Uriel N.; Netuka I.; Katz J.N.; Pagani F.D.; Connors J.M.;
Jorde U.P.; Zimpfer D.; Pya Y.; Conway J.; Anyanwu A.; Scandroglio A.M.;
Sulemanjee N.; Atluri P.; Keebler M.; Selzman C.H.; Alexis J.D.; Hayward
C.; Henderson J.; Dirckx N.; Gazzola C.; Mehra M.R.
Institution
(Gustafsson) Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
(Uriel) Columbia University College of Physicians and Surgeons and New
York Presbyterian Hospital, New York, United States
(Netuka) Insitute for Clinical and Experimental Medicine, Prague, Czechia
(Katz) NYU Grossman School of Medicine and Bellevue Hospital, New York,
NY, United States
(Pagani) University of Michigan, Ann Arbor, United States
(Connors) Brigham and Women's Hospital and Harvard Medical School, Boston,
MA, United States
(Jorde) Montefiore Einstein Center for Heart and Vascular Care, New York,
NY, United States
(Zimpfer) Medical University of Vienna, Vienna, Austria
(Pya) University Medical Center, Astana, Kazakhstan
(Conway) University of Alberta Hospital, Edmonton, AB, Canada
(Anyanwu) Mount Sinai Medical Center, New York, NY, United States
(Scandroglio) Ospedale San Raffaele, Milan, Italy
(Sulemanjee) Aurora St Luke's Medical Center, Milwaukee, WI, United States
(Atluri) Hospital of the University of Pennsylvania, Philadelphia, United
States
(Keebler) University of Pittsburgh Medical Center, Pittsburgh, PA, United
States
(Selzman) University of Utah Hospital, Salt Lake City, United States
(Alexis) University of Rochester Medical Center, Rochester, NY, United
States
(Hayward) St Vincent's Hospital, Sydney, NSW, Australia
(Henderson, Dirckx, Gazzola) Abbott, Chicago, IL, United States
(Mehra) Brigham and Women's Hospital Heart and Vascular Center, Center for
Advanced Heart Disease, Harvard Medical School, Boston, MA, United States
Publisher
American Medical Association
Abstract
Importance: The Aspirin and Hemocompatibility Events With a Left
Ventricular Assist Device in Advanced Heart Failure (ARIES-HM3) study
demonstrated that aspirin may be safely eliminated from the antithrombotic
regimen after HeartMate 3 (HM3 [Abbott Cardiovascular]) left ventricular
assist device (LVAD) implantation. This prespecified analysis explored
whether conditions requiring aspirin (prior percutaneous coronary
intervention [PCI], coronary artery bypass grafting [CABG], stroke, or
peripheral vascular disease [PVD]) would influence outcomes differentially
with aspirin avoidance. Objective(s): To analyze aspirin avoidance on
hemocompatibility-related adverse events (HRAEs) at 1 year after implant
in patients with a history of CABG, PCI, stroke, or PVD. Design,
Setting, and Participant(s): This was an international, multicenter,
prospective, double-blind, placebo-controlled, randomized clinical trial
including patients implanted with a de novo HM3 LVAD across 51 centers.
Data analysis was conducted from April to July 2024. Intervention(s):
Patients were randomized in a 1:1 ratio to receive aspirin (100 mg per
day) or placebo, in addition to a vitamin K antagonist (VKA) targeted to
an international normalized ratio of 2 to 3 in both groups. Main
Outcomes and Measures: Primary end point (assessed for noninferiority) was
a composite of survival free of any nonsurgical (>14 days after implant)
HRAEs including stroke, pump thrombosis, bleeding, and arterial peripheral
thromboembolism at 12 months. Secondary end points included nonsurgical
bleeding, stroke, and pump thrombosis events. Result(s): Among 589 of
628 patients (mean [SD] age, 57.1 [13.7] years; 456 male [77.4%]) who
contributed to the primary end point analysis, a history of PCI, CABG,
stroke, or PVD was present in 41% (240 of 589 patients). There was no
interaction between the presence of an atherosclerotic vascular condition
and effect of aspirin compared with placebo (P for interaction=.23). The
preset 10% noninferiority margin was not crossed for the studied subgroup
of patients. Thrombotic events were rare, with no differences between
aspirin and placebo in patients with and without vascular disease (P for
interaction =.77). Aspirin treatment was associated with a higher rate of
nonsurgical major bleeding events in the group with prior vascular
condition history compared with those without aspirin (rate ratio for
placebo compared with aspirin, 0.52; 95% CI, 0.35-0.79). Conclusions
and Relevance: Results of this prespecified analysis of the ARIES-HM3
randomized clinical trial demonstrate that in patients with advanced heart
failure who have classical indications for antiplatelet therapy use at the
time of LVAD implantation, aspirin avoidance was safe and not associated
with increased thrombosis risk. Importantly, elimination of aspirin was
associated with no increased thrombosis but a reduction in nonsurgical
bleeding events in patients with a history of PCI, CABG, stroke, or PVD.
Trial registration: ClinicalTrials.gov Identifier:
NCT04069156. Copyright © 2025 American Medical Association. All
rights reserved.

<79>
[Use Link to view the full text]
Accession Number
2039745787
Title
Bilateral External Oblique Intercostal Plane Block Versus Intravenous
Morphine for Rescue Pain Relief in Patients with Epidurals Following Upper
Abdominal Surgeries: A Randomized Controlled Trial.
Source
A and A Practice. 19(7) (pp e02019), 2025. Date of Publication: 01 Jul
2025.
Author
Srinivasaraghavan N.; Seshadri R.A.; Ramasamy Y.; Raj P.; Chockalingam P.;
Sankar P R P.; Modh V.; Ramakrishnan B.
Institution
(Srinivasaraghavan, Ramasamy, Raj, Chockalingam, Sankar P R, Modh)
Department of Anesthesia and Critical Care, Cancer Institute (WIA), Tamil
Nadu, Chennai, India
(Seshadri) Integrated Cancer Care Group, Tamil Nadu, Chennai, India
(Ramakrishnan) Department of Clinical Trials Services Unit, Clinical
Trials Services Unit, Cancer Institute (WIA), Tamil Nadu, Chennai, India
Publisher
Wolters Kluwer Health
Abstract
BACKGROUND: The management of postoperative pain after upper abdominal
surgery is challenging. Thoracic epidural analgesia, though effective, has
limitations, while intravenous (IV) morphine is associated with side
effects. Ultrasound-guided external oblique intercostal block (EOIB) is an
emerging regional technique for upper abdominal pain relief. We
hypothesized that EOIB would provide superior pain relief to IV morphine
in patients undergoing upper abdominal surgery. The main objective of the
study was to compare pain relief from EOIB versus IV morphine as rescue
analgesia in patients with moderate to severe pain despite an epidural
after upper abdominal surgeries. METHOD(S): This double-blinded,
randomized controlled trial was conducted at a tertiary cancer hospital
from January to November 2024. Patients aged >=18 years undergoing upper
abdominal surgery with pain on the numerical rating scale >=4 despite
epidural and IV paracetamol were randomized (1:1) to IV morphine (0.05
mg/kg, Arm A) or bilateral EOIB (0.1% bupivacaine 1 mL/kg and 4 mg
dexamethasone, Arm B). The primary outcome was the total 24-hour morphine
rescue requirement. Secondary outcomes included pain intensity difference
(PID) at 0.5, 1, 4, 8, 12, 16, 20, and 24 hours, summated pain intensity
difference at 8 and 24 hours (SPID), percentage PID in the first four
hours, pain-free hours (PFH), and adverse events. Participants and outcome
assessor nurses were blinded in the trial. RESULT(S): Of 101 screened
patients, 66 were randomized with 33 in each group. The EOIB arm had
significantly lower 24-hour morphine requirements compared to the morphine
arm median (interquartile range) 0 mg (0-1.5) vs 2.5 mg (1-6.1),
respectively; median difference (95% confidence interval [CI], 1.5
[0.00-3.40]; P =.006). Repeated measures analysis of variance with
Greenhouse-Geisser correction determined that the mean PID did not differ
among the two groups across different time points over 24 hours; F (7,434)
= 1.08, P =.37. SPID at 8 and 24 hours favored EOIB (P =.038 and P =.048,
respectively). The percentage PID in the first four hours was higher in
the EOIB arm than morphine arm, 66.6% [58.5%-100%] vs 50% [34.9%-74%]; P
=.002. PFH was significantly higher in the EOIB arm than morphine arm 4.00
[0.00-8.00] hours vs 0.00[0.00-0.37] hours; P =.015, with two patients
achieving complete pain relief (NRS = 0) for 24 hours, compared to none in
the IV morphine group. No significant adverse events were observed.
 CONCLUSION(S): EOIB provided superior and prolonged analgesia
compared to IV morphine as a supplement to epidural analgesia, reducing
opioid consumption and increasing the pain-free period in patients
undergoing upper abdominal surgery. Copyright © 2025
International Anesthesia Research Society. Unauthorized reproduction of
this article is prohibited.

<80>
[Use Link to view the full text]
Accession Number
2038615060
Title
Colchicine in Acute Coronary Syndromes: A Meta-Analysis of 12,602
Patients.
Source
Journal of Cardiovascular Pharmacology. 86(1) (pp 33-36), 2025. Date of
Publication: 01 Jul 2025.
Author
Cappannoli L.; Fracassi F.; Aurigemma C.; Romagnoli E.; Bianchini F.;
Lunardi M.; Montone R.A.; Paraggio L.; Trani C.; Liuzzo G.; Burzotta F.
Institution
(Cappannoli, Fracassi, Aurigemma, Romagnoli, Bianchini, Lunardi, Montone,
Paraggio, Trani, Liuzzo, Burzotta) Department of Cardiovascular Sciences,
Fondazione Policlinico Universitario A. Gemelli Irccs, Rome, Italy
(Trani, Liuzzo, Burzotta) Universita Cattolica del Sacro Cuore, Rome,
Italy
Publisher
Lippincott Williams and Wilkins
Abstract
Inflammation is a leading cause of ischemic heart disease. The aim of this
study is to assess whether treatment with colchicine in patients with
acute coronary syndromes is associated with improved cardiovascular
outcomes. We conducted a systematic review and meta-analysis of randomized
clinical trials of patients with acute or recent acute coronary syndromes
and treated with colchicine versus placebo. PubMed, Scopus, and the
Cochrane Central Register of Controlled Trials databases were searched.
The primary endpoint was composite of cardiovascular death, recurrent
myocardial infarction (MI), stroke, or urgent/unplanned revascularization.
Other endpoints were individual components of the primary endpoint,
all-cause death, noncardiovascular death, and diarrhea. PROSPERO ID
CRD42025648254. Three randomized clinical trials were included, involving
12,602 patients. There was no significant difference in the primary
composite endpoint between the colchicine and placebo groups (odds ratio
0.82, 95% confidence interval, 0.63-1.07, P = 0.15). Analysis of
individual components of the primary endpoint also revealed no significant
differences between the colchicine versus placebo groups: cardiovascular
deaths (P = 0.89), recurrent MI (P = 0.17), strokes (P = 0.27),
urgent/unplanned revascularizations (P = 0.14), all-cause death (P =
0.95), noncardiovascular death (P = 0.98), and diarrhea (P = 0.08). At the
leave-one-out analysis, the exclusion of the Colchicine and Spironolactone
in Patients with Myocardial Infarction (CLEAR) trial resulted in a
significant reduction in primary endpoint (P = 0.005). At further
sensitivity analyses, the exclusion of patients who did not receive an
initial twice-daily dose regimen and the exclusion of patients enrolled
after COVID-19 pandemic resulted in a significant reduction in major
adverse cardiovascular events (P = 0.01 and P = 0.001, respectively),
reflecting heterogeneity among studies. This meta-analysis raises new
questions over the indication, timing, and dosing of colchicine in
patients with recent MI. Copyright © 2025 Wolters Kluwer Health,
Inc.

<81>
Accession Number
2035554933
Title
Incidence and Influencing Factors for Steam Pops in Cardiac Ablations: A
Systematic Review.
Source
PACE - Pacing and Clinical Electrophysiology. (no pagination), 2025. Date
of Publication: 2025.
Author
Elenizi K.; Alharthi R.
Institution
(Elenizi) Department of Internal Medicine, Colleges of Medicine, Prince
Sattam bin Abdulaziz University, Alkharj, Saudi Arabia
(Alharthi) Department of Cardiology, Dr. Sulaiman Al-Habib Hospital,
Riyadh, Saudi Arabia
Publisher
John Wiley and Sons Inc
Abstract
Background: Steam pops (SPs) during cardiac ablations have emerged as a
notable phenomenon with potential implications for procedural safety and
efficacy. This is the first review of SPs, which aims to explore the
current understanding of SPs. The review investigates their incidence,
associations, predictors, clinical significance, and management
strategies. Presently, the factors that give rise to SPs have not been
completely understood, and the root cause of SPs remains elusive. To
achieve this goal, the study conducted a comprehensive review of existing
research on SPs in cardiac ablation procedures to ascertain the prevalence
and predictors of SPs. Method(s): The research involved an extensive
search of databases from their inception until April 2024 to investigate
the prevalence of SPs during cardiac ablation procedures in humans. The
primary objective of this study was to gather patient demographics,
incidence rates, and potential risk factors and predictors that could
contribute to the occurrence of SPs and determine any significant
correlations between them. The data collected were thoroughly reviewed to
identify any significant associations between the various risk factors,
predictors, and the incidence of SPs. Result(s): A comprehensive
review of literature sourced from EMBASE and PubMed identified 25 relevant
studies focused on the incidence and clinical significance of steam pops
(SPs) during catheter ablation procedures. The studies reported varying
rates of SPs, ranging from 0% to 26%, with the highest incidence observed
in atrial fibrillation (AFib) and ventricular ablation cases. The
association between SPs and factors such as catheter type, irrigation
methods, and monitoring parameters was assessed. Notably, advanced
catheter technologies, such as the QDOT MICRO and THERMOCOOL SMARTTOUCH,
demonstrated a significant reduction in SP occurrences. Additionally, the
analysis highlighted the role of temperature control and contact force in
minimizing the risk of SPs, with temperature-controlled ablation (TCA)
generally leading to fewer SPs compared to power-controlled ablation
(PCA). Despite the low incidence of severe complications, the review
underscores the importance of careful monitoring of impedance and
real-time feedback during ablation to ensure patient safety.
 Conclusion(s): SPs are not uncommon during ablation procedures with
irrigated catheters. Caution is required to avoid temperature feedback
issues. Advanced catheters are associated with a reduced incidence of
steam pops. The risks can be minimized by decreasing energy settings and
monitoring impedance changes. Copyright © 2025 Wiley Periodicals
LLC.

<82>
Accession Number
2035198354
Title
Melatonin administered postoperatively lowers oxidative stress and
inflammation and significantly recovers heart function in patients
undergoing CABG surgery.
Source
European Journal of Medical Research. 30(1) (no pagination), 2025. Article
Number: 585. Date of Publication: 01 Dec 2025.
Author
Mohammadi N.; Alizadeh M.; Akbarzadeh S.; Rezaei M.; Mahmoodi M.;
Netticadan T.; Movahed A.
Institution
(Mohammadi) Department of Clinical Biochemistry, Bushehr University of
Medical Sciences, Bushehr, Iran, Islamic Republic of
(Alizadeh) Department of Clinical Biochemistry, Faculty of Medicine,
Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic
Republic of
(Akbarzadeh) Department of Endocrine and Metabolic Diseases, The Persian
Gulf Tropical Medicine Research Center, Bushehr University of Medical
Sciences, Bushehr, Iran, Islamic Republic of
(Rezaei) Department of Cardiovascular Surgery, Faculty of Medicine,
Bushehr University of Medical Sciences, Bushehr, Iran, Islamic Republic of
(Mahmoodi) Department of Environmental Health Engineering, Faculty of
Health and Nutrition, Bushehr University of Medical Sciences, Bushehr,
Iran, Islamic Republic of
(Netticadan) Canadian Centre for Agri-Food Research in Health and
Medicine, Winnipeg, MB, Canada
(Movahed) Department of Clinical Biochemistry, Faculty of Medicine,
Bushehr University of Medical Sciences, Bushehr, Iran, Islamic Republic of
Publisher
BioMed Central Ltd
Abstract
Background: This study aimed to assess the effect of oral melatonin
consumption on improving heart function and reducing postoperative
complications in patients undergoing coronary artery bypass grafting
(CABG) surgery. Method(s): A total of 60 CABG patients in the
postoperative period were included in this randomized, double-blind,
placebo-controlled trial. The patients were divided into three groups:
Group 1 (n = 20, 5 mg melatonin), Group 2 (n = 20, 10 mg melatonin), and
the placebo group (n = 20). The patients were discharged about 8 to 10
days after the surgery. Blood samples were taken from all the patients
before and after the intervention (for 60 days), and Biochemical
parameters including creatine kinase-MB (CK-MB), lactate dehydrogenase
(LDH), malondialdehyde (MDA), tumor necrosis factor alpha (TNF-alpha),
total antioxidant capacity (TAC), nitric oxide (NO) assessed.
Echocardiography and the measurement of systolic and diastolic blood
pressure were also performed on participants. Result(s): Our results
showed that melatonin treatment significantly increased the ejection
fraction (%EF) and TAC levels in both the treatment groups compared to the
placebo group (P < 0.05). Moreover, the levels of inflammatory and
oxidative biomarkers, including TNF-alpha, MDA, and NO, decreased in the
intervention group significantly (P < 0.05). In the placebo group, %EF
decreased significantly (P = 0.042), while MDA increased (P < 0.001) and
TAC decreased (P = 0.002). No significant changes were observed in LDH and
CK-MB levels. The comparison of serum biomarkers between the two treatment
groups showed that 10 mg of melatonin was more effective than 5 mg, but
the difference was not significant (P > 0.05). Conclusion(s): The
present study showed that as a potential antioxidant, melatonin could
alleviate oxidative stress and inflammation associated with CABG and is
essential in improving overall heart function. Trial registration:
IRCT20111119008129N14, first trial registration date:
01/08/2023. Copyright © The Author(s) 2025.

<83>
Accession Number
2038206545
Title
Ten-year clinical outcomes after left main coronary artery stenting with
new-generation or early-generation DES.
Source
Revista Espanola de Cardiologia. 78(9) (pp 811-819), 2025. Date of
Publication: 01 Sep 2025.
Author
Wiebe J.; Kuna C.; Ibrahim T.; Kufner S.; Hintz I.; Justenhoven P.;
Kessler T.; Schunkert H.; Valgimigli M.; Richardt G.; Bresha J.; Laugwitz
K.-L.; Kastrati A.; Cassese S.
Institution
(Wiebe, Kuna, Kufner, Hintz, Justenhoven, Kessler, Schunkert, Kastrati,
Cassese) Department of Cardiology, Deutsches Herzzentrum Munchen,
Technische Universitat, Munich, Germany
(Wiebe, Kessler, Schunkert, Laugwitz, Kastrati) DZHK (German Centre for
Cardiovascular Research), Partner Site Munich Heart Alliance, Munich,
Germany
(Ibrahim, Bresha, Laugwitz) 1. med. Klinik, Klinikum rechts der Isar,
Technische Universitat, Munich, Germany
(Valgimigli) Division of Cardiology, Cardiocentro Ticino Institute, Ente
Ospedaliero Cantonale, Lugano, Switzerland
(Richardt) Department of Cardiology, Klinik Bad Oldesloe, Bad Oldesloe,
Germany
Publisher
Ediciones Doyma, S.L.
Abstract
Introduction and objectives: Long-term data after stenting of the left
main coronary artery (LMCA) are scarce, especially regarding
new-generation drug-eluting stents (DES). This analysis aimed to describe
the 10-year clinical outcomes of patients who underwent percutaneous
coronary intervention with different DES generations for LMCA disease.
 Method(s): Individual patient data from the randomized controlled
ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials were pooled and 10-year
clinical follow-up was obtained. The Kaplan-Meier method was used to
calculate event rates. The main endpoints of interest for this analysis
were all-cause mortality, myocardial infarction, target lesion
revascularization and definite stent thrombosis. Result(s): A total
of 1257 patients were included in this analysis, of which 650 patients
were treated with new-generation DES and 607 with early-generation DES. At
10 years, the mortality rate was more than 40% in both groups. After
statistical adjustment, 10-year mortality was significantly reduced in
patients treated with new-generation DES compared with those treated with
early-generation DES (HR<inf>adj</inf>, 0.78; 95%CI, 0.62-0.97). After 10
years, the risk of myocardial infarction (HR<inf>adj</inf>, 0.43; 95%CI,
0.23-0.80), target lesion revascularization (HR<inf>adj</inf>, 0.66;
95%CI, 0.49-0.89), and definite stent thrombosis (HR<inf>adj</inf>, 0.13,
95%CI, 0.04-0.49) was significantly reduced by new-generation DES compared
with early-generation DES. Conclusion(s): Patients undergoing
percutaneous coronary intervention for LMCA disease have high 10-year
mortality regardless of DES generation. The use of new-generation DES in
patients with LMCA disease is associated with improved long-term clinical
outcomes compared with early-generation DES. Copyright © 2025
Sociedad Espanola de Cardiologia

<84>
Accession Number
2039833138
Title
Cardiac CT and PET for Surveillance of Heart Transplant Recipients:
Systematic Review and Bayesian Meta-Analysis.
Source
JACC: Cardiovascular Imaging. (no pagination), 2025. Date of Publication:
2025.
Author
Sayed A.; Nayfeh M.; Alahdab F.; Al Rifai M.; Abramov D.; Fudim M.;
Moayedi Y.; Yousefzai R.; Al-Mallah M.H.
Institution
(Sayed, Alahdab, Al Rifai, Yousefzai, Al-Mallah) Houston Methodist DeBakey
Heart and Vascular Center, Houston, TX, United States
(Sayed) Ain Shams University, Faculty of Medicine, Cairo, Egypt
(Sayed) Rochester General Hospital, Rochester, NY, United States
(Nayfeh) Vanderbilt University School of Medicine, Nashville, TN, United
States
(Alahdab) University of Missouri, Columbia, MO, United States
(Abramov) Lomda Linda University Medical Center, Loma Linda, CA, United
States
(Fudim) Duke Clinical Research Institute, NC, United States
(Fudim) Duke University School of Medicine, Durham, NC, United States
(Moayedi) Ted Rogers Centre of Excellence in Heart Research, Peter Munk
Cardiac Centre, University Health Network, Toronto, ON, Canada
(Moayedi) Ajmera Transplant Centre, University Health Network, Toronto,
ON, Canada
Publisher
Elsevier Inc.
Abstract
Background: For noninvasive surveillance of cardiac allograft vasculopathy
(CAV), cardiac computed tomography (cardiac computed tomography [CT]) and
positron emission tomography (PET) received a Class IIa recommendation by
the 2023 ISHLT (International Society for Heart and Lung Transplantation)
guidelines. However, implementation has lagged behind because of concerns
about their ability to rule out disease and stratify risk.
 Objective(s): The purpose of this study was to define the diagnostic
and prognostic ability of PET and cardiac CT in cardiac transplant
recipients. Method(s): Electronic databases were searched for studies
evaluating CT or PET for their diagnostic (for detecting angiographic CAV)
and prognostic (for predicting major adverse cardiovascular outcomes)
value. Sensitivity and specificity were pooled using Bayesian bivariate
binormal-normal models with random-effects. HRs were pooled using Bayesian
normal random-effects models. Result(s): In total, 44 studies (32 CT
and 12 PET) enrolling 3,049 patients were included. Coronary computed
tomography angiography (CTA) showed high sensitivity (97.6%; 95% credible
interval [CrI]: 93.7%-99.1%) and specificity (82.3%; 95% CrI: 75.3%-88.3%)
for detecting any CAV. Coronary CTA also showed high sensitivity (92.6%;
95% CrI: 86.2%-96.2%) and specificity (92.6%; 95% CrI: 89.8%-94.9%) for
significant CAV. The PET CAV algorithm for detecting significant CAV
showed good sensitivity (83.9%; 95% CrI: 69.1%-92.4%) and specificity
(89.6%; 95% CrI: 82.2%-94.2%). PET-derived parameters including myocardial
flow reserve, stress myocardial blood flow, PET CAV score, and summed
stress score, predicted future major adverse cardiovascular outcomes.
 Conclusion(s): Both coronary CTA and PET can rule out significant
CAV; however, at higher pretest probabilities, coronary CTA may be
preferrable. Multiple PET-derived parameters may have prognostic value,
whereas there is insufficient evidence for the long-term prognostic value
of CT. Copyright © 2025 American College of Cardiology Foundation

<85>
Accession Number
2035313260
Title
Tissue response and clinical outcomes after cardiovascular use of porcine
small intestinal small intestinal submucosal extracellular matrix: a
systematic review.
Source
Frontiers in Cardiovascular Medicine. 12 (no pagination), 2025. Article
Number: 1532157. Date of Publication: 2025.
Author
Bruun V.J.; Jensen L.L.; Hasenkam J.M.; Jedrzejczyk J.H.
Institution
(Bruun, Jensen, Hasenkam, Jedrzejczyk) Department of Cardiothoracic and
Vascular Surgery, Aarhus University Hospital, Aarhus, Denmark
(Hasenkam, Jedrzejczyk) Department of Clinical Medicine, Aarhus
University, Aarhus, Denmark
Publisher
Frontiers Media SA
Abstract
Background: Porcine small intestinal submucosal extracellular matrix
(PSIS-ECM) is a biomaterial that has gained increasing popularity in
cardiovascular surgery over the past three decades. This popularity is due
to PSIS-ECM demonstrating properties of an ideal biological scaffold; it
is easy to use, lacks immunogenicity, is absorbable, possesses the
potential to promote native tissue growth, and exhibits remodelling
properties. We systematically reviewed the literature on the preclinical
and clinical use of this approach in cardiovascular surgery over the past
decade. Method(s): Utilizing a box-search methodology, an extensive
survey of the literature on PSIS-ECM's application in cardiovascular
surgery from 2013 until September 2023 was conducted within the PubMed and
Embase databases. Initially, 245 publications were identified. Following
title, abstract, and full-text screening, 66 articles were included in the
survey. Result(s): Among nine preclinical studies conducting
histological assessments of explants, eight did not report signs of
inflammation. Tissue remodelling was documented in six preclinical
studies. Histological examination of explants was incorporated into
thirteen clinical cohort studies, all of which demonstrated varying
intensities of inflammation and no or minimal signs of regeneration and
remodeling. The reintervention rates among clinical cohort studies range
from 4.5% to 87.5%. Eleven studies reported a reintervention rate
exceeding 15%, while six reported a reintervention rate below 15%.
 Conclusion(s): Preclinical studies corroborate the notion that
PSIS-ECM exhibits properties of an ideal biological scaffold. However,
these findings lack reproducibility in clinical settings. Combined with
reports from clinical studies showing reintervention rates exceeding 15%,
this has raised concerns about whether clinical application of PSIS-ECM
should be confined to selected cases. Copyright 2025 Bruun, Jensen,
Hasenkam and Jedrzejczyk.

<86>
Accession Number
2035193571
Title
The organ-protective effects of nitric oxide in adult patients undergoing
cardiac surgery with cardiopulmonary bypass: a systematic review and
meta-analysis.
Source
BMC Anesthesiology. 25(1) (no pagination), 2025. Article Number: 335. Date
of Publication: 01 Dec 2025.
Author
Zhang J.; Zhang H.; Wang T.; Bian L.; Li Z.; Wang J.; Teng Y.; Liu G.; Yan
S.; Ji B.
Institution
(Zhang, Zhang, Wang, Wang, Bian, Li, Wang, Teng, Liu, Yan, Ji) Department
of Cardiopulmonary Bypass, National Center for Cardiovascular Disease,
Chinese Academy of Medical Sciences & Peking Union Medical College,
National Clinical Research Center for Cardiovascular Diseases, Fuwai
Hospital, Beijing, China
(Ji) Department of Cardiopulmonary Bypass, National Center for
Cardiovascular Disease and Fuwai Hospital, No. 167 Beilishi Road, Xicheng
District, Beijing, China
Publisher
BioMed Central Ltd
Abstract
Background: Postoperative organ dysfunction remains a major challenge in
adult cardiac surgery with cardiopulmonary bypass (CPB), frequently
involving the kidneys, heart, and lungs. These complications are primarily
driven by hemolysis, ischemia-reperfusion injury, and systemic
inflammation triggered by CPB. Nitric oxide (NO), known for its
vasodilatory, anti-inflammatory, and antioxidant properties, has been
proposed as a perioperative strategy to protect vital organs. However,
evidence regarding its efficacy remains inconclusive. Method(s): We
followed PRISMA guidelines and systematically searched PubMed, Embase,
Cochrane Library, and Web of Science for randomized controlled trials
(RCTs) published up to March 1, 2025. Subgroup analyses were conducted
based on NO dosage and timing of administration. To explore potential
effect modifiers and assess subgroup interaction, we performed
meta-regression analyses. The GRADE approach was used to assess the
certainty of evidence. Sensitivity analyses and publication bias
assessments (funnel plots and trim-and-fill method) were also conducted to
evaluate the robustness of the findings. Result(s): Ten RCTs
involving 838 patients were included. NO administration was associated
with a reduced incidence of acute kidney injury (AKI) (RR: 0.78; 95% CI:
0.64-0.94; p = 0.010), and the effect remained after trim-and-fill
adjustment. mechanical ventilation (MV) duration was slightly shortened
(SMD: - 0.17; 95% CI: - 0.31 to - 0.02; p = 0.025), particularly with
postoperative administration (SMD: - 0.39; 95% CI: - 0.67 to - 0.12; p =
0.005). NO also reduced cardiac troponin I (cTnI) levels. No significant
effects were observed for low cardiac output syndrome (LCOS), mortality,
intensive care unit (ICU) length of stay (LOS), or hospital LOS.
 Conclusion(s): Inhaled NO may offer organ-specific benefits in adults
undergoing cardiac surgery with CPB, such as reduced AKI incidence and
lower cTnI levels. However, these effects did not consistently translate
into improved clinical outcomes. The observed reduction in MV duration was
not significant after adjusting for publication bias, suggesting a
possible overestimation. Current evidence is limited by small sample sizes
and small-study effects. Further large, high-quality trials in high-risk
populations are needed to confirm these findings. PROSPERO registration:
This review was prospectively registered in PROSPERO (ID:
CRD42025649095). Copyright © The Author(s) 2025.

<87>
Accession Number
2039485391
Title
Effectiveness of ultrasound-guided alveolar recruitment in thoracic
surgery with one-lung ventilation: A randomized-controlled trial.
Source
European Journal of Cardio-thoracic Surgery. 67(7) (no pagination), 2025.
Article Number: ezaf204. Date of Publication: 01 Jul 2025.
Author
Kim B.R.; Lim L.; You J.; Yoon S.; Park J.-B.; Bahk J.-H.; Seo J.-H.
Institution
(Kim) Department of Anesthesiology and Pain Medicine, Asan Medical Center,
University of Ulsan, College of Medicine, Seoul, South Korea
(Lim, You, Yoon, Park, Bahk, Seo) Department of Anesthesiology and Pain
Medicine, Seoul National University Hospital, Seoul National University,
College of Medicine, Seoul, South Korea
Publisher
European Association for Cardio-Thoracic Surgery
Abstract
OBJECTIVES Although alveolar recruitment strategy (ARS) before one-lung
ventilation (OLV) is beneficial in intraoperative oxygenation, the optimal
protocol remains unestablished. As lung ultrasound (LUS) has been used
recently, we designed a randomized controlled trial to compare preemptive
LUS-guided ARS with conventional ARS in thoracic surgery. METHODS Patients
aged 20-80 years scheduled to undergo lung resection surgery with OLV were
randomized into 2 groups: (i) control group receiving conventional ARS and
(ii) LUS group receiving LUS-guided ARS. ARS and modified LUS scoring were
performed 5 min after intubation and before emergence. Arterial blood
samples and respiratory parameters were collected every 30 min during OLV.
The primary outcome was the incidence of intraoperative hypoxaemia (SpO2 <
95%). RESULTS In total, 166 patients were included. The incidence of
intraoperative hypoxaemia was 1.2% in the LUS group and 14.3% in the
control group [risk ratio (95% CI) 0.09 (0.01-0.64), P = 0.002]. However,
the incidence of intraoperative severe hypoxaemia (SpO2 < 90%) was not
significantly different [1.2% vs 6.0%, risk ratio (95% CI) 0.20
(00.02-1.72), P = 0.213]. In the LUS before emergence, higher atelectasis
score (P = 0.005) and more significant atelectasis (P = 0.031) was
observed in the control group. Postoperative adverse outcomes were
comparable between both groups. CONCLUSIONS LUS-guided ARS before OLV was
more effective than conventional ARS in preventing intraoperative
hypoxaemia during thoracic surgery. Copyright © 2025 The
Author(s). Published by Oxford University Press on behalf of the European
Association for Cardio-Thoracic Surgery. All rights reserved.

<88>
Accession Number
2039626062
Title
COMPARATIVE STUDY OF THE EFFICACY OF POTASSIUM CHLORIDE AND SODIUM
BICARBONATE AS AN ADJUVANT TO BUPIVACAINE IN BRACHIAL PLEXUS BLOCK IN
PATIENTS UNDERGOING UPPER LIMB SURGERIES.
Source
International Journal of Academic Medicine and Pharmacy. 6(4) (pp
510-514), 2024. Date of Publication: 2024.
Author
Aravind Kumar P.; Gobinath L.; Senthil G.; Santhosh Kumar M.
Institution
(Aravind Kumar, Gobinath, Senthil, Santhosh Kumar) Government Medical
College, Tamilnadu, Namakkal, India
Publisher
Society for Healthcare and Research Development
Abstract
Background: Peripheral nerve blocks, such as brachial plexus blocks, offer
effective anaesthesia for upper limb surgeries with prolonged
postoperative pain relief and minimal haemodynamic changes. Sodium
bicarbonate and potassium chloride, as additives to bupivacaine, improved
block quality and enhanced sensory and motor blockade duration and onset
times. This study aimed to compare the efficacy of sodium bicarbonate and
potassium chloride as adjuvants to bupivacaine in supraclavicular brachial
plexus block. Material(s) and Method(s): This prospective,
randomised, double-blind study at the Government Medical College Hospital,
Namakkal included 60 patients. On the day of surgery, standard monitors
were applied, intravenous access was established, and patients were
positioned appropriately for supraclavicular brachial plexus block. Using
landmarks, a 22G needle was used for local anaesthetic injection upon
paraesthesia confirmation. The block characteristics were closely
monitored, with vital signs and potential complications observed
postoperatively for 24 h. Result(s): Group S (sodium bicarbonate)
experienced significantly longer sensory and motor block durations, faster
onset times, and extended analgesia than Group K (potassium chloride)
(P=0.0001). Both groups showed no significant differences (P > 0.05) in
demographic variables, surgery duration, heart rate, blood pressure, or
SPO2 levels, indicating haemodynamic stability. Conclusion(s): The
comparison of potassium chloride and sodium bicarbonate as adjuvants to
bupivacaine for brachial plexus block showed that potassium chloride
provided shorter onset times for sensory and motor blocks, whereas sodium
bicarbonate extended the duration of these blocks and analgesia. Both
adjuvants enhanced the block quality and were safe for use. Copyright
© 2024 Society for Healthcare and Research Development. All rights
reserved.

<89>
Accession Number
2035710359
Title
Transcatheter Aortic Valve Implantation in Cardiogenic Shock: Current
Evidence, Clinical Challenges, and Future Directions.
Source
Journal of Clinical Medicine. 14(15) (no pagination), 2025. Article
Number: 5398. Date of Publication: 01 Aug 2025.
Author
Karamasis G.V.; Kourek C.; Alexopoulos D.; Parissis J.
Institution
(Karamasis, Kourek) Cardiology Department, Attikon University Hospital,
National and Kapodistrian University of Athens Medical School, Rimini 1,
Athens, Chaidari, Greece
(Alexopoulos) 7th Department of Cardiology, Hygeia Hospital, Athens,
Greece
(Parissis) Heart Failure Unit and University Clinic of Emergency Medicine,
Attikon University Hospital, National and Kapodistrian University of
Athens Medical School, Rimini 1, Athens, Chaidari, Greece
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Cardiogenic shock (CS) in the setting of severe aortic stenosis (AS)
presents a critical and high-risk scenario with limited therapeutic
options and poor prognosis. Transcatheter aortic valve implantation
(TAVI), initially reserved for inoperable or high-risk surgical
candidates, is increasingly being considered in patients with CS due to
improvements in device technology, operator experience, and supportive
care. This review synthesizes current evidence from large registries,
observational studies, and meta-analyses that support the feasibility,
safety, and potential survival benefit of urgent or emergent TAVI in
selected CS patients. Procedural success is high, and early intervention
appears to confer improved short-term and mid-term outcomes compared to
balloon aortic valvuloplasty or medical therapy alone. Critical factors
influencing prognosis include lactate levels, left ventricular ejection
fraction, renal function, and timing of intervention. The absence of
formal guidelines, logistical constraints, and ethical concerns complicate
decision-making in this unstable population. A multidisciplinary Heart
Team/Shock Team approach is essential to identify appropriate candidates,
manage procedural risk, and guide post-intervention care. Further studies
and the development of TAVI-specific risk models in CS are anticipated to
refine patient selection and therapeutic strategies. TAVI may represent a
transformative option for stabilizing hemodynamics and improving outcomes
in this otherwise high-mortality group. Copyright © 2025 by the
authors.

<90>
Accession Number
648228430
Title
Intravenous Versus Inhaled Milrinone in Patients with Known Pulmonary
Hypertension Undergoing Cardiac Surgery: A Systematic Review and
Meta-analysis.
Source
Annals of cardiac anaesthesia. (no pagination), 2025. Date of
Publication: 05 Aug 2025.
Author
Kavanagh T.; Kilpatrick T.; Hardy B.; Lee S.; Seavill M.; Lau C.-W.M.;
Bullard S.; Green S.; Cadd M.
Institution
(Kavanagh, Kilpatrick, Lee, Lau, Bullard, Green, Cadd) Anaesthetic
Department, Royal Sussex County Hospital, University Hospitals Sussex,
United Kingdom
(Hardy) Department of Cardiothoracic Anesthesia and the Cardiovascular
Intensive Care Unit, Auckland City Hospital, Auckland, New Zealand
(Seavill) Anaesthetic Department, Conquest Hospital, East Sussex
Healthcare Trust, United Kingdom
Abstract
ABSTRACT: To summarize the evidence on the hemodynamic effects and
vasopressor requirements of adult patients with known pulmonary
hypertension (PH) undergoing cardiac surgery treated with intravenous and
inhaled milrinone. A total of 400 patients in 5 prospective (4 RCT)
studies were included for pooled analysis. There was no significant
difference in the primary outcome; mean pulmonary artery pressure (MPAP)
between groups (MD: -4.80, 95% CI -10.57 to 0.98). Inhaled milrinone was
associated with a greater systemic vascular resistance index (SVRI) (MD:
259.21, 95% CI 168.70 to 349.72) and reduction in pulmonary capillary
wedge pressure (MD: -4.64, 95% CI -5.47 to -3.81). There were no
observable differences in mean arterial pressure, pulmonary vascular
resistance, cardiac index, or central venous pressure. All studies
included were assessed to be moderate/some concern risk of bias. Inhaled
milrinone has not been shown to have a significant beneficial effect on
MPAP and SVR when compared to intravenous milrinone in patients with known
PH undergoing cardiac surgery. However, it has shown some benefits in
maintaining MAP and improving oxygenation in this patient cohort. The
study is limited by the bias of the included studies and the variability
of inhaled drug dosage and administration timing, further well-powered
randomized controlled trials are required. Copyright © 2025
Annals of Cardiac Anaesthesia.

<91>
Accession Number
2039540940
Title
Network meta-analysis of cardioplegic methods, in elective isolated
coronary artery bypass grafting.
Source
Perfusion (United Kingdom). (no pagination), 2025. Article Number:
02676591251359901. Date of Publication: 2025.
Author
Kalogerakos P.D.; Kokkinakis S.; Akoumianakis E.; Karagkounis T.; Gavalaki
A.; Kiparakis M.; Akoumianakis I.; Lazopoulos L.; Gaitanaki T.; Andreou
A.; Lasithiotakis K.; Kontopodis N.; Lazopoulos G.
Institution
(Kalogerakos, Karagkounis, Gavalaki, Kiparakis, Lazopoulos, Lazopoulos)
Department of Cardiac Surgery, General University Hospital of Heraklion,
Crete, Greece
(Kokkinakis) Department of General, Visceral, Tumor, and Transplantation
Surgery, University Hospital of Cologne, Cologne, Germany
(Akoumianakis) Department of Otorhinolaryngology - Head and Neck Surgery,
General University Hospital of Heraklion, Crete, Greece
(Akoumianakis) Cardiovascular Medicine Division, Radcliffe Department of
Medicine, University of Oxford, Oxford, United Kingdom
(Gaitanaki) Department of Cardiology, General University Hospital of
Heraklion, Crete, Greece
(Andreou, Lasithiotakis) Department of General Surgery, General University
Hospital of Heraklion, Crete, Greece
(Kontopodis) Department of Vascular Surgery, General University Hospital
of Heraklion, Crete, Greece
Publisher
SAGE Publications Ltd
Abstract
Background: Cardioplegic arrest can be induced by various methods, fueling
a long-standing controversy about their comparative merit. We aim to
compare cardioplegic methods in coronary artery disease. Method(s):
PubMed, Embase, and Cochrane databases were interrogated for randomized
trials that compared various cardioplegic methods in adult patients
undergoing elective isolated coronary artery bypass grafting. Differences
in cardioplegic composition - crystalloid or blood, route of delivery -
antegrade or retrograde, and temperature, were evaluated in a network
meta-analysis. The endpoints were mortality, myocardial infarction,
insertion of intra-aortic balloon pump, low cardiac output syndrome,
increased inotropic support, as well as cardiopulmonary bypass time,
aortic cross-clamp time, intensive care stay, hospital stay, new onset
atrial fibrillation, reperfusion ventricular fibrillation, and neurologic
event. Confidence In Network Meta-Analysis web application was employed.
 Result(s): 75 studies were included, with 6131 patients receiving one
of 13 cardioplegic methods. Warm ante/retrograde blood cardioplegia was
associated with fewer deaths (P-score 0.81), fewer intra-aortic balloon
pumps (P-score 0.77), and shorter intensive care (P-score 0.69) and
hospital stay (P-score 0.81). Cross clamp time was shorter with
crystalloid cardioplegias, while reperfusion ventricular fibrillation was
less frequent with warm blood cardioplegias. Cold cardioplegias were
associated with lower rates of new onset atrial fibrillation and stroke.
Confidence varied greatly across the endpoints. Conclusion(s): The
outcomes of this network study indicate presumable advantages of warm
ante/retrograde blood cardioplegia in elective isolated coronary artery
bypass grafting. Under the light of certain biases and mixed confidence,
the results should be cautiously interpreted. More studies are
needed. Copyright © The Author(s) 2025

<92>
Accession Number
2035692568
Title
Effect of dual direct and alternating currents on pain induced by blood
sampling and intramuscular injection processes.
Source
Pain Management. (no pagination), 2025. Date of Publication: 2025.
Author
Ezzati E.; Mahooti R.; Mohammadi S.; Kavyannejad R.
Institution
(Ezzati, Mohammadi) Department of Anesthesiology, School of Paramedical,
Kermanshah University of Medical Sciences, Kermanshah, Iran, Islamic
Republic of
(Mahooti) Emam Khomeini Hospital, Kermanshah University of Medical
Sciences, Kermanshah, Iran, Islamic Republic of
(Kavyannejad) Department of Physiology, School of Medicine, Kermanshah
University of Medical Sciences, Kermanshah, Iran, Islamic Republic of
Publisher
Taylor and Francis Ltd.
Abstract
Objective: This study investigates the effects of cathodal, anodal, and
intermittent electrical stimulation on pain intensity associated with
arterial blood sampling, venous blood sampling, and intramuscular
injection. Method(s): In a triple-blind clinical trial, 160 patients
requiring arterial, venous blood sampling, and intramuscular injection
were randomly divided into four groups. Three intervention groups received
5 mA anodal, cathodal direct, or alternating currents during the
procedure, while the control group received only a topical eutectic
mixture of local anesthetics (EMLA). Pain intensity was measured using the
visual analog scale (VAS) immediately after the procedure, while procedure
duration, number of attempts, and heart rate changes were recorded as
secondary outcome. Result(s): All forms of electrical stimulation
significantly reduced procedural pain compared to EMLA. Cathodal direct
current demonstrated the greatest analgesic effect, with mean VAS score
reductions of 2-3 points across all procedures. The time required for
arterial blood sampling in the cathodal group was significantly less than
with EMLA, while no difference was observed in the procedure time and
frequency of attempts in other processes. Furthermore, electrical
stimulation groups, particularly the cathodal mode, exhibited lower
post-procedure heart rates, suggesting attenuated physiological stress
responses. Conclusion(s): We found that applying electric currents
during the procedure reduces the pain of blood sampling or injections. The
greatest analgesia was observed with cathodal direct current stimulation
compared to other groups. Clinical trial registration: Date of
registration: 27 January 2024. Clinical Trials.gov Identifier:
IRCT20240123060780N1. URL:
https://irct.behdasht.gov.ir/trial/75119. Copyright © 2025
Informa UK Limited, trading as Taylor & Francis Group.

<93>
Accession Number
2035742603
Title
Microaxial Support as a Bridge to Repair in Post-Myocardial Infarction
Ventricular Septal Rupture: A Systematic Review and Patient-Level
Analysis.
Source
Artificial Organs. (no pagination), 2025. Date of Publication: 2025.
Author
Nasher N.; Rahimov D.; Mallur K.; Macmillan T.R.; Plestis K.A.; Rajagopal
K.; Hoopes C.W.; Entwistle J.W.; Bavaria J.E.; Tchantchaleishvili V.
Institution
(Nasher, Rahimov, Plestis, Rajagopal, Hoopes, Entwistle, Bavaria,
Tchantchaleishvili) Department of Cardiac Surgery, Thomas Jefferson
University Hospital, Philadelphia, PA, United States
(Mallur, Macmillan) Sidney Kimmel Medical College, Thomas Jefferson
University, Philadelphia, PA, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Current guidelines recommend immediate surgical repair for
post-infarct ventricular septal rupture (VSR); however, mortality remains
exceedingly high. We sought to report outcomes following delayed surgical
management bridged with microaxial support. Method(s): A
comprehensive literature search yielded 42 case reports/series comprising
78 patients who were initiated on microaxial support following the
diagnosis of post-infarct VSR. Patient-level data were extracted and
analyzed according to survival status. Result(s): Overall, 78%
(54/69) of patients were male, and the median age was 69 [IQR: 60-74]
years, with no difference in age between survivors and non-survivors.
Those who survived were significantly less likely to have a history of
prior cardiac surgery than non-survivors [3% (1/30) vs. 43% (3/7), p =
0.016], and less likely to have undergone percutaneous coronary
intervention at the time of presentation [41% (22/54) vs. 69% (11/16), p =
0.049]. There were no significant differences in culprit vessel (p =
0.875), VSR size (p = 1), or VSR location (p = 0.253). Those who survived
had a significantly higher median Qp/Qs ratio than non-survivors [3.0
[2.3-3.8] vs. 2.1 [1.9-2.3], p = 0.038]. Patients were successfully
bridged to definitive surgical management in 76% (59/78) of cases at a
median time of 8 [5-14] days following microaxial support placement. The
30-day/in-hospital mortality rate was 22% (17/78), and the overall
mortality rate was 27% (21/78). Conclusion(s): Microaxial devices can
safely and feasibly provide the necessary support to allow for a
successful delayed repair in hemodynamically unstable patients following
post-infarct VSR. Copyright © 2025 International Center for
Artificial Organs and Transplantation and Wiley Periodicals LLC.

<94>
Accession Number
2040031365
Title
Efficacy and safety of paravertebral blockade in paediatric cardiothoracic
surgery: a protocol for systematic review and meta-analysis.
Source
BMJ Open. 15(8) (no pagination), 2025. Article Number: e105008. Date of
Publication: 13 Aug 2025.
Author
Yuan Y.; Zhou J.; Zhang Y.; Zhong W.; Lu X.
Institution
(Yuan, Zhou, Zhong, Lu) Department of Anesthesiology, Henan Provincial
Chest Hospital, Henan, Zhengzhou, China
(Yuan, Zhou, Zhong, Lu) Department of Anesthesiology, Chest Hospital of
Zhengzhou University, Henan, Zhengzhou, China
(Zhang) Big Data Center for Clinical Medicine, The First Affiliated
Hospital of Zhengzhou University, Henan, Zhengzhou, China
Publisher
BMJ Publishing Group
Abstract
Introduction Paravertebral blockade (PVB) is a regional anaesthesia
technique increasingly used in paediatric cardiothoracic surgery for
postoperative pain management. However, its comparative efficacy and
safety relative to other analgesic strategies remain inadequately
synthesised. This systematic review aims to evaluate the effectiveness,
safety and complications of PVB in paediatric patients undergoing
cardiothoracic surgery. Methods and analysis This protocol adheres to the
Preferred Reporting Items for Systematic Review and Meta-Analysis
Protocols guidelines. We will search MEDLINE, EMBASE, Cochrane Library,
Web of Science, Scopus, ClinicalTrials.gov and other relevant sources from
inception to February 2025. Randomised controlled trials (RCTs) comparing
PVB with systemic opioids, epidural analgesia or placebo in patients aged
<18 years will be included. Exclusion criteria include non-RCTs, adult
populations and non-cardiothoracic surgeries. Primary outcomes include
postoperative pain intensity measured using validated scales such as Face,
Legs, Activity, Cry, Consolability Scale or Numeric Rating Scale within
24-48 hours. Secondary outcomes include opioid consumption within 24-48
hours, length of hospital stay, haemodynamic stability and complications
(eg, pneumothorax, local anaesthetic toxicity). Two reviewers will
independently screen studies, extract data and assess the risk of bias
using the Cochrane Risk of Bias-2 tool. A meta-analysis using a
random-effects model or a narrative synthesis will be conducted based on
heterogeneity (I2>=75%). Subgroup analyses will explore
variations by age group, surgical type and PVB technique. Ethics and
dissemination As this study involves secondary analysis of existing data,
ethical approval is not required. The completed review will be submitted
for open-access publication in a peer-reviewed journal to ensure
accessibility for clinicians, researchers and policymakers. PROSPERO
registration number CRD42025644837. Copyright © Author(s) (or
their employer(s)) 2025.

<95>
Accession Number
2040066062
Title
The Pathophysiologic Basis and Management of Calcific Aortic Valve
Stenosis: JACC State-of-the-Art Review.
Source
Journal of the American College of Cardiology. 86(9) (pp 659-672), 2025.
Date of Publication: 02 Sep 2025.
Author
Desai M.Y.; Braunwald E.
Institution
(Desai) Miller Family Heart, Vascular & Thoracic Institute, Cleveland
Clinic, Cleveland, OH, United States
(Braunwald) TIMI Study Group, Division of Cardiology, Brigham and Women's
Hospital, Boston, MA, United States
(Braunwald) Department of Medicine, Harvard Medical School, Boston, MA,
United States
Publisher
Elsevier Inc.
Abstract
Calcific aortic valve stenosis (CAVS) is the most frequent valve disorder
in adults, with a steadily increasing incidence with age. Currently, no
effective treatments are available to prevent or delay disease
progression. In addition to progressive calcification, there is increasing
recognition of the underlying roles of oxidative stress, chronic
inflammation, lipoprotein deposition, and induction of osteogenic
signaling in driving progression of CAVS. Although traditional markers of
CAVS progression, such as increased valve gradients and reduced areas, are
currently used to guide clinical decisions regarding valve replacement,
these measures may not capture progression of early, potentially
modifiable disease. Hence, there is a need for more sensitive markers,
such as aortic valve calcification, to monitor disease progression in
CAVS. This JACC State-of-the-Art Review provides a comprehensive
discussion of the pathogenesis and progression of CAVS and emphasizes the
unmet need for innovative medical treatments. Additionally, it explores
emerging therapeutic approaches, advanced methods for evaluating disease
progression, and cutting-edge techniques to measure therapeutic
efficacy. Copyright © 2025 American College of Cardiology
Foundation

<96>
Accession Number
2040018293
Title
Feasibility of coronary access after transcatheter aortic valve
implantation (TAVI): a systematic review and meta-analysis of
observational studies.
Source
European Heart Journal - Quality of Care and Clinical Outcomes. 11(5) (pp
565-579), 2025. Date of Publication: 01 Aug 2025.
Author
Giacobbe F.; Morena A.; Bruno F.; Nebiolo M.; De Filippo O.; Odeh Y.; Di
Pietro G.; Cabau J.R.; Conrotto F.; Kini A.; Giannino G.; Latib A.; Omede
P.; Noble S.; La Torre M.W.; Barbanti M.; Tarantini G.; Kim W.-K.;
Blumenstein J.; Boukantar M.; Htun W.W.; De Ferrari G.M.; Salizzoni S.;
D'Ascenzo F.
Institution
(Giacobbe, Morena, Bruno, Nebiolo, De Filippo, Odeh, Conrotto, Giannino,
Omede, De Ferrari, D'Ascenzo) Division of Cardiology, Cardiovascular and
Thoracic Department, Citta della Salute e della Scienza, Corso Bramante
88, Turin, Italy
(Giacobbe, Morena, Nebiolo, Odeh, Giannino, De Ferrari, D'Ascenzo)
Division of Cardiology, Department of Medical Sciences, University of
Turin, Italy
(Di Pietro) Department of Clinical, Internal, Anesthesiology and
Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy
(Cabau) Quebec Heart & Lung Institute, Laval University, Quebec City, QC,
Canada
(Kini) Division of Cardiology, Mount Sinai Medical Center, Icahn School of
Medicine at Mount Sinai, New York, NY, United States
(Latib) Montefiore-Einstein Center for Heart and Vascular Care, Montefiore
Medical Center, Albert Einstein College of Medicine, Bronx, NY, United
States
(Noble) Cardiology Division, University Hospital of Geneva, Switzerland
(La Torre, Salizzoni) Division of Cardiac Surgery, Cardiovascular and
Thoracic Department, Citta della Salute e della Scienza, Turin, Italy
(Barbanti) Universita degli Studi di Enna "Kore", Enna, Italy
(Tarantini) Cardiology Clinic, Department of Cardiac, Thoracic, and
Vascular Sciences and Public Health Padova, University of Padua, Italy
(Kim, Blumenstein) Department of Cardiology, Kerckhoff Heart and Thorax
Center, Bad Nauheim, Germany
(Boukantar) Department of Cardiovascular, Henri Mondor University
Hospital, Creteil, France
(Htun) Department of Cardiology, Detroit Medical Center, Wayne State
University, Detroit, MI, United States
(Htun) Department of Cardiothoracic Surgery, Northwell Health, Lenox Hill
Hospital, NY, United States
Publisher
Oxford University Press
Abstract
Introduction The expanding indications for transcatheter aortic valve
implantation (TAVI) to younger, lower-risk patients, entails assessing not
only the short-term clinical outcomes but also the long-term
considerations for future interventions. The prevalence of coronary artery
disease in TAVI patients is relevant, and the optimal timing of
percutaneous coronary intervention remains a question. Methods and result
We conducted a systematic literature review and meta-analysis including 20
eligible studies involving 1660 patients who underwent coronary
angiography after TAVI. The primary endpoint was the incidence of
successful selective coronary re-access. Secondary endpoints included
semi-selective and non-selective access rates. The analysis was stratified
by balloon-expandable (BEVs) and self-expandable valve (SEVs) types.
Successful coronary access after TAVI was feasible in the majority of
patients, with a higher success rate observed for the left main (LM)
compared to the right coronary artery (RCA). BEVs demonstrated the highest
success rates in coronary ostia cannulation, achieving nearly 100% success
for both LM and RCA. Among SEVs, the Acurate Neo and Evolut R/PRO showed
superior success rates in selective coronary access (68 and 77% for LM; 57
and 72% for RCA, respectively) compared to the CoreValve (46% for LM and
49% for RCA). Notably, the majority of coronary angiograms were performed
due to acute coronary syndrome, primarily non-ST-segment elevation
myocardial infarction, and unstable angina. Selective coronary engagement
after TAVI is generally achievable, with BEVs demonstrating superior
success rates compared to SEVs. Among SEVs, the Acurate NEO showed better
outcomes than the other types. Copyright © The Author(s) 2025.
Published by Oxford University Press on behalf of the European Society of
Cardiology.

<97>
Accession Number
648221507
Title
Incidence, risk factors and clinical impact of intra-stent graft
thrombosis in the thoracic aorta.
Source
European journal of cardio-thoracic surgery : official journal of the
European Association for Cardio-thoracic Surgery. (no pagination), 2025.
Date of Publication: 04 Aug 2025.
Author
Hasami N.A.; Been M.; de Kort J.F.; Geuzebroek G.S.C.; Gelpi G.; de
Vincentiis C.; Patel H.J.; Czerny M.; Heijmen R.H.; van Herwaarden J.A.;
Trimarchi S.
Institution
(Hasami, Been, de Kort, Trimarchi) Department of Vascular Surgery,
Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy
(Hasami, Geuzebroek, Heijmen) Department of Cardiothoracic Surgery,
Radboud University Medical Centre, Nijmegen, Netherlands
(Hasami, de Kort, van Herwaarden) Department of Vascular Surgery,
University Medical Centre Utrecht, Utrecht, Netherlands
(Gelpi) Department of Cardiac Surgery, Fondazione IRCCS Ca'Granda Ospedale
Maggiore Policlinico, Milan, Italy
(de Vincentiis) Department of Cardiac Surgery, Policlinico San Donato
IRCCS, Milan, Italy
(Patel) Department of Cardiac Surgery, University of Michigan, Ann Arbor,
MI, United States
(Czerny) Department of Cardiovascular Surgery, University Heart Centre
Freiburg, Freiburg, Germany
(Czerny) Faculty of Medicine, Albert Ludwigs University Freiburg,
Freiburg, Germany
(Trimarchi) Department of Clinical Sciences and Community Health,
Universita degli Studi di Milano, Milan, Italy
Abstract
OBJECTIVES: Stentgrafts in the thoracic aorta, whether placed during the
frozen elephant trunk procedure or thoracic endovascular repair, have been
associated with thrombosis. This study aimed to evaluate its incidence,
risk factors, and clinical consequences. METHOD(S): PubMed, Web of
Science, and SCOPUS were systematically searched for relevant studies.
Quality assessment was performed using the Risk of Bias in Non-Randomized
Studies of Interventions tool for cohort studies and the Joanna Briggs
Institute checklist for case reports. Certainty of evidence was evaluated
using the Grading of Recommendations Assessment, Development, and
Evaluation approach. RESULT(S): Seventeen studies were included: four
cohort studies (825 patients) and three case reports on frozen elephant
trunk, and three cohort studies (142 patients) and twelve case reports on
thoracic endovascular repair. The pooled incidence of intra-stent graft
thrombosis after frozen elephant trunk was 8.6% (95%-CI: 5.7-12.9),
typically occurring within one week and significantly associated with
older age, female sex, aneurysmal disease, and higher rates of dialysis
(43% versus 16%) and mortality (25% versus 8%). Thoracic endovascular
repair cohorts were heterogeneous and could not be pooled; therefore,
findings were synthesized narratively. One trauma cohort reported an
incidence of 20.6%. All twelve case reports involved patients treated for
trauma, with a mean time to diagnosis of 12 +/- 6.3 months; eight
presented with spinal cord injury; eleven of them underwent an
intervention to address the thrombosis. CONCLUSION(S): Intra-stent
graft thrombosis is relatively common after frozen elephant trunk and may
be underrecognized after thoracic endovascular repair, particularly in
trauma patients. Structured imaging follow-up and individualized treatment
strategies are warranted. Copyright © The Author(s) 2025.
Published by Oxford University Press on behalf of the European Association
for Cardio-Thoracic Surgery. All rights reserved. For commercial re-use,
please contact reprints@oup.com for reprints and translation rights for
reprints. All other permissions can be obtained through our RightsLink
service via the Permissions link on the article page on our site-for
further informat

<98>
Accession Number
648222404
Title
Peripheral Nerve Blocks for Enhanced Recovery in Cardiac Surgery: A
Retrospective Observational Study.
Source
Annals of cardiac anaesthesia. (no pagination), 2025. Date of
Publication: 05 Aug 2025.
Author
Sharkey A.; Khan A.A.; Saeed S.; Yunus R.A.; Ahmed U.; Manji A.A.-K.; Bose
R.; Khabbaz K.; Mahmood F.; Matyal R.
Institution
(Sharkey, Khan, Saeed, Yunus, Ahmed, Manji, Bose, Mahmood, Matyal)
Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel
Deaconess Medical Center, Harvard Medical School, Boston, MA, United
States
(Khabbaz) Department of Cardiac Surgery, Beth Israel Deaconess Medical
Center, Harvard Medical School, Boston, MA, United States
Abstract
BACKGROUND: This retrospective observational study evaluates the effect of
incorporating peripheral nerve blocks (PNBs) into an established enhanced
recovery after surgery (ERAS) protocol. The PNBs used included
pecto-intercostal fascial block (PIFB) and rectus sheath block, performed
under ultrasound guidance with the administration of a long-acting local
anesthetic, Ropivacaine. Both patient and process outcomes were assessed
to determine the effect PNBs have as part of an ERAS protocol. MATERIALS
AND METHODS: Adult patients undergoing cardiac surgery with midline
sternotomy who were expected to be extubated within 6 hours of arrival to
the intensive care unit (ICU) between October 2022 and June 2023 were
included. Patients were dichotomized by whether they received a PNB or
not. Outcomes included opioid consumption as measured by morphine
milligram equivalents (MME), ICU length of stay (LOS), postoperative
mobility, and the incidence of postoperative atrial fibrillation (POAF).
 RESULT(S): 431 patients were included: 170 (39.4%) received a PNB,
and 243 (60.6%) did not (non-PNB group). Patients who received a PNB
required a significantly shorter time to achieve first ambulation as
measured from bed to chair (15.2 hours PNB vs. 18.5 hours non-PNB, P =
0.037), significantly lower rates of atrial fibrillation (26.5% PNB vs.
32.9% non-PNB, P = 0.045), shorter LOS in the ICU (44.4 hours PNB vs. 49.7
hours non-PNB, P = 0.024). CONCLUSION(S): Incorporating PNBs as part
of a multimodal analgesic strategy for patients undergoing cardiac
surgical procedures is associated with improved patient and process
outcomes. Our finding of a reduction in POAF warrants further
investigation in an adequately powered randomized controlled
trial. Copyright © 2025 Annals of Cardiac Anaesthesia.

<99>
Accession Number
648222118
Title
Long term efficacy and safety of MICT of cardiopulmonary function in
patients after TAVR extended follow up of ENERGY study.
Source
Scientific reports. 15(1) (pp 28344), 2025. Date of Publication: 04 Aug
2025.
Author
Li Y.-S.; Ren Q.; Mu X.-B.; Xu K.; Liang Y.-C.; Zhang J.; Wang G.; Wang
Y.-X.; Wang C.-L.; Zhang Y.; Wang S.-Y.; Zhang Q.-Y.; Han Y.-L.
Institution
(Li, Ren, Mu, Xu, Liang, Zhang, Wang, Wang, Wang, Zhang, Wang, Han) State
Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD),
Department of Cardiology, General Hospital of Northern Theater Command,
Shenyang, China
(Li) Department of Cardiology, General Hospital of Northern Theater
Command Training Base for Graduate, Dalian Medical University, Dalian,
China
(Ren, Mu) Department of Cardiology, Beifang Hospital of China Medical
University, Shenyang, China
(Zhang) State Key Laboratory of Frigid Zone Cardiovascular Diseases
(SKLFZCD), Department of Cardiology, General Hospital of Northern Theater
Command, Shenyang, China
Abstract
The ENERGY study demonstrated that 3-month moderate-intensity continuous
training (MICT) improved the cardiopulmonary function and exercise
capacity for patients after transcatheter aortic valve replacement (TAVR).
However, the long-term effects remained uncertain. Therefore, the present
study evaluated the long-term efficacy and safety of MICT in patients
undergoing TAVR. 64 patients were randomized into MICT (3 times per week)
or control groups (one-time physical activity advice). Outcomes were
assessed using the 12-month changes in cardiopulmonary exercise testing
(CPET) parameters, 6-minute walk test (6MWT), SF-12 quality of life score,
New York Heart Association (NYHA) class, echocardiographic and laboratory
parameters. After 12 months, the MICT group showed significantly greater
improvements in peak VO2 (1.61 ml/kg/min, 95% CI 0.10 to 3.12, P = 0.037),
peak MET (0.56, 95% CI 0.20 to 0.93, P = 0.003), VO2AT (1.55 ml/kg/min,
95% CI 0.80 to 2.30, P < 0.001), METAT (0.35, 95% CI 0.10 to 0.61, P =
0.007), peak O2 pulse (1.04 mL/beat, 95% CI 0.03 to 2.05, P = 0.044), 6MWT
(21.24 m, 95% CI 7.10 to 35.39, P = 0.004), and mental component summary
of SF-12 (10.47, 95% CI 0.48 to 20.45, P = 0.040) compared to control
group. Long-term MICT safely and effectively enhances the cardiopulmonary
function and quality of life in patients after TAVR. Copyright ©
2025. The Author(s).

<100>
Accession Number
2040018278
Title
Sex-related differences in survival and safety outcomes after
transcatheter aortic valve replacement: a meta-analysis of reconstructed
time-to-event data.
Source
European Heart Journal - Quality of Care and Clinical Outcomes. 11(5) (pp
642-653), 2025. Date of Publication: 01 Aug 2025.
Author
Tavakoli K.; Mohammadi N.S.H.; Fallahtafti P.; Khamene S.S.; Taheri M.;
Ebrahimi P.; Bahiraie P.; Karimi E.; Alishahi M.M.; Pazoki M.; Anaraki N.;
Kazemian S.; Khanipour R.; Khalique O.K.; May H.T.; Thachil R.; Iskander
M.H.; Waheed A.; Hosseini K.
Institution
(Tavakoli, Mohammadi, Fallahtafti, Khamene, Bahiraie, Karimi, Pazoki,
Anaraki, Kazemian, Hosseini) Tehran Heart Center, Cardiovascular Diseases
Research Institute, Tehran University of Medical Sciences, North Karegar
Ave, Tehran, Iran, Islamic Republic of
(Taheri) Faculty of Medicine, Cardiology Research Center, Hamadan
University of Medical Sciences, Hamadan, Iran, Islamic Republic of
(Ebrahimi) Accident and Emergency Department (A&E), Royal Hampshire County
Hospital, Winchester, United Kingdom
(Alishahi) Faculty of Medicine, Islamic Azad University, Tehran Medical
Branch, Tehran, Iran, Islamic Republic of
(Khanipour) Department of Internal Medicine and Cardiology, HCA Florida
Bayonet Point Hospital, University of South Florida, Hudson, FL, United
States
(Khalique) Department of Cardiology, St. Francis Hospital & Heart Center,
Roslyn, NY, United States
(May) Intermountain Heart Institute, Intermountain Medical Center, Murray,
UT, United States
(Thachil) Department of Cardiology, Elmhurst Hospital, Mount Sinai College
of Medicine, New York, NY, United States
(Iskander) Department of Cardiovascular Medicine, Medical College of
Wisconsin, Milwaukee, WI, United States
(Waheed) Department of Family and Community Medicine, Pennsylvania State
University, Hershey, PA, United States
Publisher
Oxford University Press
Abstract
Aims The impact of sex-related differences on outcomes following
transcatheter aortic valve replacement (TAVR) remains inconclusive. This
study investigates sex-related differences in survival and safety outcomes
in patients with aortic stenosis undergoing TAVR. Methods and results We
systematically searched PubMed, Embase, Scopus, and Cochrane Library until
November 2024. Individual patient data (IPD) were reconstructed from
published Kaplan-Meier curves and compared using Cox-proportional hazards
model for overall survival and cardiovascular mortality. Pooled risk
ratios (RR) for safety outcomes at 30-days and 1 year were estimated using
a random-effects model. A total of 48 studies (69 355 women and 65 580
men) were included. Meta-analysis of reconstructed IPD showed that men
were at higher risk of all-cause mortality at 5 years [hazard ratio (HR):
1.24, 95% confidence interval (CI): 1.20-1.28, P < 0.001] and
cardiovascular mortality at 4 years (HR: 1.34, 95% CI: 1.21-1.49, P <
0.001) compared with women. In random-effects meta-analysis, men faced a
higher risk of permanent pacemaker implantation (RR: 1.29, 95% CI:
1.16-1.44, P < 0.001) during the first year. Men experienced a lower risk
of stroke (RR: 0.75, 95% CI: 0.64-0.87, P < 0.001) and major vascular
complications (RR: 0.58, 95% CI: 0.49-0.69, P < 0.001) at 30 days, and a
lower risk of major bleeding (RR: 0.77, 95% CI: 0.70-0.84, P < 0.001) as
well as major vascular complications (RR: 0.54, 95% CI: 0.43-0.68, P <
0.001) within the first year. Conclusion Men demonstrated poorer 5-year
overall survival and 4-year cardiovascular survival following TAVR
compared with women. Future research with extended follow-up is needed to
understand the mechanism underlying sex-specific TAVR
outcomes. Copyright © The Author(s) 2025. Published by Oxford
University Press on behalf of the European Society of Cardiology. All
rights reserved.

<101>
Accession Number
648208246
Title
Postoperative Inflammation Impairs Reverse Cholesterol Transport and Fuels
Postoperative Plaque Necrosis.
Source
Arteriosclerosis, Thrombosis, and Vascular Biology. Conference: American
Heart Association's Vascular Discovery: From Genes to Medicine 2025
Scientific Sessions. Baltimore, MD United States. 45(Supplement 1) (no
pagination), 2025. Date of Publication: 01 Apr 2025.
Author
Boucher D.; Emerton C.; Carter A.; Gordon S.; Ouimet M.
Institution
(Boucher, Emerton, Ouimet) University Ottawa Heart Institute, Ottawa, ON,
Canada
(Carter, Gordon) University of Kentucky, Lexington, KY, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Background: Over 10 million patients undergoing non-cardiac surgery
annually experience major cardiovascular complications within 30 days.
Atherosclerosis is implicated in a significant number of cases, yet how
plaque disruption is precipitated in the perioperative period remains
unclear. Reverse cholesterol transport (RCT), which facilitates
cholesterol removal via HDL and apoA-I, plays a key role in preventing
plaque progression. Surgery-associated inflammation can impair HDL
function, but its effects on RCT and plaque stability remain poorly
understood. Hypothesis: Inflammatory remodeling of the HDL proteome
impairs reverse cholesterol transport, promoting cholesterol accumulation
and necrotic core expansion in atherosclerotic plaques. Result(s):
ApoE-/- mice fed a Western diet underwent exploratory abdominal
surgery or anesthesia only (control). RCT was impaired for at least 48
hours postoperatively, paralleling reduced in vitro cholesterol efflux to
plasma and isolated HDL. Proteomic analysis via LC-MS/MS revealed
extensive postoperative inflammatory remodeling of the HDL proteome, with
a marked increase in SAA protein abundance and a concurrent reduction in
ApoA-I. This acute-phase HDL remodelling amounted to a reduction of
several cholesterol transport-related biological pathways as defined by
Gene Ontology (GO). Atherosclerotic plaques exhibited a 1.6-fold increase
in intracellular lipids (BODIPY) and perilipin-2 at 24 hours post-surgery,
with elevated cleaved-caspase-3 expression in lipid-rich cells. By day 15,
lipid-rich cells fell below control levels, while plaque necrotic core
area expanded by 1.5-fold, suggesting that acute lipid accumulation
triggers cell death and necrotic core growth. Preliminary experiments
intervening with rApoA-I postoperatively partially restored RCT, lessened
acute cholesterol accumulation in plaques, and modulated postoperative
inflammation, with ongoing studies assessing its ability to prevent
necrotic core expansion. Conclusion(s): Postoperative inflammation
profoundly impairs RCT, driving acute lipid accumulation, cell death, and
plaque destabilization. These findings highlight rapid lipid dynamics in
plaques during surgical inflammation and underscore the need for targeted
strategies to mitigate postoperative atherogenic mechanisms.

<102>
Accession Number
2035689837
Title
On-Table Extubation After Pediatric Cardiac Surgery: A Systematic Review.
Source
Paediatric Anaesthesia. (no pagination), 2025. Date of Publication: 2025.
Author
Tapioca V.; Caetano L.; Gibicoski T.; Alrayashi W.; Amaral S.
Institution
(Tapioca) Department of Medicine, Bahiana School of Medicine and Public
Health, Salvador, Brazil
(Caetano) Department of Medicine, Federal University of Paraiba, Joao
Pessoa, Brazil
(Gibicoski) Department of Medicine, Federal University of Health Sciences
of Porto Alegre, Porto Alegre, Brazil
(Alrayashi) Department of Anesthesiology, Harvard Medical School, Boston,
MA, United States
(Amaral) Department of Anesthesiology, Duke University Medical Center,
Durham, NC, United States
Publisher
John Wiley and Sons Inc
Abstract
Context: On-table extubation after pediatric cardiac surgery has been
increasingly considered a safe and effective strategy to reduce
postoperative ventilation time. However, concerns regarding reintubation
risk, patient selection, and variability in outcomes remain.
 Objective(s): To systematically review the available literature on
the effectiveness and safety of on-table extubation compared to off-table
extubation in pediatric cardiac surgery. Primary outcomes were
reintubation rate, mortality, intensive care unit (ICU) and hospital
length of stay (LOS). Secondary outcomes were arterial pH, lactate, and
PaCO<inf>2</inf> after surgery. Data Sources: MEDLINE, Cochrane
Library, Web of Science, and Embase were searched from inception to
January 8th, 2025, without language or date restrictions. Additional
studies were identified through the backward snowballing technique. Study
Selection: We included randomized controlled trials (RCTs) and
observational studies comparing on-table and off-table extubation in
pediatric patients (< 18 years) undergoing cardiovascular surgery. Studies
with overlapping populations or conference abstracts were excluded.
 Data Extraction: Two independent reviewers screened studies completed
a quality assessment, and extracted data. Result(s): Twenty-nine
studies (2 RCTs, 27 observational), including 9070 patients, met the
eligibility criteria. On-table extubation was associated with lower
reintubation rates in most studies, though findings were not consistent
across all. Mortality rates were generally comparable between groups. ICU
and hospital LOS were consistently shorter in the on-table group.
Postoperative blood gas analyses showed a better arterial pH, lactate, and
PaCO<inf>2</inf> profile in the on-table group. The risk of bias was
elevated between observational studies. Limitation(s): Selection bias
was present, as the majority of studies were observational, and the
decision for on-table extubation was largely based on clinician assessment
of suitability and stability at the end of surgery. High heterogeneity
across studies limited meta-analysis feasibility. Conclusion(s):
Although this systematic review suggests that on-table extubation may be
associated with potentially better outcomes following pediatric cardiac
surgery, no safe conclusions can be drawn about its benefit due to the
high heterogeneity and potential high risk of bias of most included
studies. Well-designed RCTs are needed to confirm the benefits and safety
of on-table extubation and to guide appropriate patient selection. Trial
Registration: International Prospective Register of Systematic Reviews
(PROSPERO): CRD42025644238. Copyright © 2025 John Wiley & Sons
Ltd.

<103>
Accession Number
648197586
Title
Left Atrial Appendage Closure versus Oral Anticoagulation for Stroke
Prevention in Atrial Fibrillation: Long-Term Outcomes from Four Randomized
Trials.
Source
Heart rhythm. (no pagination), 2025. Date of Publication: 01 Aug 2025.
Author
Kaisaier W.; Xu Z.; Guo L.; Dong Y.; Chen Y.; Lip G.Y.H.; Zhu W.
Institution
(Kaisaier, Dong, Chen, Zhu) Department of Cardiology, First Affiliated
Hospital of Sun Yat-Sen University, Guangzhou, China
(Xu) Department of emergency, Third Affiliated Hospital of Sun Yat-sen
University, Guangzhou, China
(Guo) Department of Cardiology, Jiangxi Provincial People's Hospital,
First Affiliated Hospital of Nanchang Medical College, Nanchang, China
(Lip) Liverpool Centre for Cardiovascular Science at University of
Liverpool, Liverpool John Moores University and Liverpool Heart & Chest
Hospital, Liverpool, United Kingdom; and Danish Center for Health Services
Research, Department of Clinical Medicine, Aalborg University, Aalborg,
Denmark
Abstract
BACKGROUND: Left atrial appendage closure (LAAC) is primarily indicated
for stroke prevention in atrial fibrillation (AF) patients who have
contraindications to long-term oral anticoagulants (OACs). However, the
long-term comparative benefits of LAAC versus OACs in the broader AF
population remain unclear. OBJECTIVE(S): To assess the long-term
efficacy and safety of LAAC compared with OACs in patients with AF, we
conducted a meta-analysis of randomized controlled trials (RCTs).
 METHOD(S): We systematically searched PubMed, Embase, and Cochrane
Library for eligible RCTs. Risk ratios (RRs) with 95% confidence intervals
(CIs) were calculated using fixed-effects models. RESULT(S): Four
RCTs involving 3,116 AF patients (1,736 assigned to LAAC and 1,380 to
OACs) and follow-up durations ranging from 36 to 49.6 months were
included. Compared with OACs, LAAC was associated with reduced risks of
all-cause death (RR=0.78; 95% CI: 0.64-0.95) and cardiovascular or
unexplained death (RR=0.69; 95% CI: 0.51-0.94). There were no significant
differences between the two groups in stroke or systemic embolism,
ischemic stroke or systemic embolism, and non-cardiovascular death. LAAC
was associated with significantly lower risks of hemorrhagic stroke
(RR=0.34; 95% CI: 0.16-0.76) and nonprocedural clinically relevant
bleeding (RR=0.49; 95% CI: 0.40-0.61). Major bleeding (including
procedural and nonprocedural) risk did not differ significantly between
groups. CONCLUSION(S): In this meta-analysis of RCTs, LAAC was
associated with significantly lower risks of all-cause and cardiovascular
death, hemorrhagic stroke, and nonprocedural clinically relevant bleeding
compared with OACs, without increasing the risk of thromboembolic events
or major bleeding. These findings support the consideration of LAAC as an
alternative to OAC in selected patients with AF. Copyright ©
2025. Published by Elsevier Inc.

<104>
Accession Number
2039927133
Title
Cerebrovascular Events With Self-Expanding Versus Balloon-Expandable
Valves in Patients With or Without Peripheral Arterial Disease.
Source
Journal of Invasive Cardiology. 37(8) (no pagination), 2025. Date of
Publication: 01 Aug 2025.
Author
Palmerini T.; Saia F.; Bruno A.G.; Kim W.-K.; Iadanza A.; Ghetti G.; De
Backer O.; Burzotta F.; Van Mieghem N.M.; Nardi E.; Orzalkiewicz M.;
Pilgrim T.; Aranzulla T.C.; Meertens M.M.; Taglieri N.; Joner M.; Nardi
G.; Toggweiler S.; Gallitto E.; Gargiulo M.; Testa L.; Berti S.;
Montorfano M.; Leone A.; Pacini D.; Braun D.; Castriota F.; De Carlo M.;
Barbanti M.; Leone P.P.; Nickenig G.; Piva T.; Latib A.; Vercellino M.;
Codner P.; Bartorelli A.L.; Fraccaro C.; Abdel-Wahab M.; Stone G.W.
Institution
(Palmerini, Saia, Bruno, Ghetti, Orzalkiewicz, Taglieri) Cardiology Unit,
Cardiac Thoracic and Vascular Department, IRCCS Azienda
Ospedaliero-Universitaria di Bologna, Bologna, Italy
(Palmerini, Saia, Bruno, Ghetti, Orzalkiewicz, Taglieri) Cardiac Thoracic
and Vascular Department, Universita di Bologna, Bologna, Italy
(Kim) Kerckhoff Heart Center, Bad Nauheim, Germany
(Iadanza) UOSA Cardiologia Interventistica Azienda Ospedaliera
Universitaria Senese, Siena, Italy
(De Backer) The Heart Center, Rigshospitalet, Copenhagen University
Hospital, Copenhagen, Denmark
(Burzotta) U.O.C. di Interventistica Cardiologica e Diagnostica Invasiva,
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universita
Cattolica del Sacro Cuore, Rome, Italy
(Van Mieghem) Department of Cardiology, Thoraxcenter, Erasmus University
Medical Center, Rotterdam, Netherlands
(Nardi) Research and Innovation Unit, IRCCS Azienda
Ospedaliero-Universitaria di Bologna, Bologna, Italy
(Pilgrim) Inselspital, Bern University Hospital, University of Bern, Bern,
Switzerland
(Aranzulla) A.O. Mauriziano Umberto I Hospital, Turin, Italy
(Meertens) University Hospital Cologne - Heart Center, Klinik III fur
Innere Medizin, Kardiologie, Pneumologie und internistische
Intensivmedizin, Cologne, Germany
(Joner) German Heart Centre Munich, Deutsches Herzzentrzum Munchen,
Munich, Germany
(Nardi) University Hospital Careggi, Florence, Italy
(Nardi, Toggweiler) Heart Center Lucerne, Cardiology, Luzerner,
Switzerland
(Gallitto, Gargiulo) Vascular Surgery, University of Bologna, DIMEC, IRCCS
Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
(Testa) Coronary Revascularisation Unit, IRCCS Policlinico S. Donato, San
Donato Milanese, Italy
(Berti) Unit of Diagnostic and Interventional Cardiology, C.N.R. Reg.
Toscana G. Monasterio Foundation, Ospedale del Cuore, Massa, Italy
(Montorfano) Interventional Cardiology Unit, IRCCS San Raffaele Scientific
Institute, Milan, Italy
(Leone, Pacini) Cardiac Surgery Unit, Cardiac Thoracic and Vascular
Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Coronary
Revascularisation Unit, IRCCS Policlinico S. Donato, S. Donato Milanese,
Italy
(Braun) Department of Medicine I, University Hospital Munich, Medical
faculty - LMU, Munich, Germany
(Castriota) Interventional Cardiology Unit, GVM Care and Research Maria
Cecilia Hospital, (RA), Cotignola, Italy
(De Carlo) Cardiothoracic and Vascular Department, Pisa University
Hospital, Pisa, Italy
(Barbanti) Division of Cardiology, Policlinico-Vittorio Emanuele Hospital,
University of Catania, Catania, Italy
(Leone) Cardio Center, Humanitas Research Hospital IRCCS, Rozzano-Milan,
Italy
(Nickenig) Medizinische Klinik und Poliklinik II, Herzzentrum Bonn -
Universitatsklinikum Bonn, Bonn, Germany
(Piva) Azienda Ospedaliero-Universitaria, Ospedali Riuniti Umberto I - GM
Lancisi, Ancona, Torette, Italy
(Latib) Montefiore-Einstein Center for Heart and Vascular Care, Montefiore
Medical Center, Albert Einstein College of Medicine, Bronx, NY, United
States
(Latib) Cardiovascular Research Foundation, New York, NY, United States
(Vercellino) Cardiology Unit, Cardio-Thoraco Vascular Department
(DICATOV), IRCCS Ospedale Policlinico San Martino, Genoa, Italy
(Codner) Rabin Medical Center, Petah Tikva, Israel
(Bartorelli) Unita Operativa di Cardiologia Interventistica Universitaria,
IRCCS Ospedale Galeazzi, Sant'Ambrogio, Milano Milan, Italy
(Fraccaro) Department of Cardiac, Thoracic and Vascular Sciences,
University of Padua, Padua, Italy
(Abdel-Wahab) Heart Center Leipzig, University of Leipzig, Leipzig,
Germany
(Stone) Zena and Michael A. Wiener Cardiovascular Institute, Icahn School
of Medicine at Mount Sinai, New York, NY, United States
Publisher
Cliggott Publishing Co.
Abstract
Objectives. The authors compared the risk of cerebrovascular events (CVE)
with self-expanding vales (SEV) vs balloon-expandable valves (BEV) in
patients with or without peripheral artery disease (PAD), stratified by
the access route and the complexity of PAD (Hostile score). Methods. The
PAD-related risk of CVE between SEV vs BEV was investigated using data
from the HOSTILE Registry, an observational study including 1707 patients
with severe PAD undergoing transcatheter aortic valve replacement (TAVR)
via different access routes. The relative risk of CVE with SEV vs BEV in
patients without PAD was investigated in a meta-analysis of randomized
controlled transfemoral access (TFA)-TAVR trials of patients with normal
femoral arteries. The primary endpoint was the risk of 30-day CVE.
Results. Among the 1021 patients undergoing TAVR through TFA or
transaxillary access (TAxA), 674 (66.0%) received SEVs and 329 (32.2%)
received BEVs. The 30-day propensity-adjusted risk of CVE was higher for
SEV compared with BEV (adjusted hazard ratio [HR], 2.70; 95% CI,
1.16-6.23), with no significant interaction between the transcatheter
heart valve and either the access route or the Hostile score. Similar
results were apparent at 1 year (adjusted HR, 2.98; 95% CI, 1.30-6.83). In
contrast, in a meta-analysis of 4 RCTs and 2131 patients with femoral
arteries suitable for TAVR, there were no significant differences in the
30-day rates of CVE between SEV and BEV (odds ratio, 0.58; 95% CI,
0.24-1.40). Conclusions. Compared with BEVs, SEVs were associated with
higher 30-day and 1-year rates of CVE in patients with PAD, a finding not
apparent in patients with suitable femoral arteries enrolled in randomized
controlled trials. Copyright © 2025 HMP Global. All Rights
Reserved.

<105>
Accession Number
2035659617
Title
Nitric oxide for the prevention of postoperative acute kidney injury in
patients undergoing surgery for Stanford type A aortic dissection: study
protocol for a randomized controlled trial.
Source
Trials. 26(1) (no pagination), 2025. Article Number: 284. Date of
Publication: 01 Dec 2025.
Author
Chen Z.; Han X.; Li L.; Liu M.; Yu L.; Cheng S.; Yu Y.; Liu N.
Institution
(Chen, Li, Liu, Yu, Cheng, Yu, Liu) Center for Cardiac Intensive Care,
Beijing Anzhen Hospital, Capital Medical University, Beijing, China
(Han) Department of Emergency, University of Health and Rehabilitation
(Qingdao Municipal Hospital), Qingdao, Qingdao Hospital, China
Publisher
BioMed Central Ltd
Abstract
Background: Acute kidney injury (AKI) is a frequent and serious
complication following surgery for acute type A aortic dissection (ATAAD).
Nitric oxide (NO) may reduce AKI incidence through renal-protective
mechanisms, but evidence in the ATAAD population remains limited. This
trial aims to evaluate whether perioperative administration of NO can
reduce the incidence of postoperative AKI in this population.
 Method(s): This single-center, randomized, parallel-group superiority
trial will enroll 106 adult patients undergoing ATAAD emergency surgery.
Participants will be randomly allocated in a 1:1 ratio to either receive
60 parts per million of NO during cardiopulmonary bypass and for 12 h
post-surgery, or to receive standard care without NO. The primary outcome
is AKI incidence within 48 h postoperatively, defined by Kidney Disease:
Improving Global Outcomes (KDIGO) criteria. Secondary outcomes include AKI
severity, urine output, vasoactive-inotropic score, neutrophil
gelatinase-associated lipocalin levels, sequential organ failure
assessment score, ventilator support duration, intensive care unit (ICU)
and hospital length of stay, and major adverse kidney events, cumulative
mediastinal and pericardial drainage volume. Discussion(s): This
trial will evaluate whether perioperative NO administration can reduce
early AKI and improve renal and clinical outcomes in high-risk ATAAD
patients. Findings may provide evidence for a novel nephroprotective
strategy in aortic surgery. Trial registration: ClinicalTrials.gov
NCT06622291. Registered on June 26, 2024. Copyright © The
Author(s) 2025.

<106>
Accession Number
2039996849
Title
SESSION VI.
Source
Journal of Electrocardiology. Conference: 35th International Conference on
Cardiology and Healthcare. Tokyo Japan. 91 (no pagination), 2025. Article
Number: 154006. Date of Publication: 01 Jul 2025.
Author
Anonymous
Publisher
Elsevier B.V.
Abstract
Arrhythmias Among the Young Chairs: Konrad Brockmeier & Gabriele Hessling
Konrad Brockmeier, University of Cologne, Cologne, Germany Arrhythmias in
Children and the Role of the ECG Antonio Sanzo, Policlinico San Matteo,
Pavia, Italy ECG Interpretation by Traditional Algorithms: Results from a
Large Database Gabriele Hessling, German Heart Center Munich, Munich,
Germany Arrhythmias in Children - Treatment and Settings Alpay Celiker,
VKV American Hospital, Istanbul, Turkey Arrhythmias in the Young: Problems
& How to Avoid Arrhythmias in children and the role of the ECG: K. Konrad
Brockmeiera, M. Sebudandia, M. Khalila,
S. Wendtb aPediatric Cardiology, University of
Cologne, Cologne, Germany bPediatric Cardiac Surgery,
University of Cologne, Cologne, Germany The electrocardiogram (ECG) in
humans during childhood is somewhat paralleling the development of the
human being: very complex and important changes over time. The adaptation
to intra-utero live to live after birth generates significant changes and
differences in comparison to the ECG of the adult. The use of the ECG in
diagnosis and treatment of congenital heart disease (CHD) has a lower
importance - as morphology/ function is of superior value - given by
ultrasound, MRI/ CT or catheter based data, but useful in the follow-up of
individuals with CHD. However, the screening for congenital or acquired
myocardial diseases using the ECG provide rather easy ways of
determinating underlying threats for these patients. In the setting of
dysrhythmias the ECG is mandatory. The variation of the normal ECG in
children remains a challenge and urge a further request for larger data
sets. Materials: Data of meta-analysis from studies in different age
groups in children. Result(s): Significant data provide a possible
risk stratification in either CHD and congenital or acquired myocardial
diseases. ECG - screening in children is implemented in many countries at
rather low cost and significant benefit. Discussion(s): The ECG in
children is very important. Due to the rather large variation of normal
ECG presentation in children, the impact of possible false positive
results has to be taken into account, which may threaten parents for long
and increase costs in a post-screening setting. Copyright © 2025

<107>
Accession Number
2039928702
Title
Predictors of Long-Term Major Adverse Cardiovascular Events In Patients
Who Have Undergone a Transcatheter Aortic Valve Implantation: A Systematic
Review and Meta-Analysis.
Source
Heart Lung and Circulation. Conference: 73rd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Brisbane Australia.
34(Supplement 4) (pp S440-S441), 2025. Date of Publication: 01 Aug 2025.
Author
Machado R.; Dhamoon K.; Khanna S.; Leung A.; Bhat A.; Chen H.; Gan G.;
Ying V.; Fong L.; Eshoo S.; Fahmy P.
Institution
(Machado, Leung, Bhat, Chen, Gan, Eshoo, Fahmy) Department of Cardiology,
Blacktown Hospital, Sydney, NSW, Australia
(Dhamoon) Department of Cardiology, Tweed Valley Hospital, Tweed Heads,
NSW, Australia
(Khanna) Department of Medicine, University of New South Wales, Sydney,
NSW, Australia
(Ying) Department of Intensive Care, Blacktown Hospital, Sydney, NSW,
Australia
(Fong) Department of Cardiothoracic Surgery, Westmead Hospital, Sydney,
NSW, Australia
Publisher
Elsevier Ltd
Abstract
Aim: Transcatheter aortic valve implantation (TAVI) has transformed
intervention for aortic valve disease, however, major adverse
cardiovascular events (MACE) remain significant complications. This
systematic review and meta-analysis aimed to identify predictors of MACE
in patients undergoing TAVI. Method(s): Several databases were
systematically searched to identify studies analysing incidence of MACE in
patients who underwent TAVI (PROSPERO CRD420250649862). Data including
clinical, biochemical, echocardiographic and procedural factors were
extracted, and meta-analysis was performed using a random-effects model to
produce odds ratios (OR) or standardised mean difference (SMD) for MACE.
 Result(s): Of 5,351 studies identified from the search, 16 studies
encompassing 194,911 patients were included for the meta-analysis.
Clinical predictors of MACE in patients undergoing TAVI included: prior
ischaemic heart disease (OR 1.567, p=0.015), atrial fibrillation (OR
1.282, p=0.022), chronic obstructive pulmonary disease (OR 1.260,
p=0.008), peripheral vascular disease (OR 1.464, p<0.001), chronic kidney
disease (OR 1.495, p=0.029) and lower body mass index (SMD -0.110,
p=0.003). High cardiothoracic surgical risk (EUROSCORE SMD 0.234, p=0.009
and STS Score SMD 0.202, p=0.006) was also associated with MACE.
Echocardiographic predictors of MACE included lower left ventricular
ejection fraction (SMD -0.877, p=0.013) and lower aortic valve area (SMD
-0.667, p=0.024). Aside from TAVI performed in emergency settings (OR
1.206, p<0.001), no other procedural factors were associated with higher
risk of MACE (Table). Conclusion(s): This study identified several
factors associated with MACE in patients undergoing TAVI. By providing
insight into key prognostic factors, these results can better inform
patient selection and risk stratification for aortic valve intervention.
[Formula presented] Copyright © 2025

<108>
Accession Number
648196025
Title
Erratum: Correction: Comparing the effects of ketorolac and Paracetamol on
postoperative pain relief after coronary artery bypass graft surgery. a
randomized clinical trial (Journal of cardiothoracic surgery (2020) 15 1
DOI: 10.1186/s13019-020-01125-y.).
Source
Journal of cardiothoracic surgery. 20(1) (pp 321), 2025. Date of
Publication: 02 Aug 2025.
Author
Javaherforooshzadeh F.; Abdalbeygi H.; Janatmakan F.; Gholizadeh B.
Institution
(Javaherforooshzadeh) Department of Cardiac Anesthesia, Ahvaz
Anesthesiology and Pain Research Center, Ahvaz Jundishapur University of
Medical Sciences, Ahvaz, Iran, Islamic Republic of
(Abdalbeygi, Janatmakan) Department of Anesthesia, Ahvaz Anesthesiology
and Pain Research Center, Ahvaz Jundishapur University of Medical
Sciences, Ahvaz, Iran, Islamic Republic of
(Gholizadeh) Atherosclerosis Research Center, Ahvaz Jundishapur University
of Medical Sciences, Ahvaz, Iran, Islamic Republic of

<109>
Accession Number
2039929679
Title
Early Balance Training Combined With Phase I Cardiac Rehabilitation
Following Coronary Artery Bypass Grafting: A Randomised Controlled Trial
Examining the Effects on Balance, Strength and Post-Operative Recovery.
Source
Heart Lung and Circulation. Conference: 73rd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Brisbane Australia.
34(Supplement 4) (pp S132-S133), 2025. Date of Publication: 01 Aug 2025.
Author
Pengelly J.; Atef H.; Maged A.; Ali H.; El Ghaffar H.
Institution
(Pengelly) School of Allied Health, Human Services and Sport, La Trobe
University, Bundoora, VIC, Australia
(Atef) School of Allied Health Professions, Keele University, Keele,
Newcastle, United Kingdom
(Atef, Maged, El Ghaffar) Department of Physical Therapy for Internal
Medicine, Faculty of Physical Therapy, Cairo University, Cairo, Giza,
Egypt
(Ali) Cardiothoracic Surgery Department, Faculty of Medicine, Cairo
University, Cairo, Giza, Egypt
Publisher
Elsevier Ltd
Abstract
Aim: To determine whether balance training combined with Phase I CR
improved balance, strength, hospital length of stay (LOS) and quality of
life (QoL) in post-coronary artery bypass grafting (CABG) patients beyond
Phase I cardiac rehabilitation (CR) alone. Method(s): Male CABG
patients undergoing surgery at the National Heart Institute (NHI) in
Imbaba, Cairo, Egypt were randomly allocated (1:1) to either early balance
training plus Phase I CR (CRBalance) or Phase I CR alone (CRAlone). CR
commenced within 48-hours postoperatively, consisting of 30-minutes of
moderate-intensity respiratory and mobilisation exercises, thrice daily
for 7 days. An additional 5 minutes of balance training per session was
performed by the CRBalance group. The Berg Balance Scale assessed balance
as the primary outcome. Secondary outcomes were the five-times
sit-to-stand to assess lower limb strength, the Short Form-36 Health
Survey to assess QoL and hospital LOS. Result(s): Sixty male CABG
patients (59.00+/-3.18 years) participated in the study, with 30
randomised to each intervention. Balance, lower limb strength and QoL
significantly improved, irrespective of intervention (p<0.001). However,
improvements in balance (79.14% vs 45.24%, p<0.001), lower limb strength
(49.66% vs 34.55%, p<0.001), QoL (23.28% vs 11.72%, p<0.001) and LOS
(11.47+/-1.22 days vs 14.93+/-1.36 days, p<0.001) were significantly
greater in the CRBalance group compared to the CRAlone group.
 Conclusion(s): The addition of balance training to Phase I CR,
commenced within 48-hours post-operatively, significantly improves
balance, lower limb strength and QoL, and reduces LOS, beyond that of
Phase I CR alone. Copyright © 2025

<110>
Accession Number
2039982849
Title
A Randomized Trial of Acute Normovolemic Hemodilution in Cardiac Surgery.
Source
New England Journal of Medicine. 393(5) (pp 450-460), 2025. Date of
Publication: 31 Jul 2025.
Author
Monaco F.; Lei C.; Bonizzoni M.A.; Efremov S.; Morselli F.; Guarracino F.;
Giardina G.; Arangino C.; Pontillo D.; Vitiello M.; Belletti A.; Ajello
V.; Licheri M.; Nigro Neto C.; Barucco G.; Bukamal N.A.; Faustini C.;
Mantovani L.F.; Oriani A.; Santonocito C.; Mucchetti M.; Federici F.;
Gerli C.; Porta S.; Scandroglio A.M.; Zhang H.; Pieri M.; Osinsky R.;
Lazzari S.; Leonova E.; Calabro M.G.; Amitrano D.; Turi S.; Prati P.;
Fresilli S.; D'Amico F.; D'Andria Ursoleo J.; Labanca R.; Marmiere M.;
Pruna A.; Scquizzato T.; Klrali K.; Monti G.; Carmona M.J.C.; Tanaka K.;
Likhvantsev V.; Ti L.K.; Bove T.; Paternoster G.; Singh K.; Gurcu M.E.;
Lomivorotov V.; Landoni G.; Bellomo R.; Zangrillo A.
Institution
(Monaco, Bonizzoni, Morselli, Giardina, Pontillo, Belletti, Licheri,
Barucco, Faustini, Oriani, Mucchetti, Gerli, Scandroglio, Pieri, Lazzari,
Calabro, Turi, Fresilli, D'Amico, D'Andria Ursoleo, Labanca, Marmiere,
Pruna, Scquizzato, Monti, Landoni, Zangrillo) Department of Anesthesia and
Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy
(Lei) Anesthesia Clinical Research Center, Department of Anesthesiology
and Perioperative Medicine, Xijing Hospital, Xi'an, China
(Efremov, Leonova) Saint-Petersburg State University Hospital, St.
Petersburg, Russian Federation
(Guarracino, Amitrano) Department of Cardiothoracic and Vascular
Anesthesia and Intensive Care, Azienda Ospedaliero Universitaria Pisana,
Pisa, Italy
(Arangino) Department of Cardiothoracic Anesthesia and Intensive Care,
IRCCS Centro Cardiologico Monzino, Milan, Italy
(Vitiello) San Carlo Hospital, Cardiovascular Anesthesia and Intensive
Care, Potenza, Italy
(Ajello, Prati) Department of Cardiac Anesthesia, Tor Vergata University
Hospital, Rome, Italy
(Nigro Neto) Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil
(Bukamal) Mohammed Bin Khalifa Specialist Cardiac Center, Awali, Bahrain
(Mantovani) Department of Anesthesia and Intensive Care, Maria Cecilia
Hospital, GVM International, Cotignola, Italy
(Santonocito) Department of Anesthesia and Intensive Care Medicine III,
Centro di Alte Specialita E Trapianti, Azienda Ospedaliero Universitaria
Policlinico G. Rodolico-San Marco, Catania, Italy
(Federici) Unita Operativa Complessa Anestesia E Rianimazione, Azienda
Ospedaliero-Universitaria Sant'Andrea, Rome, Italy
(Porta) S.C. Anestesia e Rianimazione Cardiovascolare, Azienda Ospedaliera
Ordine Mauriziano Umberto I di Torino, Turin, Italy
(Zhang) Department of Anesthesiology and Perioperative Medicine, Xijing
Hospital, Xi'an, China
(Pieri, Monti, Landoni, Zangrillo) School of Medicine, Vita-Salute San
Raffaele University, Milan, Italy
(Osinsky) E. Meshalkin National Medical Research Center, Department of
Anesthesiology and Intensive Care, Novosibirsk, Russian Federation
(Klrali) Kosuyolu High Specialization Education and Research Hospital,
Department of Cardiovascular Surgery, Istanbul, Turkey
(Carmona, Lomivorotov) Hospital Das Clinicas da Faculdade de Medicina da
Universidade de Sao Paulo, Instituto do Coracao, InCor, Sao Paulo, Brazil
(Tanaka) Department of Anesthesiology, University of Oklahoma Health,
Oklahoma, United States
(Likhvantsev) Federal Clinical and Research Center of Intensive Care and
Rehabilitation, Moscow, Russian Federation
(Likhvantsev) Loginov Moscow Clinical Scientific Center, Moscow, Russian
Federation
(Ti) Department of Anaesthesia, National University Hospital, Singapore
(Bove) Department of Emergency, University Hospital of Udine, Azienda
Sanitaria Universitaria Friuli Centrale Santa Maria della Misericordia,
Udine, Italy
(Bove) Department of Medicine, University of Udine, Udine, Italy
(Paternoster) Department of Health Science, Anesthesia and Intensive Care,
School of Medicine, University of Basilicata San Carlo Hospital, Potenza,
Italy
(Singh) University of Virginia Health, Charlottesville, United States
(Gurcu) Kosuyolu High Specialization Education and Research Hospital,
Department of Anesthesiology, Istanbul, Turkey
(Lomivorotov) Department of Anesthesiology and Perioperative Medicine,
Penn State Milton S. Hershey Medical Center, Hershey, PA, United States
(Bellomo) Department of Critical Care, University of Melbourne, Melbourne,
VIC, Australia
(Bellomo) Australian and New Zealand Intensive Care Research Centre,
Monash University, Melbourne, VIC, Australia
Publisher
Massachussetts Medical Society
Abstract
Background Patients undergoing cardiac surgery often receive red-cell
transfusions, along with the associated risks and costs. Early
intraoperative normovolemic hemodilution (i.e., acute normovolemic
hemodilution [ANH]) is a blood-conservation technique that entails
autologous blood collection before initiation of cardiopulmonary bypass
and reinfusion of the collected blood after bypass weaning. More data are
needed on whether ANH reduces the number of patients receiving allogeneic
red-cell transfusion. Methods In a multinational, single-blind trial, we
randomly assigned adults from 32 centers and 11 countries who were
undergoing cardiac surgery with cardiopulmonary bypass to receive ANH
(withdrawal of >=650 ml of whole blood with crystalloids replacement if
needed) or usual care. The primary outcome was the transfusion of at least
one unit of allogeneic red cells during the hospital stay. Secondary
outcomes were death from any cause within 30 days after surgery or during
the hospitalization for surgery, bleeding complications, ischemic
complications, and acute kidney injury. Results A total of 2010 patients
underwent randomization; 1010 were assigned to ANH and 1000 to usual care.
Among patients with available data, 274 of 1005 (27.3%) in the ANH group
and 291 of 997 (29.2%) in the usual-care group received at least one
allogeneic red-cell transfusion (relative risk, 0.93; 95% confidence
interval, 0.81 to 1.07; P=0.34). Surgery for postoperative bleeding was
performed in 38 of 1004 patients (3.8%) in the ANH group and 26 of 995
patients (2.6%) in the usual-care group. Death within 30 days or during
hospitalization occurred in 14 of 1008 patients (1.4%) in the ANH group
and 16 of 997 patients (1.6%) in the usual-care group. Safety outcomes
were similar in the two groups. Conclusions Among adults undergoing
cardiac surgery, ANH did not reduce the number of patients receiving
allogeneic red-cell transfusion. Copyright © 2025 Massachusetts
Medical Society.

<111>
Accession Number
2039969332
Title
Surgical ablation in non-mitral valve cardiac surgeries: a meta-analysis
of early outcomes.
Source
Heart. (no pagination), 2025. Date of Publication: 2025.
Author
Barbosa G.S.; Katsuyama E.S.; Fukunaga C.K.; Fernandes J.M.; Coan A.C.C.;
Palatianos Y.; Fabiano R.C.; Gioli-Pereira L.; Kirov H.; Doenst T.;
Caldonazo T.
Institution
(Barbosa, Kirov, Doenst) Department of Medicine, Faculdade Santa
Marcelina, Sao Paulo, Brazil
(Katsuyama, Fukunaga) Faculdade de Medicina do ABC, Santo Andre, Brazil
(Fernandes) Department of Medicine, Albert Einstein Instituto Israelita de
Ensino e Pesquisa, Sao Paulo, Brazil
(Coan) Department of Medicine, Universidade Federal do Espirito Santo,
Vitoria, Brazil
(Palatianos) Department of Internal Medicine, Northwestern Medicine
McHenry Hospital, McHenry, IL, United States
(Fabiano) Department of Medicine, Brigham and Women's Hospital, Boston,
MA, United States
(Gioli-Pereira) Albert Einstein Israelite Hospital, Sao Paulo, Brazil
(Caldonazo) Jena University Hospital, Jena, Germany
Publisher
BMJ Publishing Group
Abstract
Background Surgical ablation (SA) is a key treatment for atrial
fibrillation (AF) patients undergoing heart surgery. However, direct
comparisons between SA and non-mitral valve (non-MV) surgery alone are
lacking. We performed a systematic review and meta-analysis comparing
concomitant SA to isolated non-MV surgery in AF patients. Methods MEDLINE,
Embase and Cochrane were searched. Outcomes of interest were: (1)
postoperative AF (POAF); (2) early all-cause mortality; (3) postoperative
pacemaker implantation and (4) stroke. Additionally, a subgroup analysis
comparing randomised controlled trials (RCTs) and propensity score-matched
studies (PSM) was conducted. Risk ratios (RRs) and their respective 95% CI
were calculated using a random effects model. Results After screening 6423
citations, we included 2 RCTs and 5 PSM studies encompassing 39 348 AF
patients undergoing non-MV surgery, of whom 18 394 (46.7%) underwent SA.
Compared with isolated non-MV surgery, SA was associated with significant
POAF reduction (RR: 0.73; 95% CI: 0.67 to 0.79; I2=0%) and
higher risk of postoperative pacemaker implantation (RR: 1.34; 95% CI:
1.14 to 1.57, I2=0%) compared with surgery alone. No
differences were found in early all-cause mortality (RR: 0.96; 95% CI:
0.76 to 1.22; I2=65%) and postoperative stroke (RR: 1.06; 95%
CI: 0.89 to 1.26; I2=0%). The subgroup analysis comparing RCTs
and PSM showed significant consistency among the different designs.
Conclusions In this meta-analysis, SA was associated with POAF reduction
in non-MV surgery. In terms of safety, it was suggested that although no
difference in early mortality and postoperative stroke was observed, SA
had a higher risk of pacemaker implantation than isolated non-MV
surgery. Copyright © Author(s) (or their employer(s)) 2025. No
commercial re-use. See rights and permissions. Published by BMJ Group.

<112>
Accession Number
2039929269
Title
The Effect of Early Resistance Training Combined With Aerobic Training
Versus Aerobic Training Alone on Functional Capacity Following Rheumatic
Fever-Related Valve Replacement Surgery: A Randomised Controlled Trial.
Source
Heart Lung and Circulation. Conference: 73rd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Brisbane Australia.
34(Supplement 4) (pp S137), 2025. Date of Publication: 01 Aug 2025.
Author
Pengelly J.; Atef H.; Helmy Z.; Buckley J.; Bahjat M.; Nagy E.; El-Ansary
D.
Institution
(Pengelly) Sport, Performance and Nutrition Research Group, School of
Allied Health, Human Services and Sport, La Trobe University, Bundoora,
VIC, Australia
(Atef, Buckley) School of Allied Health Professions, Keele University,
Staffordshire, United Kingdom
(Helmy, Bahjat, Nagy) Department of Physical Therapy for
Cardiovascular/Respiratory Disorders and Geriatrics, Faculty of Physical
Therapy, Cairo University, Cairo, Giza, Egypt
(El-Ansary) School of Health and Biomedical Sciences, RMIT, Bundoora, VIC,
Australia
(El-Ansary) Department of Surgery, Melbourne Medical School, The
University of Melbourne, Melbourne, VIC, Australia
(El-Ansary) College of Health Sciences, Shanghai University of Medicine
and Health Sciences, Shanghai, China
Publisher
Elsevier Ltd
Abstract
Aim: To determine the effect of early resistance training combined with
aerobic training (RTAerobic) in Phase I Cardiac Rehabilitation (CR) on
functional capacity, P-R interval, and resting heart rate (RHR), compared
to aerobic training alone (AerobicAlone), in rheumatic fever patients
undergoing valve replacement surgery via median sternotomy.
 Method(s): Forty males (aged 20-30 years) undergoing valve
replacement surgery via median sternotomy at the National Heart Institute
(NHI) in Imbaba, Cairo, Egypt were randomised (1:1) to either RTAerobic or
AerobicAlone. Sessions commenced 48-hours post-operatively and consisted
of 20-30 minutes of moderate-intensity aerobic training thrice weekly for
four weeks. The RTAerobic group completed an additional 12 minutes of
resistance training (RT) per session. A six-minute walk test (6MWT) was
used to assess functional capacity as the primary outcome. Secondary
outcomes were P-R interval and RHR. Result(s): RTAerobic
significantly improved 6MWT distance (+118.50+/-6.75 m vs +41.75+/-6.75 m;
p<0.001) and P-R interval (-30.05+/-3.21 ms vs -11.65+/-3.21 ms; p=0.024),
beyond that of AerobicAlone. There was no significant difference in RHR
between groups (p=0.759). However, all outcomes significantly improved
without adverse events, irrespective of intervention (p<0.05).
 Conclusion(s): The addition of RT to aerobic training, commenced
within 48-hours post-operatively, is safe and significantly improves
functional capacity and P-R interval beyond that of aerobic training
alone, in young males with valvular heart disease secondary to a rheumatic
fever diagnosis, who underwent valve replacement surgery via median
sternotomy. Copyright © 2025

<113>
Accession Number
2039997694
Title
Short- and Long-Term Effects of Pulsed Ultrasound Cavitation Therapy of
Calcified Valvular Interstitial Cells in Culture.
Source
Ultrasound in Medicine and Biology. (no pagination), 2025. Date of
Publication: 2025.
Author
Clift C.L.; Goudot G.; Bogut G.; Kasai T.; van Kampen A.; Negrao Pantaleao
A.; Messas E.; Aikawa M.; Singh S.A.; Levine R.A.; Pernot M.; Aikawa E.
Institution
(Clift, Bogut, Kasai, Aikawa, Singh, Aikawa) Division of Cardiovascular
Medicine, Department of Medicine, Center for Interdisciplinary
Cardiovascular Sciences, Brigham and Women's Hospital, Harvard Medical
School, Boston, MA, United States
(Goudot, van Kampen, Negrao Pantaleao, Aikawa, Levine) Division of
Cardiology, Department of Medicine, Massachusetts General Hospital,
Boston, MA, United States
(Goudot, Messas) Universite Paris Cite, Hopital Europeen Georges Pompidou,
APHP, INSERM PARCC U970, Paris, France
(Pernot) Physics for Medicine Paris, INSERM U1273, ESPCI Paris, CNRS 8063,
PSL University, Paris, France
(Aikawa) Division of Cardiovascular Medicine, Department of Medicine,
Center for Excellence in Vascular Biology, Brigham and Women's Hospital,
Harvard Medical School, Boston, MA, United States
Publisher
Elsevier Inc.
Abstract
Objective: Calcific aortic valve disease advances via increased fibrosis
and calcification deposition, leading to progressive narrowing of the
outflow tract, left ventricular hypertrophy and cardiac failure.
Currently, surgical repair and replacement are the only strategies for
intervention. While transcatheter aortic valve replacement offers a less
invasive alternative to surgical intervention, implanted bioprosthetic
valves have limited durability. Non-invasive ultrasound therapy was shown
to not damage normal porcine aortic valve, and successfully reduced
stenosis of calcified bioprosthetic valves in vivo, as well as decrease
stenosis of native severely calcified aortic stenosis in a first-in-human
study. However, critical questions regarding the effect of ultrasound
therapy on valvular cells remain. In this study, we aimed to optimize
pulsed ultrasound cavitation (PUC) treatment for cell culture studies and
evaluate the acute and persistent effects on human valvular interstitial
cells (hVICs) in calcifying conditions. Method(s): We utilized
viability, metabolism and calcification assays as well as mass
spectrometry-based proteomics to holistically characterize the effects of
PUC treatment in hVICs. Result(s): hVICs viability and metabolism
were not significantly altered as a function of PUC treatment at short-
(48 hour) or long-term (21 day) time points. Furthermore, PUC treatment
did not increase hVICs calcification in vitro. Proteomic profiling of
hVICs showed that PUC treatment had limited persistent changes to protein
profiles compared with the acute effects of PUC treatment.
 Conclusion(s): These studies suggest that ultrasound therapy,
currently limited to very severe aortic stenosis, could be of interest at
an earlier stage of the disease. Copyright © 2025 The Authors

<114>
Accession Number
2035665985
Title
Optimizing Culotte Technique With Double Kissing Balloon Inflation.
Source
Journal of Cardiovascular Translational Research. (no pagination), 2025.
Date of Publication: 2025.
Author
Serter B.; Akman C.; Uysal H.; Dogan A.; Guner A.
Institution
(Serter, Akman, Uysal, Dogan, Guner) Department of Cardiology, Istanbul
Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and
Research Hospital, Turgut Ozal Bulvari No:11, Kucukcekmece, Istanbul,
Turkey
Publisher
Springer

<115>
Accession Number
2039929331
Title
The Efficacy and Safety of Low Dose Colchicine in Atherosclerotic
Cardiovascular Disease-A Systematic Review and Meta-Analysis.
Source
Heart Lung and Circulation. Conference: 73rd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Brisbane Australia.
34(Supplement 4) (pp S668-S669), 2025. Date of Publication: 01 Aug 2025.
Author
Tucker B.; Tucker W.; Chung J.; Figtree G.; Keech A.; Patel S.
Institution
(Tucker, Chung, Keech, Patel) Department of Cardiology, Royal Prince
Alfred Hospital, Camperdown, NSW, Australia
(Tucker, Keech, Patel) Clinical Trials Centre, Faculty of Medicine and
Health, The University of Sydney, Camperdown, NSW, Australia
(Tucker) Tweed Valley Hospital, Cudgen, NSW, Australia
(Figtree) Sydney Medical School, Faculty of Medicine and Health, The
University of Sydney, Camperdown, NSW, Australia
(Figtree) Cardiovascular Discovery Group, Kolling Institute of Medical
Research, St Leonards, NSW, Australia
(Figtree) Department of Cardiology, Royal North Shore Hospital, St
Leonards, NSW, Australia
(Patel) Coronary Diseases Group, Heart Research Institute, Newtown, NSW,
Australia
Publisher
Elsevier Ltd
Abstract
Aim: Colchicine has recently been approved for the treatment of
atherosclerotic cardiovascular disease (ASCVD). Since then, three large
trials of colchicine in ASCVD have failed to reach their primary
endpoints. Method(s): A systematic search of PubMed, Embase and
Cochrane Central Register of Controlled Trials was performed (PROSPERO
registration: CRD42024616378). The primary endpoint of major adverse
cardiovascular events (MACE) was defined as a composite of myocardial
infarction, stroke and cardiovascular death. The key secondary endpoint of
extended MACE (eMACE) was defined as MACE plus coronary revascularisation.
Pooled estimates were calculated using a random-effects model and are
presented as risk ratio (95% confidence interval). Result(s): 1624
articles were screened, 53 underwent full-text review and 11 were included
in the meta-analysis (Table). There were a total of 1983 primary endpoint
events across 30,808 included participants. Colchicine was associated with
a 17% reduction in the incidence of MACE (0.83 [0.73, 0.95]; p=0.006) and
23% reduction in the incidence of eMACE (0.77 [0.63, 0.94]; p=0.01)
(Figure). This reduction was driven by a lower rate of myocardial
infarction (0.78 [0.63, 0.95]; p=0.02) and coronary revascularisation
(0.73 [0.55, 0.97]; p=0.03). There were numerically fewer strokes in the
colchicine treated population, yet this did not reach statistical
significance (0.81 [0.63, 1.04]; p=0.11). Colchicine had no effect on
cardiovascular (0.96 [0.79, 1.15]; p=0.64) or non-cardiovascular mortality
(1.04 [0.76, 1.41]; p=0.81). Conclusion(s): Colchicine reduces the
risk of non-fatal ischaemic events in patients with ASCVD. Further studies
are required to identify a population(s) who stands to benefit most from
this promising therapy. [Formula presented] [Formula
presented] Copyright © 2025

<116>
Accession Number
648177105
Title
The Effect of Parental Active Participation on Pain and Anxiety in
Supporting Children With Cancer Experiencing a Venipuncture: A Randomized
Controlled Study.
Source
Journal of pediatric hematology/oncology nursing. (pp 27527530251342170),
2025. Date of Publication: 31 Jul 2025.
Author
Erkul M.; Bekar P.; Efe E.
Institution
(Erkul) Faculty of Health Sciences, Antalya Bilim University, Antalya,
Turkey
(Bekar) Department of Child Health and Diseases Nursing, Bucak School of
Health, Burdur Mehmet Akif Ersoy University, Turkey
(Efe) Department of Child Health and Diseases Nursing, Faculty of Nursing,
Akdeniz University, Antalya, Turkey
Abstract
BackgroundDuring cancer treatment, children are exposed to many painful
procedures. In some areas of the world, the most common exposure may be
the venipuncture procedure. This painful process causes increased anxiety
in children. Studies have reported that sometimes pain procedures are more
traumatic than the disease itself. In general pediatrics, parent support
is effective in reducing pain and anxiety during venipuncture. This study
aimed to evaluate the effect of parental involvement on relieving pain and
anxiety in children with cancer during venipuncture compared to children
whose parents were present but not involved.MethodThis randomized
controlled trial included 60 participants receiving hospitalized in the
pediatric oncology clinic. Through randomization, 30 children had parents
coached in supportive behaviors (parental involvement) and 30 children had
parents present but without coaching as a usual care control
group.ResultsCompared to children in the control group, children in the
parental involvement group had significantly lower pain (p < .001) and
anxiety (p < .001) scores reported after the procedure and lower heart
rates during the procedure (p < .05).DiscussionResults support the
efficacy of parental involvement compared to routine procedures such as
venipuncture. Building on these results, future research is needed on how
to involve the parent during the procedure and for which types of children
and parental presence have the best effect.

<117>
Accession Number
2039928896
Title
Receptor Agonists Reduce All-Cause Mortality and Non-Fatal Myocardial
Infarction in Overweight and Obese Adults Without Diabetes Mellitus:
Results of a Systematic Review and Meta-Analysis.
Source
Heart Lung and Circulation. Conference: 73rd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Brisbane Australia.
34(Supplement 4) (pp S645-S646), 2025. Date of Publication: 01 Aug 2025.
Author
Yao W.; Sathiyapal S.; Machado R.; Amarasekera A.; Tan T.
Institution
(Yao, Machado, Tan) Department of Cardiology, Blacktown Hospital,
Blacktown, NSW, Australia
(Sathiyapal, Amarasekera, Tan) Department of Cardiology, Westmead
Hospital, Westmead, NSW, Australia
(Amarasekera) Westmead Heart Rhythm Institute, Faculty of Medicine and
Health, The University of Sydney, Sydney, NSW, Australia
(Tan) School of Medicine, Western Sydney University, Sydney, NSW,
Australia
Publisher
Elsevier Ltd
Abstract
Aim: Glucagon-like peptide-1 receptor agonists (GLP1RAs) have shown
promising cardiovascular benefits beyond glycaemic and metabolic control.
This systematic review and meta-analysis aimed to evaluate the impact of
GLP1RAs on all-cause mortality and major adverse cardiovascular events
(MACE) in overweight and obese adults without diabetes mellitus.
 Method(s): A systematic search of Medline, Embase, CENTRAL, SCOPUS
and grey literature was conducted in May 2024 to identify
randomised-controlled trials (RCTs) comparing GLP1RAs to placebo in
non-diabetic overweight and obese adults which reported on all-cause
mortality or at least one MACE outcome. Data were extracted and pooled
using common- and random-effects models to calculate risk ratios (RR) with
95% confidence intervals (CI). Heterogeneity was assessed with the
I2 statistic. Result(s): Sixteen RCTs (n=32,356
participants) of 7,184 studies met inclusion criteria. All-cause mortality
data from all 16 trials showed a significant reduction associated with
GLP1RAs (RR 0.81; 95%CI 0.71-0.92; p<0.01; I2=0.0%) (Figure).
Non-fatal myocardial infarction was also significantly reduced, based on
four studies (RR 0.72; 95%CI 0.61-0.85; p<0.01; I2=0.0%).
GLP1RAs were associated with lower rates of cardiovascular death (16
studies; RR 0.84; 95%CI 0.71-1.00; p=0.05; I2=0.0%), non-fatal
stroke (3 studies; RR 0.92; 95%CI 0.74-1.14; p=0.45; I2=0.0%),
heart failure (5 studies; RR 0.49; 95%CI 0.06-4.08; p=0.36;
I2=48.0%), and coronary revascularisation (3 studies; RR 0.53;
95%CI 0.04-7.91; p=0.42; I2=40.9%), however these results were
non-significant. Conclusion(s): GLP1RAs were associated with
significantly reduced all-cause mortality and non-fatal MI in non-diabetic
overweight and obese adults. Further research is needed to evaluate the
broader cardiovascular and prognostic effects of this medication class.
[Formula presented] Copyright © 2025

<118>
Accession Number
2039929787
Title
Metabolic Surgery and Cardiovascular Outcomes: An Updated Systematic
Review and Meta-Analysis.
Source
Heart Lung and Circulation. Conference: 73rd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Brisbane Australia.
34(Supplement 4) (pp S654-S655), 2025. Date of Publication: 01 Aug 2025.
Author
Salib A.; Hay M.; Aldous E.; Abrahams T.; Nerlekar N.
Institution
(Salib) Austin Health, Melbourne, VIC, Australia
(Hay, Abrahams, Nerlekar) Victorian Heart Hospital, Melbourne, VIC,
Australia
(Aldous) Alfred Health, Melbourne, VIC, Australia
(Nerlekar) Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
(Nerlekar) Monash University, Melbourne, VIC, Australia
Publisher
Elsevier Ltd
Abstract
Aim: To evaluate the impact of metabolic surgery on cardiovascular
outcomes. Method(s): Studies with >=4-year follow-up, >200 patients,
and two cohorts of obese individuals (metabolic surgery vs. no surgery and
no medical therapy) were included. The primary outcome was total
mortality, and secondary outcomes included cardiovascular mortality,
myocardial infarction (MI), heart failure (HF), stroke, and new atrial
fibrillation (AF). Only studies reporting unadjusted hazard ratios (HR)
were analysed. Random-effects meta-analysis and meta-regression were
performed. Result(s): We included 36 studies (n=12,322,626). Mean
follow-up was 7.1+/-4.7 years, 33.8% males, mean BMI 44.1+/-6.9
kg/m2. There was a significant reduction in mortality (23
studies: HR 0.50 [0.42-0.59], p<0.001) (Figure). There was a reduction in
all secondary endpoints: cardiovascular mortality (5 studies, HR 0.57
[0.39-0.84], p=0.004), MI (15 studies, HR 0.49 [0.35-0.69], p<0.001), new
heart failure (7 studies, HR 0.41 [0.25-0.66], p=0.003), heart failure
hospitalisation (3 studies, HR 0.38 [0.27-0.53], p<0.001), stroke (16
studies, HR 0.64 [0.50-0.80], p=0.002), and new atrial fibrillation (4
studies, HR 0.57 [0.34-0.93], p=0.026). Meta-regression showed no
independent predictors. Subgroup analysis was consistent with mortality
benefit regardless of surgical approach and no between-group differences
(p(interaction)=0.94). Conclusion(s): Individuals undergoing
metabolic surgery have significantly better cardiovascular outcomes than
obese individuals who do not, regardless of procedural type. There appears
to be no specific influence of clinical risk factors on the outcome
indicating a beneficial effect on allcomers. With the advent of newer
pharmacologic therapies, comparative effects are now needed to assess
safety and longevity outcomes. [Formula presented] Copyright ©
2025

<119>
Accession Number
2039928861
Title
Early Intervention Versus Clinical Surveillance in the Management of
Asymptomatic Severe Aortic Stenosis.
Source
Heart Lung and Circulation. Conference: 73rd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Brisbane Australia.
34(Supplement 4) (pp S417), 2025. Date of Publication: 01 Aug 2025.
Author
Grbac A.; Lee M.; Chye D.; Zhou J.; Biswas S.; Gurvitch R.; Wilson W.;
Taylor A.; Lefkovits J.; Koshy A.
Institution
(Grbac, Lee, Biswas, Gurvitch, Wilson, Taylor, Lefkovits, Koshy) Royal
Melbourne Hospital, Melbourne, VIC, Australia
(Chye, Koshy) Austin Health, Melbourne, VIC, Australia
(Zhou) The Alfred Hospital, Melbourne, VIC, Australia
Publisher
Elsevier Ltd
Abstract
Aim: Asymptomatic severe aortic stenosis (AS) poses a clinical challenge
with variations in recommendations for management. In light of recent
landmark trials, we sought to perform a pooled analysis to compare
clinical surveillance to early intervention in patients with asymptomatic
AS and preserved left ventricular function. Method(s): A systematic
review of Embase and MEDLINE were preformed to identify randomized
controlled trials comparing early intervention (either surgical and
transcatheter aortic valve replacement) - with clinical surveillance in
the asymptomatic AS (PROSPERO registry: CRD42024534370). The primary
outcome was the composite of major adverse cardiovascular events (MACE)
defined by individual trial criteria (Figure). Result(s): Four
studies, the RECOVERY, AVATAR, EARLY-TAVR and EVOLVED trials - met
inclusion criteria, comprising 1,427 patients. Meta-analysis of the
primary composite outcome demonstrated a significant reduction in MACE
with early intervention (HR 0.52 [0.42, 0.63], p<0.001) with low
heterogeneity (I2=0%) (Figure). Individual components of
all-cause and cardiovascular mortality were comparable across the
intervention and clinical surveillance arms. However, early intervention
significantly reduced unplanned hospitalizations (HR 0.41 [0.32, 0.52],
p<0.001, I2=0%). Conclusion(s): Early intervention in
asymptomatic severe AS significantly lowers MACE rates, primarily through
a reduction in unplanned hospitalizations. Further research is needed to
establish optimal intervention thresholds and harmonise treatment pathways
in this complex patient cohort. [Formula presented] Copyright ©
2025

<120>
Accession Number
2039929395
Title
Outcomes in Nurse-Provided Sedation and Analgesia in Patients Undergoing
Transcatheter Aortic Valve Implantation (TAVI): A Systematic Review.
Source
Heart Lung and Circulation. Conference: 73rd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Brisbane Australia.
34(Supplement 4) (pp S706), 2025. Date of Publication: 01 Aug 2025.
Author
Dang D.; Cheung K.; Cartledge S.; Gardner E.; Stub D.
Institution
(Dang, Cheung, Cartledge, Gardner, Stub) Alfred Hospital, Melbourne, VIC,
Australia
(Stub) Monash University, VIC, Australia
Publisher
Elsevier Ltd
Abstract
Aims: To examine nurse-provided sedation and analgesia (NPSA) in patients
undergoing TAVI in the cardiac catherisation laboratory.
 Background(s): NPSA is standard practice in procedures such as
coronary intervention, cardiac implantable devices and more recently in
TAVI. NPSA enables a less invasive approach in the management of pain and
agitation, facilitating a more efficient TAVI procedure while optimising
patient comfort and safety. Method(s): A systematic review was
conducted according to the Joanna Briggs Institute Systematic Reviews
checklist and PRISMA guidelines. Searches from four databases were
conducted for primary research published after 2002. Inclusion criteria
included studies that examined NPSA in patients undergoing TAVI. Risk of
bias was assessed using the Newcastle-Ottawa Quality Assessment Form for
Cohort Studies. Result(s): Five full-text studies were included
comprising of 858 patients. Studies were published between 2015 and 2022
and were conducted in the Netherlands, United Kingdom, Czech Republic,
Ireland and the United States of America. All studies were single
observational centre studies. Patients selected for the NPSA pathway were
decided by the Heart Team. The mean age was 81.2+/-4.2 with 56.0% of
patients being male. From the 858 included patients, 18 (2.1%) patients
required anaesthetics and/or medical support due to reasons including
pericardial effusion, annular rupture, cardiac arrest, hypotension and
poor cooperation. A 100% success rate in valve deployment was reported
with a median length of stay post NPSA of two days. Conclusion(s):
When selected by the Heart Team, NPSA is a safe and feasible approach for
selected patients undergoing TAVI. Copyright © 2025

<121>
Accession Number
2035666609
Title
En Bloc Heart-Lung Transplantation: Past and Present. A Systematic Review.
Source
Clinical Transplantation. 39(8) (no pagination), 2025. Article Number:
e70270. Date of Publication: 01 Aug 2025.
Author
EL-Andari R.; Fialka N.M.; Alam A.; Khonde I.; Weatherald J.; Halloran K.;
Nagendran J.
Institution
(EL-Andari, Fialka, Khonde, Nagendran) Division of Cardiac Surgery,
Department of Surgery, University of Alberta, Edmonton, AB, Canada
(Alam) Faculty of Medicine and Dentistry, University of Alberta, Edmonton,
AB, Canada
(Weatherald, Halloran) Division of Pulmonary Medicine, Department of
Medicine, University of Alberta, Edmonton, AB, Canada
Publisher
John Wiley and Sons Inc
Abstract
Background: En bloc heart-lung transplantation (HLTx) has been utilized
for the past 50 years for the treatment of end-stage heart and lung
disease, with significant evolution in the field over that time. This is a
systematic review of HLTx and a description of the evolution and outcomes
in this patient population. Method(s): Pubmed and Embase were
searched for all articles on HLTx from the time of database inception. A
total of 1513 articles were screened, and after exclusion, 29 were
included in this systematic review. Result(s): Reported cases of HLTx
were more common in the early era (before 2000), for the indications of
cystic fibrosis, Eisenmenger's syndrome, and pulmonary hypertension. In
the contemporary era (2000-present), patients were not as commonly
transplanted for cystic fibrosis, with pulmonary hypertension and
congenital heart disease comprising the majority of cases. Rates of
short-term mortality tended to be lower in more recent studies, with only
recent studies reporting long-term survival. Discussion(s): HLTx has
evolved substantially. In tandem with isolated heart and lung
transplantation, the indications for transplant, medical therapy, and
outcomes have changed over time. While HLTx is used less frequently in
contemporary times compared to the early days of cardiothoracic
transplantation, indications for HLTx continue to exist, and the use of
HLTx will continue to be indicated. Centers with experience in HLTx should
continue to report trends in patient management and outcomes, to continue
to guide continued refinement in the field of HLTx. Copyright ©
2025 The Author(s). Clinical Transplantation published by Wiley
Periodicals LLC.

<122>
Accession Number
648186319
Title
Efficacy and safety of protamine for preventing complications in
transcatheter aortic valve replacement: a meta-analysis.
Source
Minerva cardiology and angiology. (no pagination), 2025. Date of
Publication: 01 Aug 2025.
Author
Attachaipanich T.; Attachaipanich S.; Kaewboot K.
Institution
(Attachaipanich) Department of Internal Medicine, Kansas City School of
Medicine, University of Missouri, Kansas City, MO, United States
(Attachaipanich) Graduate School of Science, Osaka University, Osaka,
Japan
(Kaewboot) Division of Rheumatology, Department of Internal Medicine,
Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok,
Thailand
Abstract
INTRODUCTION: Transcatheter aortic valve replacement (TAVR) is
increasingly performed nowadays, bleeding and vascular complications are
not uncommon. Current recommendations for the use of protamine in the
post-TAVR setting remain uncertain. This study aimed to evaluate the
efficacy and safety of protamine in this setting. EVIDENCE ACQUISITION: A
systematic search using four databases, including PubMed, Embase, Web of
Science, and Cochrane CENTRAL, was conducted from inception to October
17th, 2024, without language restrictions. The inclusion criteria were
studies that compared the efficacy or safety of protamine vs control in
post-TAVR patients. EVIDENCE SYNTHESIS: There were six studies (two
randomized and four non-randomized) included in this meta-analysis,
involving 3897 participants. We used a random-effects model for this
meta-analysis. Protamine was associated with a lower risk of major
bleeding compared to the control group, with an odds ratio (OR) of 0.47
(95% CI 0.30 to 0.74, P<0.01). Additionally, protamine was associated with
a lower risk of major vascular complications compared to the control, with
an OR of 0.45 (95% CI 0.31 to 0.65, P<0.01). Protamine also reduced the
risk of minor bleeding and life-threatening bleeding compared to the
control. For the safety outcome, the administration of protamine did not
increase the risk of stroke and myocardial infarction. CONCLUSION(S):
The administration of protamine demonstrated efficacy in reducing bleeding
and vascular complications without increasing the risk of thromboembolic
complications in the post-TAVR setting.

<123>
Accession Number
2039873174
Title
Left atrial appendage occlusion in patients with atrial fibrillation and
previous Intracranial Hemorrhage or Cerebral Amyloid Angiopathy: A
systematic review and meta-analysis.
Source
International Journal of Stroke. (no pagination), 2025. Article Number:
17474930251360076. Date of Publication: 2025.
Author
Mavridis T.; Archontakis-Barakakis P.; Chlorogiannis D.-D.; Charidimou A.
Institution
(Mavridis) Department of Neurology, Tallaght University Hospital (TUH),
The Adelaide and Meath Hospital, Incorporating the National Children's
Hospital (AMNCH), Dublin, Ireland
(Archontakis-Barakakis) Redington-Fairview General Hospital, Skowhegan,
ME, United States
(Chlorogiannis) Department of Radiology, Brigham and Women's Hospital,
Harvard Medical School, Boston, MA, United States
(Charidimou) Department of Neurology, Boston University Medical Center,
Boston University School of Medicine, Boston, MA, United States
Publisher
SAGE Publications Inc.
Abstract
Background: Patients with atrial fibrillation (AF) on oral anticoagulation
(OAC) who have a history of intracranial hemorrhage (ICrH) or cerebral
amyloid angiopathy (CAA) have an elevated risk of ICrH recurrence. Left
atrial appendage occlusion (LAAO) has emerged as a potential alternative
to OAC for stroke prevention in high-bleeding-risk AF patients. Small
observational studies suggest that LAAO may be safe and feasible in
patients with ICrH, when using single or dual antiplatelet therapy or
short-term OAC post-procedure, though data remain limited. This systematic
review and meta-analysis aims to consolidate evidence on the safety and
efficacy of LAAO in patients with prior ICrH or CAA. Method(s): We
conducted a systematic review and meta-analysis examining the safety and
efficacy of LAAO in patients with non-valvular AF and prior ICrH and/or
CAA. PubMed/MEDLINE and EMBASE (via Scopus) databases were systematically
searched from inception until 29 February 2024. Eligible studies included
randomized control trials, observational studies, and case series (10
participants) reporting stroke events in patients with AF and previous
history of ICrH and/or CAA undergoing LAAO. Pooled incidence rates (IRs)
with corresponding 95% confidence intervals (CIs) were calculated for
primary outcomes (post-procedural ischemic stroke and recurrent ICrH) and
secondary outcomes. Result(s): Fourteen studies including 1235
patients met inclusion criteria. The pooled average follow-up period was
17.1 months. The pooled IRs for ischemic stroke, recurrent ICrH, and major
hemorrhage were 2% (95% CI: 1-3%, I2 = 2%), 2% (95% CI: 0.4-3%,
I2 = 45%) and 3% (95% CI: 1-5%, I2 = 54%),
respectively. In prespecified subgroup analyses of studies focusing on
patients with intraparenchymal hemorrhage and/or CAA, pooled IRs for
ischemic stroke, recurrent ICrH, and major hemorrhage IR of 4% (95% CI:
1-8%), 4% (95% CI: 0.4-10%) and 6% (95% CI: 3-12%), respectively.
 Conclusion(s): LAAO may be a safe and effective treatment for
selected AF patients with a history of ICrH and/or CAA, but the quality of
evidence is poor. Future randomized controlled trials are essential to
validate LAAO's efficacy and long-term safety. Copyright © 2025
World Stroke Organization

<124>
Accession Number
2039969583
Title
Perioperative intranasal dexmedetomidine for the prevention of chronic
postsurgical pain following thoracoscopic surgery: protocol for a
multicentre randomised controlled trial.
Source
BMJ Open. 15(8) (no pagination), 2025. Article Number: e105832. Date of
Publication: 08 Aug 2025.
Author
Xu L.; Zhang Y.; Che L.; Shen L.
Institution
(Xu, Che, Shen) Department of Anesthesiology, Peking Union Medical College
Hospital, Beijing, China
(Zhang) Peking Union Medical College Hospital, Beijing, China
Publisher
BMJ Publishing Group
Abstract
Introduction Chronic postsurgical pain (CPSP) is common among patients
undergoing thoracic surgery, with an incidence of up to 43.99% even with
video-assisted thoracoscopic surgery (VATS). CPSP is associated with
prolonged opioid use and significantly reduced quality of life. Currently,
there are no consistently effective preventive measures. Poor
perioperative sleep quality has been increasingly recognised as a key
contributing factor to CPSP. Therefore, improving perioperative sleep
quality is a potentially modifiable factor in the prevention of CPSP.
Dexmedetomidine, an alpha2-adrenergic receptor agonist, has been shown to
improve sleep quality in various patient populations. However, direct
evidence supporting its role in reducing the incidence of CPSP is lacking.
The aim of this multicentre randomised controlled trial is to investigate
the efficacy of perioperative intranasal dexmedetomidine to optimise sleep
and reduce the incidence of CPSP. Methods and analysis This prospective,
randomised controlled trial will enrol 364 patients undergoing elective
VATS. Eligible patients who meet the inclusion and exclusion criteria will
be randomly assigned to either the dexmedetomidine group or the control
group. Patients in the dexmedetomidine group will receive perioperative
intranasal dexmedetomidine spray, while those in the control group will
receive an equivalent volume of intranasal normal saline. Assessments will
be conducted at baseline, on postoperative days 1, 2 and 3, and at 1, 3
and 6 months after surgery. The primary outcome is CPSP at 3 months
postoperatively. Secondary outcomes include sleep quality, emotional
status, pain intensity and opioid consumption. Ethics and dissemination
The study protocol was approved by the Peking Union Medical College
Hospital Institutional Review Board (Ethics Review Committee No.
I-25PJ0337) on 7 February 2025. The trial was registered on
ClinicalTrials.gov on 16 March 2025, in accordance with ICMJE guidelines.
The results will be published in academic journals and disseminated at
research conferences. Copyright © Author(s) (or their
employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use.
See rights and permissions. Published by BMJ Group.

<125>
Accession Number
2039928748
Title
Prognostic Significance of Concomitant Transthyretin Cardiac Amyloidosis
and Severe Aortic Stenosis: Insights From a Systematic Review and
Meta-Analysis.
Source
Heart Lung and Circulation. Conference: 73rd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Brisbane Australia.
34(Supplement 4) (pp S335-S336), 2025. Date of Publication: 01 Aug 2025.
Author
Zaka A.; Mutahar D.
Institution
(Zaka, Mutahar) Gold Coast University Hospital, Gold Coast, QLD, Australia
Publisher
Elsevier Ltd
Abstract
Aim: Severe aortic stenosis (AS) and cardiac amyloidosis (CA) frequently
coexist in elderly populations. The prognostic significance of dual
pathology CA-AS in the context of transcatheter aortic valve implantation
(TAVI) is not widely established. We performed a systematic review and
meta-analysis to compare 1-year mortality of patients with concomitant
CA-AS to those with isolated AS. Method(s): PubMed, EMBASE, Web of
Science and Cochrane databases were searched until 26 February 2025 for
all multivariable-adjusted or propensity-matched observational studies
evaluating clinical outcomes in CA-AS patients. Summary odds ratios with
95% confidence intervals (CI) were calculated using random-effects model,
with pre-specified subgroup analyses for patients undergoing TAVI.
 Result(s): Fifteen observational studies (775,319 severe AS patients)
met inclusion criteria. The mean follow-up duration was 22.4 months, mean
age was 81.5 years and 56.3% were men. The pooled odds ratio for all-cause
mortality in CA-AS patients was 1.21 (95% CI 0.81-1.80). There was no
statistically significant difference in 1-year all-cause mortality between
CA-AS and isolated AS (OR 1.38, 95% CI 0.80-2.37) (Figure 1) or between
CA-AS patients undergoing TAVI compared to medical management (OR 0.94,
95% CI 0.56-1.58) (Figure 2). Conclusion(s): The presence of
concomitant CA does not significantly impact the 1-year all-cause
mortality of patients with severe AS undergoing TAVI. [Formula presented]
[Formula presented] Copyright © 2025

<126>
Accession Number
648189065
Title
The Low-Risk TAVR Trials - A Critical Appraisal of the Current Landscape.
Source
American heart journal. (no pagination), 2025. Date of Publication: 29
Jul 2025.
Author
Jorgensen T.H.; Thyregod H.G.H.; Blankenberg S.; Leon M.; Sondergaard L.;
Prendergast B.; De Backer O.
Institution
(Jorgensen, Thyregod) Rigshospitalet, Copenhagen University Hospital,
Copenhagen, Denmark
(Blankenberg) Department of Cardiology, UKE, Hamburg, Germany
(Leon) Clinical Research Foundation and Columbia University Hospital, New
York, NY, USA
(Sondergaard) Abbott, Santa Clara, CA, USA
(Prendergast) St Thomas' Hospital and Cleveland Clinic London, London,
United Kingdom
(De Backer) Rigshospitalet, Copenhagen University Hospital, Copenhagen,
Denmark; Department of Clinical Medicine, University of Copenhagen,
Copenhagen, Denmark
Abstract
The low-risk TAVR vs. SAVR RCTs - PARTNER-3, Evolut Low-Risk, DEDICATE,
and NOTION-2 - demonstrate that TAVR is at least as effective as SAVR in
terms of early mortality and disabling stroke, although outcomes varied
across studies. The excellent outcomes observed in the PARTNER-3 trial
reflect the highly selected patient population, while the NOTION-2 trial
highlights the challenges posed by anatomical variations, such as bicuspid
aortic valves. These findings highlight the importance of a personalized
approach guided by a multidisciplinary Heart Team, taking into account
both clinical and anatomical aspects when choosing between TAVR or
SAVR. Copyright © 2025. Published by Elsevier Inc.

<127>
Accession Number
2039928501
Title
Aortic Stenosis and Adverse Outcomes in Patients Undergoing Non-Cardiac
Surgery: A Systematic Review and Meta-Analysis.
Source
Heart Lung and Circulation. Conference: 73rd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Brisbane Australia.
34(Supplement 4) (pp S401-S403), 2025. Date of Publication: 01 Aug 2025.
Author
Place A.; Rodrigues T.S.; Naimo P.; Lee M.; Batchelor R.; Gurvitch R.;
Wilson W.; Taylor A.; Lefkovits J.; Koshy A.
Institution
(Place, Naimo, Lee, Batchelor, Gurvitch, Wilson, Taylor, Lefkovits, Koshy)
Royal Melbourne Hospital, Melbourne, VIC, Australia
(Rodrigues, Koshy) Austin Health, Melbourne, VIC, Australia
Publisher
Elsevier Ltd
Abstract
Aim: Aortic stenosis (AS) is a recognised risk factor for patients
undergoing non-cardiac surgery (NCS), however there is conflicting data
regarding perioperative outcomes in this patient cohort. This results in
delays in surgery or proceeding with an unclear estimation of risk. This
systematic review and meta-analysis aimed to evaluate the perioperative
risks associated with NCS in patients with AS. Method(s): A
systematic review and meta-analysis was conducted using MEDLINE and EMBASE
databases. The endpoints of this study were all-cause-in-hospital
mortality or 30-days mortality, non-fatal myocardial infarction (MI) and
HF. All-cause mortality was estimated using a fixed effect model.
Descriptive statistics were reported and random-effects model estimated
pooled risk using relative risks (RR) with a 95% confidence interval(CI),
presented in forest plots. Result(s): Nineteen studies (n=100,486)
were included to estimate a pooled mortality risk in AS patients
undergoing NCS. Overall mortality risk in AS patients of any severity was
3.8%(95%CI 3.7%-3.9% Figure 1A) and 9.6%(95%CI 7.7%-12.1% Figure 1B) in
patients with severe AS. Meta-analysis of fourteen comparative studies
(n=2,885,254) was performed, assessing outcomes in patients with and
without AS. Patients with AS undergoing NCS had significantly higher
all-cause mortality (RR1.58, 95%CI [1.18, 2.12], p<0.001,
I2=90.58% Figure 2), MI (RR 1.79, 95%CI [1.20, 2.67], p<0.001,
I2=4.92% Figure 3) and HF (RR2.06, 95%CI [1.19, 3.59], p=0.01,
I2=82.55% Figure 4). Conclusion(s): Our findings have
immediate clinical relevance demonstrating a risk of mortality nearing 10%
in patients with AS undergoing NCS. These results address previous
ambiguity and highlight the importance of further research of
perioperative management in this patient cohort to mitigate such risk.
[Formula presented] [Formula presented] [Formula presented] [Formula
presented] Copyright © 2025

<128>
Accession Number
2039929706
Title
A Case of Percutaneous Coronary Intervention in Unstable Left Main
Spontaneous Coronary Artery Dissection.
Source
Heart Lung and Circulation. Conference: 73rd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Brisbane Australia.
34(Supplement 4) (pp S394), 2025. Date of Publication: 01 Aug 2025.
Author
Pointon S.; Trytell A.; Arunothayaraj S.
Institution
(Pointon, Trytell, Arunothayaraj) Department of Cardiology, St Vincent's
Hospital Melbourne, Fitzroy, VIC, Australia
Publisher
Elsevier Ltd
Abstract
Background: Spontaneous coronary artery dissection (SCAD) is an uncommon
cause of acute coronary syndrome (ACS) which typically presents in younger
patients with few traditional cardiovascular risk factors. Up to 90% of
patients with SCAD are women. There are no randomised controlled trials
for SCAD management to date, therefore current management is largely based
on registry observations and application of non-SCAD ACS guidelines.
Medical management of SCAD is generally recommended, however coronary
revascularisation is indicated in cases of haemodynamic instability,
ongoing ischaemia, malignant arrhythmia and left main coronary artery
(LMCA) involvement. Case Presentation: A 39-year-old female presented to
hospital with a three-day history of recurrent chest pain and was
diagnosed with a non-ST elevation myocardial infarction. She was nine
months postpartum and had a background of hypertension,
hypercholesterolaemia, and gestational diabetes. She proceeded to an
inpatient coronary angiogram, which demonstrated LMCA SCAD. During the
angiogram she experienced persistent chest pain with widespread ST
depression and haemodynamic instability, hence the decision was made to
perform an intravascular ultrasound guided stent to the LMCA, extending
into the proximal left anterior descending artery. Repeat coronary
angiography three months later demonstrated patent stents without
significant stenosis. Discussion(s): SCAD is an uncommon but
increasingly recognised aetiology of ACS. SCAD is predominantly diagnosed
following coronary angiography, with higher diagnostic accuracy when
intracoronary imaging is used. While considered to be best managed
medically, this case reminds clinicians of the importance of intracoronary
imaging, and that coronary revascularisation has a significant role in
haemodynamically unstable patients with SCAD. Copyright © 2025

<129>
Accession Number
2039929420
Title
Right Heart Indices Predict Major Adverse Cardiovascular Events in
Patients With Left Ventricular Assist Devices: A Systematic Review and
Meta-Analysis.
Source
Heart Lung and Circulation. Conference: 73rd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Brisbane Australia.
34(Supplement 4) (pp S342-S343), 2025. Date of Publication: 01 Aug 2025.
Author
Wilson D.; Mubashir M.; Khanna S.; Bhat A.; Ying V.; Ghelani D.
Institution
(Wilson, Khanna, Bhat) Department of Cardiology, Blacktown Hospital,
Blacktown, NSW, Australia
(Wilson) Western Sydney University, Campbelltown, NSW, Australia
(Mubashir, Ying, Ghelani) Department of Intensive Care Unit, Blacktown
Hospital, Blacktown, NSW, Australia
Publisher
Elsevier Ltd
Abstract
Aim: Left ventricular assist devices are increasingly being utilised as a
therapeutic modality for patients with end stage heart failure both as
destination therapy and as a bridge to cardiac transplantation. This
systematic review and meta-analysis aims to evaluate the pre-implantation
haemodynamic and echocardiographic factors that are associated with MACE,
including ventricular arrhythmias, right heart failure, stroke and need
for ischaemic revascularisation, in patients post-LVAD. Method(s): A
comprehensive literature search of medical databases and grey literature
was conducted. Studies were included if they reported MACE and relevant
haemodynamic and echocardiographic parameters (2000-2025; English Only).
Data for all variables were extracted and those with low heterogeneity
were then meta-analysed using a random-effect model for odds ratios (OR)
or standardised mean differences (SMD). Result(s): Out of 1,710
studies that were screened, 48 peer-reviewed articles fulfilled criteria
for inclusion. A total of 9,532 patients were included in the
meta-analysis, with 18 factors assessed (Table). Our meta-analysis
identified that predictors of MACE in patients post-LVAD implantation
included the following haemodynamic variables: right atrial pressure (SMD
0.390, p<0.001), indexed pulmonary arterial pressure (SMD -0.344,
p=0.001), central venous pressure (SMD 0.179, p=0.017); and the following
echocardiographic variables: tricuspid annular plane systolic excursion
(SMD -0.468, p=0.002), tricuspid regurgitation (OR 1.393, p=0.045), right
ventricular dysfunction (OR 1.540, p=0.001). Conclusion(s): The
meta-analysis demonstrated an association between right heart haemodynamic
and echocardiographic indices and increased rates of MACE post-LVAD
implantation, which may be utilised in clinical decision-making regarding
patient eligibility, suitability and prognosis for mechanical cardiac
assist device therapy. [Formula presented] Copyright © 2025

<130>
Accession Number
2039985604
Title
Transcatheter Mitral Valve Replacement Using Contemporary Dedicated
Devices: A Systematic Review and Meta-Analysis.
Source
Structural Heart. 9(9) (no pagination), 2025. Article Number: 100702. Date
of Publication: 01 Sep 2025.
Author
Zorman M.J.; Dangas K.; Vibhishanan J.; Castle J.; Eastwick-Jones K.;
Coronelli M.; Alabdaljabar M.S.; Foster K.; Silva D.; Patel P.; Johns E.;
Piankova P.; Ordonez-Mena J.; Dawkins S.; Newton J.; Eleid M.F.; Guerrero
M.E.; Cahill T.J.
Institution
(Zorman, Dangas, Vibhishanan, Castle, Eastwick-Jones, Coronelli, Piankova,
Dawkins, Newton, Cahill) Oxford Heart Centre, Oxford University Hospitals
NHS Foundation Trust, Oxford, United Kingdom
(Zorman, Alabdaljabar, Foster, Silva, Patel, Johns, Eleid, Guerrero)
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United
States
(Ordonez-Mena) Nuffield Department of Primary Care Health Sciences,
University of Oxford, Oxford, United Kingdom
Publisher
Cardiovascular Research Foundation
Abstract
Background: Dedicated transcatheter mitral valve replacement (TMVR)
devices have emerged as a promising strategy for treating mitral
regurgitation (MR) in high-risk patients with complex native valve
anatomy. Early experience spans multiple devices utilizing both
transapical and transseptal access. The aim of this study was to evaluate
procedural, 30-day, and midterm outcomes of TMVR with contemporary
dedicated mitral devices in patients with native MR. Method(s): A
systematic search of Medline, Embase, and Cochrane Library (January
2010-January 2025) was conducted. Pooled outcome estimates were derived
using random-effects models, excluding legacy devices and cases of mitral
stenosis. Result(s): Thirteen studies (914 patients) were included in
the analysis. The mean age was 75.4 years, and 69.8% had functional or
mixed MR. Technical success was 96.3%. Residual MR was mild or less in 99%
of patients at 30 days and 98% at 1 year. All-cause mortality was 11.0% at
30 days and 26.4% at 1 year. Over a mean follow-up of 12.1 months, rates
of heart failure (HF) hospitalizations, cerebrovascular events, and valve
reinterventions were 26.2, 5.6, and 6.0 events per 100 patient-years,
respectively. Compared with transseptal access, transapical showed higher
30-day major bleeding (19.2% vs. 10.4%, p = 0.03) and all-cause mortality
at 30 days (14.0% vs. 4.7%, p <0.001) and 1 year (27.7% vs. 13.1%, p =
0.005). Midterm rates of HF readmissions, major bleeding, and valve
reinterventions were comparable between access routes. Conclusion(s):
Contemporary dedicated TMVR devices demonstrate high technical success and
sustained MR reduction. Transseptal access is associated with lower
morbidity and mortality. Further research is needed to improve longer-term
mortality and HF hospitalizations following TMVR with dedicated mitral
devices. Copyright © 2025 The Author(s)

<131>
Accession Number
2039928615
Title
Transcatheter Edge-to-Edge Mitral Valve Repair (M-TEER) With Multiple
MitraClips.
Source
Heart Lung and Circulation. Conference: 73rd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Brisbane Australia.
34(Supplement 4) (pp S723), 2025. Date of Publication: 01 Aug 2025.
Author
Thaw K.; Murdoch D.; Lander K.; Zeng E.; Lau K.; Walters L.; Appadurai V.;
Raffel C.; Scalia G.; Walters D.
Institution
(Thaw, Murdoch, Lander, Zeng, Lau, Walters, Appadurai, Raffel, Scalia,
Walters) The Prince Charles Hospital, Chermside, QLD, Australia
Publisher
Elsevier Ltd
Abstract
Background: More than half of all patients undergoing M-TEER have more
than one device implanted. Objective(s): This study aimed to assess
the impact of using one versus multiple MitraClips on mitral valve area
(MVA), mean pressure gradient (MPG), mitral regurgitation (MR) reduction
and clinical outcomes. Method(s): This retrospective analysis of 65
consecutive patients undergoing M-TEER from our single-centre divided
patients into a "single clip" group (n=31) and a "multiple clip" group
(n=34). The baseline characteristics of both groups were similar, with the
mean age of 79 years in both groups. Result(s): Post procedure, mean
DELTAMVA was -2.6 +/-1.1cm2 in single clip group and
-4.0+/-2.0cm2 in multiple clip group (p=0.001, Figure 1). The
DELTAMVA% was -45%+/-12% in single clip group compared to -56%+/-16% in
multiple clip group (p= 0.003, Figure 2). Surprisingly, there was no
difference in post-procedure MPG (1.8+/-0.7 versus 2.0+/-0.9 mmHg, p=ns)
and DELTAMPG (3.6 +/-1.8 versus 4.3+/-2.2 mmHg, p=ns). The single clip
group showed a trend towards achieving residual MR <=1 (80%) compared to
the multiple clip group (53.4%). There were no differences in clinical
outcomes (all cause, cardiovascular mortality and major adverse
cardiovascular events) between the two groups at 30 days.
 Conclusion(s): The use of multiple devices in M-TEER results in
significantly greater reductions in mitral valve area compared to a single
clip, but surprisingly, it does not lead to substantially higher
transmitral gradients. [Formula presented] [Formula
presented] Copyright © 2025

<132>
Accession Number
2039929914
Title
Vasoplegia in Advanced Heart Failure-An Insidious Vascular Crisis.
Source
Heart Lung and Circulation. Conference: 73rd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Brisbane Australia.
34(Supplement 4) (pp S359-S360), 2025. Date of Publication: 01 Aug 2025.
Author
Ho E.; Sindone J.; Zhang J.; Gu K.; Chen H.; Khanna S.; Gan G.
Institution
(Ho, Zhang, Gu, Chen, Khanna, Gan) Department of Cardiology, Blacktown
Hospital, Blacktown, NSW, Australia
(Sindone) Department of Cardiology, Royal Prince Alfred Hospital,
Camperdown, NSW, Australia
(Gan) Department of Cardiology, Westmead Hospital, Westmead, NSW,
Australia
Publisher
Elsevier Ltd
Abstract
Aim: Vasoplegia is characterised by widespread dilatation of vasculature,
leading to a decrease in vascular resistance and hypotension. Though it is
recognised as a complication of shock and cardiac surgery, its occurrence
in advanced heart failure (AHF) has not been well studied. This
meta-analysis aims to review the incidence of vasoplegia in patients with
AHF and evaluate the contributing factors and outcomes associated with the
condition. Method(s): Using PRISMA principles, we performed a
systematic literature search of medical databases (Embase, PubMed,
CENTRAL) to identify studies evaluating vasoplegia in AHF. Key clinical
associations as well as outcomes were extracted and those with low
heterogeneity were evaluated using a random-effect model for odds ratio
(OR) or standardised mean differences (SMD). Result(s): Six studies
of patients with AHF requiring mechanical circulatory support were
included. Of 1476 patients, 476 (30%) developed vasoplegia. The
development of vasoplegia was associated with higher early (30-day, OR
2.48; CI 1.45-4.22, p<0.01) and late (1-year, OR 1.92; CI 1.15-3.19,
p=0.01) mortality as well as acute renal impairment (OR 3.78; CI
1.16-12.43, p=0.03). Patients who developed vasoplegia were more likely to
be men (OR 1.97; CI 1.24-3.13, p<0.01) treated with angiotensin receptor
blockers (OR 1.38; CI 1.03-1.83, p=0.03), with higher serum creatinine
(SMD 0.58; CI 0.13-1.03, p=0.01) and requiring dopamine support (OR 2.45;
CI 1.37-4.36, p<0.01) (Figure 1). Interestingly, patients treated with ACE
inhibitors were less likely to develop vasoplegia (OR 0.743; CI 0.58-0.94,
p=0.02). Conclusion(s): Vasoplegia is common in patients with AHF and
associated with poorer outcomes. Further research is required. [Formula
presented] Copyright © 2025

<133>
Accession Number
2035653451
Title
De Novo Letermovir for Cytomegalovirus Primary Prophylaxis in Heart
Transplant Recipients: A Case Series.
Source
Clinical Transplantation. 39(8) (no pagination), 2025. Article Number:
e70271. Date of Publication: 01 Aug 2025.
Author
Morado F.; Han E.E.; Nanda N.; Cartus R.; Akkad A.
Institution
(Morado, Cartus) Keck Medicine of USC, Department of Clinical Pharmacy,
University of Southern California, Los Angeles, CA, United States
(Han) USC Mann School of Pharmacy, Titus Family Department of Clinical
Pharmacy, University of Southern California, Los Angeles, CA, United
States
(Nanda, Akkad) Division of Infectious Diseases, Department of Medicine,
Keck School of Medicine, University of Southern California, Los Angeles,
CA, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Cytomegalovirus (CMV) is a significant infection affecting
solid organ transplant recipients (SOTr). Valganciclovir is the drug of
choice for CMV prophylaxis but is associated with an undesirable side
effect profile. Letermovir, a CMV DNA terminase complex inhibitor, is not
associated with the myelotoxicity seen with valganciclovir. Currently,
letermovir is approved for CMV prophylaxis in hematopoietic cell and
kidney transplant recipients, but not for heart transplant recipients
(HTR), where data are very minimal. Method(s): A chart review was
conducted on 22 patients who received letermovir post-heart
transplantation for CMV prophylaxis at an academic medical center.
Patients were monitored for CMV disease, CMV DNAemia, CMV blip, and
myelotoxicity. Result(s): Most patients (81.8%) were at moderate risk
for CMV disease (CMV seropositive/negative donor and CMV-seropositive
recipient). Of the 22 patients, 12 completed CMV prophylaxis with
letermovir, while 10 were switched to valganciclovir, primarily due to
insurance non-coverage (9 out of 10 patients). One patient developed a CMV
blip to 297 IU/mL and was switched to valganciclovir. No patients
developed CMV infection or disease while on letermovir, and no
myelotoxicity was observed. Conclusion(s): Letermovir may be a
potential option for primary prevention of CMV prophylaxis in
HTR. Copyright © 2025 Precisionheor. Clinical Transplantation
published by John Wiley & Sons Ltd.

<134>
Accession Number
2039928596
Title
Ventricular Arrhythmia and Sudden Death Outcomes Before and After
Percutaneous Valve Repair for Mitral Regurgitation.
Source
Heart Lung and Circulation. Conference: 73rd Annual Scientific Meeting of
the Cardiac Society of Australia and New Zealand. Brisbane Australia.
34(Supplement 4) (pp S726-S727), 2025. Date of Publication: 01 Aug 2025.
Author
Cameron J.; Sutherland N.; Chow C.; Han H.; Yudi M.; Sabbag A.; Raman J.;
Sanders P.; Farouque O.; Lim H.
Institution
(Cameron, Yudi, Farouque, Lim) Department of Cardiology, Austin Health,
Melbourne, VIC, Australia
(Cameron, Chow, Yudi, Farouque, Lim) Faculty of Medicine, Dentistry and
Health Sciences, The University of Melbourne, Melbourne, VIC, Australia
(Sutherland, Chow) Department of Cardiology, Northern Health, Melbourne,
VIC, Australia
(Han) Victorian Heart Institute, Monash University, Clayton, VIC,
Australia
(Sabbag) The Davidai Center for Rhythm Disturbances and Pacing, Chaim
Sheba Medical Center, Tel Hashomer, Israel
(Raman) Department of Cardiac Surgery, Austin Health, Melbourne, VIC,
Australia
(Sanders) Centre for Heart Rhythm Disorders, South Australian Health and
Medical Research Institute, The University of Adelaide and Royal Adelaide
Hospital, Adelaide, SA, Australia
Publisher
Elsevier Ltd
Abstract
Aim: Whether percutaneous mitral valve repair (pMVR) reduces ventricular
arrhythmias (VA) or sudden cardiac death (SCD) remains uncertain. Current
clinical guidelines do not consider arrhythmic burden an indication for
pMVR. We provide an integrated perspective on the limited evidence
available. Method(s): A systematic review was conducted using PubMed
in August 2024 to identify studies reporting VA rates pre- and post-pMVR.
Eligible studies included patients undergoing transcatheter edge-to-edge
repair (TEER) using 'MitraClip' for symptomatic secondary mitral
regurgitation (MR), with documented arrhythmia outcomes. Result(s):
Five studies (Table) comprising 372 patients were identified. The pooled
mean age was 71.8 years, with 28.2% being female. All studies reported a
reduction in VA following pMVR. Premature ventricular contractions (PVCs)
decreased in one study, while non-sustained ventricular tachycardia (NSVT)
and ventricular tachycardia/ventricular fibrillation (VT/VF) were reduced
in four studies. Despite this consistent signal of VA reduction, a
residual arrhythmic risk remained. Interpretation is limited by study
heterogeneity and the comorbid, elderly population included.
 Conclusion(s): Reduced VA burden following pMVR is
pathophysiologically plausible. Correction of MR and subsequent reduction
of mechanical stress may mitigate VA triggers, although the risk is not
eliminated. pMVR shows promise in reducing VA and potentially lowering SCD
risk in MR patients. However, the current evidence base is limited,
highlighting the need for further studies to validate these findings.
[Formula presented] Copyright © 2025

<135>
Accession Number
2039972487
Title
Ultrasound Guided Versus Conventional Closure Device Deployment Following
Transfemoral Endovascular Procedures: A Systematic Review and
Meta-analysis.
Source
European Journal of Vascular and Endovascular Surgery. (no pagination),
2025. Date of Publication: 2025.
Author
Kalaja I.; Smeets R.R.; Wegner M.; Macherey-Meyer S.; Heyne S.;
Espinola-Klein C.; Mees B.M.E.; Meertens M.M.
Institution
(Kalaja, Espinola-Klein, Meertens) Department for Cardiology III -
Angiology, University Medical Centre of the Johannes Gutenberg-University,
Mainz, Germany
(Smeets) Department of Vascular Surgery, Slingeland Hospital, Doetinchem,
Netherlands
(Smeets, Mees) Department of Vascular Surgery, Maastricht University
Medical Centre, Maastricht, Netherlands
(Wegner) Department of Vascular and Endovascular Surgery, Faculty of
Medicine, University Hospital Cologne, University of Cologne, Cologne,
Germany
(Macherey-Meyer, Heyne, Meertens) Clinic III for Internal Medicine,
University of Cologne, Faculty of Medicine and University Hospital
Cologne, Cologne, Germany
Publisher
W.B. Saunders Ltd
Abstract
Objective: Femoral access site complications influence short term survival
and outcomes in patients undergoing endovascular procedures. While
ultrasound guided puncture is a reliable method to reduce such
complications, ultrasound guidance is rarely used for closure device
deployment. Data Sources: Web of Science, PubMed, and the Cochrane
Library. Review Methods: A systematic literature search was conducted to
assess the safety and efficacy of ultrasound guided vascular closure
device deployment compared with vascular closure device deployment without
ultrasound guidance, referred to as conventional closure. All studies
reporting on ultrasound guided closure in transfemoral arterial
interventions were eligible, and those directly comparing ultrasound
guided with conventional closure were included in the meta-analysis.
 Result(s): Overall, 2 738 patients receiving ultrasound guided
closure were included: 1 025 for introducer sheaths measuring 12 F or
larger and 1 713 for introducer sheaths smaller than 12 F. The incidence
of access complications was 5.7% (range 0.8 - 21.6%) for large sheath
procedures and 2.6% (range 0.9 - 4.7%) for small sheath procedures. The
meta-analysis, which included 2 339 patients who received ultrasound
guided closure and 1 175 who underwent conventional closure, showed that
ultrasound guided closure was associated with reduced access site
complications compared with conventional closure (odds ratio [OR] 0.49,
95% confidence interval [CI] 0.37 - 0.65; p < .001). This was consistently
seen both for small sheath (OR 0.45, 95% CI 0.28 - 0.75; p = .002) and
large sheath procedures (OR 0.50, 95% CI 0.37 - 0.71; p < .001), but with
a low certainty of evidence in the Grading of Recommendations Assessment,
Development, and Evaluation (GRADE) analysis. Conclusion(s):
Ultrasound guided vessel closure of the femoral artery appeared to be
associated with a lower rate of overall access site complications compared
with conventional closure techniques. Therefore, ultrasound guided closure
might offer the potential to increase procedural and patient safety in
percutaneous arterial access. Copyright © 2025 The Authors

EPICORE Embase Updates

Saturday, August 23, 2025

EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Followers

Blog Archive

About Me